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ABSTRACT 
Debilitating age-associated neurodegenerative disorders (NDs) are a major 
public health challenge in increasingly ageing societies. Currently approved 
therapeutics are successful in slowing the progression of NDs but not in 
reversing or preventing the symptoms. A major goal of neurodegeneration 
research is therefore to identify potential new therapies for these devastating 
and eventually fatal disorders.  
In this study, multiple well-defined C. elegans neurodegeneration 
models were integrated to uncover effective therapeutic interventions that 
target shared pathogenic pathways. Using locomotion behaviour and lifespan 
as phenotypic readouts, the well-established anti-epileptic drug ethosuximide 
was identified as a promising compound with the potential to combat more 
than one ND. It not only rescued the short lifespan and chemosensory 
defects of a C. elegans null mutant model of the rare autosomal dominant 
human ND known as adult-onset neuronal ceroid lipofuscinosis (ANCL), but 
also ameliorated the mobility defect and short lifespan of worm tauopathy 
and polyglutamine models based on transgenic expression of mutant human 
disease proteins. The ability of ethosuximide to rescue these phenotypes did 
not correlate well with levels of aggregated Tau and polyglutamine protein, 
suggesting that ethosuximide suppresses proteotoxicity without preventing 
protein aggregation. Although the main proposed therapeutic target of 
ethosuximide in epilepsy is the T-type calcium channel, deletion of its worm 
homologue, cca-1, did not affect the increase in locomotion and lifespan in 
the tauopathy model. This suggests that ethosuximide counteracts 
proteotoxicity via a novel mechanism.  
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To further investigate how ethosuximide might exert its 
neuroprotective properties, we conducted global gene expression analyses 
using the Affymetrix C. elegans whole genome microarray platform and 
compared the transcriptome of ethosuximide-treated ANCL models and wild-
type worms to that of unexposed controls. Various downstream bioinformatic 
investigations including gene ontology analyses, regulatory motif discovery, 
publication enrichment analysis, comparative analyses with curated data 
sources and literature were performed and revealed a wide range of DAF-16-
dependent transcriptional alterations. C. elegans DAF-16 is the sole 
orthologue of the mammalian FOXO family of transcription factors (TFs) that 
are implicated in the regulation of a wide range of physiological processes. 
Genes commonly regulated in ethosuximide-treated animals have varied 
roles in lipid metabolism, redox homeostasis, longevity/ageing, chromatin 
remodelling and ubiquitination. Many ethosuximide-responsive genes also 
contained DAF-16 regulatory elements within their promoter regions and 
were known to be among the top most responsive DAF-16 TF targets. The 
importance of DAF-16 in ethosuximide-mediated protection was further 
substantiated by RNA interference and cell culture experiments. 
Ethosuximide was shown to consistently induce the transcriptional activity of 
a subset of mammalian FOXO target genes and conferred protection against 
expanded polyglutamine peptides-induced aggregation in mammalian 
neuronal cells. These findings should encourage further screening and 
characterisation of other neuroprotective compounds, and ultimately may 
assist in expediting translational drug research and clinical testing for new 
therapeutic targets to combat protein conformational disorders in general.   
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CHAPTER 1: INTRODUCTION 
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1.1 OVERVIEW OF HUMAN NEURODEGENERATIVE 
DISEASES 
Despite two decades of intense molecular research and the identification of 
many specific causative mutations, debilitating neurodegenerative diseases 
(NDs) including the common and renowned disorders such as Alzheimer's 
disease (AD) and Parkinson's disease (PD), and other less frequent forms 
such as Hungtinton's disease (HD), spinocerebellar ataxia (SCA), 
amyotrophic lateral sclerosis (ALS) and prion diseases afflict millions 
worldwide and remain a significant and unresolved financial and social 
burden facing ageing populations. Therapies for these devastating and 
eventually fatal disorders are lacking and pharmaceutical research on new 
potential treatments has been one of the main fields of investigation.  
NDs are characterised by progressive neuropsychiatric dysfunction 
and the loss of structure and function of specific neuronal circuitry that in turn 
result in behavioural symptoms. NDs can occur either on a completely 
hereditary basis (e.g. HD) or sporadically in the majority of cases (e.g. AD, 
PD, ALS). In spite of the diversity in the underlying genes involved, 
inheritance patterns, clinical manifestation and exact sites of neuropathology, 
the rare, early onset familial (also known as Mendelian) forms and the more 
prevalent late-onset sporadic forms of different NDs share some common 
genetic origins and pathological hallmarks such as the progressive and 
chronic nature of the disease, the extensive loss of specific neuronal 
subtypes, synaptic dysfunctions, the formation and deposition of misfolded 
protein aggregates (Muchowski, 2002, Taylor et al., 2002, Soto and Estrada, 
2008). Research and technological innovations over the past 10 years have 
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made considerable progress in the elucidation of mechanisms of ND initiation 
and progression that lead to neurodegeneration. Emerging common themes 
in the pathogenesis of neurodegeneration include: aberrant phosphorylation, 
palmitoylation and acetylation of disease-causing proteins, protein misfolding, 
deficient ubiquitin–proteasome system (UPS) or autophagic process to clear 
disease-causing proteins, altered RNA metabolism, oxidative stress, 
mitochondrial dysfunction, excitotoxicity, disrupted axonal transport, 
neuroinflammation and microglial activation (Ehrnhoefer et al., 2011). 
Linkage analysis, high-throughput sequencing and genome-wide association 
studies (GWAS) have also identified susceptibility genes in many NDs (Table 
1.1) with the promise to help unravel even more genes, novel loci and 
common genetic variants associated with the diverse collection of human 
NDs. Thus developments of therapeutic interventions that are applicable 
across the broad spectrum of NDs and target the shared pathogenic 
mechanisms may offer the best hope for a future neuroprotective therapy.  
1.1.1 Alzheimer’s disease  
AD is the most common ND, affecting 35 million patients worldwide. 
Clinically, it is characterised by progressive loss of short-term memory and 
cognitive domains toward a state of profound dementia. AD is pathologically 
characterised by neuronal loss and the formation of extracellular amyloid 
plaques and intracellular neurofibrillary tangles (NFTs) due to aggregation of 
two proteins, amyloid-β (Aβ) and Tau, respectively (Gandhi and Wood, 
2010). AD is genetically heterogeneous, and can be caused by one or more 
of several genes as well as environmental factors. There are two different 
forms of AD. The first is early-onset familial AD (< 40 years), which accounts 
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for less than 5% of all AD cases (Campion et al., 1999), and is caused by 
rare single dominant mutations in genes encoding amyloid precursor protein 
(APP), and/or the enzymes involved in APP processing: γ-secretase 
components presenilins (PSEN), PSEN1 and PSEN2 (Shastry, 1998). 
Missense mutations in these three genes favour the aberrant proteolytic 
processing of APP by the amyloidogenic pathway as well as increasing the 
self-aggregation of Aβ into amyloid fibrils. The sequential cleavage of APP is 
mediated by the concerted action of both β-secretase [β-site APP-cleaving 
enzyme, BACE] and γ-secretase complex which consists of PSEN1 or 
PSEN2, anterior pharynx defective 1, presenilin enhancer 2 and nicastrin 
which lead to the generation of the extracellular Aβ peptide (Takasugi et al., 
2003, Turner et al., 2003). This peptide fragment is prone to aggregation and 
is a primary component of amyloid senile plaques which are fundamental to 
the pathogenesis of AD and can be detected in the post-mortem brain 
samples of patients with AD. Aβ has also been found to accumulate in 
muscles of patients with inclusion body myositis (IBM). The causes of the 
more common sporadic late-onset AD (> 65 years) are genetically complex 
with heritability estimates up to 80%, and are clinically and pathologically 
similar to familial cases. Its complex aetiology is attributed to interactions 
between susceptibility genes involved in lipid homeostasis (APOE, 
CLU/APOJ, ABC1, ABCA7), endocytosis (BIN1, PICALM, CR1, CD2AP), 
membrane-spanning 4 domains family proteins (MS4A6A, MS4A4E), and 
environmental risk factors such as age, hypertension, oestrogen 
supplements, smoking, stroke, heart disease, depression, arthritis, and 
diabetes (Bertram et al., 2010, Ridge et al., 2013). The inheritance of the ε4 
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allele of apolipoprotein is the single strongest genetic risk factor for sporadic 
AD (Maioli et al., 2012).  
In addition to amyloid plaques, AD, Pick's disease, corticobasal 
degeneration, Down's syndrome and specific types of frontotemporal 
dementia (FTD): frontotemporal dementia with parkinsonism chromosome 17 
type (FTDP-17) and frontotemporal lobar dementia (FTLD) are associated 
with intraneuronal accumulation of NFTs. There is a strong clinical and 
pathologic overlap between FTD, AD and ALS. NFTs are composed of the 
microtubule-associated protein Tau which aggregates into insoluble fibrillar 
deposits when it is hyperphosphorylated (Mandelkow and Mandelkow, 1998) 
and is detectable in post-mortem brain samples of patients with AD. 
Mutations in genes encoding Tau (MAPT), progranulin (GRN), and 
chromatin-modifying protein 2B (CHMP2B) have been identified in FTD. 
Certain mutations in Tau (missense and deletions) including: G272V, 
delK280, P301L, P301S, V337M, G389R, and R406W may lead to reduced 
microtubule binding and an increased propensity to aggregate (Ingram and 
Spillantini, 2002). Other proposed pathogenic mechanisms include 
inflammation and cerebral hypoperfusion. Together, these are all important 
targets for disease-modifying therapies (Ehrnhoefer et al., 2011). 
1.1.2 Neuronal ceroid lipofuscinoses 
The neuronal ceroid lipofuscinoses (NCLs) represent the most common 
group of diverse hereditary NDs of children (Haltia, 2006), distinguished from 
other NDs by an excess accumulation of autofluorescent, electron dense 
storage materials ceroid and lipofuscin in multiple tissues including neurons 
(Jalanko and Braulke, 2009). Another quintessential feature shared by these 
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genetically distinct types of NCLs is the progressive and selective loss of 
neurons particularly in cerebral and cerebellar cortex and, less constantly in 
retina, leading to dementia, epilepsy, blindness and motor deterioration 
(Schulz et al., 2013). Despite being lesser studied than other major NDs, our 
understanding of the molecular basis of different NCLs has advanced 
significantly in recent years as defective NCL genes and the corresponding 
proteins have been established for all major typical and atypical NCL forms 
by using various early clinical, neuropathological, biochemical and molecular 
genetic studies (Haltia, 2006), as well as animal models (canines, sheep, 
mice) (Goebel et al., 1982, Mayhew et al., 1985, Pardo et al., 1994, Koike et 
al., 2000). To date, mutations that cause NCL have been found in at least 14 
human genes (CLN1/PPT1, CLN2/TPP1, CLN3, CLN4/DNAJC5, CLN5, 
CLN6, CLN7/MFSD8, CLN8, CLN10/CTSD, CLN11/GRN, CLN12/ATP13A2, 
CLN13/CTSF, CLN14/KCTD7, CLCN6, CLCN7 and SGSH) (Peltonen et al., 
2000, Siintola et al., 2006a, Kmoch et al., 2013). Over 260 causative 
mutations were identified and multiple sets of molecular data have also 
shown that different mutations in a single NCL gene can give rise to different 
forms of NCLs (Mitchison and Mole, 2001).  
The typical NCL symptoms and characteristic lysosomal storage 
material have been shown to be caused by defects in either lysosomal 
enzymes (CLN1/PPT1, CLN2/TPP1, CLN10/CTSD, CLN13/CTSF) or in 
novel transmembrane proteins of unknown function (CLN3, CLN6, 
CLN7/MFSD8, CLN8) (Boustany, 2013, Schulz et al., 2013). More recent 
work has shown that mutations in a synaptic chaperone gene 
(CLN4/DNAJC5) (Noskova et al., 2011), a granulin precursor gene 
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(CLN11/GRN) (Smith et al., 2012a), ATPase gene (CLN12/ATP13A2) (Bras 
et al., 2012) and a potassium channel gene (CLN14/KCTD7) (Staropoli et al., 
2012) also cause NCLs.  
Depending on the age at onset of symptoms, characteristic clinical 
features, histological findings, and genetic loci, these genetically distinct 
subtypes of NCLs are classified as congenital, infantile, late infantile, juvenile 
or adult. A mutation in the CLN10/CTSD gene causes lysosomal enzyme 
cathepsin D deficiency and results in the congenital NCL form where 
accumulation occurs in the majority of tissues and starts as early as the first 
semester and death occurs in early infancy (Siintola et al., 2006b). Infantile 
onset NCL is associated with the deficiency of the lysosomal enzyme 
palmitoyl protein thioesterase 1 (PPT1) and mutation in a potassium channel 
gene (KCTD7) (Vesa et al., 1995, Staropoli et al., 2012). Late infantile-onset 
NCL is the most genetically heterogeneous form. While classical late 
infantile-onset NCL is associated with the deficiency of the lysosomal 
enzyme tripeptidyl peptidase 1 (CLN2/TPP1), causative mutations for variant 
late infantile-onset NCL are found in CLN1/PPT1, CLN5, CLN6, 
CLN7/MFSD8 and CLN8 genes (Kousi et al., 2009). Juvenile onset NCL is 
caused due to many mutations and polymorphisms in the CLN3 and CLN1 
genes (Palmer et al., 2013).  
Adult-onset NCL which is also known as Kufs and Parry disease has 
an autosomal recessive and an autosomal dominant form (Mimura et al., 
1992, Burneo et al., 2003, Ivan et al., 2005). Onset is usually in the fourth 
decade of life but earlier presentations have also been reported (Schulz et 
al., 2013). While autosomal recessive mutations in CLN3, CLN5, CLN6, 
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CLN10/CTSD CLN11/GRN, CLN13/CTSF and PPT1 genes have been 
observed in the Kufs variant forms of ANCL (Siintola et al., 2006a, Smith et 
al., 2013), the genetic and molecular basis of ANCL with dominant 
inheritance (Parry’s disease) was not known until recently. Using a 
combination of linkage analysis, copy-number analysis, gene-expression 
analysis, and exome sequencing, several independent groups have 
discovered that CLN4B, autosomal-dominant adult-onset NCL, is caused by 
mutations in the DNAJC5 gene encoding the cysteine-string protein alpha, 
(CSPα) (Benitez et al., 2011, Noskova et al., 2011, Velinov et al., 2012, 
Cadieux-Dion et al., 2013). CSPα is a neuroprotective presynaptic co-
chaperone with an essential physiological role in presynaptic proteostasis 
and the maintenance of exocytotic release of neurotransmitter, hormones 
and enzyme precursors. Numerous studies have also provided critical 
insights into the neuroprotective role of CSPα in NDs. CSPα has been linked 
to both HD and PD as it was shown to not only interact with mutant huntingtin 
in vitro (Miller et al., 2003), but also functionally overlap in vivo with α-
synuclein, for preventing neurodegeneration (Chandra et al., 2005). Deletion 
of CSPα in flies and mice impairs synaptic function and results in 
neurodegeneration, behavioural deficits and premature death (Zinsmaier et 
al., 1994, Fernandez-Chacon et al., 2004).  
1.1.3 Polyglutamine disorders 
Among the dynamic repeat expansion diseases, the diverse polyglutamine 
(polyQ) disorders represent the most common class of hereditary NDs, 
encompassing nine NDs: HD, spinobulbar muscular atrophy (SBMA), 
dentatorubral pallidoluysian atrophy (DRPLA) as well as SCA types 1, 2, 3, 6, 
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7 and 17 (Kakizuka, 1998, Kopito and Ron, 2000, Stefani and Dobson, 
2003). With the exception of SBMA, an X-linked recessive disease, all other 
polyQ disorders are autosomal dominantly inherited. Each of these disorders 
is caused by abnormal exonic trinucleotide cytosine–adenine–guanine (CAG) 
repeat expansions, within disease-causative genes in different chromosomes 
and exhibits ageing- and CAG tract length-dependent onset, selective 
neuronal vulnerability, and a progressive, usually fatal, clinical course. Each 
disorder has a characteristic pathological threshold polyQ length below which 
disease does not occur (Gusella and MacDonald, 2000, Zoghbi and Orr, 
2000). HD, the most common and a fully penetrant polyQ disease, is 
triggered by the expression of at least 36 CAG repeats located in exon 1 of 
the HTT gene, which encodes the large and multifunctional huntingtin protein 
(Htt). SCA1, an inherited cerebellar ataxia, arises as a result of at least 39 
CAG repeats present in exon 8 of the ATXN1 gene on chromosome 6p23, 
which codes for the ataxin-1 protein involved in RNA metabolism and 
transcriptional regulation, and SCA3 (also known as Machado-Joseph 
disease, MJD) is induced by a CAG expansion repeat of at least 60 or more 
in exon 10 of the ATXN3 gene (14q32.1) encoding the ataxin-3 protein with 
deubiquitinating activity (Fiszer and Krzyzosiak, 2013). A hallmark of polyQ-
expansion diseases is the intranuclear, intracellular and/or extracellular 
aggregation of expanded polyQ proteins which is a well-conserved 
pathological feature and has been the focus of extensive investigation 
(Stefani and Dobson, 2003). Studies from mouse models of polyQ diseases 
have demonstrated that the onset of apparent symptomatic impairment often 
precedes detectable neuropathology (Figiel et al., 2012). Common themes 
10 
 
that emerge from studies of pathogenesis and neuronal dysfunction in polyQ 
diseases include transcriptional dysregulation of intracellular Ca2+ 
homeostasis, impairment of the UPS, decreased axonal transport, alterations 
in levels of brain-derived neurotrophic factor (BDNF) and neuronal growth 
factor (NGF), RNA toxicity, altered intracellular trafficking, sequestration of 
critical cellular proteins in aggregates, aberrant caspase activation, altered 
energy metabolism, and synaptic and mitochondrial dysfunction (La Spada et 
al., 2011). PolyQ pathogenesis has been attributed to a gain of function due 
to the toxicity of the proteins carrying a polyQ expansion (Orr and Zoghbi, 
2007). However, the exact mechanisms underlying expanded polyQ toxicity, 
neuronal dysfunction, progression of symptoms, and, ultimately, neuronal 
death remain unclear. 
1.1.4 Parkinson’s disease  
PD belongs to the family of synucleopathies and is the second most common 
ND after AD (Lesage and Brice, 2009). Clinically, it is characterised by a 
progressive motor syndrome comprising bradykinesia, postural instability, 
rigidity, resting tremor which have been long attributed to the selective 
degeneration of nigral-striatal dopaminergic (DAergic) neurons, as well as 
non-motor features of cognitive decline, neuropsychiatric symptoms, sleep 
disturbance and autonomic dysfunction (Chaudhuri et al., 2006). 
Pathologically, PD is characterised by the loss of DAergic neurons in the 
substantia nigra pars compacta, and the presence of intraneuronal 
cytoplasmic inclusions called Lewy bodies in surviving neurons of affected 
brain regions, which are rich in α-synuclein. As with AD, the prevalence of 
PD increases with age and it is largely a late-onset sporadic 
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neurodegenerative condition (Gandhi and Wood, 2010). Rare and early-
onset familial PD, which accounts for 5-10% of all cases is usually 
monogenic in origin, and is caused by either autosomal-dominantly 
(SNCA/PARK1/4, UCHL1/PARK5, LRRK2/PARK8, PARK11, 
VPS35/PARK17, EIF4G1/PARK18) or autosomal-recessively 
(Parkin/PARK2, PINK/PARK6, DJ-1/PARK7, ATP13A2/PARK9, 
PLA2G6/PARK14, FBX07/PARK15) inherited mutations (Table 1.1) (Gandhi 
and Wood, 2010). These genetic mutations were shown to converge onto 
several main cellular pathways which are associated with mitochondrial 
metabolism, synaptic transmission (exocytosis and endocytosis), sorting and 
recycling of endosomal receptors, and autophagy–lysosomal pathways. A 
number of genes such as α-synuclein (SNCA/PARK1) and leucine-rich 
repeat kinase 2 (LRRK2/PARK8) which account for a substantial proportion 
of autosomal-dominant PD cases, have also provided insight into the 
sporadic forms of PD. Mutations in LRRK2 are the most frequent genetic 
cause of familial PD (Zimprich et al., 2004). Almost 80 LRRK2 gene variants 
have been reported worldwide, at least seven are proven pathogenic 
mutations and appear to cause PD pathogenesis by enhancing the kinase 
activity, inhibiting the GTPase activity, and altering the dimerisation, 
subcellular localisation or distinct protein interactions of LRRK2 (Gómez-
Suaga et al., 2014). These include: N1437H, R1441C/G/H, Y1699C, 
S1761R, G2019S, I2012T and I2020T (Cookson, 2010). Genomic 
multiplications (duplications, triplications) and missense mutations in the 
SNCA gene, including A53T, A30P, H50Q, G51D, E46K, though extremely 
rare in sporadic PD, are the second most common cause of dominantly 
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inherited PD. The SNCA gene product α-synuclein is abundantly expressed 
in the central nervous system and is the primary structural component of 
Lewy bodies. Recent work provided important evidence for a gain of function 
by α-synuclein to underlie PD pathophysiology and mechanisms leading to 
pathogenic function of α-synuclein may include formation of membranous 
pores that permeabilise cellular membranes (Martin et al., 2011), 
neuroinflammation, prion-like spreading, sequestration in Lewy bodies, and 
interplay between Tau, microtubule dysfunction and metal dyshomeostasis 
(Chege and McColl, 2014). 
However, incomplete penetrance of these mutations suggests 
additional genetic risk factors and interactions with the environment are 
crucial for developing disease. Indeed, recent genetic findings have identified 
rarer causes of familial PD or parkinsonism, which include mutations in: 
DNAJ genes (DNAJC6, DNAJC13), inflammation genes (HLA-DRA), 
glucocerebrosidas (GBA), GTP cyclohydrolase 1 (GCH1), membrane-
associated genes (GAK–DGKQ, RAB7L1, BST1), vacuolar protein sorting 35 
(VPS35) and eukaryotic translation initiation factor 4 gamma 1 (EIF4G1) 
(Trinh and Farrer, 2013). VPS35 is an essential component of the retromer 
cargo-recognition complex involved in endosomal-lysosomal trafficking. The 
identification of an aspartate to asparagine substitution (D620N) in VPS35 by 
multiple groups thus provides a compelling genetic link for retromer 
dysfunction in familial autosomal dominant and sporadic PD (Vilarino-Guell et 
al., 2011, Zimprich et al., 2011), and most recent work further suggested that 
perturbed endosome-to-trans-Golgi network (TGN) transport and impaired 
association with the actin-polymerising Wiskott-Aldrich syndrome and SCAR 
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homolog (WASH) complex caused by D620N mutation could contribute to PD 
aetiology (McGough et al., 2014).  
Furthermore, mutations in Parkin (PARK2), PINK1 (PARK6) and DJ1 
(PARK7) have been linked to autosomal recessive juvenile onset 
parkinsonism (Gandhi and Wood, 2010) and were shown to affect 
mitochondrial biogenesis and induction of autophagy. More rarely, 
recessively inherited forms of atypical parkinsonism are caused by mutations 
in the ATPase type 13A2 (ATP13A2), phospholipase A2, group VI (PLA2G6), 
pantothenate kinase (PANK2) and F-box only protein 7 (FBXO7) genes 
(Trinh and Farrer, 2013). Supporting the hypothesis that dysfunction of 
mitochondrial complex I, oxidative stress and compromised energy level of 
DAergic neurons are implicated in the pathogenesis of PD, exposing worms, 
rodents or primates to compounds which inhibit mitochondrial complex I 
activity and induce oxidative stress, such as methyl 4-phenyl 1,2,3,6-
tetrahydropyridine (MPTP), paraquat, and rotenone, caused selective 
DAergic neuronal loss, neuronal dysfunction as well as protein accumulations 
immunopositive for α-synuclein (Hisahara and Shimohama, 2010). Taken 
together, these discoveries have highlighted the importance of the UPS, 
mitochondrial metabolism, oxidative stress, synaptic transmission, 
endosomal trafficking and autophagy–lysosomal pathways in PD 
pathogenesis. Other genes, such as ubiquitin UCHL1/PARK5, probable 
nuclear receptor NR4A2/NURR1 and serine protease HTRA2/OMI, have also 
been associated with PD, although their roles remain unclear (Gandhi and 
Wood, 2010). 
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Disease name Human gene Function C. elegans gene 
AD GENES 
EOFAD 
APP 
Neuronal development and 
synaptic formation and repair 
apl-1 
PSEN1/2 
Gamma-secretase activity 
sel-12, hop-1 and 
spe-4 
APH1/2 
aph-1, pen-2 and 
aph-2 
AD, FTD MAPT Microtubule stabilisation ptl-1 
LOAD APOE (ϵ4-allele) Lipid/cholesterol metabolism – 
ALS GENES 
Familial and sporadic 
ALS with or without 
FTD 
SOD1 Superoxide metabolism sod-1 
TARDBP RNA metabolism tdp-1 
FUS RNA metabolism fust-1 
OPTN Vesicular transport – 
VCP Vesicular transport cdc-48.1/2 
UBQLN2 Proteasome ubqnl-1 
C9ORF72 
regulate endosomal trafficking 
and autophagy in neuronal 
cells 
alfa-1 
SQSTM1 Autophagy sqst-2 
PFN1 Cytoskeleton dynamics pfn-1 
Rare causes of ALS 
or ALS-like 
syndromes 
DCTN1 Cytoskeleton dynamics dnc-1 
ALS2 Endocytosis 
– 
Familial and sporadic 
ALS with or without 
FTD 
CHMP2B Vesicular transport 
FIG4 Vesicular transport C34B7.2 
HNRNPA2B1 RNA metabolism hrp-1 
Sporadic ALS ELP3 – 
– 
Juvenile ALS SETX RNA processing 
Typical ALS HNRNPA1 RNA processing hrp-1 
Sporadic ALS ATXN2 – atx-2 
Familial and sporadic 
ALS 
ANG Blood vessels formation 
– 
Juvenile ALS SPG11 DNA damage 
Typical and atypical 
ALS 
VAPB Vesicular transport vpr-1 
NEFH Cytoskeleton dynamics H39E23.3 
Familial ALS ARHGEF28 RNA metabolism rhgf-1 
NCL GENES 
Infantile NCL CLN1/PPT1 
Palmitoyl-protein thioesterase 
1 precursor 
F44C4.5/ppt-1 
Congenital ovine 
NCL 
CLN10/CTSD Cathepsin D precursor R12H7.2b/asp-4 
Late infantile NCL 
CLN2/TPP1 
Tripeptidyl-peptidase 1 
precursor – 
CLN5, CLN6, CLN8 
– 
Juvenile NCL CLN3 
F07B10.1/cln-3.1 
C01G8.2/cln-3.2 
ZC190.1/cln-3.3 
Adult-onset NCL CLN4/DNAJC5 
neuroprotective presynaptic 
co-chaperone 
dnj-14 
PD GENES 
EOPD PARK1/PARK4/SNCA Neurotransmitter release – 
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Disease name Human gene Function C. elegans gene 
PARK2/Parkin 
Target proteins for 
degradation, maintenance 
mitochondrial function 
pdr-1 
Classical PD 
PARK3 
– 
– 
PARK5/UCHL1 ubh-1 
EOPD 
PARK6/PINK1 
Oxidative stress response, 
maintenance mitochondrial 
function 
pink-1 
PARK7/DJ-1 Redox sensor, antioxidant djr-1.1, djr-1.2 
Classical PD PARK8/LRRK2 Mixed lineage kinase lrk-1 
Atypical PD with 
dementia, spasticity, 
and supranuclear 
gaze palsy 
PARK9/ATP13A2 
– 
capt-6 
Classical PD PARK10 
– 
Late-onset PD PARK11 
Classical PD 
PARK12 
PARK13/HTRA2 Mitochondrial serine protease 
Early-onset dystonia-
parkinsonism 
PARK14/PLA2G6 
– 
Early-onset 
parkinsonian-
pyramidal syndrome 
PARK15/FBX07 
Classical PD 
PARK16 
PARK17/VPS35 
Autophagy; endosome-to-
Golgi retrieval 
vps-35 
PARK18/EIF4G1 – – 
Late-onset PD GBA Lysosome F11E6.1, TO4A8.7 
POLYQ GENES 
HD HTT 
Transcriptial repressor, 
membrane trafficking, 
endocytosis 
– 
SBMA AR 
Nuclear receptor, androgen 
response 
DRPLA ATN1 
Nuclear receptor corepressor, 
transcriptional corepressor 
SCA1 ATXN1 
RNA processing, transcription 
factor, transcriptional 
corepressor, general 
repressor of transcription 
K04F10.1 
SCA2 and ALS ATXN2 RNA binding protein. D2045.1/atx-2 
SCA3, MJD ATXN3 
Transcription factor, 
transcriptional coactivator, 
transcriptional repressor, 
histone H2B deubiquitinase 
atx-3 
SCA6 CACNA1 A 
Voltage-gated calcium 
channel, transcription factor 
– SCA7 ATXN7 
Integral member of SAGA 
complex, regulation of histone 
acetylation and ubiquitination 
SCA17 ATXN17 
General transcription factor, 
member of TFIID complex 
SMA GENES 
 
SMA SMN1/2 
spliceosomal snRNP 
assembly and in pre-mRNA 
splicing 
smn-1 
Table 1.1: Known human neurodegenerative disease (ND) associated-genes and their C. 
elegans orthologues. Human NDs: AD, Alzheimer's disease; ALS, Amyotrophic lateral sclerosis; 
DRPLA, dentatorubral pallidoluysian atrophy; EOFAD, early-onset familial Alzheimer's disease; EOPD, 
early-onset Parkinson’s disease; FTD, Frontotemporal dementia; HD, Huntington’s disease; LOAD, 
late-onset Alzheimer's disease; MJD, Machado–Joseph disease; NCL, neuronal ceroid lipofuscinosis; 
PD, Parkinson’s disease; SBMA, spinobulbar muscular atrophy; SCA, spinocerebellar ataxias; SMA, 
Spinal muscular atrophy. 
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1.1.5 Amyotrophic lateral sclerosis 
ALS, also known as Lou Gehrig’s disease, is the most common late-onset 
motor neuron disease characterised by the progressive degeneration of 
upper (cortical) and lower motor neurons (spinal cord), the loss of myelin in 
the spinal cord, the presence of neuroinflammation, muscle dysfunction, and 
eventually paralysis (Pasinelli and Brown, 2006). The vast majority (90-95%) 
of ALS cases are sporadic (Boillée et al., 2006), however, a small percentage 
is familial in origin, exhibiting an autosomal dominant mode of inheritance. 
Mutations in the copper/zinc superoxide dismutase (SOD1) gene (Rosen et 
al., 1993) has been identified as the most common source of familial ALS 
causing approximately 20% of cases (Barber and Shaw, 2010). As a result, 
the majority of ALS research has focused on the role of SOD1 mutations in 
disease pathogenesis. The widely expressed homodimeric, cytosolic 
enzyme, SOD1 catalyses the conversion of unstable superoxide radicals 
(•O2
-) to oxygen (O2) and hydrogen peroxide (H2O2), providing an important 
antioxidant defence. Since overexpression of mutant human SOD1 in mice 
causes a motor neuropathy similar to ALS, whereas knockout of endogenous 
murine SOD1 has no such effect, it was hypothesised that SOD1 mutations 
resulting in familial ALS are due to a toxic gain of function. The proposed 
mechanisms of SOD1 toxicity include mitochondrial dysfunction, axonal 
dysfunction, excitotoxicity and neuroinflammation (Chen et al., 2013). 
In recent years, key developments have revealed a novel ND 
spectrum with ALS overlapping clinically and pathologically with other 
neurodegenerative conditions including FTD. Identification of additional 
genes predisposing for familial ALS and/or ALS-FTLD including 
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transactivating response element DNA binding protein-43 (TDP-43) 
(Sreedharan et al., 2008), Fused-in-sarcoma (FUS) (Dormann et al., 2010), 
C9ORF72, vesicle-associated membrane protein (VAMP)/synaptobrevin-
associated membrane protein B (VAPB/ALS8), Ataxin 2 (ATAX2), Ubiquitin-
like protein ubiquilin2 (UBQLN2), Optineurin (OPTN), D-amino acid oxidase 
(DAO), Amyotrophic lateral sclerosis 2 (ALS2), Valosin-containing protein 
(VCP), MAPT, Dynactin 1 (DCTN1), Angiogenin and Senataxin (SETX) have 
facilitated better understanding of ALS pathogenesis (Gros-Louis et al., 2006, 
Hardiman, 2011). The common molecular pathways associated with these 
different ALS related genes mainly involve intracellular trafficking (axonal 
transport, vesicle docking and transport, microtubule and neurofilament 
stabilisation) and RNA metabolism (alternative splicing abnormalities, RNA 
binding) (Chen et al., 2013). Attention has been devoted specifically to the 
ubiquitously expressed DNA/RNA binding protein (TDP-43), which is 
implicated in repression of gene transcription, alternative exon splicing and 
mRNA stability (Fiesel et al., 2012). It has been increasingly associated with 
multiple NDs, primarily in the pathogenesis of ALS with cognitive impairments 
spectrum of diseases because of consistent deposition of ubiquitinated TDP-
43 inclusions in these diseases. Dominant mutations in the TARDBP gene, 
encoding TDP-43, were repeatedly reported as a primary cause of ALS in 
about 3% of familial cases and 1.5% of sporadic cases (Swarup et al., 2011). 
In 2011, two groups (DeJesus-Hernandez et al., 2011, Renton et al., 
2011) simultaneously and independently reported that a heterozygous 
expanded hexanucleotide repeat (GGGGCC) located in the first intron or 
promoter region of the C9ORF72 gene is a major contributing factor to the 
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chromosome 9p21-linked diseases ALS and FTD. This initial discovery was 
quickly followed by further research on independent cohorts of patients from 
all over the world to uncover potential disease mechanisms and C9ORF72 
mutations are increasingly associated with other human NDs such as AD and 
PD with a broad phenotypic spectrum. Accumulating evidence strongly 
implicates both a loss-of-function disease mechanism due to decreased level 
of C9ORF72 transcript and a toxic RNA gain-of-function mechanism in the 
pathogenesis of C9ORF72-related diseases. Repeat expansion may 
generate insoluble and toxic dipeptide repeat (DPR) proteins through repeat-
associated non-ATG (RAN) translation (Ash et al., 2013), and formation of G-
quadruplex by GGGGCC-repeating RNA and DNA was also shown to cause 
abortive transcription which in turn affects efficient C9ORF72 protein 
production (Haeusler et al., 2014). Despite the observation that the 
hexanucleotide repeat expansion is the most common genetic abnormality of 
sporadic and familial ALS and FTD in European countries, accounting for 
60% of familial ALS/FTD, up to 21.0% of sporadic ALS and 7–10% sporadic 
FTD, the pathogenic repeat expansion was rarely present in patients from 
Asian countries, such as Korea, China and Japan (Liu et al., 2014).  
1.1.6 Spinal muscular atrophy  
Spinal muscular atrophy (SMA) is an autosomal recessive neuromuscular 
disease caused by the homozygous deletion, rearrangement, or mutation of 
the ubiquitously expressed telomeric Survival Motor Neuron gene SMN1, 
which predominantly produces a full-length functional SMN protein, coupled 
with the inability of centromeric homologue SMN2 which only produces low 
levels of functional full-length SMN to compensate for the loss of SMN1, 
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resulting in a deficiency of the SMN protein. The multifunctional SMN has an 
essential housekeeping role in all cells to facilitate small nucleolar 
ribonucleoprotein (snRNP) biogenesis, pre-mRNA splicing, transcription, 
translation, signal transduction, stress granule formation, intra-cellular 
trafficking, axonal transport and postnatal muscle nerve terminal maturation 
(Seo et al., 2013). SMA remains one of the most frequent genetic causes of 
infant mortality. Degeneration and loss of anterior horn lower motor neurons 
in the spinal cord and cranial nerve nuclei, the classic hallmark of SMA, leads 
to progressive denervation of skeletal and intercostal muscles, proximal 
muscle weakness, with subsequent atrophy of the corresponding muscles, 
paralysis and premature death in more severe cases due to respiratory 
failure (Crawford and Pardo, 1996). Based on the age of onset and the level 
of motor function, SMA has been classified as four clinical types ranging from 
congenital forms to asymptomatic cases. Although SMN1 is the pathogenic 
gene for SMA, SMN2 also participates in the pathogenesis of SMA as a 
critical mutation in SMN2 was shown to cause aberrant splicing of the 
majority of transcripts, leading to the production of a truncated and rapidly 
degraded protein (SMNΔ7) (Mitrpant et al., 2013). Furthermore, the copy 
number of SMN2 modifies and correlates with the clinical severity of SMA 
and therefore can be potentially targeted for therapy. Despite intense 
research and increased knowledge of the cellular roles of SMN, the specific 
molecular pathways involved in SMA pathogenesis are still largely unknown, 
and there is currently no curative therapy available for SMA (Ling et al., 
2012). Preclinical research to elucidate key pathogenic events and identify 
promising treatments for SMA has relied heavily upon murine models. 
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Recent work has suggested that SMA is a multi-system disorder, affecting a 
range of cells and tissues (liver, lung, bones, blood vessels, heart, 
gastrointestinal, pancreas) other than neuromuscular system (Hamilton and 
Gillingwater, 2013). Genetic and pharmacological modifiers capable of 
correcting aberrant splicing and stabilising mRNA, SMN and SMNΔ7, and/or 
increasing the abundance specific activity of SMN have also been proposed 
as promising therapeutic targets (Seo et al., 2013).  
 
1.2 ATTRIBUTES OF CAENORHABDITIS ELEGANS AS A 
MODEL FOR HUMAN NEURODEGENERATIVE DISEASE 
The inherent intricacies and neurological complexity of the human brain have 
hampered faster advances in understanding the molecular mechanisms 
behind NDs. Much of our current understanding of the molecular basis and 
the pathophysiology of NDs is offered by the studies in cultured cells and 
diverse animal models such as yeast (Saccharomyces cerevisiae), worm 
(Caenorhabditis elegans), fly (Drosophila melanogaster) and mouse (Mus 
muluscus) which have been constructed over the years to try to mimic the 
pathogenesis of NDs. None have been totally successful as the models 
available so far do not reproduce the full constellation of changes that 
compose the characteristic neuropathological phenotype seen in human 
NDs, due to the unique complexities of the human brain. While studies on 
unicellular models such as yeast or bacteria, as well as immortalised cell 
lines, primary neuronal cultures have been carried out (Hall and Yao, 2005, 
Falkenburger and Schulz, 2006, Winderickx et al., 2008), these systems lack 
intercellular physiological pathways (e.g., neurotransmitter circuitry). In 
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contrast, vertebrate disease models offer in vivo opportunities and extensive 
similarity to the human brain. However, testing the therapeutic value of small 
molecules in mice and other mammalian model systems are expensive and 
require time-consuming experimental designs which can be prohibitive. 
Recent interests have turned to invertebrate models which bridge the gap 
between the simplicity of in vitro studies and the complexity of the human 
brain, and they allow for a more high-throughput and mechanistic approach. 
C. elegans, in particular, is a powerful model as it lacks many of the 
complexities of mammalian systems but retains the advantages of an intact 
organism. It excels in its simplicity, ability to reproduce asexually, fully 
sequenced genome, short generation time (≈ 3 days) and lifespan (≈ 3 
weeks), considerable reproductive capacity (250-300 offspring), economy of 
testing susceptibility to RNA interference (RNAi), ability to self or cross-
fertilise, distinctive behavioural and neuropathological defects, coupled with a 
surprisingly high degree of biochemical conservation.  
Such experimental malleability is particularly advantageous, as C. 
elegans nervous system maturation and subsequent progressive stages of 
neuronal degeneration occur over a matter of days and can be assessed in 
large isogenic populations. The transparency of worms also facilitates the 
visualisation of any desired neurons and fluorescently-tagged proteins and 
assessment of the impact of pathogenic proteins within an intact animal in 
both temporal- and tissue-specific fashions. Recently, optogenetic techniques 
have been adapted to C. elegans, such that the neuronal activity can be 
measured by monitoring calcium levels and neurons can be activated by blue 
light stimulation of channelrhodopsin (Husson et al., 2013). The cell lineage 
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and location of each of the 959 somatic cells which constitute this organism, 
including the morphology and the complete wiring diagram of the physical 
and chemical connections between C. elegans’ 302 neurons (White et al., 
1976, White et al., 1986, Hall and Russell, 1991), have been fully 
determined, thereby allowing the dissection of simple and complex 
behaviours at the level of individual cells and genes (Hobert et al., 2002). 
Together, the 302 neurons make approximately 5000 chemical synapses, 
600 gap junctions, and 2000 neuromuscular junctions (White et al., 1986), 
thus conferring unparalleled precision and control in the identification and 
manipulation of neuronal cells (Pouya et al., 2011). Extensive 
characterisations of whole C. elegans genome have also revealed 
remarkable homology with the human genome and physiology, with about 
70% of human disease-related genes having a clear C. elegans homologue 
(Kuwabara and O'Neil, 2001), including many that have been implicated in 
NDs (Table 1.1). Remarkable similarities exist at the molecular and cellular 
levels between nematodes and vertebrates neurons. For example, ion 
channels, receptors, classic neurotransmitters [acetylcholine, glutamate, γ-
aminobutyric acid (GABA), serotonin, and dopamine (DA)] and vesicular 
transporters are similar in both structure and function between vertebrate and 
C. elegans (Hardaway et al., 2012). Physiological processes and signalling 
pathways such as formation, trafficking, and release of synaptic vesicles, and 
regulation of nervous system development by common guidance and polarity 
cues i.e. Netrin, Slt, Wnt, and Par protein complexes (Cáceres et al., 2012) 
are also highly conserved  between the nematode and vertebrates. In 
addition, C. elegans lacks a vascular system which enables the studying of 
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neuronal damage independently of vascular damage (Duan and Sesti, 2013). 
C. elegans also mainly encodes a single functional orthologue of the 
corresponding human gene, thus bypassing the complications of extensive 
functional redundancy observed among many mammalian proteins to model 
and shed important light on the specific biological functions of any gene of 
interest.  
Despite its relative neuronal simplicity, C. elegans has different 
neuronal classes that constitute its rudimentary nervous system, including 
interneurons, chemosensory, mechanosensory, and thermosensory types; 75 
motor neurons innervate the body wall muscles (excluding the head); 56 of 
these are cholinergic and 19 are GABAergic (Teschendorf and Link, 2009). 
These neurons enable C. elegans to exhibit a repertoire of simple and well-
characterised behaviours which can be experimentally assessed to study 
specific neuronal dysfunction and degeneration (Figure 1.1), as certain NDs 
confer differential vulnerability of specific neuronal populations which lead to 
distinct clinical phenotypes expression; and when combined with biophysical 
assays can also facilitate the examination of protein solubility in neurons of 
interest (Teixeira-Castro et al., 2011). Much debate has surrounded the 
mechanisms underlying age-dependent motor activity decline in C. elegans. 
Initial detailed examination of representative sensory and motor neurons 
have previously demonstrated that during neuronal ageing, there is little, if 
any, neuronal cell death and no signs of any neuronal degeneration despite 
advanced age and extensive behavioural decline. Instead, C. elegans 
senescence was attributed to widespread deterioration of surrounding 
somatic tissues which parallels sarcopenia in vertebrates (Herndon et al., 
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2002). Recent reports have described progressive morphological changes in 
C. elegans neurons such as aberrant outgrowths and beading along neuron 
processes and age associated synaptic deterioration (Tank et al., 2011, Toth 
et al., 2012). Further functional analysis of the aging nervous system and 
muscles revealed that motor neurons, not body-wall muscles exhibit 
progressive functional deterioration, beginning in early life. Lifespan-
extending mutations and pharmacological stimulation of synaptic 
transmission in the aging nervous system was also shown to slow down the 
rate of functional aging and potentiate locomotion activity in aged worms (Liu 
et al., 2013). In light of these observations, it is clear that the impact of 
different challenges i.e. genetic perturbations or exposure to drugs and 
various external stimuli on the survival and function of defined neuronal 
populations in C. elegans nervous system can be readily studied. For 
example, inhibitory GABAergic and excitatory cholinergic motor functions can 
be assessed by quantifying the motility (amplitude and frequency of body 
bends on solid surface or in liquid) and foraging behaviour of the worm, 
respectively. Behaviours such as reduced motility is a typical characteristic of 
neuromuscular disease and have already been automated to allow for higher 
throughput analysis (Helmcke et al., 2010). Motor, mechanosensory, 
chemosensory, DAergic and serotoninergic functions can be evaluated by 
measuring the pharyngeal pumping rate and behavioural changes in 
response to mechanical, osmotic, and chemical stimuli. In addition, the ability 
to generate primary C. elegans neuronal cultures can also expedite the 
functional analysis of neuron subtypes and allow direct assessment of their  
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Figure 1.1: C. elegans nervous system marked by enhanced green fluorescent protein (EGFP) 
expression (driven by rab-3 promoter) in all worm neurons. Scale bar, 100 μm 
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responses to toxic insults. For all these reasons, C. elegans is a powerful 
model that can translate findings from basic behavioural and cognitive 
neuroscience into an improved understanding of NDs in humans, and to 
assist in expediting translational drug research and clinical testing for the 
development of new therapeutic interventions against NDs (Leung et al., 
2008).  
 
1.3 OVERVIEW OF C. ELEGANS NEURODEGENERATIVE 
DISEASE MODELS  
C. elegans is frequently among the first animal models generated for newly 
identified ND genes and is useful for rapidly addressing mechanistic 
questions and testing therapeutic options. A large number of C. elegans 
models for ND have been developed by knocking-out, knocking-down and 
over-expression of many human ND-associated proteins (plus and minus 
mutations) or the equivalent worm orthologues. Appendix Table A1 displays 
a summary table illustrating the available human ND models of C. elegans. 
Strong parallels were especially observed in the genotype-to-phenotype 
correlations between the human NDs and the phenotypes of transgenic C. 
elegans ND models, which therefore support the validity of the approach as 
expression of mutant human proteins in C. elegans can closely model a 
fundamental property of these mutations in humans.  
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1.3.1 Modeling the pathophysiology of Alzheimer’s disease  
 
1.3.1.1 Aβ and presenilin 
Investigation of mechanisms underpinning AD has been facilitated by the 
development of both mutant and transgenic C. elegans AD models of Aβ 
toxicity. The C. elegans genome encodes genes in which mutations are 
correlated with AD (Table 1.1). These include: an APP-related gene, apl-1, 
which encodes APL-1 (amyloid precursor-like protein) that lacks the Aβ 
peptide; a Tau orthologue (ptl-1), three presenilin orthologues (sel-12, hop-1 
and spe-4) and three genes whose product proteins combine to form the 
canonical functional γ-secretase complex (aph-1, pen-2 and aph-2). 
However, C. elegans does not appear to encode a β-secretase orthologue, 
and therefore lacks BACE1-like activity which is required to generate Aβ from 
its precursor, APP. Nevertheless, characterisations of these C. elegans 
orthologues via AD-related gene deletions or RNAi knockdown have provided 
significant functional insights into the role and regulation of the mammalian 
counterparts (Dimitriadi and Hart, 2010, Ewald and Li, 2012).  
The inability of C. elegans to generate Aβ has been circumvented by 
Christopher Link who pioneered the modeling of β-amyloidosis in nematodes 
by expressing the human Aβ gene in the worm muscle cells (Link, 1995). To 
date, Link and colleagues have generated multiple convincing C. elegans Aβ 
peptide models, amongst which the constitutive (unc-54) and inducible Aβ 
muscle-specific expression (myo-3) have been used extensively for 
mechanistic studies of Aβ toxicity (Link, 1995, Link et al., 2003, Wu et al., 
2006) due to their significant methodological advantages (ease of phenotypic 
scoring and sensitivity of muscle cells to RNAi) (Dimitriadi and Hart, 2010). 
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The constitutive Aβ model displayed an age-dependent paralysis phenotype 
and intramuscular Aβ accumulations that co-localised with amyloid specific 
dyes (thioflavin S and Congo Red) (Link, 1995, Fay et al., 1998, Link et al., 
2001). Subsequent models were engineered to inducibly express Aβ upon 
temperature upshift, either in muscle (Link et al., 2003) or pan-neuronally 
(Dosanjh et al., 2010), with distinct differences in the severity of phenotypes. 
While a fully penetrant paralysis phenotype independent of amyloid 
deposition was obtained in worms with inducible Aβ muscle expression (Link, 
2006), inducible, pan-neuronal expression of the Aβ resulted in intraneuronal 
deposition of Aβ along with relatively mild dysfunctions in chemotaxis to 
benzaldehyde, serotonergic transmission, associative learning and 
experience-dependent learning, and no overt locomotion defects were found 
(Link, 2006, Wu et al., 2006, Dosanjh et al., 2010). This temperature 
inducibility was engineered following introduction of temperature-inducible Aβ 
transcript into worms harbouring a temperature-sensitive mutation in a gene 
essential for mRNA surveillance (smg-1). Upshifting temperature from the 
permissive (16°C) to non-permissive/restrictive (23°C) conditions induces Aβ 
production by inactivating the nonsense-mediated decay pathway, which 
result in stabilisation of the Aβ1-42 mRNA and substantial translation of 
transgenic transcripts (~5-fold increase). Recently developed transgenic Aβ 
models include a novel model that expresses Aβ in the secretory pathway of 
glutamatergic neurons (a neuronal subtype particularly susceptible to AD) 
using the eat-4 promoter (Treusch et al., 2011). While this transgenic strain 
was not reported to have any gross visible phenotypes, visualisation of the 
glutamatergic neurons with a Peat-4::GFP construct demonstrated that Aβ 
29 
 
expression led to an age-dependent glutamatergic neurodegeneration. 
Furthermore, following demonstration that the existing C. elegans Aβ models 
are in fact predominately expressing amino-truncated Aβ3-42 instead of the 
more disease relevant form, Aβ1-42, McColl et al. (McColl et al., 2012) 
generated a new transgenic model of C. elegans that expresses and 
accumulates full-length human-Aβ1-42 peptide which aggregates and results 
in more severe and fully penetrant age progressive-paralysis. 
1.3.1.2 Tau  
Intraneuronal accumulation of NFTs composed of the microtubule binding 
protein Tau in cell bodies is the second hallmark of AD and other NDs, such 
as Pick’s disease, Down’s syndrome, and FTDP-17. Protein with Tau-like 
repeats (PTL-1) is the sole C. elegans orthologue of members of the 
mammalian MAPT(Tau)/MAP2/MAP4 family and regulates both organismal 
and neuronal ageing in a cell-autonomous manner (Goedert, 1996, 
McDermott et al., 1996, Chew et al., 2014). Like the case of apl-1 in AD, ptl-1 
loss-of-function does not appear to recapitulate the human Tau pathology, 
since mutations in ptl-1 resulted in only touch insensitivity, premature touch 
neuron aging and shortened life span (Chew et al., 2013). Various transgenic 
Tau models expressing human Tau have therefore been generated. Despite 
using different isoforms of human MAPT and FTDP-17 mutations, these 
models yielded complementary findings in regards to the effects of neuronal 
Tau expression (Kraemer et al., 2003, Miyasaka et al., 2005, Brandt et al., 
2009). While Kraemer et al. (Kraemer et al., 2003) employed the aex-3 
promoter to drive pan-neuronal expression of the most abundant human 
brain Tau isoform (1N4R) and FTDP-17- mutant Tau sequences (V337M and 
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P301L), Miyasaka et al. (Miyasaka et al., 2005) drove expression of human 
wild-type adult Tau isoforms (0N4R and 0N3R) and FTLD-17-mutant Tau 
(P301L and R406W) in the mechanosensory neurons using the mec-7 
promoter. In another model, Brandt et al. overexpressed wild-type, 
pseudohyperphosphorylated (PHP) and phosphorylation-resistant human 
fetal Tau pan-neuronally under the rgef-1 promoter (Brandt et al., 2009). All 
these transgenic mutant Tau lines exhibited robust phenotypes and clear 
biochemical changes that recapitulate key observations of the human 
disease, including severe locomotion impairments, abnormal neuronal 
morphology, decreased neurotransmission, accumulation of insoluble, 
phosphorylated Tau, axonal degeneration, age-dependent neuronal 
degeneration and loss. 
More recently, Fatouros et al. (Fatouros et al., 2012) and Di Domenico 
et al. (Di Domenico et al., 2012) utilised the V337M mutant Tau expressing 
lines to generate new models for further elucidation. Rather than comparing 
phenotypes of transgenic versus non-transgenic animals, as was done in 
previous C. elegans Tau studies, Fatouros et al. established and compared a 
new Tau model co-expressing either pro-aggregant mutated form of human 
Tau (deletion of K280) or anti-aggregant mutated forms of human Tau (I277P 
and I308P) from a rab-3 pan-neuronal promoter, along with full length human 
Tau V337M. This resulted in pronounced phenotypic differences with pro-
aggregant transgenic line exhibiting high levels of Tau aggregation that in 
turn caused uncoordinated movement in adults, axonal defects, and 
alterations in presynaptic structure, while anti-aggregant transgenic lines had 
low levels of Tau aggregates and displayed only mild phenotypes with 
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significantly less morphological abnormalities. Di Domenico et al. co-
expressed human wild-type and mutated PD gene LRRK2 with Tau V337M 
to elucidate possible contributions of mutated LRRK2 in Tau-dependent 
neurodegenerative processes since mutations in the MAPT have been 
shown to be associated with FTD and parkinsonism (Hutton et al., 1998) and 
new studies have demonstrated possible pathophysiological interplay 
between LRRK2 and Tau or α-synuclein (Di Domenico et al., 2012, 
McCormick et al., 2013). 
1.3.2 C. elegans models of neuronal ceroid lipofuscinosis 
Interest in NCLs has led to the development of models in diverse organisms. 
Like the other NDs, NCL research could benefit from work on the worm 
homologues of human defective NCL genes. Studies have shown that C. 
elegans has orthologues of genes involved in the congenital, infantile, 
juvenile and adult-onset forms of NCL (Table 1.1) (de Voer et al., 2008).  
Worm aspartyl protease gene asp-4 is the orthologue of the human 
cathepsin D-encoding CTSD/CLN10 gene that is mutated in the congenital 
NCL. Though no worm strains carrying deleterious asp-4 mutations are 
available, RNAi knockdown experiments have suggested that asp-4 mediates 
neuronal necrosis and is required for neurodegeneration (Syntichaki et al., 
2002). 
Orthologues of the PPT1/CLN1 and CLN3 genes involved in the 
infantile and the juvenile forms of NCL, respectively, have been identified in 
C. elegans. As mentioned above, mutations in PPT1 was shown to cause the 
infantile NCL and to date a disproportionate amount of research has been 
conducted on the function of PPT1. Two different C. elegans ppt-1 mutant 
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strains were isolated. However, studies have shown that the phenotypes of 
both ppt-1 deletion mutants are too mild to be used in genetic modifier 
screens. The ppt-1 mutants do not exhibit neuronal degeneration or 
accumulation of storage material that are characteristics of infantile NCL. 
Moreover, despite observations of delayed egg laying, decreased health 
span and mild mitochondrial defect, most ppt-1 mutants displayed no 
morphological, locomotion or neuronal defects (Porter et al., 2005). 
In contrast to other model organisms, C. elegans has three CLN3 
orthologues, designated cln-3.1, cln-3.2, and cln-3.3. Single mutant worm 
juvenile NCL models were generated by knocking out cln-3.1, cln-3.2, or cln-
3.3. Due to redundancy, all three single mutant models were phenotypically 
wild-type with only slightly reduced brood-size and lifespan observed. A cln-3 
triple mutant model was also generated and its behaviour and integrity of the 
nervous system were subsequently explored. However, no functional 
aberrations or morphological defects were detected, thus indicating that the 
cln-3 genes are not essential (de Voer et al., 2008, Bond et al., 2013). 
Our lab has recently conducted research on a new and potentially 
useful C. elegans model of the adult-onset NCL to analyse the function of the 
worm DNAJC5 homologue. In C. elegans, the dnj-14 gene is the sole 
orthologue of human CSP, the product of DNAJC5, and two mutant alleles of 
dnj-14, ok237 and tm3223 were isolated and phenotypically characterised. 
Both mutant strains were shown to be phenotypically similar to CSP knockout 
mice, and to some extent, CSP knockout Drosophila, as they exhibited 
increased mortality, age-dependent locomotion, neurotransmission and 
chemosensory neuron defects, with the latter phenotype manifested later as 
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neurodegeneration in the sensory cilia (Kashyap et al., 2014). This model 
provided insight into the conservation of CSP function as dnj-14, was shown 
to be a key neuroprotective gene like its mammalian homologue, and its 
potential for future chemical genetic screening was also demonstrated 
following identification of pharmacological suppressors that ameliorated dnj-
14 lifespan and neuronal defects, which will be discussed in details below.  
1.3.3 C. elegans models of polyglutamine repeat diseases 
Although C. elegans does not possess an Htt orthologue, diverse transgenic 
models where varying numbers of polyQ tracts are expressed in different 
sets of neurons, muscle cells and even intestine cells have been widely used 
to model several aspects of polyQ neurotoxicity to address the mechanisms 
underlying the impact of aggregation prone proteins on cellular function and 
to identify novel disease modifiers. The progressive nature of polyQ-
mediated toxicity, protein aggregation and general severity of phenotype 
demonstrated in these models is age and polyQ tract length dependent, 
recapitulating critical aspects models of polyglutamine expansion diseases 
have made significant contributions to the field. 
Initial studies using C. elegans to investigate polyQ pathogenesis have 
limited the expression of polyQ to small subsets of neurons. The first C. 
elegans model of polyQ-mediated neurotoxicity was established by 
expressing an N-terminal 171 residue fragment of huntingtin with 150 CAG 
repeats (Htt171-Q150) (Faber et al., 1999) in the non-essential bilateral pair 
of chemosensory neurons (ASH, ASI, PHA, and PHB) using the osm-10 
promoter. Htt-Q150 expression was found to induce age-dependent sensory 
process degeneration (demonstrated by a defective uptake of lipophilic 
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fluorescent dyes via the endings of chemosensory neurons), formation of Htt-
positive cytoplasmic aggregates, perturbed function of the neurons 
(demonstrated by the defective sensory response to touch which is mediated 
by ASH sensory neurons) and eventual death of chemosensory neurons. In a 
similar neuronal HD model (Parker et al., 2001), Htt57-Q128 fused to GFP 
constructs were expressed in ALM and PLM mechanosensory neurons of the 
body using the mec-3 promoter. Expanded polyQ tracts caused increased 
touch receptor dysfunction and axonal perturbations, without 
neurodegeneration (Parker et al., 2001). Behavioural and biophysical 
analyses of a pan-neuronal C. elegans polyQ model that broadly expresses 
expanded polyQ fragments in different subsets of neurons under the rgef-1 
promoter revealed polyQ length-dependent aggregation, neurotoxicity, and a 
dynamic pathogenic threshold at a length of 35-40 glutamines (Brignull et al., 
2006a).  
In addition to above mentioned neuronal models, the Morimoto lab 
sought to delineate mechanisms underlying polyQ aggregation and toxicity 
through generations of the muscle-specific models (Satyal et al., 2000) that 
express fluorescent proteins bearing varying numbers of polyQ tracts in 
pharyngeal and body wall muscles (Nass and Hamza, 2001, Nass et al., 
2005) using the myo-3 and unc-54 promoters, respectively. The resultant 
phenotypes were reminiscent of human disease progression. They also 
explored the effects of polyQ on cellular capacity for protein folding via 
simultaneous expression of temperature-sensitive (ts) protein mutants and 
polyQ transgenes. Furthermore, separate in vivo models also used the 
muscle-specific unc-54 promoter to drive either 17 amino acid residues 
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derived from the DRPLA protein (DRPLAP) (Yamanaka et al., 2004) or 
huntingtin exon 1 (Wang et al., 2006) and these models confirmed that 
protein folding is critical in the toxicity of expanded polyQ fragments.  
Despite encoding orthologues for most SCA caused by polyQ 
expansions, C. elegans models have only been generated and characterised 
for SCA2 and SCA3 (Kiehl et al., 2000, Ciosk et al., 2004, Rodrigues et al., 
2011, Teixeira-Castro et al., 2011). Two C. elegans MJD/SCA3 pathogenesis 
models were recently generated and provided important insights regarding 
the pathogenic mechanisms involving aggregation, proteolysis and toxicity of 
expanded ataxin 3 (ATXN3). The pan-neuronal MJD model expresses polyQ-
expanded ATXN3 protein under the rgef-1 promoter (Teixeira-Castro et al., 
2011), while the new muscle-specific ATXN3 model expresses polyQ-
containing C-terminal domain of the ATXN3, with various polyQ lengths (Q45 
or Q63) in body wall muscle cells using the unc-54 promoter (Christie et al., 
2014). Both models exhibited polyQ length-dependent aggregation that 
correlated with toxicity, as demonstrated by overt motor dysfunctions. 
However, unlike some previously described polyQ models (Morley et al., 
2002, Brignull et al., 2006a), neither aging nor proteotoxic stress affect the 
aggregation and toxicity of this ATXN3 C-terminal fragment in body wall 
muscle cells.  
1.3.4 Modeling the pathophysiology of Parkinson’s disease  
1.3.4.1 α-synuclein  
All established familial PD genes are strictly conserved in the nematode with 
most residue positions mutated in PD patients encoding identical amino acids 
in C. elegans orthologues: Parkin (pdr-1), PINK1 (pink-1), UCHL-1 (ubh-1), 
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DJ-1 (djr-1.1, djr-1.2), LRRK2 (lrk-1), ATP13A2 (capt-6), and GBA (F11E6.1, 
TO4A8.7), with the exception of α-synuclein (Table 1.1). Knockout models of 
these orthologues either exhibited DAergic neurodegeneration, or were 
sensitised to mitochondrial toxins (Ved et al., 2005, Karpinar et al., 2009, 
Saha et al., 2009, Sämann et al., 2009), and have produced some important 
insights into their normal function. A plethora of transgenic models of 
synucleinopathy have now been established by multiple laboratories with 
pan-neuronal (aex-3), dopaminergic (dat-1) and motor-neuron (unc-30, acr-
2)-target expression of both wild-type and mutant human α-synuclein 
expression and have facilitated the identification of multiple neuroprotective 
genetic factors that are conserved across species. 
While pan-neuronal expression of wild-type, or pathogenic mutant 
(A53T and/or A30P) human α-synuclein gave rise to variable phenotypes as 
a result of the specific promoters (aex-3, unc-51) used in the transgene 
constructions, preferential neuronal dysfunctions in DAergic neurons were 
consistently reported by three groups following their expressions in DAergic 
neurons driven by the DA-specific dat-1 promoter. These include reduced 
dopamine content, age-dependent DAergic neuron degeneration, motor 
deficits reversible by dopamine administration, defective dopamine-
dependent behaviour, intracellular α-synuclein aggregates similar to Lewy 
bodies, and similar patterns of pharmacological vulnerability as those 
described above for familial PD genetic knock outs, which is reversed by 
treatment with antioxidants (Lakso et al., 2003, Ved et al., 2005, Kuwahara et 
al., 2006). 
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Following the approach initially developed for polyQ-induced 
aggregation (Nollen et al., 2004), numerous research groups have also 
constructed α-synuclein muscle models to uncover regulators of α-synuclein 
aggregation by expressing α-synuclein::GFP (or YFP) fusion fragments using 
the unc-54 promoter (Hamamichi et al., 2008, van Ham et al., 2008). The 
Caldwell (Caldwell et al., 2010) and Plasterk (Nollen et al., 2004) groups both 
demonstrated that α-synuclein::GFP (or YFP) fusion protein expressed in 
body-wall muscles cells leads to the formation of visible fluorescent 
aggregates, as previously observed for GFP::polyQ (Caldwell et al., 2010). 
Additionally, Kuwahara et al. (Kuwahara et al., 2012) recently studied the role 
of serine-129 phosphorylation on α-synuclein neurotoxicity by pan-neuronally 
overexpressing nonphosphorylatable S129A-α-synuclein or phosphorylation 
mimic S129D-α-synuclein using the unc-51 promoter, and observed severe 
motor dysfunction, growth retardation and synaptic abnormality in the 
transgenic S129A-α-synuclein model. 
1.3.4.2 Toxin-induced 
Environmental toxin exposure has been extensively linked to increased risk 
of developing nonhereditary PD. The well-characterised DAegic neurons of 
C. elegans are highly sensitive to many classic neurotoxins previously used 
to model PD in higher organisms, such as 6-hydroxydopamine (6-OHDA),  
MPTP, and rotenone (Braungart et al., 2004, Ved et al., 2005, Marvanova 
and Nichols, 2007, Saha et al., 2009). Exposure to these toxins exclusively 
degenerates DAergic neurons in C. elegans and leads to PD syndromes that 
share similar features both in humans and mice (Ishiguro et al., 2001, Nass 
et al., 2001, Cao et al., 2005, Nass et al., 2005, Ved et al., 2005, Marvanova 
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and Nichols, 2007). 6-OHDA and the reactive, neurotoxic metabolite of 
MPTP, 1-methyl-4-phenylpyridinium (MPP+), selectively accumulate in the 
mitochondria of DAergic neurons and impair mitochondrial respiration by 
inhibiting complex I of the respiratory chain, and increase reactive oxygen 
species (ROS) generation and/or mitochondrial dysfunction, thereby inducing 
DAergic neurodegeneration and cell death. 6-OHDA is structurally similar to 
dopamine and is actively taken up by DAergic and noradrenergic transporters 
on DAergic cells (Nass et al., 2001). MPTP is highly lipophilic and readily 
crosses the mammalian blood-brain barrier and cell membranes. It converts 
to the active toxic metabolite MPP+ intracerebrally by the monoamine 
oxygenase B in astrocytes (Braungart et al., 2004), and is secreted via the 
extraneural monoamine transporter to be actively taken up by DAergic cells 
via DA transporters (Aitlhadj et al., 2011). Analogous to the findings with 6-
OHDA, MPP+-induced DAergic neurodegeneration in C. elegans is 
associated with behavioural defects i.e. significantly reducing mobility 
(Braungart et al., 2004).  
Recent studies have shown that in addition to chemical exposure, 
heavy metals, such as manganese (Mn2+), methylmercury (MeHg), aluminum 
and other environmental contaminants i.e. fungicides, pesticides, 
insecticides, can generate potent models of dopamine neuron-cytotoxicity as 
they caused a wide range of phenotypic abnormalities as well as DAergic 
neurodegeneration (Aschner et al., 2013).  
1.3.4.3 Leucine-rich repeat kinase 2  
Although the majority of PD studies conducted in C. elegans have focused on 
α-synuclein models, several LRRK2 neurodegenerative worm models have 
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recently been generated and are of considerable interest. LRRK2 was 
reported to play an important role in modulating mitochondrial dysfunction, 
since deletion and depletion of the C. elegans LRRK2 orthologue, lrk-1 
sensitised worms to the ER stress induced by tunicamycin and the 
mitochondrial toxic rotenone, respectively. To study the possible gain-of-
function phenotype acquired by LRRK2 mutations, transgenic C. elegans 
models with pan-neuronal or DAergic neuronal overexpression of human 
LRRK2 WT, R1441C/G, G2019S and K1347A mutations were developed 
using either the snb-1 or dat-1 promoter, and pathogenic mutant forms 
resulted in an age-dependent degeneration of DAergic neurons, locomotor 
dysfunction, behavioural abnormalities and dopamine deficiency (Saha et al., 
2009).  
1.3.5 C. elegans amyotrophic lateral sclerosis models 
1.3.5.1 Superoxide dimutase (SOD-1) 
Just as aforementioned protein-misfolding disorders have been modeled in 
worms, a number of C. elegans models have been developed to study 
various aspects of ALS pathogenesis. Mutations in SOD1 are the most 
common known cause of familial ALS. Since both deletion and RNAi knock-
down of any of the five forms of SOD in C. elegans had relatively little effect 
on the worm and the resulting phenotypes do not appear to mimic 
neuromuscular aspects of ALS (Doonan et al., 2008), a number of transgenic 
lines expressing mutant forms of human SOD1 found in familial ALS patients 
under a range of promoters have been generated and recapitulated the 
motor neuron degeneration and paralysis characteristic of ALS patients 
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(Witan et al., 2008, Gidalevitz et al., 2009, Wang et al., 2009b, Sleigh and 
Sattelle, 2010, Li et al., 2013). 
No morphological abnormalities or discernible phenotypes were 
observed in the first C. elegans model of SOD1 toxicity, which express 
human wild-type and familial ALS-associated human SOD1 (A4V, G37R and 
G93A) constructs under the control of either the muscle-specific myo-3 
promoter or the universal heat-shock inducible hsp-16.2 promoter (Oeda et 
al., 2001). However, worms expressing mutant SOD1 were found to be 
preferentially sensitive to paraquat-induced oxidative stress which in turn 
significantly reduced the degradation rate of mutant SOD1 protein, and 
caused aberrant accumulation of mutant human SOD1 proteins in muscle 
cells. In subsequent studies, transgenic worms expressing dimeric forms of 
wild-type and misfolding mutant (G85R) human SOD1 behind a pan-neuronal 
promoter (sng-1) were generated. Larvae expressing mutant G85R SOD1 
homodimers only displayed a marginal reduction in locomotion, while lifespan 
in the presence of paraquat was no different to control. In contrast, mutant 
heterodimer-expressing (with wild-type SOD1) worms showed reduced 
cellular aggregation, a highly significant decrease in motility and a shortened 
lifespan when exposed to paraquat (Witan et al., 2008). With another well-
characterised model, pan-neuronal expression (snb-1 promoter) of a mutant 
form of SOD1 (unfused G85R or fused G85R-YFP), but not wild-type SOD1, 
resulted in a clear age-dependent impairment of locomotion and neuronal 
transmission. Interestingly, the observed phenotype correlated with intra-
neuronal SOD1 protein aggregation which appeared to be restricted to 
certain mechanosensory neurons despite the pan-neuronal expression of 
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SOD1 (Wang et al., 2009b). More recently, a C. elegans model was 
generated to express WT or mutant G93A SOD1 exclusively in GABAergic 
motor neurons. Mutant G93A SOD1-expressing lines showed an age-
dependent paralysis accompanied by significant SOD1 aggregation and 
axonal guidance defects (Li et al., 2013).  
SOD1 toxicity in C. elegans muscle cells was also examined by 
Gidalevitz and co-workers (Gidalevitz et al., 2009) using WT and mutant 
SOD1-YFP fusion proteins (G85R, G93A, and truncated 127X) driven by the 
unc-54 promoter. Consistent with the neuronal aggregation seen by Wang et 
al. (Wang et al., 2009b), only mild cellular dysfunction were evident in the 
body muscle cells expressing the three distinct SOD1 mutations (Gidalevitz 
et al., 2009). 
1.3.5.2 TDP-43, FUS and C9ORF72  
Genes recently shown to be mutated in ALS include the DNA/RNA binding 
proteins TDP-43 and FUS, and C9ORF72, a novel familial and sporadic ALS 
causative gene. Since very little is currently known about the biological role of 
C9ORF72, work from genetically convenient model organisms such as C. 
elegans could shed light on the molecular pathogenic mechanisms of 
C9ORF72 toxicity and provide further insights into the disease state. Parker’s 
group has recently characterised the loss of function of C. elegans C9ORF72 
orthologue F18A1.6, also called, alfa-1 (ALS/FTD associated gene 
homologue). It was observed that decreased expression of alfa-1 caused 
sensitivity to osmotic stress, age-dependent motility defects, leading to 
paralysis and neurodegeneration specifically of the GABAergic motoneurons 
(Therrien et al., 2013).  
42 
 
Efforts to understand the mechanism of ALS and Frontotemporal lobar 
degeneration with ubiquitinated inclusions (FTLD-U) have led to the 
development of model systems exhibiting some features of RNA-binding 
proteins pathology. Deletion of C. elegans TDP-43 orthologue, TDP-1 caused 
sensitivity to oxidative and osmotic stresses and discernible defects in 
fertility, growth, and locomotion. However, paradoxically, worms lacking tdp-1 
have a longer lifespan (Ash et al., 2010, Liachko et al., 2010, Zhang et al., 
2012b). Both pan-neuronal (snb-1 promoter) and motor neuron specific (unc-
25 and unc-47 promoters) C. elegans models of TDP-43 and FUS 
proteinopathy have been generated and recapitulated various characteristic 
features seen in ALS and FTLD-U patients. Attention has been specifically 
devoted to TDP-43 as there are currently only two C. elegans FUS 
transgenic models. In contrast to the aforementioned SOD1 worm models, 
transgenic expression of the WT form of TDP-43, was highly neurotoxic. Ash 
et al. (Ash et al., 2010) first reported that the pan-neuronal expression of 
human TDP-43 or its C. elegans orthologue TDP-1 caused neurotoxicity and 
protein aggregation, and further correlated the uncoordinated phenotype with 
defasciculation of the GABAergic motor neurons. Liachko and colleagues 
(Liachko et al., 2010) similarly found that pan-neuronal overexpression of WT 
human TDP-43 caused motor defects. However, overexpression of various 
human ALS-associated TDP-43 mutants (G290A, A315T, or M337V) caused 
more severe phenotypes that are analogous to the phenotypes observed in 
ALS and FTLD-U patients. These include: progressive paralysis, reduced 
lifespan, and degeneration of motor neurons accompanied by 
hyperphosphorylation, truncation, and ubiquitination of the TDP-43 protein 
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that accumulates in detergent insoluble protein deposits. Intriguingly, the 
severity of motor dysfunction and neurodegeneration was observed to be 
highly correlated with TDP-43 phosphorylation levels, but not with protein 
aggregation. However, Zhang and colleagues (Zhang et al., 2012b) 
demonstrated that TDP-43 misfolding and high aggregation propensity do 
contribute to its neurotoxicity as pan-neuronal expression of full-length and 
truncated human TDP-43 variants resulted in robust behavioural phenotypes 
including the locomotor defects, synaptic transmission abnormalities and 
formation of insoluble protein aggregates. Parker’s group (Vaccaro et al., 
2012) further developed models which express human WT or mutant TDP-43 
specifically in GABAergic motor neurons using an unc-47 promoter. 
Interestingly, the overexpression of mutant TDP-43, but not wild-type TDP-
43, caused an adult-onset, progressive paralysis phenotype accompanied by 
GABAergic neurodegeneration and synaptic transmission impairment. 
1.3.6 C. elegans model of spinal muscular atrophy  
The C. elegans genome harbours a single smn-1 gene, which encodes a 
highly conserved SMN orthologue (Miguel-Aliaga et al., 1999). The first of 
two C. elegans smn-1 alleles generated, smn-1(ok355), is a genetic null that 
possesses a deletion removing all but 87 bp at the 3′ end of the gene, 
resulting in SMN-1 loss of function and neuromuscular function deficits. Since 
smn-1 deletion is homozygous lethal, the ok355 allele must be maintained 
using a balancer chromosome that allows the differentiation of genotypes 
through expression of GFP (Briese et al., 2009). Like in Drosophila, mutant 
animals proceed through embryogenesis due to maternal SMN-1 contribution 
from the heterozygous parental generation. Once depleted, the smn-1 
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homozygotes become discernible from wild-type larvae and exhibit 
pleiotropic defects including late larval arrest, decreased lifespan, defects in 
motility and pharyngeal pumping. smn-1(ok355) animals are indistinguishable 
from wild-type for up to two days post hatching, suggesting both that muscles 
are successfully targeted and reached by developing motor neurons and that 
SMN-1 plays a vital role in later development and adult life, as indicated in a 
severe mouse model of SMA. Moreover, neuromuscular function rapidly and 
progressively declines in early larval stages; specifically, both thrashing rate 
in solution and pharyngeal pumping rate become significantly reduced 
leading to larval lethality, and few homozygous mutant animals reach 
adulthood. Interestingly, the mutant displays no cholinergic motor neuron loss 
or gross defects in nervous system morphology in contrast to humans and 
mice. smn-1(ok355) was also used to show that pan-neuronal SMN-1 
expression can partially rescue the phenotype of the mutant, whereas 
muscle-directed expression has little effect, similar to the situation seen in 
mice (Briese et al., 2009, Dimitriadi and Hart, 2010, Sleigh and Sattelle, 
2010).  
Sleigh et al. (Sleigh et al., 2011) recently isolated and characterised 
the second, weaker C. elegans smn-1 allele, smn-1(cb131). This represents 
a less severe SMA mutant model that obviates the need for a balancer 
chromosome and expensive equipment required to separate genotypes. The 
smn-1(cb131) worms display a range of mild defects including a minor 
motility defect caused by reduced synaptic neurotransmission, similar to the 
null, but remain fertile, thus should greatly facilitate drug screening for 
compounds that improve motor function.  
45 
 
1.4 C. ELEGANS AS A MODEL TO DECIPHER GENETIC 
ASPECTS OF NEUROTOXICITY 
Much of the current knowledge about modifiers of NDs using model 
organisms has been gathered from candidate approaches and unbiased 
genetic screens which use induced mutations i.e. knockouts/knockdowns and 
overexpression, in fixed genetic backgrounds. Though study of C. elegans 
orthologues of human ND-associated genes have produced some important 
insights into their normal function, most of the knowledge about NDs 
acquired in C. elegans came from transgenic models expressing the human 
disease proteins. We recently performed an integrated analysis of the data 
available from genetic screens of regulators of neurodegeneration in various 
disease models in yeast, fly and worms (Chen and Burgoyne, 2012), but 
uncovered relatively few shared genetic factors that affect several or all 
disease models as many of the regulators may be organism or disease-
specific. Several of the shared regulators that have been robustly 
demonstrated in different model systems are chaperones, ubiquitin-related 
enzymes [including the E3 ligase, C terminus of the Hsc70-interacting protein 
(CHIP) which directly links the two pathways], histone deacetylases and 14-
3-3 proteins. Interestingly, other shared regulators emerged which have not 
previously been considered as key regulators of neurodegeneration including 
peroxisomal acyl-CoA oxidase, which suggest novel targets for ND therapy. 
1.4.1 Aβ  
As mentioned above, studies of AD-related genes and pathways in C. 
elegans have provided important insights into the general function and 
pathways of AD-related genes and toxicity of specific Aβ species. Using both 
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deletion mutants and transgenic animals overexpressing APL-1, the 
importance of maintaining neuronal APL-1 within homeostatic levels was 
demonstrated, as either loss of APL-1 or overexpression of APL-1 resulted in 
lethality (Hornsten et al., 2007, Wiese et al., 2010). Follow up studies further 
revealed a role of APL-1 in C. elegans sensory plasticity as pan-neuronal, 
ectopic and targeted expression of APL-1, were shown to disrupt chemotaxis 
response, associative and non-associative learning which are mediated via 
TGF-β signaling and decreased insulin/IGF-1 signaling (Hassan et al., 2009, 
Ewald et al., 2012). Studies of the C. elegans presenilin orthologues sel-12 
and hop-1 have also linked AD to the apoptotic and Notch-pathway signaling, 
which were later confirmed in vertebrates (Leung et al., 2008). However, 
most of the knowledge about molecular processes underlying AD acquired in 
C. elegans came from transgenic worm models with tissue-specific or 
inducible expression of human Aβ. Using both the constitutive and 
temperature-inducible muscle Aβ models, a combination of studies has 
demonstrated that the Aβ1-42 toxicity is highly dependent on genes implicated 
in general protein degradation pathways or longevity (Cohen et al., 2006, 
Florez-McClure et al., 2007, Fonte et al., 2008). It has been demonstrated 
that decreased insulin receptor signaling following RNAi knockdown of the 
insulin/IGF-1 receptor, DAF-2, reduced Aβ1-42 toxicity in the C. elegans body 
wall muscles through the opposing activities of two downstream transcription 
factors (TFs), heat shock factor 1 (HSF-1), which regulates Aβ 
disaggregation, and DAF-16, which facilitates the formation of larger, less 
toxic Aβ aggregates. RNAi knockdown of either daf-16 or hsf-1 enhanced Aβ 
toxicity with opposing effects on the Aβ1-42 aggregation. Dietary restriction, 
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which extends lifespan in C. elegans, has also been found to reduce Aβ (and 
polyQ) toxicity in a HSF-dependent manner (Steinkraus et al., 2008). The 
critical role of endogenous chaperone proteins in regulation of Aβ toxicity 
was also assessed (Fonte et al., 2002, Fonte et al., 2008). Mass 
spectrometry revealed that two HSP70 orthologues (C15H9.6 and 
F26D10.3), three αB-crystallin-related small heat shock proteins (HSP-16s) 
[T27E4.3 (HSP-16.1), Y46H3A.d (HSP-16.2), and T27E4.3 (HSP-16.48)], 
and a putative orthologue of a mammalian small glutamine-rich 
tetratricopeptide repeat-containing protein (SGT) proposed to bind to hsc7C 
(R05F9.10) co-localise and co-immunoprecipitate with Aβ (Fonte et al., 
2002). Further investigation of the biological role of HSP-16.2 on Aβ toxicity 
in the temperature-inducible transgenic model demonstrated that increased 
HSP-16.2 protein expression by either ectopic overexpression HSP-16 or a 
protective heat shock treatment substantially suppressed the Aβ-induced 
paralysis phenotype and Aβ oligomerisation without affecting the total Aβ 
protein accumulation (Fonte et al., 2008, Wu et al., 2010). The inducible 
model has also been used to demonstrate a role for autophagy in countering 
Aβ toxicity (Florez-McClure et al., 2007) and was also subjected to two 
microarray studies which revealed up-regulated expression of αB-crystallin, 
tumour necrosis factor-induced protein 1 (TNFAIP1) and arsenite-inducible 
protein (AIP-1) upon Aβ induction, and their relevance to AD were further 
validated by similarly observed functions for their human counterparts (Link 
et al., 2003, Hassan et al., 2009). Recent findings provided strong genetic 
evidence that enzymes of O-GlcNAc cycling OGT-1 and OGA-1 are key 
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regulators of proteostasis and might be the potential targets to treat AD 
(Wang et al., 2012, Hanover and Wang, 2013). 
Using the new AD model with transgenic Aβ expression in 
glutamatergic neurons, genes involved in clathrin mediated endocytosis, 
such as unc-11, unc-26, Y44E3A.4, which are known AD risk factors in 
humans and were originally identified in a yeast modifier screen, suppressed 
glutamatergic neurodegeneration (Treusch et al., 2011). Furthermore, the 
protective function of human repressor element 1-silencing transcription 
factor (REST) is also conserved in worms as mutations in the C. elegans 
functional REST orthologue spr-4, which suppressed the sel-12/PSEN egg-
laying defect (Lakowski et al., 2003), also significantly accelerated 
glutamatergic neurodegeneration (Lu et al., 2014). 
1.4.2 Tau 
The transgenic mutant Tau V337M worms have been subjected to both 
classic forward genetic and RNAi-based reverse genetic screens to identify 
modifiers that would exacerbate or alleviate the Tau-induced behavioural 
defects. Forward genetic screens based on classical chemical mutagenesis 
and positional cloning identified two novel candidate genes, sut-1 and sut-2 
(Suppressor of Tau Pathology), whose loss of function strongly ameliorated 
the Tau-induced neurodegeneration (Kraemer et al., 2003). Follow-up 
genetic studies and yeast two-hybrid screens further revealed that SUT-1 
and SUT-2 may participate in the pathological pathway activated by Tau 
(Kraemer and Schellenberg, 2007, Guthrie et al., 2009). It was suggested 
that SUT-1 suppresses Tau pathology defects by modulating actin dynamics, 
via its interaction with UNC-34, the cytoskeletal regulated protein Enabled 
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(ENA) (Kraemer and Schellenberg, 2007). It was also hypothesised that 
SUT-2, a zinc finger-containing protein ameliorates Tau pathology by 
affecting centrosome and/or aggresome function, via its direct interaction with 
ZYG-12, a HOOK protein family member and this interaction was further 
validated in vitro as human MSUT-2 also binds HOOK2 (Guthrie et al., 2009). 
A full genome RNAi feeding screen in which 16,757 RNAi clones were 
assayed resulted in the identification of six genes that exacerbated only the 
Tau-induced behavioural defect (Kraemer et al., 2006). These genes 
encoded proteins with a range of functions, including phosphorylation [e.g. 
glycogen synthase kinase 3β (GSK3B)], chaperone activity [e.g. heat-shock 
protein 70 (HSP70)], neurotransmission and signalling (e.g. Munc13-4), 
nucleic acid function (e.g. sir-2.3) and proteolysis [e.g. CTSE (cathepsin E)]. 
Reassuringly, mammalian orthologues of these modifier genes had been 
previously implicated in human Tauopathies and Tau-mediated pathology in 
other models. In addition, over-expression of human HSP70 in the Tau model 
of touch insensitivity significantly improved their touch response, whereas 
over-expression of the mammalian GSK-3β kinase slightly exacerbated Tau-
induced neurodegeneration (Miyasaka et al., 2005), the latter observation 
being consistent with Drosophila studies (Jackson et al., 2002). Furthermore, 
using the transgenic muscle Tau model (unc-54::Tau::GFP), it was reported 
that RNAi-mediated knock down of the cochaperone CHIP in C. elegans 
promotes accumulation of abnormally phosphorylated Tau, demonstrating an 
important role of CHIP in the ubiquitin-dependent degradation of Tau (Dickey 
et al., 2006). 
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1.4.3 PolyQ  
C. elegans is a highly tractable tool for the study of polyQ protein dynamics 
and toxicity and has been extensively used to determine how polyQ 
pathogenicity contributes to neurodegeneration. Utilising the C. elegans 
neuronal HD model that expresses Htt-Q150 in ASH sensory neurons (Faber 
et al., 1999), processes characteristic of apoptotic cell death, histone 
deacetylases (HDACs), autophagy and cAMP (Cyclic adenosine 
monophosphate) response element-binding protein (CREB) have been 
implicated in HD. Loss-of-function mutations and/or RNAi knock down of C. 
elegans genes mediating autophagy (bec-1, atg-7, atg-18), CREB (crh-1), 
CREB binding proteins (cbp-1), polyQ enhancer-1 (pqe-1) and majority of 
HDAC genes (hda-1, hda-2, hda-4, hda-5, hda-6, hda-10, hda-11, sir-2.1, sir-
2.2), were discovered to exacerbate Htt-Q150 aggregation and 
neurodegeneration (Faber et al., 2002, Parker et al., 2005, Bates et al., 
2006). In contrast, the loss of ASH function was reversed in a ced-3/caspase 
mutant background and hda-3/HDAC deletion and depletion significantly 
reduced Htt-Q150-induced degeneration when hda-1 activity was not 
compromised (Bates et al., 2006). Complete loss of sir-2.3/HDAC activity 
also had no effect. The same polyQ toxicity model was also used in 
conjunction with primary cell culture neurons to demonstrate that 
posttranslational modification of mutant Htt by increased acetylation at lysine 
residue 444 (K444) may significantly improve the clearance of accumulated 
mutant Htt and actively targeting proteins for degradation by autophagy, 
leading to neuroprotection both in vitro and in vivo (Jeong et al., 2009). The 
complex roles of specific HDACs in regulating Htt-polyQ toxicity was further 
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explored in another neuronal HD model that expresses Htt-Q128 in touch 
receptor neurons, and increased expression of the C. elegans orthologue of 
silent regulator information 2 (sir-2.1), a class III HDAC, was shown to 
ameliorate Htt-Q128 toxicity through the activity of daf-16 transcription factor 
(TF) (Parker et al., 2005). Additionally, Htt-Q128 worms were also utilised in 
a large-scale functional RNAi screen to identify modifiers of Htt-Q128-
induced touch insensitivity. Interestingly, some of the RNAi hits identified 
from this C. elegans screen were up-regulated in the striatum of mouse HD 
models (Lejeune et al., 2012), thus underscoring the relevance of using C. 
elegans models for the identification of potential therapeutic targets for 
human NDs. In-depth analysis of positive hits emphasised a role for cell 
differentiation/survival, metabolic and neurodegenerative disease pathways 
in the modulation of expanded-polyQ cytotoxicity (Lejeune et al., 2012). 
Using the same model, C. elegans huntingtin-interacting protein 1 orthologue 
(hipr-1) and other synaptic endocytosis proteins were shown to protect 
against polyQ neuronal dysfunction (Parker et al., 2007). Tauffenberger et al. 
(Tauffenberger et al., 2012) further reported that loss of function mutations in 
tdp-1 and fust-1, worm orthologues of human TDP-43 and FUS can reduce 
Htt-Q128-mediated behavioural defects and neurodegeneration, and their 
neuroprotective effects were further validated in mammalian neurons. 
However, suppression of Htt-Q128 toxicity by tdp-1 is independent of hdac-
6/HDAC6, but dependent on progranulin (pgrn-1/PGRN), a known TDP-43 
target (Tauffenberger et al., 2012).  
PolyQ muscle-specific model systems have also been utilised to 
screen for modifiers. A dramatic delay of polyQ toxicity and appearance of 
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protein aggregates by loss of AGE-1, the C. elegans orthologue of 
phosphoinositide 3-kinase (PI3K) (Morley et al., 2002) was observed in a 
body wall muscle-specific model. The same model was then used in a 
genome-wide RNAi screen which yielded 186 genes with diverse functions 
that, when knocked down, caused premature aggregation of polyQ35 
aggregates (Nollen et al., 2004). A subsequent RNAi screen of human 
orthologues of these C. elegans modifiers showed a subset that are also 
suppressors of mHTT aggregation in human cells (HEK293) expressing HTT-
Q74-GFP (Teuling et al., 2011). Other independent muscle HD models 
demonstrated the protective effects of C. elegans p97 homologues CDC-48.1 
and CDC-48.2 (Yamanaka et al., 2004), and ubiquilin (Wang et al., 2006) in 
polyQ-induced toxicity, as well as for investigating the role of mitochondria 
dynamics in relation to expanded polyglutamine HD protein toxicity (Wang et 
al., 2009a). Most recently, RNAi knockdown of dnj-27/ERdj5, an ER luminal 
protein upregulated in response to ER stress, was shown to exacerbate the 
impaired mobility of a polyQ40 muscle model, suggesting that dnj-27 
interacts with polyQ and protects against polyQ induced paralysis (Munoz-
Lobato et al., 2013). Temperature sensitive mutant proteins (UNC-54, 
dynamin, Ras, paramyosin) have also been used as probes for the cellular 
folding environment as studies revealed that transgene-induced polyQ 
expression in muscles or neurons of animals carrying temperature-sensitive 
mutations in genes unrelated to polyQ toxicity further exacerbated genetic 
defects and polyQ aggregation phenotype (Gidalevitz et al., 2009). 
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1.4.4 PD 
Numerous groups have made particular use of transgenic and toxin-induced 
C. elegans PD models for elucidating genetic pathways involved in PD 
(Lakso et al., 2003, Hamamichi et al., 2008, van Ham et al., 2008). In 
particular, gene expression changes of α-synuclein expressing nematode 
lines have been widely monitored and permitted further insights into the 
neuropathologic mechanisms of α-synuclein. An unifying theme that has 
arisen from multiple whole genome forward, RNAi knockdown and microarray 
screenings of C. elegans models of α-synuclein overexpression-induced 
toxicity is a strong connection with mitochondrial function, proteostasis and 
endomembrane trafficking (Cooper et al., 2006, Vartiainen et al., 2006, Gitler 
et al., 2008, Hamamichi et al., 2008, Ichibangase et al., 2008). Interestingly, 
different worm orthologues of known recessive PD genes such as pink-
1(PINK1), pdr-1 (parkin), djr-1.1 (dj-1) and capt-6 (ATP13A2) consistently 
appear in most modifier screens as suppressors of α-synuclein-induced 
toxicity (Ved et al., 2005, Gitler et al., 2008, Hamamichi et al., 2008, van Ham 
et al., 2008). The Pdat-1::WT α-synuclein model (Cao et al., 2005) 
demonstrated the neuroprotective role of an ER-associated chaperone, 
TorsinA/TOR-2 and a GTPase involved in ER-to-Golgi transport, Rab1A 
(Cooper et al., 2006). The pan-neuronal α-synuclein models of Kuwahara et 
al. (Kuwahara et al., 2006) that overexpress human α-synuclein (WT, A53T, 
A30P) under the control of the unc-51 promoter were utilised in a large-scale 
RNAi screen, which led to the identification of ten enhancers of α-synuclein-
induced neurotoxicity, mostly consisting of components from the endocytic 
pathway. Phosphorylation of α-synuclein at Ser-129, a characteristic 
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posttranslational modification evident in synucleinopathy lesions, was also 
detected in a subset of these transgenic worms (Fujiwara et al., 2002). 
Recent gene expression profiling of pan-neuronal S129A-transgenic models 
revealed strong upregulation of daf-16/FOXO pathway genes, which the 
authors proposed to act against the dysfunction caused by the S129A-α-
synuclein (Kuwahara et al., 2012). Another whole genome microarray 
analysis was performed on a transgenic C. elegans model overexpressing 
human α-synuclein under the aex-3 promoter and demonstrated the effect of 
pan-neuronal α-synuclein on proteasome, mitochondrial complex and 
nucleasome gene expression (Vartiainen et al., 2006). These data therefore 
not only provide support for the role of dysfunctional mitochondria and 
inhibition of proteasomal function in synucleopathies, but also suggest a 
novel mechanism of neurodegeneration (i.e. regulation of nuclear protein in 
mediating neurotoxicity) for future study. 
RNAi screening of two similar transgenic lines expressing α-synuclein 
in body wall muscle cells identified lysosomal trafficking genes (vps-41, 
W08D2.5/ATP13A2), lipid- and vesicle-associated genes (W02A11.2, hgrs-1) 
and aging-associated genes (sir-2.1, lagr-1) as modifiers that strongly 
protects against α-synuclein aggregation (Hamamichi et al., 2008, van Ham 
et al., 2008). The effect of several of these genes has been independently 
confirmed. Most recent work further substantiated the critical role of 
lysosomal trafficking in cellular homeostasis, maintenance and pathogenesis 
of synucleinopathies. While expression of the human orthologue, hVPS41 
protected DAergic neurons from both α-synuclein- and 6-OHDA-induced 
DAergic neurodegeneration in C. elegans, as well as human SH-SY5Y 
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neuroblastoma cells from the toxic effects of the dopamine-specific 
neurotoxins 6-OHDA and rotenone (Ruan et al., 2010), identified interacting 
partners of ATP13A2 were also shown to impact α-synuclein aggregation 
and α-synuclein-induced neurodegeneration (Usenovic et al., 2012). 
1.4.5 ALS  
Both RNAi screenings and whole genome expression profiling have been 
performed using the ALS models. While genome-wide RNAi screening of 
transgenic G85R SOD1 neuronal model (Wang et al., 2009b) and G93A 
SOD1 muscle aggregation models (Silva et al., 2011b) isolated enhancers 
(protein chaperones, TGF-β, SUMO and topoisomerase I) and suppressors 
(which are also Q35 aggregation suppressor modifiers: cytoskeleton 
components and matrix proteins, posttranslational modifying enzymes, 
energy, metabolism, gene expression and protein synthesis related 
modifiers) of mutant SOD1 aggregation, respectively, a comprehensive RNAi 
screen of over 450 C. elegans kinases using a C. elegans model of mutant 
M337V TDP-43 proteinopathy identified twelve kinases that improved TDP-
43-driven behavioural phenotypes (Liachko et al., 2013).  
Consistently, loss of function mutations of TDP-43 or FUS suppressed 
neurotoxicity and neurodegeneration in several ALS models (Zhang et al., 
2011, Vaccaro et al., 2012, Zhang et al., 2012b) as well as in a C. elegans 
model of HD (Tauffenberger et al., 2012), suggesting that there may be 
genetic interactions amongst genes linked to neurodegeneration. 
Interestingly, abnormal ER stress and proteostasis which have been a 
recurrent theme in the sporadic and familial cases of ALS, was also revealed 
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as a highly affected biological process in a recent transcriptome analysis of 
tdp-1(ok803) (Zhang et al., 2012b, Therrien and Parker, 2014). 
Recent studies have similarly demonstrated that alterations in the IIS 
pathway which is a well characterised genetic modifier of aging and several 
aforementioned NDs in C. elegans, can also robustly modulate the solubility 
and neurotoxicity of ALS related proteins i.e. mutant SOD1 and TDP-43 as 
assessed by mobility, protein aggregation and longevity of transgenic 
models. Reduced daf-2 activity was shown to suppress the toxicity and 
protein aggregation of both G85R SOD1 and TDP-43, an effect that might be 
due to an increased capacity for clearance/folding in these worms. HSF-1 
was not only recovered as an enhancer of G85R SOD1-YFP 
aggregation/toxicity in a full genome feeding RNAi screen, but also a potent 
regulator of the TDP-43-induced neurotoxicity (Zhang et al., 2011, Boccitto et 
al., 2012). Introduction of mildly destabilising temperature-sensitive missense 
mutations which previously enhanced polyQ aggregation and elevation of 
environmental temperature strongly exacerbated the phenotypic defects and 
cellular toxicity of SOD1::YFP and TDP-43::YFP, respectively. This 
phenomenon seen in distinct models of disease involving protein misfolding 
and aggregation supports the hypothesis that dysfunction in conformational 
diseases may not be due to the misfolding/aggregation toxicity of the 
causative mutant but may be attributed to a global disruption in protein 
folding homeostasis (Gidalevitz et al., 2009). 
1.4.6 SMA 
A high-throughput genome-wide RNAi screen using the loss-of-function smn-
1(ok355) allele explored the genetic circuitry affecting SMN neuromuscular 
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function. While no suppressors were found, four enhancers ncbp-2, T02G5.3, 
grk-2, and flp-4 were uncovered and subsequently tested for function as 
smn-1 neuromuscular modifier genes using the pharyngeal pumping assay. 
Excellent concordance of modifier gene action in both C. elegans and 
Drosophila was further demonstrated, since twelve candidate SMN modifier 
genes that originally enhanced SMN loss of function defects in a previous 
Drosophila screen also enhanced SMN loss of function defects in C. elegans 
and vice versa. Bioinformatic analysis of these cross-species modifier genes 
revealed endocytosis and RNA processing as specific cellular pathways that 
are critical genetic modulators of SMN function (Dimitriadi and Hart, 2010). 
In another study, the human E3 ubiquitin ligase, mind bomb 1 (Mib1) 
was proposed as a novel therapeutic target for SMA as it ubiquitinates and 
catalyses the degradation of SMN, and was further validated as a conserved 
cross-species modifier of SMN loss-of-function defects. Depletion of C. 
elegans Mib1 orthologue mib-1 by RNAi knockdown significantly ameliorated 
the pharyngeal pumping neuromuscular defects of smn-1-deficient animals, 
and MIB-1 was also shown to directly impact SMN-1 function independently 
of Notch signalling (Kwon et al., 2013). 
 
1.5 EXPLORING THERAPEUTIC STRATEGIES IN C. ELEGANS 
MODELS OF NEURODEGENERATIVE DISEASES  
In addition to its value for screening for genetic contributors to diseases, 
numerous groups have also capitalised on C. elegans model system to 
screen for chemical compounds prior to validation in vertebrate models. 
Several large-scale, high-throughput drug screens (HTS) utilising recent 
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technological advances have been performed and identified effective 
bioactive compounds, novel antimicrobial compounds, specific inhibitors of 
SKN-1 and drugs that alter misfolded protein accumulation. The efficacy of 
some compounds such as fluphenazine was further validated in mammalian 
cell line and mouse models (O'Reilly et al., 2014).  
Numerous C. elegans neurodegeneration models have been used to 
test the effects of individual drugs [e.g., resveratrol in a polyQ model (Parker 
et al., 2005); acetaminophen in multiple PD models (Locke et al., 2008); 
methylene blue in a ALS model (Vaccaro et al., 2012) and riluzole in a SMA 
model (Dimitriadi et al., 2013)] or relatively small collections of compounds 
[e.g., subcomponents of Gingko biloba extracts in Aβ toxicity models (Wu et 
al., 2006), candidate HD drugs in a polyQ model (Voisine et al., 2007)]. C. 
elegans findings with potential therapeutic relevance are illustrated in 
Appendix Table A1. Many compounds such as resveratrol (Parker et al., 
2005), methylene blue (Vaccaro et al., 2012), PBT2 (Cherny et al., 2012) and 
clioquinol (Matlack et al., 2014) also displayed protective effects beyond C. 
elegans models, with efficacy in Drosophila and zebrafish as well as mouse 
ND models. 
1.5.1 Aβ  
The Aβ-induced paralysis observed in the well-characterised muscle-specific 
strains has provided a valuable phenotype for straightforward quantification 
of the effects of treatments on Aβ toxicity and validation of potential 
therapeutic interventions for AD. C. elegans strain CL2006 which 
constitutively expresses human Aβ1-42 has been elegantly used to 
demonstrate the neuroprotective effects of a diverse range of compounds: 
59 
 
natural products - specific gingkolides (Wu et al., 2006), soya isoflavone 
glycitein (Gutierrez-Zepeda et al., 2005), green tea component 
epigallocatechin gallate (Abbas and Wink, 2009, Abbas and Wink, 2010) and 
coffee extract (Dostal et al., 2010); FDA-approved drugs - tannic acid, 
bacitracin, rifampicin (Lublin et al., 2011); amyloid-binding dye thioflavin T 
(Alavez et al., 2011), reserpine (Arya et al., 2009) and antidepressant 
fluoxetine; polyphenolic compounds – curcumin and ferulic acid (Jagota and 
Rajadas, 2012) in Aβ toxicity (Keowkase et al., 2010b). These treatments 
conferred considerable life-span extension and cellular stress tolerance 
(Gutierrez-Zepeda et al., 2005, Wu et al., 2006), since most compounds were 
shown to attenuate the rate of toxic human Aβ1-42 mediated paralysis, 
suppress the Aβ1-42 induced toxic ROS and hydrogen peroxide levels and 
inhibit Aβ1-42 oligomerisation and deposits (Smith and Luo, 2003, Wu et al., 
2006). Recent studies have also demonstrated how the antibiotic tetracycline 
and its analogues (Diomede et al., 2010), and ethanol extract of Liuwei 
Dihuang (Sangha et al., 2012) successfully protected the CL4176 inducible 
Aβ1–42 muscle-specific expression model from the Aβ1-42 insult and oxidative 
stress by inhibiting Aβ1-42 oligomerisation and reducing superoxide 
production. Oleuropein aglycone, the main polyphenol in extra virgin olive oil 
was recently shown to protect against amyloid toxicity in both constitutive and 
inducible Aβ1-42 models (Diomede et al., 2013). In addition, two recent large, 
unbiased yeast-based screens of pharmacological modifiers identified the 8-
hydroxyquinoline chemical scaffold (8-OHQ), a class of clinically relevant 
bioactive metal chelators as neuroprotective compounds that reduced 
proteotoxicity associated with the aggregation of several ND-specific 
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proteins: TDP-43, α-synuclein, polyglutamine proteins, or Aβ1-42 (Tardiff et al., 
2012, Matlack et al., 2014). Notably, two closely related 8-OHQs - PBT2 and 
clioquinol, which conferred neuroprotective benefits in mouse models of AD, 
with the former also effective in improving cognition and reducing Aβ in 
cerebrospinal fluid in a small Phase IIA trial in AD patients - were further 
shown to rescue Aβ1-42 toxicity in C. elegans body wall muscle cells (McColl 
et al., 2012) and glutamatergic neurons (Matlack et al., 2014) . 
1.5.2 Tau 
Using transgenic FTDP-17 tauopathy models, a novel compound belonging 
to the aminothienopyridazine class, cmp16, was shown to effectively 
ameliorate the worms’ motility and neuronal defects (Fatouros et al., 2012). 
In a recent screen of a library of FDA-approved compounds, dopamine D2 
receptor antagonism was presented as a promising strategy for targeting tau-
induced neurotoxicity, as antipsychotics such as azaperone, flupenthixol, 
perphenazine, and zotepine improved the phenotypic features of Tauopathy 
in worms. Azaperone, in particular, effectively ameliorated mutant Tau-
induced functional defects and reduced the level of insoluble Tau 
aggregation (McCormick et al., 2013). 
1.5.3 PolyQ  
Voisine et al. (Voisine et al., 2007) screened candidate pharmacological 
compounds utilising a HD model in which the pqe-1 genetic mutant 
background greatly enhanced Htt-Q150-mediated toxicity. Both lithium 
chloride and mithramycin alleviated neuronal cell death, while trichostatin A, 
a class I and class II HDAC inhibitor provided significant neuroprotection. 
Using the same HD model, Varma et al. (Varma et al., 2007) discovered that 
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small molecular inhibitors of metabolism (mitochondrial and glycolytic 
function) such as rotenone, oligomycin and 4-dinitrophenol rescued neuronal 
loss and degeneration by activating caspase inhibition and ERK and AKT 
prosurvival signalling and their efficacy were further validated in cell culture 
and Drosophila HD models. Resveratrol, a demonstrated activator of sirtuin 
deacetylases, also effectively alleviated Htt-Q128 toxicity in both worm and 
neuronal culture models (Parker et al., 2005). Recently, treatment of a C. 
elegans model of MJD with 17-(allylamino)-17-demethoxygeldanamycin (17-
AAG), an HSP90 inhibitor, successfully decreased the mutant ATXN3 
aggregation and improved locomotor activity (Teixeira-Castro et al., 2011). 
Treatment of the same model with valproic acid (VA), another HDAC inhibitor 
and a well-known anti-epileptic drug, also led to improved locomotor activity 
accompanied by a decrease in mutant ATXN3 aggregation. Therefore, HDAC 
inhibitors which promote histone acetylation over deacetylation and were also 
known to provide protection against polyQ mediated toxicity in vertebrate and 
Drosophila neurons may hold promise as preventive therapy in polyQ 
diseases. 
Other pan-neuronal or neuron specific HD models facilitated the 
identification of other potential therapeutic interventions, including the anti-
cancer agent β-lapachone (Shin et al., 2013), D. officinarum root extracts 
(Yang et al., 2012) and a phenol glycoside salidroside (Xiao et al., 2014), 
which conferred protection against polyQ neuronal toxicity. Treating C. 
elegans muscle polyQ models with hydroxylamine, icariin and celecoxib 
derivatives: NG-094, icariside II and OSU-03012 ameliorated polyQ-mediated 
protein aggregation and protected against polyQ proteotoxicity (Cai et al., 
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2011, Ching et al., 2011, Haldimann et al., 2011). Aspirin, an analgesic 
agent, was also shown to significantly improve polyQ-mediated animal 
paralysis, reducing the number of Q35-YFP aggregates and delaying polyQ-
dependent acceleration of aging (Ayyadevara et al., 2013). 
1.5.4 PD 
Multiple PD models, notably the toxin-induced models have aided in the 
discovery and validation of potential pharmacological interventions for PD. 
Chemical screens have suggested that compounds which protect 
mitochondria or increase autophagy protect against α-synuclein toxicity (Ved 
et al., 2005, Wolozin et al., 2011). Braungart et al. (Braungart et al., 2004) 
performed a HTS with the C. elegans MPTP model of PD and found that 
several anti-PD drugs can ameliorate MPTP-induced mobility defects in this 
model. Notably, lisuride and apomorphine which are dopamine receptor 
agonists, as well as rottlerin (protein kinase C inhibitor) ameliorated the 
behavioural defects at low concentration. In addition, nomifensine (dopamine 
transporter inhibitor), nicotine (nAch receptor antagonist), selegiline (MAO-B 
inhibitor), MPEP (mGluR-5 inhibitor), amantadine, α-lipoic acid (antioxidant) 
and ascorbic acid (AA) were useful at higher concentrations (Ved et al., 
2005). In another screen, two mammalian DA D2 receptor agonists, 
bromocriptine and quinpirole, were identified to confer significant 
neuroprotection independent of DA receptors in a 6-OHDA-induced DAergic 
neurodegeneration model of PD (Marvanova and Nichols, 2007). Similarly, a 
low concentration of acetaminophen (analgesic and antipyretic) was reported 
by Locke et al. (Locke et al., 2008) to significantly protect against 6-OHDA 
toxicity-induced DAergic neurodegeneration in Pdat-1::GFP expressing worms. 
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However, the protection appears to be selective as acetaminophen was not 
neuroprotective against α-synuclein-induced neurodegeneration at any 
concentration tested. The anti-epileptic drug, VA provided significant 
dopaminergic neuroprotection in a C. elegans PD model associated with 
human α-synuclein overproduction which was further shown to be mediated 
through ERK-MAPK signalling (Kautu et al., 2013). Most recent studies have 
also demonstrated the neuroprotective effects of phytocompounds such as n-
butylidenephthalide, curcumin, N-acetylcysteine and vitamin E on 6-OHDA-
induced degeneration of DAergic neurons and their ability to attenuate α-
synuclein accumulation. n-butylidenephthalide, in particular, has the greatest 
neuroprotective capacity and was shown to also restore food-sensing 
behaviour and the dopamine level in a pharmacological or transgenic C. 
elegans PD model as well as enhancing the life span of 6-OHDA-treated 
animals (Fu et al., 2014a). Acetylcorynoline, the major alkaloid component 
derived from Corydalis bungeana, a traditional Chinese medical herb 
demonstrated the same neuroprotective effects when applied to the same 
pharmacological and transgenic C. elegans PD models (Fu et al., 2014b). 
Kinase-targeted inhibition of LRRK2 protein activity was recently 
established as an effective treatment for PD as LRRK2 kinase inhibitors 
consistently mitigated pathogenesis caused by different LRRK2 mutations. 
Liu et al. (Liu et al., 2011b) showed that though GW5074, an indoline 
compound, and sorafenib, a Raf kinase inhibitor, did not have protective 
effects against α-synuclein- and 6-OHDA-induced toxicity, they increased 
survival and reduced DAergic neurodegeneration in G2019S-LRRK2 
transgenic C. elegans and Drosophila. Yao et al. (Yao et al., 2012) further 
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demonstrated the potency of kinase inhibitors as they were able to 
pharmacologically rescue both the behavioural deficit and neurodegeneration 
manifested by the expression of mutant LRRK2 G2019S and R1441C in vivo 
using two LRRK2 inhibitors, TTT-3002 and LRRK2-IN1, which also potently 
inhibited in vitro kinase activities of LRRK2 wild-type, R1441C and G2019S 
at nanomolar to low micromolar concentrations when administered either pre-
symptomatically or post-symptomatically.  
1.5.5 ALS  
Treatment with methylene blue (MB), an aggregation inhibitor of the 
phenothiazine class not only rescued toxic phenotypes (including neuronal 
dysfunction and oxidative stress) associated with mutant TDP-43 and FUS in 
C. elegans and zebrafish ALS models (Vaccaro et al., 2012), but also 
ameliorated Tau mediated toxicity in a newly established C. elegans model of 
Tau (Fatouros et al., 2012). Using transgenic TDP-43 models, Tauffenberger 
et al. evaluated 11 compounds previously reported to enhance longevity in C. 
elegans and resveratrol (polyphenol), rolipram (phosphodiesterase 4 
inhibitor), reserpine (antihypertensive), ethosuximide (anticonvulsant), trolox 
and propyl gallate (antioxidants) were revealed as effective candidates that 
protected against mutant TDP-43 toxicity in motor neurons (Tauffenberger et 
al., 2013). Recent genetic experiments by Kraemer’s group suggested that 
inhibiting cell division cycle kinase 7 (CDC7) kinase activity reduces 
phosphorylation of TDP-43 and the consequent neurodegeneration. Small 
molecule inhibition of CDC-7 by PHA767491 was further shown to robustly 
reduce TDP-43 phosphorylation and prevent TDP-43 dependent 
neurodegeneration both in vitro and in vivo (Liachko et al., 2013). 
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1.5.6 SMA 
Riluzole, an anti-glutamate agent proven to slow the progression of ALS and 
extend the ALS patients' survival by two to three months, was shown to also 
improve the neuromuscular function of the smn-1(ok355) null mutant model 
of SMA by activating the small conductance Ca2+-activated K+ (SK) channels 
which significantly increase both the motility and pharyngeal pumping rates of 
worms during feeding, as well as preventing axonal defects in Smn-deficient 
rat hippocampal neurons (Dimitriadi et al., 2013). Through screening of the 
National Institute of Neurological Disorders and Stroke (NINDS) collection of 
chemical compounds with subsequent validation assays in a mutant SMA 
model with a milder and fertile smn-1(cb131) allele, two FDA-approved drugs 
- 4-aminopyridine (potassium channel blocker) and gaboxadol hydrochloride 
(agonist of a specific extrasynaptic, δ-containing GABAA receptor subtype, 
α4β3δ), and one novel compound - N-acetylneuraminic acid (Neu5Ac) were 
shown to rescue at least one aspect of smn-1 phenotypic dysfunction (Sleigh 
et al., 2011) with potential for further study in vertebrate models for the 
treatment of SMA. 
1.5.7 ANCL 
Our recent data indicated that the newly established dnj-14 null mutant model 
of ANCL has potential for identifying generic neuroprotective interventions 
rather than drug targets that are disease specific. A focused chemical screen 
revealed that the natural polyphenolic compound resveratrol could ameliorate 
the short lifespan and chemosensory phenotypes of the dnj-14 mutants. A 
partial rescue of neurodegeneration phenotype was also observed. The 
mechanism of resveratrol action was deduced to be PDE4 inhibition-
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dependent as the cAMP phosphodiesterase inhibitor, rolipram was shown to 
mimic resveratrol in rescuing dnj-14 (Kashyap et al., 2014). In contrast to 
other worm neurodegeneration models (Parker et al., 2005, Karuppagounder 
et al., 2009, Bizat et al., 2010, Tauffenberger et al., 2013), resveratrol acted 
in a sir-2.1-dependent manner, as sir-2.1; dnj-14 double mutants showed full 
lifespan rescue by resveratrol. 
 Taken together, C. elegans ND models have extensively broadened 
the research on human NDs and will continue to facilitate the identification of 
novel pathways and drug targets, and expedite translation to clinical testing. 
Using a selection of the aforementioned neuronal worm models to screen for 
generally neuroprotective agents effective in multiple models is a potentially 
efficient strategy for therapeutic drug discovery for NDs. Neuronal ND models 
directly capture the neurodegeneration seen in NDs have already been 
shown to identify neuron-specific regulators as well as generally 
neuroprotective compounds that alleviate the functional consequences of 
protein misfolding common to neurodegeneration. 
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1.6 AIMS AND OBJECTIVES 
The specific aims of this study were to:  
1. Test the applicability of multiple C. elegans ND models for 
neuroprotective drug screening. 
2. Identify generally neuroprotective compounds that alleviate the 
pathological phenotypes of selected ND models. 
3. Investigate the mechanism of action of efficacious drugs. 
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CHAPTER 2: METHODS 
  
69 
 
2.1  MATERIAL AND REAGENTS  
2.1.1  Chemicals and consumables 
If not stated otherwise, enzymes, chemicals, kits and solutions used for 
molecular and biochemical analysis listed in Table 2.1 were utilised 
according to manufacturer's instructions. 
Table 2.1: Lists of reagents used in this study 
 
Consumables Manufacturer 
Hard-Shell® Low-Profile Thin-Wall 96-Well 
Skirted PCR Plates 
BioRad, Hemel Hempstead, UK 
iTaq™ Universal SYBR® Green Supermix 
Supermix 
BioRad, Hemel Hempstead, UK 
Ampicillin Calbiochem, Nottingham, UK 
Kanamycin Calbiochem, Nottingham, UK 
Proteinase K Invitrogen, Paisley, UK 
RNase free Dnase I Invitrogen, Paisley, UK 
UltraPure™ DNAse/RNAse-Free Distilled 
Water 
Invitrogen, Paisley, UK 
SYBR Safe DNA gel stain Invitrogen, Paisley, UK 
TRIzol® Reagent Invitrogen, Paisley, UK 
Recombinant RNasin® Ribonuclease 
Inhibitor 
Invitrogen, Paisley, UK; 
Promega UK Ltd., Southampton, UK 
Restriction enzymes ApaI, ApalI, BsrgI, 
NcoI, SacII 
New England Biolabs, Hitchin, UK 
M-MuLV Reverse Transcriptase (RNase 
H-) 
New England Biolabs, Hitchin, UK 
OneTaq Quick-Load 2X Master Mix with 
Standard Buffer - 100 rxns 
New England Biolabs, Hitchin, UK 
Deoxynucleotide (dNTP) Solution Set - 8 
μmol of each 
New England Biolabs, Hitchin, UK 
HighRanger Plus 1kb Ladder 300-10000bp Norgen Biotek (Thorold, ON, Canada) 
Random Primers 
Bioline, Taunton, MA; 
Promega UK Ltd., Southampton, UK 
Isopropyl β-D-1-thiogalactopyranoside 
(IPTG) 
Sigma-Aldrich, UK 
Ethosuximide Sigma-Aldrich, UK 
Succinimide Sigma-Aldrich, UK 
5-Hydroxy-1,4-naphthoquinone (Juglone) Sigma-Aldrich, UK 
6-Hydroxydopamine hydrobromide Sigma-Aldrich, UK 
Resveratrol (>99%) Sigma-Aldrich, UK 
The PureYield™ Plasmid Midiprep System Promega UK Ltd., Southampton, UK 
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Consumables Manufacturer 
Qiagen RNeasy Mini Kit, Qiagen, Crawley, West Sussex, UK 
QIAprep Spin Miniprep Kit Qiagen, Crawley, West Sussex, UK 
Absolutely RNA Microprep Kit Stratagene, Cambridge, UK 
Dulbecco modified Eagle medium (DMEM) Gibco®, Invitrogen, UK 
Fetal Calf Serum (heat-inactivated) (FCS) Gibco®, Invitrogen, UK 
Penicillin-Streptomycin Gibco®, Invitrogen, UK 
Trypsin-EDTA (1×), liquid Gibco®, Invitrogen, UK 
PromoFectin transfecting agent  
transfection reagent 
PromoKine, Heidelberg, Germany 
RPMI-1640 medium, with sodium 
bicarbonate 
Sigma-Aldrich, UK 
Sytox Orange® nucleic acid dye  Invitrogen, Paisley, UK 
NuPAGE® 12% Bis-Tris Gels Invitrogen, Paisley, UK 
NuPAGE® MOPS SDS Running Buffer (for 
Bis-Tris Gels only) 
Invitrogen, Paisley, UK 
SeeBlue® Plus2 Pre-Stained protein 
standard 
Invitrogen, Paisley, UK 
2.1.2  Oligonucleotides  
All oligonucleotides used in this study were synthesised by Sigma-Aldrich.  
Table 2.2: Lists of all used oligonucleotides 
Oligo Name Sequence 5' to 3' 
Amplicon 
Size (bp) 
Purpose 
C. elegans 
pmp-3  F  TGGTGTCGCGATTACTGTAG 
283 qRT-PCR 
pmp-3  R  GATTTGTTGTCGCAGAGTGG 
act-1 F  CTACGAACTTCCTGACGGACAAG  
102 qRT-PCR 
act-1 R  CCGGCGGACTCCATACC 
cyp-34A9 F  CGAGACTCTTGCCGTAGACC 
149 qRT-PCR 
cyp-34A9 R  TTCCACCGGTAACCTCTGTC 
cyp-34A9 F  TAACCGATAGGCCAAAGACG 
281 qRT-PCR 
cyp-34A9 R  ACAAGATCTCTTCCCGATGC 
cyp-35B1 F  CAAAGATGGAGCAGGAGAGG 
131 qRT-PCR 
cyp-35B1 R  ATTGAATCCTGCGACCAAAG 
cyp-14A3 F  CAAAGGACCGTTACCATTGC 
283 qRT-PCR 
cyp-14A3 R  TTGAAGCCTCCAGTTGTCTC 
ugt-25 F  ATGACTCACGGAGGTCTTGG 
108 qRT-PCR 
ugt-25 R  TGCAAGCATATTCGCATTTC 
gst-4 F  TGCTCAATGTGCCTTACGAG 
173 qRT-PCR 
gst-4 R  AGTTTTTCCAGCGAGTCCAA 
gst-10 F  AAGAGATTGTGCAGACTGGAG 99 qRT-PCR 
71 
 
Oligo Name Sequence 5' to 3' 
Amplicon 
Size (bp) 
Purpose 
gst-10 R  AGAACATGTCGAGGAAGGTTG 
clec-85 F 
CCTGATGATAAGTATATTGGAGACCTGT
GCTACTC 
94 qRT-PCR 
clec-85 R 
GGTTTTGGCTGTAGCACGCCGACTGAGC
ATCC 
ttr-44 F  GACGTCTGATCTGTGGAGAC 
301 qRT-PCR 
ttr-44 R  TCCAGGTTGAGAACTCCAAG 
dhs-26 F  AACATCTGCAGGATCTTGGG 
297 qRT-PCR 
dhs-26 R  CACAAAGTGATTGCCCATCC 
dod-6 F  TCCTCGTCATCATGTCTGTC 
148 qRT-PCR 
dod-6 R  CACTTTCCGCAAGTCTTTGG 
ugt-53 F  AACTTCCCTTTACCCCGAAC 
276 qRT-PCR 
ugt-53 R  TGTTTCGCTTTACGAATCGC 
ins-2 F  TCTGTCTCCTCTTCACAACTG 
203 qRT-PCR 
ins-2 R ACATTCTCCACATGTTGCAAGC 
pph-6 F  ACATGGAGGACTTTCACCTG 
307 qRT-PCR 
pph-6 R  ATAGCAGTAGTTTGGAGCCG 
dnj-14 (ok237) Full F GAAAATTGGTGATGATGCTGCAGG 
WT 2590, 
ok237 361 ok237 
genotyping 
PCR 
dnj-14 (ok237) Mid F CGCCAATATCTCCAGTCTCCAATG WT 1736, 
ok237 none dnj-14(ok237) R GTCTCCCAGAGGCAGTCGAACAAC  
daf-16(mu86) F 1  CCCACATTCGTGTGGGTTTTCTAGTCG WT 11385, 
mu86 405 
mu86 
genotyping 
PCR 
daf-16(mu86) out R CGTTATCAAATGCTCCTTGCATTGAATC 
daf-16(mu86) int R GCGTCAGTTCCGATCTGATATGAAC 
WT 635, 
mu86 none 
daf-16(+) F GCAATGTGGACAGCTCGGCGGAGC WT 436, 
mu86 none 
mu86 
homozygotes 
genotyping daf-16(+) R CAGATAAGAGAGAGTCTTATAGGG 
cca-1(ad1650) Avery 
F 
CCGCAATTTGCCCTCCACAT 
WT 3310, 
ad1650 930 
ad1650 
genotyping 
PCR 
cca-1(ad1650) Avery 
R 
ATGAGGATGGCGAAGAGGACC 
cca-1(ad1650) F CGGAAATATTAACTGTCATTCTGGA WT 1350, 
ad1650 none 
ad1650 
homozygotes 
genotyping cca-1(ad1650) R CGTGCCTTCACAACCGAACTG 
Tau F CAAGCTCGCATGGTCAGTAA 
425 
Tau 
genotyping Tau R TTCTCAGTGGAGCCGATCTT 
Mice 
Ccng2 F AGGGGTTCAGCTTTTCGGATT 
112 qRT-PCR 
Ccng2 R AGTGTTATCATTCTCCGGGGTAG 
Cdkn1a F CCTGGTGATGTCCGACCTG 
103 qRT-PCR 
Cdkn1a R CCATGAGCGCATCGCAATC 
Cdkn1b F TCAAACGTGAGAGTGTCTAACG 
103 qRT-PCR 
Cdkn1b R CCGGGCCGAAGAGATTTCTG 
Gadd45a F AGACCCCGATAACGTGGTACT 
318 qRT-PCR 
Gadd45a R TGATCCATGTAGCGACTTTCC 
Sod2 F CAGACCTGCCTTACGACTATGG 
113 qRT-PCR 
Sod2 R CTCGGTGGCGTTGAGATTGTT 
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Oligo Name Sequence 5' to 3' 
Amplicon 
Size (bp) 
Purpose 
Rbl2 F AACTTCCCCATGATTAGCGATG 
97 qRT-PCR 
Rbl2 R GGTTAGAACACTGAAGGGCATTT 
Cat F GCGTCCAGTGCGCTGTAGA 
199 qRT-PCR 
Cat R TCAGGGTGGACGTCAGTGAA 
Eif4ebp1 F GGGGACTACAGCACCACTC 
171 qRT-PCR 
Eif4ebp1 R CTCATCGCTGGTAGGGCTA 
Bcl2l11 F CCCGGAGATACGGATTGCAC 
96 qRT-PCR 
Bcl2l11 R GCCTCGCGGTAATCATTTGC 
Gapdh F AGGTCGGTGTGAACGGATTTG 
123 qRT-PCR 
Gapdh R TGTAGACCATGTAGTTGAGGTCA 
Actb F GGCTGTATTCCCCTCCATCG 
154 qRT-PCR 
Actb R CCAGTTGGTAACAATGCCATGT 
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2.1.3  Nematode strains and materials 
Table 2.3: List of all utilised C. elegans strains and genotypes. 
 
Strain Genotype Origin 
N2 DRH C. elegans wild type var. Bristol CGC 
RM2754 dnj-14(ok237)X CGC 
 
dnj-14(tm3223)X NBRP 
JD21 cca-1(ad1650)X CGC 
AM134 rmIs126 [Punc-54::Q0::YFP::unc-54 3′-UTR] CGC 
AM138 rmIs130 [Punc-54::Q24::YFP::unc-54 3′-UTR] CGC 
AM140 rmIs132 [Punc-54::Q35::YFP::unc-54 3′-UTR] CGC 
AM141 rmIs133 [Punc-54::Q40::YFP::unc-54 3′-UTR] CGC 
CZ1200 lin-25(n756ts)X; juIs76[Punc-25::GFP + lin-15(+)] BC Kraemer 
CK10 bkIs10 [Paex-3::h4R1N TauV337M + Pmyo-2::GFP] BC Kraemer 
CK49 CZ1200 bkIs10 [Paex-3::h4R1N TauV337M + Pmyo-2::GFP] BC Kraemer 
CB1370 daf-2(e1370)III CGC 
CF1038 daf-16(mu86)I CGC 
TJ356 zIs356 [Pdaf-16::daf-16a/b::GFP + rol-6] CGC 
LM99 smn-1(ok355) I/hT2[bli-4(e937)+let-?(q782)+qIs48Pmyo-2::GFP]  CGC 
HA659 rtIs11[Posm-10::GFP + Posm-10::HttQ150 +dpy-20(+)] CGC 
HA759 pqe-1(rt13); rtIs11[Posm-10::GFP + Posm-10::HttQ150 +dpy-20(+)] CGC 
CB112 cat-2(e1112) CGC 
PD8120 smg-1(cc546) CGC 
 
N2 Ex[Pdat-1::α-syn(WT) + Pdat-1::GFP] CGC 
 
juIs76 [Punc-25::GFP + lin-15(+) + Pmyo-2::GFP] J Johnson 
UA57 baIn4 [Pdat−1::GFP + Pdat−1::CAT-2] RD Blakely 
BY250 vtIs7 [Pdat−1::GFP] RD Blakely 
CL2355 smg-1(cc546) dvIs50 [Psnb-1::Aβ1−42::long 3’-UTR + Pmtl-2::GFP]  CD Link 
CL2122 dvIs15 [Punc-54 + Pmtl-2::GFP] CD Link 
 
Psnb-1::G85R SOD1-YFP J Wang 
 
Psnb-1::WT SOD1-YFP J Wang 
CL2166 dvIs19 [(Pgst-4::GFP::NLS]III CGC 
Strains obtained by crossings 
AMG119 cca-1(ad1650)X ; bkIs10 [Paex-3::h4R1N TauV337M + Pmyo-2::GFP] X Chen 
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2.2  MOLECULAR BIOLOGY METHODS 
2.2.1 Transformation of plasmids into chemically competent E.coli 
To amplify DNA constructs by plasmid miniprep or midiprep methods, 
plasmid DNA was transformed into chemically competent E.coli strain XL1, 
prepared in-house, via heat shock treatment. A 50 μl aliquot of bacteria was 
thawed on ice before incubation with 0.5 μl of DNA in pre-chilled Eppendorf 
tubes on ice for 30 minutes. After heat shock treatment at 42°C for 45 
seconds, the sample was put immediately back on ice for 2 minutes followed 
by addition of 950 μl super optimal broth with catabolite repression (SOC) 
medium (2% (w/v) tryptone, 0.5% (w/v) yeast extract, 10 mM NaCl, 2.5 mM 
KCl, 10 mM MgCl2, 20 mM glucose) and incubation at 37°C for 1 hour with 
continuous shaking at 220 rpm. 25 μl of the transformed E.coli were spread 
onto LB-agar plates (1% (w/v) tryptone, 0.5% (w/v) yeast extract, 1% (w/v) 
NaCl, 1% (w/v) agar), containing the required antibiotic (100 μg/ml ampicillin 
or 50 μg/ml kanamycin) and cultured overnight at 37°C.  
2.2.2  Purification of plasmid DNA 
Discrete E. coli colonies containing the relevant plasmid were picked to 
inoculate 30 ml of LB media (1% w/v tryptone, 0.5% w/v yeast extract, 8.56 
mM NaCl) containing a selection antibiotic and were grown overnight at 
37°C, 250 rpm. The cultures were then pelleted by centrifugation (12000 x g, 
10 minutes) and plasmid DNA were extracted from the bacterial pellet using 
either a QIAprep Spin Miniprep Kit (Qiagen) or a PureYield Plasmid Midiprep 
System (Promega) following the manufacturer’s guidelines. The plasmid DNA 
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concentration was determined spectroscopically with the NanoDrop® Lite 
(Thermo Fisher Scientific, Waltham, MA, USA) at 260 and 280 nm. 
2.2.3  DNA digestion with restriction endonucleases 
Plasmids were digested with restriction endonucleases (NEB) that were 
selected using ApE (A plasmid Editor; 
http://biologylabs.utah.edu/jorgensen/wayned/ape/). 5 μl of miniprep or 
midiprep DNA was added to 0.5 μl of restriction enzyme, 2 μl of 10x bovine 
serum albumin (BSA) and 2 μl of 1x reaction buffer (NEB) in 20 μl of total 
reaction volume. The reaction was incubated at 37°C for at least one hour.  
2.2.4  Separation and isolation of DNA fragments  
Agarose gel electrophoresis was used to separate DNA fragments according 
to their size. To load the DNA solution into the gel pockets, DNA fragments 
were combined with 6x DNA loading buffer (0.35% (w/v) orange G, 0.1% 
(w/v) bromophenol blue, 30% (w/v) sucrose) and separated by gel 
electrophoresis using a 2% (w/v) agarose gel containing SYBR® Safe DNA 
Gel Stain (Life Technologies). Electrophoresis was carried out in Tris-
acetate-EDTA buffer (40 mM Tris, 20 mM acetic acid, 1 mM EDTA) at 90 V 
for 45-60 minutes. 10 μl of HighRanger Plus 100bp DNA ladder (Norgen 
Biotech) was run alongside the samples as a size reference. The DNA was 
visualised with UV light in a ChemiDoc XRS (BioRad) with Quantity One 
software (BioRad; v4.6.3).  
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2.3  C. ELEGANS BASED METHODS 
2.3.1  Maintenance and propagation of C. elegans strains  
C. elegans strains were cultured on 6 cm nematode growth medium agar 
(NGM; 2% (w/v) agar, 0.3% (w/v) NaCl, 0.25% (w/v) peptone, 1 mM CaCl2, 5 
μg/ml cholesterol, 25 mM KH2PO4, 1 mM MgSO4) at 20°C, seeded with 50 μl 
E. coli strain OP50 culture as a food source, using standard methods 
(Brenner, 1974). Worm strains were maintained at 20°C, except for strains 
CL2355, CL2122 and PD8120 utilised in Chapter 3, which were maintained 
for 36 hours at 17°C, and upshifted to 25°C to induce transgene expression. 
C. elegans strains used in this study are detailed in Table 2.3, they were 
either obtained from Caenorhabditis Genetics Center (CGC, University of 
Minnesota, USA) or generously provided by the labs in which the strain had 
been constructed. dnj-14(tm3223)X was obtained from the National 
Bioresource Project for the Experimental Animal “Nematode C. elegans” 
based in the lab of Dr Shohei Mitani (Tokyo Women’s Medical University, 
Tokyo, Japan). N2 var. Bristol was used as wild type strain. Worms were 
transferred from an old plate to a new plate either by picking individual worms 
with a tungsten wire, or by cutting out a chunk of agar and putting it on a new 
plate. 
2.3.2  Axenisation and decontamination of C. elegans cultures 
For the decontamination of C. elegans strains, worms were subjected to 
alkaline hypochlorite treatment or by transferring original worms to fresh 
plates on a daily basis. For bleach sterilisation, a relatively full plate of gravid 
adults was washed with 3.5 ml sterile H2O and collected in a 15 ml Falcon 
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tube. 1.5 ml bleach mixture (two parts commercial bleach to one part 5 M 
NaOH) was added and the falcon tube was vortexed well every 2 minutes for 
10 minute to destroy the cuticle of gravid animals and allow the release of 
eggs. Axenised eggs were collected by centrifugation at 1300 x g, 4°C for 2 
minutes and washed twice with 5 ml sterile H2O. The supernatant was 
removed and the pellet of eggs was transferred to the edge of a seeded 
plate.  
Sterilisation and synchronisation of stocks by alkaline hypochlorite 
treatment was essential in Chapter 5 due to the large-scale C. elegans 
culture for the highly sensitive microarray experiment and subsequent RNA 
interference (RNAi) analyses. Contamination during RNA sample 
preparations and carrying over of either OP50 bacteria or HT115 RNAi 
bacteria needs to be avoided. 
Limited egg-lay was also applied to age-synchronise nematodes. 5-15 
gravid adults were plated to lay eggs for 6 hours and then removed to set the 
eggs in synchrony. All the eggs released in that time period have been 
shown to be well synchronised. Some strains are more prolific than other 
strains, so times and numbers of animals were adjusted accordingly. 
2.3.3  Freezing and recovery of C. elegans stocks 
For indefinite storage C. elegans strains were frozen and kept at -80°C. 
Worms of 2-3 freshly starved 60 mm plates (containing many L1-L2 stage 
larvae) were washed off plates with 1.5 ml M9 buffer (5 g/l NaCl, 3 g/l 
KH2PO4, 6 g/l Na2HPO4, 1 mM MgSO4) and collected in a 15 ml falcon tube. 
After adding an equal volume of freezing solution (100 mM NaCl, 50 mM 
KH2PO4, 30% (w/v) glycerol, 5.5 mM NaOH, 3 mM MgSO4), the worm 
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suspension was mixed well and aliquoted evenly between four cryovials (750 
μl per tube). The cryovials were packed in a styrofoam box wrapped in tissue 
to achieve a slower freezing rate and put in a -80°C freezer. An aliquot was 
thawed the following day and plated to check there were surviving worms. 
Working populations of worms were refreshed from frozen stocks periodically 
to combat any genetic drift from normal strain maintenance. For recovery of a 
C. elegans stock, a frozen aliquot was thawed at room temperature and 
transferred onto a fresh NGM plate. 
2.3.4  Administration of pharmacological compounds 
All pharmacological compounds were obtained from Sigma-Aldrich. 
Concentrated solutions of each drug were prepared by dissolving compounds 
in 1 × phosphate-buffered saline (PBS; 2.7 mM KCl, 138 mM NaCl, 1.5 mM 
KH2PO4, 20.4 mM NaH2PO4 [pH 7.2]), dimethyl sulfoxide (DMSO) or ethanol 
at 50-100 mg/ml, and were added to molten NGM that had been autoclaved 
and cooled to 50-60°C. The mixture was agitated to ensure the compounds 
were dissolved and poured into 60-mm petri dishes. Vehicle control NGM 
plates containing equivalent amounts of PBS, DMSO or ethanol were also 
prepared. Freshly poured drug plates were stored in the dark at 4°C until 1-2 
days before use and then moved to room temperature and seeded with 
E. coli OP50. Worms were grown for two generations on drug plates to 
ensure effective exposure (Figure 2.1). 10-20 gravid adults of test strains 
were cultured in the presence of the drug to lay eggs for 6 hours and then 
removed to set the eggs in synchrony. Plates were inverted and transferred 
to a container where descendants were then grown at 20°C for three days 
and selected for analysis at the L4 stage (defined as day 0). 
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Positive effect: suppression of motility defect/ extension of lifespan
Go to the next 
molecule
Step 6. Validation and further optimisations with in vitro mammalian cultures and mammals 
Step 2. C. elegans ND model was exposed to test compound /vehicle control. 
Treatments were initiated from the time of hatching and continued until death
Step 3. Multiple concentrations of candidate drugs tested to identify 
optimal effective dose which was used for subsequent experiments
Examination of locomotion/lifespan No effect
Step 4. Secondary analysis in multiple worm models 
Step 1. Characterisation and selection of C. elegans ND models
Robustness
Penetrance
Step 5. Identification of mode-of-action (MOA)
  
Figure 2.1: Experimental design for screening potential therapeutic compounds in 
neuorodegenerative disease (ND) models. Step 1. Selection of the C. elegans ND models for 
screening. Phenotypic criteria of chosen models were tested and ones with the most robust and 
reproducible behaviour phenotypes are well suited for assessing drug effects. Step 2. Selected ND 
models were grown for two generations on drug plates from conception to death to ensure effective 
exposure. Experiments involving pharmacological compounds were always done in parallel with a 
control group exposed to vehicle alone. Responses of worm ND model to drugs were assessed by 
comparing the locomotion and lifespan under various drug treatment concentrations which are 
parameters indicative of the worm physical healthiness. Compounds that cause significant rescue of 
locomotion impairment and increase in lifespan are considered good candidates for further testing. 
Drugs that failed to improve this measure of disease protein-related behavioural phenotypes at multiple 
concentrations of drug were not evaluated further. This testing was conducted in duplicate, and we 
found reproducible improvement of the pathological phenotypes for selected ND models. Step 3. The 
dose responses of promising compounds were profiled and effective doses were retested and serial 
dilutions were made to define the highest possible dose exempt of deleterious effect. Step 4. The 
efficacy of promising compounds was further evaluated in multiple NDs. Step 5. Explore the MOA of 
promising compounds i.e. test whether they alter biochemical endpoints such as levels of soluble and 
insoluble tau protein or reduce aggregation load. Step 6. These promising compounds may be further 
subjected to in vitro testing using human cells and in vivo testing in mammalian models of NDs. 
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2.3.5  Lifespan assay 
For measurements of lifespan, parental worms were cultured and progeny 
were selected for analysis at the L4 stage (defined as day 0). In order to 
maintain statistical power, the starting number of worms was 10-20% higher 
than the intended final 50 hermaphrodites for each concentration. 
Approximately 25 hermaphrodites were cultured on each petri dish. Animals 
were scored every 1-2 days for survival by examining for touch provoked 
movement. Worms which did not display spontaneous movement or 
response to repeated touching were scored as dead. Worms found on 
contaminated plates, displayed internally hatched progeny, an extruded 
gonad, or desiccation caused by crawling off the agar were censored and 
excluded from the data. At least two trials were performed for all genotypes, 
and the data shown represent the average of replicates. Worms were 
transferred frequently during the first week of adulthood until the cessation of 
progeny production. Lifespan assays performed to test the effects of drug 
compounds or RNAi treatments on lifespan were always transferred onto 
fresh plates every 2-4 days to ensure the presence of active compound and 
to maximise RNAi efficacy. 
2.3.6  Behavioural scoring  
2.3.6.1 Thrashing assay  
Thrashing assays quantify motor deficits in liquid medium and have been 
used extensively in studies of ND models as a measure of disease-
associated cellular toxicity.  Developmentally synchronised worms were 
transferred to 50 μl drops of Dent’s Ringer solution (DRS; 10 mM HEPES, 
140 mM NaCl, 6 mM KCl, 3 mM CaCl2, 1 mM MgCl2, pH 7.4) containing 
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0.1% (w/v) bovine serum albumin (BSA) to observe their thrashing 
movements. To assess their locomotory ability, the number of thrashes was 
counted for 1 minute after 10 minutes of equilibration. A thrash was counted 
when both the head and tail bent more than 45 degrees away from the 
anterior-posterior axis and back again. Animals with moving heads and stick-
like bodies were scored as partially paralysed but were also analysed for 
head movements the left or right of the central body axis (lateral head 
movement) and for attempts at forward motion (forward advancement). 
Individuals were categorised as immobilised following 10 seconds of 
inactivity. 10-20 worms per strain were subjected to thrashing assays which 
were conducted at 20°C. 
2.3.6.2  Nose touch avoidance assay 
Nose touch avoidance was assayed by placing the blunt end of an eyelash 
hair, glued to a toothpick on an animal path while the animal was moving 
forward perpendicular to the direction of movement as previously described 
(Kaplan and Horvitz, 1993). These assays were conducted on NGM plates 
containing a thin layer of bacterial lawn. This was done by spreading 100 μl 
of an overnight culture of E. coli OP50 and allowing it to dry for a couple of 
hours. Animals were scored 10 times each for response to nose touch. 
Avoidance behaviour was quantified as the percentage of trials in which the 
animals responded to touch with an eyelash by stopping forward motion or 
initiating a reversal. This function is mainly carried out by ASH neurons. No 
more than 10 trials were conducted on a single worm at a time to avoid 
habituation and a minimum of 10 animals was tested for each genotype.  
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2.3.6.3  Self-brood size assay 
When the synchronised population reached L4, individual hermaphrodites 
were picked onto 35-mm plates. Thereafter, the adult parents were 
transferred to new plates daily until the mother either failed to produce 
progeny for two consecutive days or died.  Animals that crawled off of or 
burrowed into the NGM agar and did not return to the surface were not 
included in the data set. The progeny of the previous plate were counted the 
next day. The number of progeny from the various plates was added up and 
total number of progeny produced was counted once the offspring had 
matured to adulthood to give the final brood size. 
2.3.7  RNA interference (RNAi) by feeding 
RNAi experiments were conducted using feeding protocols according to 
standard procedures. RNAi in C. elegans was accomplished by feeding 
worms HT115 (DE3) bacteria expressing target-gene double-stranded RNA 
(dsRNA) from the pG-L4440 vector (Timmons et al., 2001). E. coli strain 
HT115 lacks the dsRNA-specific RNase III but contains an isopropyl β-D-1-
thiogalactopyranoside (IPTG)-inducible T7 RNA polymerase (Timmons et al., 
2003), carrying the pG-L4440 vector containing gene-specific RNAi trigger 
sequences. All RNAi feeding clones were obtained from the Vidal C. elegans 
Open Reading Frame (ORF) RNAi feeding library (Source Bioscience, 
Nottingham, UK) (Rual et al., 2004). 
90-mm plates of Luria-Bertani (LB) agar (1% tryptone, 0.5% yeast 
extract, 1% NaCl, 1.5% agar) with 100 μg/ml ampicillin were poured. 
Bacterial strains used for RNAi were streaked on separate plates grown from 
the frozen stock and incubated overnight at 37°C. Two discrete colonies from 
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each plate were each grown in 30 ml LB containing 100 μg/ml ampicillin 
overnight at 37°C, 220 rpm. The plasmid was then purified using the QIAprep 
Spin Miniprep Kit (Qiagen) and the correct insert verified by restriction 
endonuclease digest. Bacterial culture was also incubated with 1 mM IPTG at 
37°C, 220 rpm for an additional 4 hours to allow the bacteria to produce 
dsRNA. 50 μl of the ten-fold concentrated cultures were spotted onto 1 mg/ml 
ethosuximide or vehicle control NGM plates supplemented with 100 μg/ml 
ampicillin and 2 mM IPTG media 4-7 days after pouring. RNAi-plates lose 
RNAi efficiency along with time course, so they were prepared newly in every 
experiment. RNAi plates were always kept in the dark, as IPTG is light 
sensitive.  
RNAi treatments were performed as whole-life treatments and second 
generation RNAi feed worms were synchronised on fresh RNAi plates 
supplemented with test compound (ethosuximide) or vehicle (PBS). Feeding 
of HT115 carrying the pG-L4440 vector without an insert (L4440) served as 
the empty vector (no knock-down) negative control, whereas hsp-1 was used 
as a positive control, as it gives a sterile phenotype (Simmer et al., 2003). 
2.3.8  Genomic DNA extraction and single worm PCR  
To determine whether a worm is homozygous or heterozygous for a 
particular deletion allele, individual worms were picked into 10 μl of lysis 
buffer, consisting of diluted 5x Phusion® HF Buffer (NEB) and Proteinase K, 
and was frozen at −80°C. After one cycle of freeze-thawing, samples were 
incubated in a thermal cycler at 65°C for 90 minutes, followed by 95°C for 15 
minutes. 2 μl of this lysate was typically used for genotyping PCR reactions 
using the primers listed in Table 2.2. PCR was performed in a final volume of 
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25 μl using 12.5 μl of OneTaq Quick-Load 2× Master Mix (NEB), 2 μl of 
template, forward and reverse primers (1 μl of 10 μM) and 9.5 μl of 
diethylpyrocarbonate-treated (DEPC) water. PCR amplifications rounds used 
95°C for 2 minutes, followed by 30 cycles of 95°C for 30 seconds, 55°C for 
30 seconds, 72°C for 30 seconds, with a final extension of 72°C for 5 
minutes. Amplified products were then subjected to analysis on 2% agarose 
gels. 
2.3.9  Total RNA preparation from C. elegans 
Total RNA was isolated from 30 gravid adult hermaphrodite worms using the 
Absolutely RNA Microprep Kit (Stratagene) following the vendor’s protocol 
with slight alterations. Briefly, the worms were transferred into 100 μl of Lysis 
Buffer- β-mercaptoethanol mixture and frozen at −80°C for 15 minutes. After 
three cycles of freeze-thawing, each sample was vortexed for 5 seconds with 
100 μl of 70% ethanol and RNA was purified following the DNAse treatment 
step.  
2.3.10  Reverse transcription and RT-PCR  
For generation of cDNA, 10 μl of total RNA from previous step was reverse 
transcribed using the Tetro cDNA synthesis kit with random hexamer primers 
(Bioline) according to the manufacturer's protocol.  Reverse-Transcriptase 
PCR (RT-PCR) analysis was performed in a final volume of 50 μl using 25 μl 
of 2 x MyTaq master mix (Bioline), 5 μl of cDNA, and forward and reverse 
primers (2 μl of 10 μM). PCR amplifications rounds used 95°C for 2 minutes, 
followed by 30 cycles of 95°C for 30 seconds, 55°C for 30 seconds, 72°C for 
30 seconds, with a final extension of 72°C for 5 minutes. To control for 
equivalent levels of input RNA to verify homogeneous loading and cDNA 
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integrity, primers targeting the housekeeping gene β-actin were used as 
internal control. Amplified products were then subjected to analysis on 2% 
agarose gels. 
2.3.11  Genetic crosses 
2.3.11.1  Generation and maintenance of males 
New strains are often generated by crossing two existing strains.  Males were 
generated either by mating hermaphrodites with males from a wild-type male 
stock, or by heat-shocking hermaphrodites. Heat-shock increases the 
incidence of non-disjunction of the X-chromosome during meiosis and 
therefore leads to a higher incidence of males. Ten plates each containing 10 
L4 hermaphrodites were exposed to 31°C for 6 hours and the progeny of 
these animals were then screened for males. Mating plates were typically 
maintained with nine males and three hermaphrodites on each plate, and 
worms were allowed to mate for 3 days to create a population rich in males 
(F1 progeny with approximately 50% males).  
2.3.11.2  Crosses and selection of transgenic mutants 
Genetic crosses of the stable integrated CK10 Paex-3::Tau V337M; Pmyo-
2::GFP transgenic worms and cca-1(ad1650) deletion mutant worms in 
Chapter 4 were done by first crossing N2 males to CK10 Paex-3::Tau V337M; 
Pmyo-2::GFP hermaphrodites, to generate transgenic heterozygous males 
verified by pharyngeal GFP expression. This strategy allows unequivocal 
identification of progeny derived from mating, because fluorescent progeny 
(Pmyo-2::GFP) must be heterozygous by definition. Transgenic male offspring 
were then back-crossed to isolate homozygous GFP (-Tau)-expressing 
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males. These were then mated with hermaphrodites of the same strain in 
order to create a population rich in males. Homozygosity was distinguished 
via uncoordination and coiler phenotypes as heterozygotes exhibited normal 
movement on plates. More robust GFP expression was also observed in the 
homozygous worms than the heterozygotes. GFP (-Tau)-expressing males 
were subsequently crossed twice with cca-1(ad1650) mutant hermaphrodites 
(generating cross progeny heterozygous for the Tau GFP transgene and the 
cca-1 mutation in the 1st round). Parents were removed from the mating plate 
after overnight mating. Hermaphrodite progeny of the F1 generation, which 
are homozygous for the cca-1(ad1650) mutation but heterozygous for Tau 
GFP were isolated and allowed to self fertilise to give rise to an F2 
generation, which includes worms homozygous for both transgene array and 
mutation. This enabled the differentiation between homozygous wildtype, as 
well as worms heterozygous or homozygous for the mutant cca-1(ad1650) 
allele. F2 progeny were then singled out and their progeny (the F3 
generation) were screened to determine the genotype of the F2 parent. 
Homozygosity of the F2 generation hermaphrodites was determined by 100% 
propagation of the GFP expression signal in F3 progeny.  
2.3.11.3  Crosses and selection of deletion mutants 
In the case of the dnj-14(ok237) and daf-16(mu86) deletion mutant worms as 
well as dnj-14(ok237) and daf-2(e1370) deletion mutant worms depicted in 
Chapter 5, dnj-14(ok237) were first crossed with N2 males to obtain dnj-
14(ok237) males, before dnj-14(ok237) males were mated to either daf-
16(mu86) or daf-2(e1370) hermaphrodites. Twenty F1 cross progeny were 
singled onto individual plates and selfed at 20°C. PCR-based genotyping 
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(2.3.8) of the parental F1 animals confirmed the heterozygosity of the 
particular deletion alleles. Due to the slow growth phenotype of dnj-
14(ok237), slow growing F2 cross progeny of the dnj-14(ok237) and daf-
16(mu86) cross were singled on NGM plates to lay eggs and both dnj-
14(ok237) homozygosity and daf-16(mu86) deletion were analysed by single 
worm PCR. Because worms homozygous for the daf-2(e1370) allele at 25°C 
exhibit the constitutive dauer phenotype, F1 hermaphrodites (putative daf-
2(e1370)/+; dnj-14(ok237)/+) were singled on NGM plates to lay eggs at 
25°C. After 3-4 days, F2 animals which exhibit 100% constitutive dauer 
phenotype were selected and transferred to 15°C to recover and finish 
development before the dnj-14(ok237) deficiency was checked by PCR.  
2.3.12  Microscopic analysis of C. elegans 
2.3.12.1  Live imaging 
Images were captured with a Nikon Eclipse Ti microscope driven by NIS-
Elements 2.3 software (version 2.3; Nikon) using 300 ms exposure time at a 
magnification of 200x and 400x using a 20x and a 40x objective, respectively. 
Microscopy of living animals was performed by mounting the worms on cover 
glass (22 x 40 mm, VWR International, PA) in a 5 μl drop of polyethylene 
glycol (PEG)/glycerol. PEG/glycerol mounting medium is a blend of equal 
percentage (20:20) of PEG 20000 and glycerol in PBS which immobilises the 
nematode. Slides were rapidly sealed with a clean glass coverslip (13 mm, 
VWR International, PA). In all imaging experiments, between 5-10 C. elegans 
were mounted on a single slide and individual worms were randomly 
selected. Scoring was completed within 15-20 minutes of placing the 
coverslip, as the accuracy of this criterion for mortality is lost after the worms 
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are covered longer. GFP is subject to photobleaching, and the worms’ 
condition deteriorates under a coverslip on the microscope. (Under ideal 
circumstances, scoring can be completed in 5-10 minutes). Scoring was 
therefore halted when fading or deterioration became apparent. Animals 
damaged in handling, or animals whose intestinal tracts appeared to be 
breaking down and were assumed to be dead, were excluded from scoring.  
2.3.12.2  Quantification of axonal degeneration  
Worms were synchronised and imaged under fluorescence microscopy as 
described above. They were scored for the number of gaps in the ventral and 
dorsal nerve cords. Although C. elegans has 19 GABAergic motor neurons, 
counts in control and experimental groups were slightly less than 19, 
presumably due to the occasional inability to distinguish individual cell bodies 
in closely opposed pairs of neurons. 
2.3.12.3  6-hydroxydopamine cell death assay and quantitative 
analyses of neuronal degeneration 
The 6-hydroxydopamine (6-OHDA) toxicity assay was performed as 
described previously (Nass et al., 2001, McDonald et al., 2007) with slight 
modifications. At 24 hours after synchronisation, L2/L3 BY250 worms were 
washed with sterile water from large 90-mm NGM plates at 20°C and 
transferred to glass conical tubes. An equal volume of 6-OHDA (Sigma-
Aldrich) stock solution (100 mM 6-OHDA in 20 mM ascorbic acid (AA), the 
latter is required in order to stabilise 6-OHDA in solution) was added to the 
worm suspension to achieve the final concentrations of 50 mM 6-OHDA in 10 
mM AA. Vehicle control animals were treated with 10 mM AA alone. Worms 
were then incubated in the dark for 1 hour at room temperature with gentle 
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agitation every 10 minutes.  After treatment, the worms were washed with M9 
buffer, the supernatant was discarded and the process was repeated. Worms 
were then placed on NGM plates seeded with OP50 bacteria and incubated 
at 20°C until analysis of Pdat-1::GFP expression at time points ranging from 2 
to 72 hours after 6-OHDA exposure. For each time point, 20-40 worms per 
strain were immobilised with PEG/glycerol mounting medium as described 
above (2.3.12.1) and were analysed in at least three independent 
experiments, with a total of 71-120 animals scored in the same manner. In 
quantifying dopaminergic (DAergic) neurodegeneration, a worm was scored 
as ‘wild type (WT)’ when a full complement of all six anterior DAergic neurons 
is present with neuronal processes (the prominent dendrites in CEP neurons 
or axons in ADE neurons) were intact and fully extended to their target areas; 
neuron was scored as ‘partially degenerating’ when at least one degenerative 
change such as dendrite blebbing of any of the four neuronal dendrites or cell 
body rounding was observed; neuron was scored as ‘completely 
degenerating’, when loss of neuronal dendrites or cell bodies were evident. 
All six anterior DAergic neurons were scored in each animal. The percentage 
of nematodes in a population with intact anterior dopamine neurons was 
determined.  
 
2.4  PROTEIN BIOCHEMICAL METHODS 
2.4.1  Preparation of C. elegans protein extracts 
Extracts were prepared following growth of worms to near-confluency on 
seven 90-mm diameter NGM plates. Worms were harvested in M9 buffer and 
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were frozen at -80°C overnight. The worm pellets were thawed on ice before 
use and homogenised using a Mikro-Dismembrator (Braun Biotech 
International, Melsungen, Germany) at 2000 rpm for 2 minutes in an equal 
volume of worm lysis buffer [140 mM KCl, 1 mM EDTA, 50 mM HEPES pH 
7.4, 2% SDS and 1 tablet of protease inhibitor cocktail (Sigma)] with acid-
washed glass beads (425-600 μm; Sigma) added to the level of the 
meniscus. Three holes were made in the base of each tube with a BD 
Microlance™ 3 25G hypodermic needle (Becton Dickinson & Co. Ltd, 
Ireland). The tube was placed in a 15 ml Falcon and crude protein extracts 
were centrifuged at 5000 rpm for 5 minutes at 4°C to obtain the lysates, 
followed by centrifugation at 13000 rpm at 4°C for 20 minutes to remove the 
worm debris and insoluble material. The supernatant was collected and 
aliquots were either used immediately or stored at -80°C.  
 Protein samples were also prepared by picking, freeze-thawing, and 
boiling 25-50 worms of selected strains in Laemmli buffer (4% (w/v) SDS, 
20% (v/v) glycerol, 10% (v/v) 2-mercaptoethanol, 0.004% (w/v) bromphenol 
blue and 0.125 M Tris HCl, pH 6.8) at 95°C for 25 minutes. 
2.4.2  Sequential extraction of Tau protein  
Soluble and insoluble fractions were obtained using the methods previously 
employed to extract aggregation-prone proteins from mouse and worms 
(Ishihara et al., 1999, Guthrie et al., 2009, David et al., 2010), with 
modifications (Figure 2.2). Extracts were prepared following growth of mixed 
stage populations of vehicle and ethosuximide treated Tau V337M worms to 
near-confluency on twenty 90-mm diameter NGM plates. Worms were 
washed off plates with M9 buffer and the collected worm pellets were then 
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stored at -80°C. After the freeze thaw cycle, frozen animals were directly 
homogenised using a Mikro-Dismembrator at 2000 rpm for 2 minutes in an 
equal volume of high-salt reassembly (RAB) buffer (100 mM MES, 1 mM 
EGTA, 0.5 mM MgSO4, 20 mM NaF, 0.75 M NaCl, 0.5 mM PMSF, 0.1% 
protease inhibitor cocktail, pH 7.0) with acid-washed glass beads (425-600 
μm; Sigma) added to the level of the meniscus. Crude protein extracts were 
centrifuged at 5000 rpm for 5 minutes at 4°C to obtain the lysates, followed 
by ultracentrifugation at 40000 rpm at 4°C for 40 minutes. The supernatant 
was subsequently boiled for 5 minutes, and the sample was centrifuged at 
13000 rpm, 4°C for 15 minutes. The supernatant constitutes the RAB 
fraction. The resulting RAB-insoluble material was re-homogenised with  
radio-immunoprecipitation assay (RIPA) buffer (150 mM NaCl, 1% Nonidet P-
40, 0.5% deoxycholate, 5 mM EDTA, 0.1% (w/v) SDS, 50 mM Tris, 0.5 mM 
PMSF, 0.1% protease inhibitor cocktail, pH 8.0) by sonication and ultra-
centrifuged for 20 minutes at 40000 rpm to remove membrane proteins. The 
supernatant is the RIPA fraction yielding abnormal detergent soluble Tau. 
Finally, the RIPA-insoluble pellets were sonicated to resuspend, and were re-
extracted with 70% formic acid (FA) to solubilise detergent-insoluble Tau, to 
remove worm cuticlar debris and recover most insoluble cytoskeletal 
aggregates. This was then centrifuged at 13000 rpm for 15 minutes. The FA  
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Vehicle control worms Ethosuximide treated worms
High-salt reassembly buffer 
(RAB)
Detergent rich buffer 
(RIPA)
70% formic acid
Supernatant yield 
soluble tau proteins
Formic acid insoluble pellets 
(contains worm cuticle)
Supernatant yield 
detergent-soluble tau 
proteins
Supernatant yield 
abnormal, highly 
insoluble tau proteins
  
Figure 2.2: Flow chart of sequential extraction steps to isolate aggregation prone tau proteins 
(detailed in the Methods section). Equivalent masses of vehicle control and ethosuximide treated 
worms were homogenised in high-salt reassembly (RAB) buffer and blotted to estimate total tau 
protein. The supernatant following centrifugation constitutes the fraction of soluble Tau and the pellet is 
extracted with radio-immunoprecipitation assay (RIPA) buffer to extract detergent soluble material. The 
resultant RIPA insoluble material are finally extracted with 70% formic acid (FA) yielding the detergent 
insoluble fraction. Supernatants are blotted to estimate differing levels of Tau solubility with the RAB 
fraction representing the most soluble phase and the FA fraction representing the most insoluble 
phase. 
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fraction was then thoroughly dried using SpeedVac and resuspended by 
sonication in Laemlli buffer. 
2.4.3  Protein electrophoresis 
The supernatant from sequential fractions or protein extracts was mixed with 
equal volumes of Laemmli buffer and boiled at 95°C for 5 minutes. Samples 
were separated by electrophoresis through pre-cast NuPAGE® 12% Bis-Tris 
Gels and the corresponding MOPS buffer. Combs were removed from the 
gels and samples were loaded alongside 5 μl pre-stained protein ladder. 
Gels were run at 120 V until the dye reached the bottom of the gel.  
2.4.4  Western blot analysis  
The fractionated proteins were transferred to nitrocellulose membranes 
submerged in transfer buffer (0.025 M Tris, 0.192 M glycine, 20% methanol) 
in a BioRad Trans-blot Electrophoresis Transfer Cell, at 25 V overnight. 
Nitrocellulose was blocked for one hour in phosphate-buffered saline (PBS; 
2.7 mM KCl, 138 mM NaCl, 1.5 mM KH2PO4, 20.4 mM NaH2PO4 [pH 7.2]) 
and 3% (w/v) dried skimmed milk with gentle rocking. The primary antibody 
was applied at an appropriate dilution in PBS supplemented with 3% (w/v) 
dried skimmed milk and incubated on a rocker at room temperature for 60 
minutes. The nitrocellulose was washed three times in PBS with 0.1% Tween 
20 (PBS-T) for five minutes before incubation with an appropriate 
horseradish peroxidase (HRP)-conjugated secondary antibody (Sigma) at 
1:400 dilution for one hour on a rocker. The nitrocellulose was rinsed with 
PBS-T and immunoreactivity visualised using enhanced chemiluminescence 
(ECL) reagents A (2.5 mM luminol, 400 μM p-coumaric acid, 100 mM 
Tris.HCl pH 8.5) and B (0.018% H2O2, 100 mM Tris.HCl pH 8.5) mixed 1:1. 
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Images were captured using a ChemiDoc™ XRS gel imaging system running 
the Quantity One analysis software (Bio-Rad). The relative abundance of 
protein levels was quantified from the Western blots using the ImageJ 1.44p 
software. The intensity of protein was normalised against beta-actin. 
Table 2.4: List of antibodies and their dilutions used for western 
blotting. 
Antibodies Manufacturer Final Dilution 
Anti-actin from mouse, monoclonal Sigma-Aldrich, UK 1 in 1000 
Anti-GFP from mouse IgG1κ 
(clones 7.1 and 13.1), monoclonal 
Roche, Welwyn, UK 1 in 1000 
Tau Monoclonal Antibody, Mouse 
(T46) 
Invitrogen, Paisley, UK 1 in 1000 
Anti-GFP, Rabbit IgG Fraction 
(Anti-GFP, IgG), polyclonal  
Sigma-Aldrich, UK 1 in 400 
Anti-Mouse IgG (whole molecule) -
Peroxidase antibody produced in 
goat  
Sigma-Aldrich, UK 1 in 400 
 
2.5  MICROARRAY HYBRIDISATION AND ANALYSIS 
2.5.1  C. elegans growth and collection  
Maintenance of large synchronous cultures of old nematodes is challenging 
due to the offspring generated during the onset of reproductive output. 
Rather than using fluorodeoxyuridine to inhibit embryonic development, 
which has recently been shown to affect the worm (Aitlhadj and 
Stuerzenbaum, 2010, Davies et al., 2012) and temperature sensitive strain 
GE24, pha-1(e2123), in which reproduction resembles wild type at 15°C, but 
is 100% embryonic lethal at 25°C, we first treated gravid N2, dnj-14(ok237) 
and dnj-14(tm3223) adults with hypochlorite to release embryos. 
Synchronised embryos were then hatched on ethosuximide plates and grown 
at 20°C until day 2 of adulthood. 50 gravid hermaphrodites of each strain 
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were then picked to lay eggs on one drug dish for six hours at room 
temperature. Progeny were grown and 400 were selected at the L4 stage 
and transferred every 2 days until day 6 of adulthood was reached. 40 
hermaphrodites were cultured on each Petri dish. When worms reached age 
day 6, they were washed off plates using 100 µl DNase/RNase-free distilled 
water (Invitrogen) and 400 µl of TRIzol® Reagent (Invitrogen) was added and 
the mixture was vortexed for 2 minutes. Worms were stored at -80°C until 
RNA isolation. Four individual replicates were reared and processed in 
tandem. 
2.5.2  Total RNA extraction and purification  
Total RNA was extracted using a combined TRIzol® Reagent (Invitrogen) and 
RNAeasy (Qiagen) column method. Following one freeze and thaw cycle, 
samples were disrupted and homogenised on a vortex shaker in a 4°C cold 
room for 40 minutes. A further 200 μl of TRIzol® was added and vortexed 
before the second freeze and thaw cycle. 140 μl of chloroform was added 
before centrifugation at 12000 x g for 15 minutes at 4°C. Following two 
separations of aqueous upper phase with chloroform, RNA was precipitated 
by adding dropwise to an equal volume of 70% ethanol made in RNase-free 
water. RNA was then treated with RNase-free DNase I (Qiagen) before 
purification and concentration using RNeasy Mini Kit (Qiagen) according to 
manufacturer's instructions. RNA concentration and purity were quantified 
spectroscopically using a NanoDrop 1000 spectrophotometer (Thermo Fisher 
Scientific, Waltham, MA, USA) with A280/A260 and A260/A230 ratios between 
1.8-2.6 being considered acceptable RNA. 24 purified total RNA samples 
free from genomic DNA were then submitted to the Liverpool Genome 
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Facility Unit where they were fluorescently labelled with different fluorophores 
during reverse-transcription, combined and hybridised to Affymetrix C. 
elegans GeneChips (Affymetrix, High Wycombe, UK). Dr. Lucille Rainbow 
first performed RNA quality control in which the reliability of the RNA samples 
was ascertained using an Agilent 2100 Bioanalyser RNA 6000 Nano chips. 
An RNA integrity number (RIN) between 1 and 10 was then assigned, 1 = 
degraded and 10 = intact. In this study, RIN of greater than 7 out of 10 was 
accepted for further analysis by microarray and all RNA samples submitted 
showed no signs of degradation. The best three preparations per condition 
were used for subsequent RNA amplification, labelling and hybridisation to 
Affymetrix C. elegans GeneChips. The remaining preparations were used for 
qPCR validation of microarray results. 100 ng of total RNA was used as initial 
input, and the Affymetrix GeneChip 3’IVT Express Kit was used for target 
preparation for microarray expression analysis according to manufacturer’s 
instructions. 15 μg of aRNA was fragmented, and 12.5 μg labelled 
fragmented aRNA was hybridised for 16 hours on C. elegans Genome arrays 
at 45°C in a GeneChip Hybridisation Oven 640. Following hybridisation the 
arrays were washed on a GeneChip® Fluidics Station 450 using the 
GeneChip Hybridisation, Wash and Stain kit and fluidics script FS450_0004 
and scanned using the GeneChip® Scanner 3000 7G. 
2.5.3  Data generation and diagnostic analysis  
Initial diagnostic and differential expression (DE) analysis of the microarray 
data were performed by Dr. Yongxiang Fang from the Department of 
Functional and Comparative Genomics using the statistical analysis tools R 
packages Affy (version 2.15.2) which has been widely used in statistical 
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analysis of biological data and limma (version 3.14.4) that is specialised for 
Affymetrix data. Background correction and normalisation of raw Affymetrix 
array data were conducted using Robust Multi-array Average (RMA) function 
built in Affy package (Irizarry et al., 2003). The data model is a linear model 
which has 6 parameters representing the log2 expression of 9 sample groups 
respectively. The 9 contrasts were evaluated based on the outcomes of 
model fitting. The interested contrasts were obtained by approach of making 
contrasts built in limma package. The significance test of the estimated logFC 
(log2 Fold Change) for each contrast was performed by empirical Bayes 
function packed in limma and p-values were adjusted using Benjamin and 
Hochberg False discovery rate (FDR) control approach to deal with the effect 
of multiple tests (Benjamini and Hochberg, 1995). DE genes with a FDR 
corrected p-value less or equal to than 0.01 and fold change greater than 2 
were called significantly differentially expressed.  
2.5.4  Bioinformatic analysis 
To analyse and interpret gene expression data, differentially expressed 
genes (DEGs) which are consistently responsive to ethosuximide treatment 
in all conditions relative to untreated control were considered. 
2.5.4.1 Gene Ontology analysis  
The functional annotation and clustering of putative ethosuximide targets 
were assessed using both the Database for Annotation, Visualization and 
Integrated Discovery (DAVID) v6.7 (http://david.abcc.ncifcrf.gov/) software 
(Dennis et al., 2003, Huang et al., 2008) from the National Institutes of 
Health, and the mENCODE Modmine bioinformatic suite 
(http://intermine.modencode.org/) (Contrino et al., 2012, Smith et al., 2012b) 
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in order to identify trends in the biological processes and molecular functions 
of the identified DEGs. For gene enrichment analysis, Affymetrix C. elegans 
probe IDs of commonly regulated DEGs were first submitted to DAVID 
(http://david.abcc.ncifcrf.gov/) as a “Gene list” and following selection of C. 
elegans background, were converted to either Ensembl or Worm Base IDs 
using the Gene ID Conversion Tool (>90% converted). For GO Term 
analysis, the “Biological Process”, “Cellular Component” and “Molecular 
Function” categories were studied using the GO FAT default settings. 
Functional annotation clustering was performed with the default criteria and 
prevalence of annotation terms within the list of DE genes was compared to 
the prevalence in the whole C. elegans genome. Protein domains and 
pathway enrichment were also determined using DAVID by querying the 
Interpro and Kyoto Encyclopedia of Genes and Genomes (KEGG) 
databases, respectively. Enriched genes were obtained by performing Gene 
Functional Classification Clustering using threshold count 5, EASE 0.1 and 
medium stringency. GO terms and domains with less than 4 genes were 
discarded and an enrichment score over 1.3 represents a significant 
enrichment. Enrichment in GO categories, protein domains, pathways and 
publications were also assessed using modENCODE modMine. Human 
orthologues of the corresponding worm genes were derived from the 
OrthoList online tool (http://www.greenwaldlab.org/ortholist.). Within the 
search window, the list of enriched C. elegans DEGs was inputted as 
Ensembl gene IDs to retrieve the predicted human genes which were in the 
Ensembl ENSG ID format. All orthologous genes with a duplicate output in 
one of the species were counted only as one gene. 
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2.5.4.2 Motif analysis  
Using complementary algorithms, we analysed within up to 200 bp of 
intergenic sequence upstream of common DEGs to identify shared DNA 
motifs. Regulatory Sequence Analysis Tools (RSAT; 
http://rsat.bigre.ulb.ac.be/rsat/) (Turatsinze et al., 2008) was first used to 
retrieve the 200 bp upstream sequences of C. elegans genes, which were 
then submitted to RSAT oligo analysis (Thomas-Chollier et al., 2008, 
Thomas-Chollier et al., 2011) and peak-motifs analysis (Thomas-Chollier et 
al., 2012a, Thomas-Chollier et al., 2012b), multiple expectation maximisation 
for motif elicitation (MEME, http://meme.nbcr.net/meme/), BioProspector 
(http://seqmotifs.stanford.edu) and SCOPE motif finder 
(http://genie.dartmouth.edu/scope/), in each case specifying an 
oligonucleotide length of 6-8 bases while all the other parameters were set as 
default, to identify sequence elements that were statistically overrepresented. 
To display consensus motifs generated from BioProspector, retrieved motif 
matrices in TRANSFAC format were analysed by WebLogo 
(http://weblogo.berkeley.edu/logo.cgi). 
2.5.4.3 Cross-database analyses 
In order to increase the coverage of gene expression annotations and gain 
further insights into complex chemical-gene interaction networks, our 
microarray data was compared with 2 public high-content data repositories: 
Serial Pattern of Expression Levels Locator (SPELL Version 2.0.3, 
http://spell.caltech.edu:3000/) (Hibbs et al., 2007) and Comparative 
Toxicogenomic Database (CTD, http://ctdbase.org/). Stringent subsets of 
commonly up- or down-regulated ethosuximide-responsive genes were 
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queried both combined as well separately in the SPELL search engine. 
Ethosuximide was directly searched within CTD for known therapeutic 
information, cross-species chemical-gene/protein interactions, and chemical- 
and gene-disease associations. 
2.5.5  Real-time quantitative PCR 
2.5.5.1 Primer design and analysis 
qRT-PCR primers (Table 2.2) were designed using the DNA Dynamo 
Sequence Analysis Software (Blue Tractor Software, Llanfairfechan, UK) to 
the following criteria: gene specific primers were all between 20 and 25 bp 
long; the product of the PCR was between 280-330 bp in length; the product 
spanned an intron to give differentially sized genomic and cDNA products; 
the melting temperatures of the primer pairs were matched and were 
between 55 and 60°C. act-1 and pmp-3 which showed no significant changes 
in microarray analysis and has been extensively used as normalising genes 
in differential expression studies in C. elegans (Zhang et al., 2012d) were 
chosen as reference genes. The compatibility and specificity of these primers 
were tested on samples from the microarray, and analysed by gel 
electrophoresis (2.2.4). Only primer sets showing single bands of the 
expected size were used for qPCR analysis. Melting curve analysis during 
qPCR was also performed with each primer pair to ensure that quantification 
is the result of only one product. 
2.5.5.2  cDNA Synthesis and quantitative real-time RT-PCR  
For each synthesis reaction, appropriate RNA sample volume was calculated 
with the results from the spectrophotometry and added to ensure the 
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presence of 200 ng of total RNA for each sample in the group, and 1 µl of 
random primers (250 ng/µl; Promega), 1 µl of dNTPs (10 mM; Invitrogen), 
and RNase-free water were added up to a volume of 12 μl. Samples were 
mixed, centrifuged briefly and incubated for 5 minutes at 70°C, and then 
immediately chilled on ice for 2 minutes. After this first incubation, 4 μl of 5X 
M-MuLV RNaseH- Reaction buffer for RT, 2 μl of 0.1 M DTT, 1 μl of 
RNaseOUT (40U/μl) and 1 μl of ProtoScript M-MuLV Reverse Transcriptase 
(NEB) were added to the 12 µl mix as a master mix. Contents were then 
incubated in a G-Storm GSX thermal cycler (GRI, Braintree, UK) first at 25°C 
for 5 minutes followed by 1 hour at 42°C before 2 minutes at 92°C to 
inactivate the RT enzyme. The cDNA was diluted (1:50) with DEPC treated 
water and stored at −80°C until required.  
For gene expression analysis, master mixes for diluted cDNA samples 
mixed with DEPC water and selected qRT-CPR primers mixed with iTaq™ 
Universal SYBR® Green Supermix (BioRad) were made and added to 96-well 
plates sequentially to make a final reaction volume of 10 μl per well. A non-
template control (sample was substituted by sterile water) was also included. 
Reactions were performed using an IQ5 real-time PCR detection system 
(Bio-Rad). The thermocycler was programmed to first heat to 95°C for 3 
minutes, followed by 40 cycles of a 10 seconds denaturation step at 95ºC, a 
30 seconds annealing step at 58°C, and a 30 seconds elongation step at 
70ºC. The final cycle consisted of 30 seconds at 95ºC and after the 
thermocycling reaction, a 65-95°C melt curve with a gradient of 0.5°C was 
inserted, allowing detection of possible nonspecific products. All qRT-PCR 
reactions were carried out on 3 biological replicates with three technical 
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replications and transcript expression was analysed using Bio-Rad CFX 
Manager 3.0 software. The relative expression of each gene was calculated 
by normalising the Ct values for test genes to the two reference genes (act-1, 
and pmp-3). 
 
2.6  MAMMALIAN CELL BASED METHODS 
2.6.1  Cell culture 
A mouse neuroblastoma cell line was used as the prototype neural progenitor 
cells in this study. Cells were passaged every 2-5 days. Adherent Neuro2A 
(N2A) cells were maintained as a monolayer culture in 75 cm2 culture flasks 
in Dulbecco's Modified Eagle Medium (DMEM Gibco) supplemented with 
10% foetal bovine serum (FBS), 1% penicillin/streptomycin and 1% non-
essential amino acids (Gibco) and maintained in 75 cm2 flasks at 37°C in a 
humidified atmosphere of 95%air/5% CO2. Cells were subcultured at or near 
confluency by trypsinisation (0.25% trypsin; Mediatech Inc.) followed by 
dispersion of the cells into single cell suspension in new growth medium and 
plating onto new growing surfaces. Cell counts were assessed by applying 
an equal mixture of trypan blue dye and cell suspensions to the chambers of 
a haemocytometer. 
Cells in the four corner squares were counted, excluding cells that touched 
the upper and left hand side edges of the squares. The mean number of cells 
per square was calculated, and this number was multiplied by 1.0x104 to give 
the number of cells per ml. Depending on the analytical method, cells were 
diluted appropriately and seeded on different types of plates. For qRT-PCR 
103 
 
analysis, cells were grown on 6-well plates and seeded in duplicate for 
condition. For microscopy, cells were seeded on glass-bottom 35 mm dishes 
(10 mm glass surface diameter, MatTek Corporation, Ashland, MA, USA). 
2.6.2  Transfection  
Cells were taken at 60-80% confluence and plated out in 35-mm glass 
bottom dishes (MatTek, Ashland, MA). To stimulate differentiation prior to 
transient transfection and to limit the loss of compound activity as a result of 
protein binding in the serum-cultured cell lines, N2A cell media was 
exchanged for DMEM supplemented with 2% FBS, 1% penicillin-
streptomycin, 20 µM retinoic acid and 0.56 mg/ml ethosuximide. In all the 
experiments, cells in medium with equal volumes of PBS served as the 
controls. Cells were then transiently transfected with 3 μg of polyQ97-eGFP-
pcDNA3.1(+) Myc His plasmid constructs (a generous gift from Professor 
Stephen High, University of Manchester, originally made by Professor Ron 
Kopito’s lab in Stanford) or polyQ25-eGFP-pcDNA3.1(+) Myc His control 
plasmid construct using PromoFectin transfection reagent (PromoKine) 
according to the manufacturer’s protocol. The transfection reaction mixture 
was incubated at room temperature for 30 minutes to allow the lipid and DNA 
complexes to associate then added dropwise to the cells. Cells were then 
maintained at 37°C before being used in experiments. 
2.6.3  Ethosuximide treatment and RNA extraction 
To analyse the effect of ethosuximide on the expression of FOXO targeted 
genes, qRT-PCR was used. Cells were plated subconfluently at a density of 
1.5×106 cells per well in flat bottom 6-well microtiter plates in a total volume 
of 3 ml growth medium supplemented with 10% regular FBS. After overnight 
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incubation to allow cells to adhere to wells, media was exchanged for DMEM 
containing 2% FBS, 1% penicillin/streptomycin and 20 μM retinoic acid to 
induce N2A cell differentiation. After 24 hours, N2A cells were treated with 
vehicle control (PBS) or increasing concentration of ethosuximide (100 μg/ml, 
0.56 mg/ml and 1 mg/ml, covering the clinically relevant concentrations) for 5 
hours. A stock solution of ethosuximide was prepared in PBS at a 
concentration of 100 mg/ml. Following treatment, the full content of a 6-well 
culture plate was pooled for each experimental condition. Total RNA was 
then isolated from 3 independent treatments of N2A cells by first 
homogenising cells directly in RLT buffer (Qiagen) containing β-
mercaptoethanol and guanidine and subsequently using RNeasy Mini Kit 
(Qiagen) following manufacturer's instructions. To avoid DNA contamination, 
the samples were exposed to an on-column treatment with RNase-Free 
DNase 1 (Qiagen).  The isolated total RNA were quantified by use of OD 
measurement at 260 and 280 nm using a spectrophotometer (Thermo Fisher 
Scientific, Madison, WI, USA) (all RNA samples had an A280/A260 ratio >1.8).  
2.6.4  cDNA synthesis and real-time RT-PCR quantification of mRNA 
expression of FOXO target genes  
1 μg of DNase-treated total RNA was reverse transcribed to cDNA and qRT-
PCR was run as described in 2.5.5.2. Mouse gene-specific primer sequences 
obtained from PrimerBank (http://pga.mgh.harvard.edu/primerbank/) were 
validated by RT-PCR and gel electrophoresis. For each sample, the Ct 
values for test genes were normalised to that for the reference genes 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and β-actin (ACTB), 
and a sample without cDNA was used as no template control. Transcript 
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expression analysis was performed with Bio-Rad CFX Manager 3.0 software 
(Biorad), which automatically set the baseline and the threshold. 
2.6.5  Confocal laser scanning microscopy and image analysis 
Live transfected cells were imaged using a a Leica AOBS SP2 microscope 
(Leica Microsystems, Heidelberg, Germany) with an optimal pin hole of 1 airy 
unit and using both a 20x dry objective with a 0.5 numerical aperture and a 
63x water-immersion objective with a 1.2 numerical aperture. The 
percentages of aggregates and rate of cell death were determined at 24, 48 
and 72 hours post-transfection. To monitor neuronal viability, media was 
aspirated before cells were incubated for 20 minutes in 2 ml of Krebs-Ringer 
buffer [20 mM Hepes (pH 7.4), 145 mM NaCl, 10 mM glucose, 5 mM KCl, 3 
mM CaCl2, 1.3 mM MgCl2 and 1.2 mM NaH2PO4] containing 0.5 μM SYTOX 
Orange® nucleic acid dye (Invitrogen) at 37°C and 5% CO2. For dual imaging 
of EGFP-tagged polyQ proteins and dying/non-viable cells labelled with 
SYTOX Orange®, cells were excited with 488 nm and 453 nm lasers and light 
was collected at 465-500 nm (Alexa 488) and 615-690 nm (Alexa 594), 
respectively. The channels of the images were taken sequentially with a 
frame average of 1. Five to ten low- and high-magnification fields were 
randomly taken for each condition. EGFP and SYTOX Orange® fluorescence 
and phase images were exported as Tiff files and were superimposed by 
using the Leica LAS AF Lite imaging software. A minimum of 50 cells per 
condition were counted either manually or by using the ImageJ Java-based 
imaging software (NIH, USA) in which GFP channel images were measured 
with the ‘Analyze particles’ command with a threshold of 180-255. Average 
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percentage of transfected cells with aggregates was calculated from three 
independent experiments.  
 
2.7  STATISTICAL ANALYSIS 
If two data sets were being directly compared, Student’s t-test was used. For 
comparison of multiple data sets i.e. age-dependent thrashing in one 
analysis, a one-way analysis of variance (ANOVA) was used. These tests 
were performed in Microsoft Office® Excel® 2007.  
Lifespan analyses were performed using the Online Application for the 
Survival Analysis of Lifespan Assays (OASIS; 
http://sbi.postech.ac.kr/oasis/introduction/) (Yang et al., 2011). Mean 
lifespans were compared using the log-rank (Mantel-Cox) test, and mortality 
at more specific time points was compared using Fisher’s exact test.  
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CHAPTER 3: PHENOTYPIC 
CHARACTERISATION AND 
SELECTION OF C. ELEGANS 
NEUORODEGENERATIVE 
DISEASES MODELS 
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3.1 INTRODUCTION 
In order to delineate the complex patho-mechanisms of human 
neurodegenerative disorders (NDs), a large number of animal models have 
been generated and have facilitated the testing of potential therapeutic 
strategies and investigation of disease progression in a manner not possible 
in humans. Modeling of NDs has been primarily conducted in mouse and 
invertebrate models which reproduce cellular and behaviour phenotypes akin 
to the broader clinical manifestations. The employment of a plethora of 
powerful model organisms with shorter generation times such as C. elegans, 
S. cerevisiae and D. melanogaster, has expedited the initial screening of 
genetic and pharmacological modifiers and target characterisation which in 
turn can not only illuminate a prospective cellular cause of protein-misfolding 
diseases like HD, PD, ALS and AD, but also the neuroprotective mechanisms 
against underlying functional aspects of neurodegeneration (Brignull et al., 
2007, Kearney, 2011) 
In particular, the use of the nematode C. elegans as a primary 
platform to probe the poorly defined disease mechanisms of NDs and a more 
rapid and cost-effective means towards novel gene and drug discovery has 
escalated over the last decade. As described in Chapter 1, the C. elegans 
nervous system functionally recapitulates many of the characteristics of the 
vertebrate brain. This along with other major advantages offered by C. 
elegans i.e. its amenability to high-throughput genetic, genomic, proteomic, 
and drug screening approaches have facilitated the evaluation of the 
pathological similarities between targeted C. elegans neurons and human 
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disease neurons to provide new insights into different aspects of the human 
neurodegenerative maladies.  
Indeed, a diverse set of informative, tissue-specific C. elegans ND 
models have been developed by molecular, genetic and chemical 
manipulations (Appendix Table A1), i.e. using mutagenesis (deletion libraries, 
transposon based insertion), RNA interference (RNAi)-mediated knockdown, 
transgenic overexpression of exogenous neurodegeneration-associated, 
aggregative proteins in specific tissues, or acute and chronic exposure to 
neurotoxins (Johnson et al., 2010). The most widely studied are the tissue-
specific transgenic models which manifest abnormal behavioural or 
pathological phenotypes that faithfully recapitulate the salient cellular, 
molecular and pathological aspects of several distinct human NDs 
processes. These models have been based on muscular or neuronal 
expression of aggregation-prone proteins such as mutant Tau, SOD1 and α-
synuclein proteins, polyQ constructs, Huntingtin fragments and toxic Aβ1-42, 
with features that are reflective of the human NDs including accumulation of 
disease proteins in abnormal aggregates and toxic disease protein-induced 
neuronal loss and dysfunction. Most of these models were subjected to 
medium- or high-throughput genome-wide forward and reverse genetic 
screens to identify genetic regulators and cellular processes of α-synuclein 
inclusion formation (van Ham et al., 2008), polyQ (Nollen et al., 2004) and 
mutant SOD1 aggregation (Wang et al., 2009b), α-synuclein and polyQ-
induced toxicity (Parker et al., 2007), presenilin function (Link, 1995) and 
Tau-induced pathology (Kraemer et al., 2006), as well as chemical screens 
that directly explore effective pharmacological compounds that prevent or 
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improve loss of neuronal function in ND states prior to testing in higher 
organisms (Braungart et al., 2004, Voisine et al., 2007, Sleigh et al., 2011, 
McCormick et al., 2013). A handful of lead molecules originating from worm-
based screening assays such as insulin sensitisers for the treatment of type 
2 diabetes or insulin resistance, and voltage gated ion channel modulators to 
treat arrhythmia are already in advanced stages of drug discovery (Artal-
Sanz et al., 2006). Numerous novel compounds and known human drugs 
were efficacious in worm ND models and, more importantly, shown to be 
transferrable to mammals (Parker et al., 2005, Cherny et al., 2012, Vaccaro 
et al., 2012, Matlack et al., 2014).  
To date, diverse genetic modifier screens in multiple ND model 
systems have identified a plethora of genes and pathways that can be 
modulated to delay and even prevent disease states. Most of these genetic 
modulators and underlying cellular mechanisms affected appear to be 
disease specific despite the shared feature of protein misfolding/aggregation. 
Unlike most identified genetic modifiers, chemical modifiers are not disease-
specific and have therapeutic potential for multiple NDs (Chen and Burgoyne, 
2012). It was reported that generally neuroprotective interventions can be 
identified by searching for compounds that are able to compensate for the 
loss of an endogenous physiological neuroprotective factor (Sleigh et al., 
2011). Work from our lab has shown that dnj-14, the worm orthologue of the 
human DNAJC5 gene mutated in Adult-onset Neuronal Ceroid Lipofuscinosis 
(ANCL), is an evolutionarily conserved neuroprotective protein and can be 
found in all neurons. Thus drugs that can bypass its function may be 
generally neuroprotective, and would require further assessment using 
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different worm models. Indeed, the C. elegans null mutant model of ANCL 
containing loss of function mutations in dnj-14 has already demonstrated its 
potential for chemical genetic screening, by identifying a sir-2.1-independent 
neuroprotective effect of resveratrol (Kashyap et al., 2014). 
Each model system has unique experimental advantages and the 
integration of different analyses across a range of different disease models 
offers exceptional promise for multi-model target discovery, an in depth 
understanding of ND pathology, and guiding the development of therapeutic 
interventions by identifying new pharmacological and genetic modifiers of ND 
pathology.  
In this perspective, we take a combinatorial approach by integrating 
multiple well-defined disease-specific C. elegans models for pathogenesis of 
the different ND-associated proteins to test therapeutic interventions that 
target shared pathogenic pathways. In this chapter, nine models of various 
different NDs were selected and characterised. Several assays were 
performed to measure different outcomes of toxicity exhibited by distinct 
models. Yet the heterogeneity, incomplete manifestations and lack of 
reproducibility displayed by most ND models tested are likely to obscure their 
ability to reliably detect modifiers and yield information that parallels human 
NDs and these models were therefore dismissed. Three distinct worm ND 
models: ANCL, FTDP-17 and ALS models which involve deletion of an 
endogenous neuroprotective gene (dnj-14) and pan-neuronal expression of 
disease-associated mutant Tau and SOD1 proteins, exhibited robust and 
reproducible phenotypes, and are therefore ideal for the modifier screening 
depicted in Chapter 4.  
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3.2 RESULTS 
3.2.1 Selection of C. elegans neurodegenerative disease models for 
phenotypic characterisation  
To establish tractable models for efficient probing of the age-
dependent human NDs, our first step, as shown in Appendix Table A1, was 
to gather information from literature on all existing C. elegans NDs models. 
Many studies have relied heavily on transgenic models with muscle-specific 
expression of misfolded proteins for reasons of experimental convenience: 
muscle-specific promoters are strong and well-characterised; muscle cells 
are significantly larger than neurons to provide an easy means to study 
transgene expression, product localisation, protein-induced toxicity and 
protein aggregation; facilitating work under comparatively low magnification; 
muscle cells are also more amenable to RNAi, in comparison to neurons 
(Lehmann et al., 2012). 
Given that pathologies of human NDs usually manifest primarily in 
neurons and processes, the threshold for pathology relevant to neurons is 
likely very different to muscle cells. Models with transgene expression in 
neuronal tissues may therefore more accurately represent the disease 
protein-induced toxicity seen in ND. Expression in muscle does not directly 
capture the neurodegeneration seen in ND and could lead to identification of 
muscle-specific regulators not expressed in neurons. Also certain neuronal 
tissue-specific genes that affect neurodegeneration and the actual site where 
the misfolded proteins in question cause disease, are likely to be missed (van 
Ham et al., 2009). Thus, all the muscle expression models were excluded 
from our initial list. The remaining neuronal models were prioritised by 
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assessing the robustness, reproducibility and reliability of their reported 
neurodegenerative phenotypes, availability of the models and ease of 
scoring.  
An important prerequisite for effective high-throughput genetic or 
pharmacological screening, is the availability of a robust disease model that 
reliably exhibits the critical manifestations of the corresponding NDs. C. 
elegans models with weak or non-existent phenotypes are less likely to be 
informative and were thus excluded. It is essential for the selected disease 
models to generate phenotypes that are pathologically relevant to human 
disease states and can be scored quickly and easily for improvement to 
accommodate extensive screening paradigms. Readily assayed 
neurodegenerative phenotypes i.e. motility defects of a number of the models 
would provide a particularly suitable, direct and sensitive read-out for high-
throughput screening of large numbers of drug candidates or molecular 
targets of protein-evoked neurotoxicity. Disease-related phenotypes should 
not only be robust and easily discernible, so that the models would be 
informative without having to look at subtle behavioural differences, but also 
quantitative to facilitate the detection of not just the strong modifiers, but also 
weak modifiers that may still significantly modify the phenotype. Low 
phenotypic variability would also be favoured in order to gain power in the 
statistical identification of positive hits (Garcia-Alcover et al., 2013). 
In this regard, nine distinct C. elegans neuronal models of various 
forms of human NDs (Table 3.1) that developed robust neurodegenerative 
phenotypes were chosen, obtained and analysed based on their well 
characterised pathology. To further control for phenotypic variability, almost 
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all of our selected transgenic models are outcrossed stable integrants, as this 
ensures all worms have the same transgene expression levels within the 
isogenic population and the removal of background and unwanted mutations 
from the integration process. This in turn can help to reduce clonal 
heterogeneity. 
Although C. elegans ND models are increasingly used for genetic and 
chemical screening, their relatively rapid disease-onset seems simplistic and 
questionable in the context of complex, chronic NDs (Weinberg and Wood, 
2009). Not all worm ND models generated can be used for subsequent 
screens. Some are of limited suitability to investigate particular mechanisms 
in detail depending on the intention of the experiment. It is therefore 
necessary to address the appropriateness of the selected ND models before 
considering their use as model system for screening. Phenotypic 
characterisation of the selected disease models was our next step in 
establishing informative models for which neuron-specific, novel modifiers of 
disease protein-mediated pathogenesis can be identified. 
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Type of 
disease 
model
NDs Genotype Phenotypic Analysis Reported Phenotype
Mutant ANCL
dnj-14 -/-
Locomotion, pharyngeal pumping, 
lifespan, food-race, aldicarb, 
chemotaxis, mechanosensation,
and fluorescence microscopy
Short lifespan; age-dependent progressive impairment
in locomotion; chemosensory defects;
neurodegeneration
Mutant SMA
smn-1 -/- Locomotion, pharyngeal pumping, 
lifespan 
Thrashing rate progressively declined and almost
completely ceased after 5 days post-L1. Pharyngeal
pumping rates showed a rapid and progressive decline.
Mean lifespan is 6.0 days Vs 17.7 days for N2
Transgenic 
overexpression
FTDP-17
TauV337M Locomotion, aldicarb, 
fluorescence microscopy 
Strongly defective locomotion; accumulation of
insoluble tau; neurodegeneration; impaired presynaptic
cholinergic transmission; reduced lifespan
Transgenic 
overexpression
ALS
G85R SOD1-YFP Locomotion, aldicarb and 
fluorescence microscopy
Severely reduced forward crawling, thrashings and were
strongly resistant to aldicarb
Transgenic 
overexpression
AD Aβ1−42
Locomotion, chemotaxis, 5-
hydroxytryptamine sensitivity, 
lifespan, food-sensing assay, egg 
laying 
Defective in chemotaxis toward benzaldehyde,
associative learning, and thrashing; hypersensitive to
serotonin; forms amyloid deposits; partial sterility due
to germline proliferation defects and embryonic lethality
Transgenic 
overexpression
HD
Htt-Q150
Dye filling, nose-touch
Accelerated polyQ mediated neurodegeneration. Vast
majority (>90%) of ASH neurons undergo cell death in
less than three days; severe defect in the nose touch
response
Transgenic 
overexpression
PD α-syn WT
Food-sensing assay, dopamine 
level measurement, fluorescence 
microscopy, toxicant exposures, 
oxygen consumption  and  
mitochondrial membrane potential 
analysis 
Failure in modulation of locomotory rate in response to
food
Transgenic 
overexpression
PD CAT-2
Fluorescence microscopy, food-
sensing assay 
Chemical 
treatment
PD
GFP WT 
subjected  to 
6-OHDA + 
ascorbic acid
Fluorescence microscopy 
Neuronal process blebbing, cell body rounding with
process loss, and cell body loss reproducibly appear in
this order within a few hours.
 
  
Table 3.1: Selected C. elegans neuronal models of human neurodegenerative diseases (NDs) for 
phenotypic characterisation. Transgene expressions of many C. elegans ND models are limited to 
muscle cells. In our study, neuronal-relevant models were favoured as they provide better relevance to 
NDs than muscle expression models. Neuronal models were subsequently prioritised on the basis of 
information presented in the literature. In each case we independently confirmed the pattern of 
expression of the promoters and validated the reliability of the chosen models by analysing their 
neurodegenerative phenotypes. A combination of imaging and behavioural analyses that were applied 
in our study to verify previous observations are highlighted in bold. We assessed the robustness, 
reliability and reproducibility of selected ND models to determine whether they are suitable for future 
modifier screening: NDs: FTDP-17, Frontotemporal dementia with parkinsonism-17; ALS, Amyotrophic 
lateral sclerosis; AD, Alzheimer’s disease; HD, Huntington’s disease; PD, Parkinson’s disease, SMA, 
Spinal muscular atrophy. 
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3.2.2 Neuropathological characterisation of established C. elegans 
neuronal models of human NDs 
3.2.2.1 Characterisation of C. elegans Adult-onset Neuronal Ceroid 
Lipofuscinosis (ANCL) 
As mentioned in Chapter 1, both in vitro and in vivo studies have 
demonstrated a potential generally neuroprotective role of the presynaptic 
chaperone cysteine string protein (CSP), which is supported by recent 
findings that mutations in the human CSPα gene DNAJC5 result in ANCL, a 
rare hereditary neurodegenerative disorder clinically characterised by 
progressive deterioration of cognitive and motor skills, generalised seizures 
and premature death (Noskova et al., 2011). DNJ-14 is the worm orthologue 
of the DNAJC5 gene mutated in ANCL and loss of function mutations in C. 
elegans dnj-14 have been the main focus of our lab. In-depth 
characterisation of a neuronal worm ANCL model and demonstration of its 
potential for chemical screening were pursued by another PhD student before 
the initiation of this study (Kashyap et al., 2014). It was reported that dnj-14 is 
a key neuroprotective gene like its mammalian homologue, CSP, since two 
mutant alleles of dnj-14, ok237 and tm3223, recapitulated important features 
of ANCL and neurodegeneration by exhibiting age-dependent aggravation of 
motor dysfunction, a reduction of neurotransmitter release and severe 
progressive chemosensory defects which precede neurodegeneration of 
sensory neurons (Kashyap et al., 2014). As shown in Figure 3.1, dnj-14 
mutants also exhibited a significant higher mortality compared to the wild-
type (WT) N2 [Mean lifespan in days of adulthood with SEM: N2=19.11 ± 
0.62; dnj-14(ok237)=15.79 ± 0.44], with a 17% reduction (p<0.0001) in the  
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Figure 3.1: C. elegans ANCL model has a short lifespan. Kaplan-Meier survival curves of 
synchronously ageing ANCL model dnj-14(ok237) and wild-type (WT) N2 DRH hermaphrodites 
cultured at 20 °C. Worms were age-synchronised by timed-egg lay and once the progeny reached L4 
stage, 25 worms were transferred onto individual seeded plates, and monitored for survival every 
alternate day and transferred to fresh plates to prevent progeny formation. Day 0 corresponds to L4 
stage. The lifespan of populations of synchronised dnj-14(ok237) worms was observed and compared 
with the WT N2 strain. Statistical analysis was performed using Online Application for the Survival 
Analysis of Lifespan Assays (OASIS; http://sbi.postech.ac.kr/oasis/introduction/) (Yang et al., 2011). 
Log-rank (Mantel-Cox) test was used to calculate significance. The lifespan of dnj-14(ok237) mutants is 
significantly lower (***p<0.0001) than the WT N2. Above represented are pooled data from two 
independent biological replicate studies. Mean lifespan in days of adulthood: N2=19.11 ± 0.62 (n=105); 
dnj-14(ok237)=15.79 ± 0.44 (n=108).  
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mean lifespan. Utilisation of the dnj-14(ok237) mutants and their lifespan as 
phenotypic readout in a previous focused drug screen identified a sir-2.1-
independent neuroprotective effect of resveratrol (Kashyap et al., 2014), thus 
confirming the suitability of this model for neuroprotective drug screening.  
3.2.2.2 Establishment of physiological defects in a C. elegans model for 
Alzheimer’s disease (AD) 
To consolidate the previous observations of Aβ1-42 induced toxicity in C. 
elegans, we selected and obtained the strain CL2355 [smg-1(cc546ts); snb-
1::Aβ1-42::long 3′-UTR] which was engineered to inducibly express the signal 
peptide::Aβ1-42 pan-neuronally upon temperature upshift (Dosanjh et al., 
2010, Lublin and Link, 2013). It also harbours strong intestinal GFP courtesy 
of the co-injected Pmtl-2::GFP construct (Figure 3.2A). Strain CL2122 is the 
empty vector control with no Aβ1-42 that also controls for intestinal GFP 
expression, while strain PD8120 was used as a control for the hypomorphic 
smg-1(cc546ts) mutation in the background of CL2355. To assess 
neurotoxicity-associated phenotypes arising from transgenic expression of 
diseased proteins in C. elegans neurons, we examined behavioural 
phenotypes regulated by the nervous system and associated neuronal 
dysfunction. A simple, yet effective, method to assay neuronal function in C. 
elegans is by assessing thrashing behaviour. When placed in liquid, WT 
animals thrash actively by repeatedly moving the head and tail to the same 
side of body, the rate of which can be determined by counting the frequency 
of the elicited continual body bends per minute. We assayed and compared 
the motor activity of young and aged adult Aβ1-42 expressing CL2355 and 
control worms reared at the permissive (17°C) and restrictive temperature 
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(25°C) conditions. The motility of CL2355 worms grown at both 17°C and 
25°C was similar to that of CL2122 control animals of the same age at early 
adulthood, with only minor motor disturbance but no obvious abnormality 
(Figure 3.2B). Additional ageing caused motility defects such that, by day 
five, aged CL2355 had > 65% reduction in motility relative to that of CL2122 
(Figure 3.2C) and smg-1(cc546ts) (Figure 3.2D) grown at 25°C. This 
decrease in motility was only greatly enhanced by the seventh day of 
adulthood, as the thrashing rate by the 7-day-old CL2355 animals was < 35% 
that of CL2122 and smg-1(cc546ts) at 25°C (Figures 3.2 A-D). This effect is 
therefore Aβ1-42-expression-dependent since aged control animals CL2122 
and smg-1(cc546ts) only showed minor degrees of age-related decline. 
However, the thrashing defect of this neuronal AD model is only semi-
penetrant, due to a high degree of worm-to-worm variability. By visual 
inspection, the behavioural phenotype of individual CL2355 animals varied 
greatly from being WT to having severely impaired locomotion.  
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Figure 3.2: Movement defects of temperature-inducible Aβ1-42-neuronal expression C. elegans 
strain CL2355. A) Fluorescence microscopy of a non-induced worm with basal expression of mtl-
2::GFP. mtl-2 metallothionein gene is expressed exclusively in the intestine; the intensity of mtl-2::GFP 
expression varies in a temperature-dependent manner. Head of worm is to left. Scale bar represents 
200 μm. B-D) Quantification of movement defects following temperature-dependent induction of Aβ1-42 
in transgenic CL2355 animals. A thrashing assay was used to determine whether the neuronal 
expression of Aβ1-42 would affect the behavioural phenotypes of the AD model. Aβ1-42 transgenics and 
controls were assayed for motility in liquid medium at different ages. Synchronised worms of strain 
CL2122 (empty vector control with no Aβ1-42), temperature-inducible Aβ1-42-neuronal expression strain 
CL2355 and strain PD8120 smg-1(cc546ts) mutant were maintained at 17°C, and the temperature was 
then up-shifted to 25°C at 36-48 hrs after hatching to induce the expression of Aβ1-42. Rate of body 
thrashing in liquid for CL2355 raised at 25°C on agar media plates is significantly different from that of 
CL2122 and PD8120 as locomotion was greatly diminished in the aged neuronal Aβ1-42 strain but not in 
both control strains. The error bars denote standard error of the mean (SEM) from three repetitions of 
the experiment, and differences were considered non-significant (n.s. p>0.05) or significant (*p<0.05, 
**p<0.01, ***p<0.0001). Statistical analysis: t-test to compare control worms with CL2355 neuronal Aβ1-
42 expressing worms before temperature induction, and after temperature induction. 
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3.2.2.3 Characterisation of frontotemporal dementia with parkinsonism-
17 (FTDP-17) models 
The two C. elegans FTDP-17 models studied here are transgenic for the 
human Tau protein with the V337M FTDP-17 mutation (Kraemer et al., 
2003). The integrated transgene array is expressed in all neurons. While 
CK10 worms carry both the mutant Tau transgene and the Pmyo-2::GFP 
reporter marker for pharyngeal expression (Figure 3.3B), CK49 are triple 
transgenic worms generated by crossing CK10 with a CZ1200 strain 
expressing Punc-25::GFP GABAergic marker transgene only (Figure 3.3A) and 
therefore contain the Paex-3::
 Tau V337M, Pmyo-2::GFP and Punc-25::GFP 
reporter marker transgenes (Figure 3.3C). Using a synchronised population 
of worms, locomotion at several time points throughout adulthood were 
quantified with the thrashing assay (Figure 3.3D), as motor deficits have 
been shown to be a reliable indicator of Tau pathology in C. elegans. CK10 
and CK49 lines were dumpy and small, and exhibited significantly greater 
impairment of movement than N2 WT and CZ1200 which serve as non-
transgenic (non-Tg) and GFP transgenic control worms, respectively. CK10 
worms were partially paralysed and displayed a distinctive dorsal coiler 
phenotype that is typically associated with mutations causing motorneuron 
dysfunction. They were also unable to move co-ordinately as a result of the 
severe neurotoxicity of this mutant protein, but are capable of intermittent 
short bursts of very fast head thrashes. CK49 were severely uncoordinated 
(Unc), dumpy, unresponsive and they barely bend in liquid with little or no 
displacement from the starting position. Each mutant Tau-expressing line 
never displayed fast body movement even as young adults as their strikingly  
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Figure 3.3: Pan-neuronal expression of mutant human Tau transgenes resulted in severe 
locomotion defects. A-C) Visualisation of GFP-labelled strains used. A) Strain CZ1200 expressing 
only an integrated Punc-25::GFP transgene in GABAergic neurons was included as a control. Scale bar 
represents 200 μm. B) CK10 animals have strong signal in the pharynx that derives from the integrated 
Pmyo-2::GFP reporter. C) Strain CK10 was crossed with CZ1200 to generate a triple transgenic line that 
is homozygous for three integrated transgenes - mutant Tau transgene, the Punc-25::GFP GABAergic 
and Pmyo-2::GFP pharyngeal marker transgenes. All worms depicted are young adults and are oriented 
with anterior end left, posterior end right and ventral side down. D, E) Quantification of movement 
defects induced by the expression of mutant Tau. Time points for locomotion assessments were 
chosen to span the majority of normal worm life span. D) Transgenic CK10 and CK49 worms displayed 
significantly reduced body thrashes in liquid compared with N2 and CZ1200 which serve as non-
transgenic (non-Tg) and GFP transgenic control worms, respectively. CK10 worms are severely 
uncoordinated and displayed partial paralysis and dorsal coiling phenotypes, but are capable of 
intermittent short bursts of very fast head thrashes; CK49 demonstrated an additional decrease in 
movement beyond the severe impairment present at day 1 of adulthood as worms aged, approaching 
complete paralysis by day 8. N2 WT and CZ1200 worms moved normally and exhibited minor 
movement decline as worms age until day 8 of adulthood. E) Double transgenic control worms 
expressing both Pmyo-2::GFP and Punc-25::GFP marker transgenes displayed WT body thrash rates. 
Results shown represent the average data from two independent experiments. For each assay, at least 
ten animals were used for each genotype and their average values are shown. The error bars denote 
SEM from three repetitions of the experiment. Statistical significance ***p<0.0001 in all cases, 
compared with the non-transgenic worms (N2) was determined using paired Student's t-test. 
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severe locomotion phenotype manifested during larval stages and persisted 
throughout the development and aging, culminating in nearly complete 
paralysis by day 8 of adulthood. These are therefore distinguished from 
normal worm aging-related declines in motility. N2 WT and CZ1200 show 
decreased motility as worms age, with significant N2 movement decline 
demonstrated by day 8 of adulthood; they do not become paralysed except at 
extremely advanced ages, typically ~18-20 days.  
Once the decline in behavioural response was established, it was 
important to confirm if the loss of behaviour is caused by loss of neuronal 
function associated with pan-neuronal expression of Tau V337M protein. 
Neuronal structural defects, notably, neurodegeneration in the VD- and DD-
type classes of GABAergic motor neurons have been demonstrated in 
neurodegenerative C. elegans models (Kraemer et al., 2003, Fatouros et al., 
2012). unc-25 encodes the GABA biosynthetic enzyme glutamic acid 
decarboxylase (Jin et al., 1999) and hence the addition of the Punc-25::GFP 
marker in CK49 worms allowed the structural and morphological integrity of 
the GABAergic neuronal network to be inspected in more detail for possible 
motorneuron abnormalities associated with transgene expression that may 
account for the motility defect. In strain CZ1200 carrying the GFP reporter 
alone, both the dorsal and ventral nerve cords are continuous and contain 
the normal complement of 19 inhibitory motor neurons (Figure 3.4A; C-F, left 
panels). The uncoordinated behaviour of CK10 and CK49 was already 
apparent at day 1 of adulthood, indicating that the simple expression of 
mutant human Tau was sufficient to cause constant neuronal dysfunction. 
Indeed, CK49 exhibited profound degeneration of the GABAergic motor 
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neuron network whereby persistent discontinuities and exaggerated 
varicosities appeared in the axonal bundles of the dorsal and ventral nerve 
cords (Figures 3.4 A and B; C-F, right panels) that were also already visible 
at day 1 of adulthood. Though the number of axonal gaps in CK49 did not 
rise with age, an extension of gaps was observed in neurites of both the 
ventral and dorsal nerve cords (Figure 3.4E and F, right panels). 10-day-old 
worms from the mutant lines showed degenerating axons throughout the 
ventral and dorsal nerve cords. These neuronal structural defects are 
therefore consistent with the severe motor defects exhibited by CK49.  
A general caveat of using transgenic markers in C. elegans is that 
they can produce various levels of cytotoxicity and are likely to be of no 
interest in the context of normal cellular physiology. We therefore performed 
additional control experiments to ensure that the robust phenotypic traits 
observed stem from Tau V337M induced- neurotoxicity, not as a result of an 
overabundance of the reporter proteins or transgene insertion. A double 
transgenic negative control with expression of both Pmyo-2::GFP
 and Punc-
25::GFP was generated. As shown in Figures 3.3E and 3.4B, introduction of 
two GFP reporter constructs did not produce any significant defects, as 
double transgenic control worms showed no locomotion impairments or 
axonal degeneration with very few, if any, gaps compared with CK49 worms. 
In contrast, the CK49 phenotype is more severe than both CK10 and CK10; 
Pmyo-2::GFP, thus suggesting that driving GFP transgene expression in GABA 
neurons might have exacerbated the effect of Tau expression.  
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Figure 3.4: Assessment of neurodegenerative changes in GABAergic motor neurons by visual 
scoring of GFP reporter. Triple transgenic CK49 worms expressing the Paex-3::V337M Tau, Pmyo-
2::GFP, and a Punc-25::GFP reporter transgene marking the cell bodies and processes of all C. elegans 
GABAergic neurons was compared with CZ1200 single transgenic for Punc-25::GFP and double 
transgenic control expressing both Pmyo-2::GFP and Punc-25::GFP markers to score for 
neurodegenerative neuronal loss. A, B) Graph plotting the average number of ventral (VG) and dorsal 
(DG) cord gaps at different ages of adulthood. C-F) All panels are micrographs of representative whole 
worms. CZ1200 (left panels) and CK49 (right panel) were examined at age 1 day (C), 5 days (D), and 
10 days (E). In CZ1200, intact ventral and dorsal cords were observed. In contrast, CK49 mutant Tau 
transgenic GABAergic reporter strain exhibited severe degeneration of neuronal processes. VC and 
DC gaps (arrows) are disruptions in the continuity of the ventral and dorsal nerve cords, respectively. 
The error bars denote SEM from two repetitions of the experiment. At least 10 worms were scored per 
strain and per time point. Scale bar represents 200 μm for all panels except for the last two panels (F) 
which are high magnification of boxed areas of Figure 3.4 E.  
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`During the routine maintenance of the CK49 stocks, several 
independent WT revertants arose spontaneously and displayed a complete 
behavioural and morphological reversion to the WT phenotype. Isolation of 
revertants from Unc worms gave rise to a mixed population of phenotypically 
WT and Unc worms. It is possible that the presence of the toxic transgenes in 
the CK49 strain has increased its tendency to modify (suppress) phenotypes 
similar to what was observed with an ALS and polyQ model (Gidalevitz et al., 
2006, Gidalevitz et al., 2009). Its low progeny number further renders this 
strain particularly unstable, resulting in segregation of lines revertant from 
toxic to WT phenotype during selection.  
A series of experiments was performed to examine the nature of the 
incorporated Tau transgene in the revertants. The presence of Tau transgene 
was first confirmed using the single-worm PCR for a fragment of human 
MAPT cDNA, and strong signals for the expected 425 bp band was detected 
in the all mutant-Tau expressing lines including the revertants, but not in the 
CZ1200 GFP reporter line (Figure 3.5A). Therefore, reversion is not due to 
loss of the Tau transgene. 
We then asked if the expression of the Tau transgene was inhibited at 
the level of mRNA. In order to compare the Tau transcript levels, RT-PCR 
analysis was carried out which revealed that there was no transcriptional 
silencing of the integrated array as the expression levels of Tau mRNA were 
detectable in both paralysed and revertants (Figure 3.5B). No obvious 
changes were observed apart from insignificant dampening of the Tau 
expression. 
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To examine whether the revertant phenotypes observed result from 
changes in the level of Tau V337M protein, the overall Tau protein level was 
studied by western blotting using anti-Tau antibody and demonstrated that 
human Tau protein expression was barely detectable in the revertants, 
whereas Tau proteins were expressed at similar levels with an expected Mw 
of about 64 kDa in both CK10 and CK49 Unc lines (Figure 3.5C). The 
observation of slight reduction in GFP expression but near absence of Tau 
expression in CK49 revertants reflects minimal Tau V337M proteotoxicity and 
suggests that the phenotypic reversion was likely due to inefficient translation 
of the transgene-derived mRNA or increased protein degradation or turnover 
due to unknown changes in these revertant worms. As a result, the 
expressed level of Tau was insufficient to exert its deleterious effect on the 
worms. 
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Figure 3.5: Analysis of spontaneous phenotypic reversion. A) The upper panel shows the 
detection of Tau transgene. Single-worm PCR for a 425 bp fragment of Tau cDNA, which was detected 
in the CK10, CK49 Unc and CK49 revertant lines, but not in the GFP reporter line, CZ1200 WT control. 
DNA size marker in bp. B) RT-PCR expression analysis of Tau transcript in WT, CK49 Unc and CK49 
revertant lines. The picture shows amplification bands of fourteen PCR reactions (including the parallel 
internal control) starting with seven different amounts of template cDNAs. No detectable Tau 
expression differences were observed among all CK49 transgenic lines. The endogenous C. elegans 
gene actin served as an internal control. Both PCR and RT-PCR analysis were repeated three times 
with identical results. C) Biochemical confirmation of protein over-expression. Representative western 
blot of total protein levels from independently integrated V337M Tau-strains, as indicated. The blots 
were probed with a T46 Tau antibody, which recognises the C-terminal region of both non-
phosphorylated and phosphorylated Tau and thus detect total Tau levels; anti-actin antibody was used 
as loading control and anti-GFP. CK49 revertants and CZ1200 worms showed no reactivity to the T46 
Tau antibody, while CK10 Tau proteins are expressed at similar levels to those of CK49 Unc. The 
major full-length isoform of Tau at 64 kDa in size is indicated. Multiple bands present in rat brain lysate 
indicate Tau truncation products, alternate start sites, or cleavage products of full-length Tau. The 
doublet GFP bands evident in all CK49 lines are due to the presence of two GFP markers. The 
numbers below the gel represent the quantification of Tau signals using ImageJ software which were 
normalised against actin. The values are relative to CK49 Unc levels. 
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3.2.2.4 Pan-neuronal expression of an ALS-associated mutant version 
of human SOD1 in C. elegans produces severe locomotor defects  
To explore the potential use of a worm ALS model of SOD1 toxicity, we 
obtained and studied two distinct models engineered to express human WT 
SOD1 and mutant SOD1 exclusively in neurons (Psnb-1::WT SOD1-YFP and 
Psnb-1::G85R SOD1-YFP (Figure 3.6A), which will hereafter be referred as 
WT SOD1-YFP and G85R SOD1-YFP worms, respectively. While WT SOD1 
proteins can bind to copper and zinc, the catalytically inactive mutant G85R 
is deficient in copper and zinc binding and significantly destabilised (Wang et 
al., 2009b). Previous literature has shown that the WT and the G85R mutant 
SOD1 were significantly different in their neurotoxic properties. In our study, 
both the WT SOD1-YFP and G85R SOD1-YFP worms developed profound 
locomotor defects compared to N2 worms at all stages of adulthood, as 
measured by their thrashing rate in liquid medium (Figure 3.6B). WT SOD1-
YFP worms exhibited a mild worsening effect with an average of ∼54% 
decrease in locomotor activity compared to N2 WT. As anticipated, G85R 
SOD1-YFP mutant exhibited particularly strong motility defects that were 
consistently more severe than those of the WT SOD1-YFP such that their 
thrashing was reduced by > 85% relative to WT SOD1-YFP counterparts at 
all time points (p<0.0001). On average, G85R SOD1-YFP worms exhibited 
minimal movement in isotonic liquid. Given that ALS may involve the 
deposition of non-mutant SOD, the observation that WT SOD1-YFP is mildly 
toxic in this model suggests that this model might also have relevance to 
ALS.  
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Because the motor dysfunction phenotypically resembles that of the 
FTDP-17 models, the basis for the defective locomotion of the SOD1 
transgenic C. elegans could therefore also result from the abnormalities of 
motor neurons that innervate the body wall muscles. Using fluorescence 
microscopy, we looked for similar neuronal structural defects associated with 
mutant Tau expression that may account for the severe motility defect in the 
ALS models. However, we could not detect any age-dependent gross 
abnormalities in nervous system morphology of either WT SOD1-YFP or 
G85R SOD1-YFP worms (Figures 3.6 C and D), and no differences in YFP 
intensity were evident by eye when observing the two worm strains. This, 
however, does not preclude subtle neuronal defects. Previous studies have 
noted differing characteristics of fluorescence of neuronal cell bodies along 
the ventral nerve cord that are suggestive of aggregate formation (Wang et 
al., 2009b), but were unable to identify a direct correlation between motor 
neuron loss/gross defects in nervous system and locomotory activity (Lakso 
et al., 2003, Boccitto et al., 2012). 
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Figure 3.6: Transgenic C. elegans expressing neuronal SOD-1 develops pronounced movement 
defects. A) Expression pattern of YFP-tagged human SOD1 (hSOD1) driven by the pan-neuronal snb-
1 promoter was assessed by fluorescence microscopy. Lateral view of stably-transformed WTSOD1-
YFP transgenic L4 animal showing expression of fluorescent protein in nerve ring region, in ventral 
nerve cord, in dorsal nerve cord, as well as in commissural and lateral neuronal cell bodies, and in tail 
region. The large motor neurons in the ventral cord and lateral wall neuron are easily detectable. Head 
of worm is to right. B) Motor activity, as measured by thrashing scores for 0-day-old (L4) to 8-day-old 
animals, shows age-related reductions in motor activity in all strains used. The G85R hSOD1-YFP 
strains had significantly impaired locomotion than the WT hSOD1-YFP strain (***p<0.0001). Asterisks 
indicate the significance between G85R hSOD1-YFP and WT hSOD1-YFP controls, whereas hash 
marks indicate the significance between WT hSOD1-YFP and N2 WT. Error bars represent the 
standard error of means (SEM). The figure is representative of two independent experiments. C, D) 
Despite evident motor dysfunction, only subtle differences in the fluorescent pattern of neuronal cell 
bodies along the ventral nerve cord were detected in G85R hSOD1 worms, even during later adult life. 
Scale bar represents 200 μm. 
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3.2.2.5 Reproducible neurodegeneration in the dopaminergic neurons 
of 6-OHDA-induced PD model 
Previous studies have established that WT C. elegans dopaminergic 
(DAergic) neurons are highly sensitive to treatment with neurotoxins. 
Exposure to an appropriate concentration of neurotoxins have led to loss of 
the fluorescent DA neuronal marker due to degeneration of DA neurons, and 
generated ideal pharmacological models for identification of neuroprotective 
compounds or potential functional partners of PD-related genes. We chose to 
use the dopamine-selective neurotoxin, 6-hydroxydopamine (6-OHDA), for its 
experimental convenience. To determine whether C. elegans DAergic 
neurons are sensitive to the 6-OHDA in vivo as previously reported, the 
integrated Pdat-1::GFP reporter strain BY250, which expresses strong and 
specific green fluorescence in all eight DAergic neurons (Figure 3.7A) was 
utilised in our experiment, and degeneration of the six anterior DAergic 
neurons in response to either 10 mM ascorbic acid (AA) alone (vehicle 
control) or both 50 mM 6-OHDA and 10 mM AA were analysed. Addition of 
AA helps to stabilise 6-OHDA in solution. GFP-labeled DAergic neurons were 
examined for the presence of all six anterior DAergic neurons at time points 
2, 24 and 48 hours after 6-OHDA treatment and were scored for evidence of 
DAergic neuron survival. The amount of nematodes exhibiting WT anterior 
DAergic neurons, partial or complete DAergic neurodegeneration was 
determined in the whole population. Consistent with published reports, the 
characteristic degenerative changes of GFP fluorescence in DAergic neurons 
were detected in 6-OHDA-treated worms as their DAergic neurons undergo a  
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Figure 3.7: Characterising the 6-OHDA-induced responses in C. elegans A) DA neurons cell 
bodies and neurites in BY250 worms were visualised using an integrated Pdat-1::GFP DA transporter 
marker. C. elegans has eight DA neurons: six are located in the anterior region, which can be 
subclassified in pairs as two anterior deirid neurons (ADE), two dorsal cephalic neurons (CEP) which 
are postsynaptic to the ADE neurons and two ventral CEPs that are not postsynaptic to the ADEs; two 
posterior deirid neurons (PDE) located posteriorly are also shown. Arrows depict the four CEP neuron 
processes and indicate the ADE and PDE cell bodies in a young worm. Anterior is to the left. B) 
Representative examples of worms scored which display the three characteristic stages of DA 
neurodegeneration in response to 6-OHDA. Magnification of anterior region of C. elegans shows only 
the anterior-most DA neurons. WT: In this example, all six anterior DA neurons of this worm appear 
robust and the dendrites are intact and fully extended. Neuronal process blebbing; cell body rounding: 
this worm exhibited prominent cell body rounding (asterisk) and dendrite blebbing (arrows); cell body 
loss: this worm exhibited a complete loss of GFP in most DA neurons as CEP and ADE neurons have 
all degenerated and are no longer visible in any focal plane, only retention of GFP expression in the 
remnants of neuron cell bodies and broken neuritis. All scale bars represent 20 μm. C) Percentage of 
worms exhibiting WT, partially or completely degenerating ADEs and CEPs neurons/dendrites after 6-
OHDA treatment at different time points is presented. The six anterior DA neurons were examined for 
each worm (at least 30 worms/condition) following exposure to either 10 mM AA alone as vehicle 
control or both 50 mM 6-OHDA and 10 mM AA, and the GFP expression pattern in the respective cells 
was examined 2, 24 and 48 hours post-exposure (see Materials and Methods). Data are depicted as 
means from six independent experiments. D) Representative worms from the analysis charted in 
Figure 3.7C performed 24 hours post-6-OHDA-exposure are presented. BY250 worms treated with AA 
alone expressed intact and strong GFP in all six DA neurons and dendrites in the heads. Meanwhile, 
majority of BY250 incubated with 50 mM 6-OHDA showed a marked GFP expression reduction in the 
dendrites of ADEs and CEPs, many of the cell somas became round (asterisk) and blebs appeared 
along the dendrites of CEPs (arrows).  
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reproducible death from exposure to 50 mM 6-OHDA that begins within ∼2 
hours of treatment. These acute, reproducible changes include readily 
observable CEP dendrite blebbing and cell body rounding (Figure 3.7B). A 
complete loss of GFP expression was also observed in DAergic neurons and 
dendrites at later time points i.e. 48 hour post-exposure (Figures 3.7 B and 
C). 
As shown in Figures 3.7 D and E, which are representative 
fluorescence images of GFP expression in multiple BY250 worms at 24 
hours post-6-OHDA-exposure, 6-OHDA triggered differing degrees of 
DAergic neurodegeneration in each worm. Most of the cell somas became 
round and blebs appeared along the dendrites (Figure 3.7E). Quantitatively, 
70% of AA alone–treated vehicle controls displayed intact and strong GFP in 
all six DAergic neurons. However, 70-80% of worms exhibited degenerating 
neurons and processes after treatment with both 50 mM 6-OHDA and 10 mM 
AA (Figures 3.7 C-E).  
3.2.2.6 Homozygous deletion of C. elegans smn-1 results in a rapid 
decline in neuromuscular function 
The first C. elegans model developed for human spinal muscular atrophy 
(SMA) was a smn-1(ok355) null mutant in which a large deletion in the gene 
homologous to SMN, smn-1, caused a complete loss of smn-1 function which 
in turn causes lethality (Briese et al., 2009). A balanced strain LM99 was 
obtained to facilitate identification of heterozygous and homozygous animals 
which were subsequently assayed for thrashing. Heterozygous animals are 
overtly normal and are distinguishable by pharyngeal GFP, while 
homozygous progeny have no GFP expression. We will hereafter refer to   
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Figure 3.8: Motor activity of SMA mutant model as measured by the trashing assay. Thrashing 
rates of N2 WT and smn-1(ok355) heterozygotes and homozygotes after 10 minutes in Dent’s solution 
were counted manually. Age-related reductions in motor activity were observed in all strains. smn-
1(ok355) heterozygotes showed slightly lower score than non-transgenic N2 animals, whereas smn-
1(ok355)
-/- 
consistently thrashed at a slower rate than its age-synchronised counterparts. Thrashing of 
smn-1(ok355)
-/-
 animals progressively declined and almost completely ceased after 5 days post-L1 
stage. The error bars denote SEM from two independent experiments, and differences were 
considered non-significant (n.s. p > 0.05) or significant (***p < 0.0001).  
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smn-1-/- and smn-1(ok355)/hT2[qIs48] animals as homozygotes and 
heterozygotes, respectively. Animals that are homozygous for smn-1-/- can 
survive for several days due to partial maternal rescue. It has been 
suggested that heterozygotes load sufficient SMN-1 maternal protein and/or 
mRNA into oocytes to support development through embryogenesis and 
early larval stages (Dimitriadi and Hart, 2010). As previously observed, 
during early development, the thrashing rate of homozygous smn-1-/- larvae 
did initially resemble the heterozygotes and N2 WT animals. Eventually 
maternally-loaded smn-1 product is lost and homozygotes undergo larval 
arrest. Not only did their thrashing progressively decline and almost 
completely cease after 5 days post-L1 (Figure 3.8), homozygotes grew 
slower than their heterozygote siblings, were shorter, sterile, and most died 
before reaching adulthood. In contrast, there were no statistically significant 
differences between heterozygotes and N2 WT in locomotor activity at any 
time point throughout the assay. 
3.2.2.7 C. elegans polyQ models exhibit perturbed neuronal dysfunction 
without neuronal cell death  
The two HD models chosen for characterisations were, firstly, strain HA659 
which co-expresses GFP with an N-terminal human huntingtin fragment 
containing a polyQ tract of 150 residues (Htt-Q150) strongly in non-essential 
ASH neurons and more weakly in other neurons (Figure 3.9A). Secondly, 
strain HA759 in which the Htt-Q150 is expressed in ASH sensory neurons of 
polyglutamine enhancer-1 (pqe-1) mutant sensitised background that was 
previously suggested to specifically accelerate expanded polyQ-induced 
toxicity and causes age-dependent ASH neuronal death within 3 days. First, 
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we addressed the ASH functionality of both HA659 and HA59 in a nose-
touch assay (Figure 3.9B). On day 3 of adulthood, N2 WT animals stopped 
forward motion and reversed in response to nose touch in 70-80% of nose 
touch trials. Htt-Q150 and OSM-10::GFP co-expression in young HA659 and 
HA759 animals produced mild nose touch abnormalities when challenged 
with a mechanosensory stimulus, as worms responded in only 58% of nose 
touch trials. However, aged HA659 and HA759 worms on day 8 of adulthood 
were strongly defective for ASH-mediated nose touch avoidance response. A 
modest but significant defect was observed for HA659 (51%) and a 
pronounced defect was observed for HA759 in which Htt-Q150 caused a 
marked decrease in this response to 14% (Figure 3.9B). 
To verify ASH apoptotic cell death, we used fluorescence microscopy 
to assess ASH neuron viability in young 3-day-old and aged 8-day old HA659 
and HA759 adults by monitoring the presence or absence of GFP 
expression. Previous studies have indicated that in pqe-1(rt13) mutant 
animals expressing Htt-Q150, the vast majority (>90%) of HA759 ASH 
neurons became absent in less than three days predominantly during larval 
stages, indicative of rapid neurodegeneration and neuronal cell death. Apart 
from occasional dendritic breaks, we failed to observe the highly penetrant 
ASH cell death in any young (day 3) or old (day 8) HA759 worms. As shown 
in Figures 3.9 C and D, expression of the Htt-Q150 transgene in sensitised 
background did not significantly increase the percentage of dead ASH 
neurons scored as the vast majority of ASH neurons remained 
morphologically intact. There was a minimum of ASH neuronal death, with 
11% dead cells observed at 3 days, increasing at 8 days to just 20%.  
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Figure 3.9: PolyQ expansion perturbs ASH function in aged animals. A) Expression pattern of 
Posm-10::GFP  in C. elegans assessed by fluorescence imaging. osm-10 is expressed in a bilateral pair 
of chemosensory neurons in all larval and adult animals known as amphid (ASH, ASI) in the head and 
phasmid (PHA, and PHB) in the tail. Its function is required in the main avoidance/osmotic avoidance 
neuron ASH. B) Nose touch response depends directly on ASH sensory neurons’ function. To test 
nose-touch response, an eyelash was placed in front of a forward moving worm’s nose and avoidance 
behaviour was quantified as mean % of trials in which the transgenic or control animals responded to 
nose touch responded by stopping forward motion or immediately recoiled. Worms were scored 10 
times each for response to nose touch.
 
Results here show that young worms all have normal nose 
touch response. However, on day 8, HA659 had significantly impaired response to nose touch as 
compared to wild type. Htt-Q150 expression in sensitised ASH neurons leads to a severe defect in the 
nose touch response of HA759 model. Error bars indicate SEM. C, D) Assessment of ASH survival. 
Live neurons express GFP, and neuronal death is evaluated by a loss of GFP fluorescence in bilateral 
ASH neurons. ASH neuronal viability was assayed in live animals at the times indicated. However, the 
highly penetrant ASH apoptotic cell death was not evident in any young (day 3) or old (day 8) HA759 
worms. n ≥ 10 animals per strain were imaged. Scale bars, 20 μm 
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3.3. DISCUSSION 
The study of behavioural and neuropathological phenotypes of the ND 
models has been plagued by inconsistent results across laboratories. This 
stems from the technical differences (i.e. transgenic constructs, modes of 
gene targeting, transgene expression levels and scoring criteria for various 
phenotypes) and the intrinsic differences between the models (i.e. the 
manner by which specific C. elegans tissues respond to misfolded proteins). 
In this study, we selected and characterised well-defined neuronal C. elegans 
models of various forms of human ND that were shown previously to develop 
profound neuronal dysfunctions associated with protein misfolding and 
aggregation to identify lines with the most robust phenotypic differences, best 
suited for genetic and preclinical therapeutic efficacy studies. We focused on 
behavioural phenotypes of the chosen ND models, particularly behaviours 
that have been established as neuronally controlled. Among the behavioural 
assays that have been well established in C. elegans to assess neuronal 
toxicity-evoked phenotypic abnormalities include thrashing, body bend, 
paralysis, chemotaxis, pharyngeal pumping, food-sensing and egg-laying 
(Leung et al., 2008). The thrashing assay was applied in our study, since the 
most striking behavioural phenotype of our selected models was the loss of 
coordinated movement leading to nearly complete paralysis and this has 
been used as the read-out for many previous genetic and pharmacological 
screens (Alavez et al., 2011, Tauffenberger et al., 2012, Liachko et al., 2013, 
McCormick et al., 2013, Munoz-Lobato et al., 2013). More than 60 neurons in 
the C. elegans nervous system innervate muscle cells to evoke the wave of 
muscle contraction-relaxation leading to locomotion; it is therefore not 
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surprising that dysfunction or loss of these neurons results in lack of 
coordination and paralysis, and contribute to the neurodegenerative demise. 
Accumulating evidence indicates that proteostasis (protein 
homeostasis) is a critical component of longevity and several studies using 
transgenic C. elegans models of protein-misfolding disorders have led to the 
discovery that genes (Morley et al., 2002, Hsu et al., 2003, Morley and 
Morimoto, 2004, Cohen et al., 2006) and compounds (Calamini et al., 2011, 
Fatouros et al., 2012, Lublin and Link) which prolong lifespan also restore 
proteostasis. The short C. elegans lifespan is therefore associated with the 
age-dependent onset of NDs and has also been monitored as a read-out in 
multiple screens (Nussbaum-Krammer and Morimoto, 2014). However, 
whether C. elegans lifespan is a robust neurodegenerative biomarker is 
debatable as recent work suggested that lifespan extension is not a straight 
prediction for neuroprotective properties (Tauffenberger et al., 2013). 
Nevertheless, numerous compounds such as EGb761 (Wu et al., 2002) 
reserpine (Srivareerat et al., 2009, Saharia et al., 2012), trehalose (Honda et 
al., 2010), metformin (Onken and Driscoll, 2010), celecoxib (Ching et al., 
2011), ferulsinaic acid (Sayed, 2011), NG-094 (Haldimann et al., 2011), 
astragalan (Zhang et al., 2012a), salidroside (Xiao et al., 2014), thioflavin T, 
curcumin and rifampicin (Alavez et al., 2011) were shown to enhance lifespan 
and ameliorate proteotoxicity of Aβ and/or polyQ protein aggregation models.  
In line with these studies, deletion of an endogenous neuroprotective 
gene dnj-14, the sole C. elegans orthologue of the CSP-encoding DNAJC5 
gene that is mutated in ANCL resulted in a reproducible and significant 
lifespan reduction, which parallels with the increased mortality associated 
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with mutations in DNAJC5 homologues in humans (Benitez et al., 2011, 
Noskova et al., 2011, Velinov et al., 2012, Cadieux-Dion et al., 2013), mice 
(Fernandez-Chacon et al., 2004) and flies (Zinsmaier et al., 1994). The 
biochemical and genetic analysis of CSP function in various systems 
produced compelling evidence that CSP could be a key player in 
neuroprotection against several if not one ND. Such an involvement was 
hinted at by the discovery that impaired/toxic proteins typically found in NDs 
may interfere with CSPα, SNARE complex assembly, dynamin1 assembly 
and ion channel complexes, and in part, contribute to neurodegeneration 
(Donnelier and Braun, 2014). The recent identification of CSPα as a human 
ND gene and the implication of CSP in AD (Dolzhanskaya et al., 2014), 
ANCL (Noskova et al., 2011), HD (Miller et al., 2003) and PD (Chandra et al., 
2005) strongly suggest that this presynaptic co-chaperone could be generally 
neuroprotective in multiple NDs. CSP was shown to functionally overlap in 
vivo with the PD protein, α-synuclein, for preventing neurodegeneration. The 
profound neurodegeneration and lethality in CSP mutant mice can be 
ameliorated by transgenic overexpression of normal α-synuclein and 
exacerbated in α-synuclein knock-out mice (Fernandez-Chacon et al., 2004, 
Chandra et al., 2005). Similarly, it was also suggested that CSP binds to 
mutant Htt, but not to normal Htt. The sequestration and subsequent 
depletion of CSP by expanded polyQ stretches eliminates the robust 
inhibition of N-type Ca2+ channels promoted by CSP (Miller et al., 2003). 
Studies by multiple independent labs have consistently shown that the 
cellular CSP-neuroprotective pathways are also compromised in ANCL 
(Benitez et al., 2011, Noskova et al., 2011, Velinov et al., 2012, Cadieux-Dion 
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et al., 2013) which further strengthen the claim that CSPα could be generally 
neuroprotective in multiple NDs. Moreover, very recent work has implicated 
CSPα in AD, as unusually severe disease course and lysosomal lipofuscin 
inclusions, previously believed to be exclusive to NCLs were found to be 
present in very early onset (age 30) and rapidly progressing AD caused by a 
novel presenilin1 mutation (Dolzhanskaya et al., 2014). A pronounced 
decrement of CSPα was observed in postmortem AD frontal cortex (Zhang et 
al., 2012c) and the SNARE complex assembly was also impaired in human 
brain tissue from patients with AD (Sharma et al., 2012). An alternative 
approach to identify generally neuroprotective interventions is to search for 
compounds that are able to compensate for the loss of an endogenous 
physiological neuroprotective factor such as CSPα (Sleigh et al., 2011). As 
explained before, the extreme severity of fly csp mutants coupled with the 
unfeasibility of performing high throughput screens in mice suggests that the 
worm dnj-14 model may be a more efficient platform for screening 
neuroprotective factors. Indeed, prior to my studies, a focused drug screen 
which had been performed in the lab on the dnj-14(ok237) mutants to identify 
compounds that compensate the loss of dnj-14 demonstrated the pro-
longevity properties of resveratrol on the C. elegans ANCL model, and was 
subsequently shown to act via a PDE-inhibition-dependent and sir-2.1-
independent manner (Kashyap et al., 2014). dnj-14 mutant is therefore an 
efficient model that could contribute significantly to the study of the molecular 
basis of age-related NDs and the identification of potential therapeutic 
targets. 
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It has been suggested that a phenotype with a complete penetrance of 
100% is most suitable for pharmacological or genetic screening purposes 
(Garcia-Alcover et al., 2013). The pronounced motor dysfunction of both the 
FTDP-17 and ALS models is a reproducible phenotype shown by many 
researchers and our observations (severe locomotion impairments, profound 
degeneration of the GABAergic motor neuron network) are consistent with 
previous findings that aberrations in these disease proteins result in 
aggressive neuropathologies resembling those found in transgenic fly/mouse 
models and human patients. The robust early-onset phenotype decouples 
the Tau aggregation-mediated toxicity from age-related alterations of 
proteostasis; its rapid occurrence is also within a timeframe that allows for 
efficient testing, and therefore, would be a particularly suitable read-out for 
time- and cost-effective pharmacological or genetic screens to uncover 
specific modulators of Tau and SOD pathologies (Boccitto et al., 2012, 
Fatouros et al., 2012). However, one must be cautious in comparing the 
effects of treating animals with a pharmacological agent altering the timing 
/course of neuronal degeneration, and the consequences of toxic mutant 
transgenes that have a chronic loss of activity (Wang et al., 2012). Our 
observation of a complete phenotypic reversion in CK49 FTDP-17 model 
corresponds to what were previously observed with transgenic ALS and 
polyQ models. The utility of the CK49 strain for future screening is therefore 
restricted, since it is likely that any physiological effects seen upon relatively 
acute pharmacological treatments would be masked by the occurrence of or 
the selection for adaptive changes in protein homeostasis and gene 
expression (Wang et al., 2012). Performing assays on freshly 
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thawed/crossed worms or periodically re-building the strain can circumvent 
the generation of revertants, but would not be an effective long term solution.  
The alternative CK10 Tau model which displays less severe, yet still robust 
phenotypic defects may better inform on drug testing. CK10 does not revert 
and has already facilitated the identification of dopamine D2 receptor 
antagonist as a potential neuroprotective strategy for targeting Tau 
aggregation and neurotoxicity in a primary drug screen (McCormick et al., 
2013). 
We also observed progressive and robust locomotion deficits in the 
SMA model which are in accordance with previous studies. However, a 
caveat of using the smn-1(ok355) null mutant for screens is the severity of 
the mutation which compromises the viability of the worm and therefore 
making identification of modifiers of the phenotype very demanding (Edens et 
al., 2014). Indeed, the sudden manifestation and rapid progression of the 
neuromuscular defects, in concert with the technical difficulties associated 
with partition of smn-1 homozygotes make screening of the locomotor 
phenotype particularly challenging (Sleigh and Sattelle, 2010) and to date no 
drug screening has been performed in this null-mutant SMA model. However, 
recent technical improvements in C. elegans handling most prominently the 
development of the Complex Object Parametric Analyzer and Sorter (the 
COPAS BioSorter) and microfluidic worm manipulation have now overcome 
many of the practical limitations in using this C. elegans model for HTS 
(Pulak, 2006). The COPAS BioSorter has been successfully used to 
ascertain data on the length and genotype of smn-1(ok355) to separate the 
null mutant worms, based on their small size and lack of GFP fluorescence, 
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and in a subsequent genome-wide RNAi screen uncovered multiple genetic 
modifiers of the SMA model (Dimitriadi and Hart, 2010). In a similar manner, 
this approach could be adapted to screen compound libraries for drugs that 
ameliorate smn-1 loss-of-function defects. Indeed, this method has already 
been successfully used in high-throughput neurotoxin screening (Boyd et al., 
2010), thus indicating the potential of this instrument for large-scale 
phenotyping and screening for neuroprotective compounds in various other 
NDs. Genetic screens for modifiers of the deleterious phenotypes of smn-
1(ok355) identified the small conductance Ca2+-activated K+ (SK) channels 
as a cross-species invertebrate SMN modifier which was further manipulated 
pharmacologically (Dimitriadi and Hart, 2010, Dimitriadi et al., 2013). 
Activating the SK channel by an SK channel activator riluzole was shown to 
improve the neuromuscular function of the smn-1(ok355) null mutant by 
significantly increasing both its motility and pharyngeal pumping rates during 
feeding, as well as preventing axonal defects in Smn-deficient rat 
hippocampal neurons. An E3 ubiquitin ligase, mind bomb 1 (Mib1) was also 
identified as a cross-species modifier as depletion of Mibl increased the SMN 
protein levels in cultured cells and significantly ameliorated the smn-1(ok355) 
pharyngeal pumping defects (Kwon et al., 2013). To overcome the drawback 
of smn-1(ok355) null mutant and aid the development of drug screening, 
Sleigh and colleagues identified a less severe smn-1(cb131) mutant allele 
that causes weak motor defects and a slightly reduced lifespan, and more 
closely resembles the severity of SMA (Sleigh et al., 2011). Using this 
mutant, they screened a library of chemicals for potential drugs and identified 
six chemicals that could ameliorate the mild defects of the worms. The most 
146 
 
effective ones include two FDA-approved drugs, 4-AP (a potassium channel 
blocker) and gaboxadol hydrochloride (a GABAA receptor agonist), and one 
novel compound Neu5Ac (a monosaccharide).  
We found that some phenotypes, i.e. defective food sensing 
behaviours or cilia dye-filling, while quantifiable, are not robust and sensitive 
enough to be rapidly used and would be technically difficult to assay on a 
large-scale (data not shown). The food sensing assay has been used to 
assess the effect of overexpression on the function of DA neurons and has in 
numerous studies demonstrated the defective, dopamine–mediated basal 
slowing response behaviour of neuronal α-synuclein PD models (Kuwahara 
et al., 2006) and the impaired, serotonin-controlled, enhanced slowing 
response behaviour of neuronal Aβ1-42 model (Dosanjh et al., 2010). It 
yielded equivocal results in our study (data not shown), since the inability to 
control for behaviour during a given observation window has made speed 
measurements variable. The age-dependent alterations in basal slowing 
response, though observed, were inconsistent in our selected PD models 
with α-synuclein or CAT-2 overexpression (data not shown). Similarly, though 
the pan-neuronal expression of the Aβ1-42 induced age-dependent motility 
impairments in our chosen CL2355 AD model, the defect was only semi-
penetrant due to high individual phenotypic variability, thereby rendering this 
model inappropriate for high-throughput screening purposes. However, most 
recent work has demonstrated that the technical difficulties and highly 
variable behavioural parameters of this neuronal AD model can be 
circumvented by utilising motion tracking analysis which accurately and 
efficiently assesses the locomotion speed of multiple worms for a longer 
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duration (Machino et al., 2014). This approach further revealed that Aβ 
toxicity affects the embryonic stage as well as the adult phases. 
Despite cumulative results which have consistently suggested that 
chemical manipulation is a very potent method for quantitative evaluation of 
anti-PD drugs (Schober, 2004, Betarbet et al., 2006) and small-scale screens 
have used them to identify compounds neuroprotective against 6-OHDA 
(Marvanova and Nichols, 2007) and MPP+ toxicity (Braungart et al., 2004, 
Mocko et al., 2010, De Jesus-Cortes et al., 2012), pharmacological models 
may not be ideal for extensive use in our future screens. One issue that 
arises was the marked variability in the effects of 6-OHDA treatment and in 
the time to degeneration among different studies (Wolozin et al., 2011), with 
some groups observing severe DA neuronal loss with dosages as low as 5 
mM two hours after exposure and other groups observing survival up to 72 
hours after exposure (Kuwahara et al., 2006, Hamamichi et al., 2008). While 
6-OHDA was effective in lesioning DAergic neurons in our 6-OHDA model 
which exhibited full sensitivity to its toxicity, 30-40% of our vehicle control 
population treated with ascorbic acid alone also displayed mild degenerative 
changes which have not been reported before. Overall, a major limitation of 
pharmacological models has been the tenuous relationship between the 
experimental manipulations used to induce the loss of DAergic neurons and 
the pathophysiological mechanisms leading to PD in humans (Chesselet et 
al., 2008). Since the basis for this model derives from sensitivity to an 
exogenous agent which induces rapid and acute DAergic neurodegeneration, 
the effect may be too strong to accurately represent the progressive nature of 
PD pathology (Betarbet et al., 2006), thus limiting the utility of the 6-OHDA 
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model for evaluating the neuroprotective influence of promising hits. In 
addition, behavioural assessment of most toxin-induced models has been 
minimal (Chesselet et al., 2008), and discrepancies often result due to the 
various methodologies that have been used for analysing DAergic 
degeneration and fluorescence intensity levels.  
While behavioural impairment of the FTDP-17 model manifested itself 
through neuronal morphological abnormalities, it is noticeable that despite 
measurable neuronal dysfunctions in both ALS and HD models studied here, 
there were no observable cell deaths, even during later adult life. This 
resembles the observation in an earlier report of Parker et al. (Parker et al., 
2001) where polyQ expansion in C. elegans PLM neurons abolished touch 
sensitivity function but did not induce cell death. This lack of cell death 
suggests physiological relevance to both SOD1 and polyQ toxicities in 
mammalian neurons which are likely to be functionally affected for a period of 
time before being subjected to cell death (Wang et al., 2009b).  
The deficits seen for the HD models in the present set of experiments 
were much less pronounced than those in other publications. Previous 
studies have consistently illustrated that enhanced mutant huntingtin toxicity 
in HA759 animals severely impairs both ASH survival and function. Though a 
strong, late-onset defect in nose touch response was observed for both 
HA659 and HA759 worms in our study, analysis of ASH neuronal integrity in 
these Htt-Q150 expressing animals failed to detect any highly penetrant ASH 
cell death in young or even old adult HA759 worms. Apart from this lack of 
phenotypic robustness and reproducibility, our chosen models for polyQ 
toxicity have other limitations. Since the huntingtin fragments are expressed 
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in only four cells, not only can cellular specificity of degeneration not be 
addressed, but biochemical and microarray assays would also be difficult. In 
addition, not all of the genes that have been implicated in HD are expressed 
in the ASH neurons, the selective neuronal susceptibility of these models to 
polyQ-mediated degeneration could therefore hinder the throughput 
efficiency.  
Though neuroprotective activities of several compounds have 
previously been confirmed in our selected HD and 6-OHDA-inducd PD 
models (Marvanova and Nichols, 2007, Voisine et al., 2007), thus validating 
the utilisation of these models as a chemical screen platform for drugs that 
slow down polyQ toxicity- and neurotoxin-mediated degeneration, we have to 
consider that evaluating different levels of damage would not be a useful 
measure for high-throughput screening, given the quantity of worms on a 
slide and the short time available for viewing. Attempting to assess the extent 
of damage can also lead to ambiguity and inaccuracy in scoring. Fine details 
are likely lost due to dopaminergic and chemosensory neurons entering and 
exiting different focal plane and glare from brighter neuronal bodies can 
overwhelm any degenerative differences that might exist in surrounding 
neuronal structures.  
In summary, from the lines compared in this work, our data support 
the utility of the ANCL, FTDP-17 and ALS models for future screening. The 
results from the AD and HD models phenotyping were not robust enough to 
justify using these lines for testing potential chemical and genetic modifiers. 
The results from the neurotoxin-induced PD and SMA models phenotyping 
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were encouraging, but their utilities for screening are limited by technical 
difficulties. 
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CHAPTER 4: ETHOSUXIMIDE IS 
NEUROPROTECTIVE IN 
MULTIPLE C. ELEGANS 
NEURODEGENERATIVE 
DISEASE MODELS 
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4.1 INTRODUCTION 
A major challenge in current neurodegeneration research is the identification 
of effective disease-modifying therapies which arises from an insufficient 
knowledge about the contribution of multiple pathways to disease 
pathogenesis. Over the past decades, C. elegans has increasingly been 
used as a model system to study the underlying molecular mechanisms that 
give rise to neurodegeneration because of its well defined genetic 
characteristics, abundance, short lifespan and tractability to genetic 
manipulation. Indeed various laboratories have developed and characterised 
a diverse set of C. elegans models of various human neurodegenerative 
diseases (NDs), including Alzheimer’s (Link, 1995), Parkinson’s (Nass et al., 
2001) and polyglutamine expansion diseases (Satyal et al., 2000). Genetic 
screens performed in these models have identified a variety of genes that 
can suppress or increase disease progression and are thus potential 
therapeutic drug targets. However, relatively few of these genetic modifiers 
are common to more than one disease model, despite the shared feature of 
protein misfolding/aggregation (van Ham et al., 2009, Chen and Burgoyne, 
2012).  
Complementary to its utility for screening for genetic contributors to 
NDs, C. elegans is a useful pharmacological model for testing potential 
neuroprotective compounds. Numerous well-characterised ND models have 
been readily exploited for triaging compounds from large libraries consisting 
of novel and pre-approved drugs, and for testing the effects of individual 
drugs, prior to validation in vertebrate models. Attention has mainly focused 
on screening existing FDA-approved medications rather than novel 
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compounds, as repurposing of drugs pre-approved for other indications 
obviates the need for early toxicity trials and thus expedites translation to 
clinical testing (Corbett et al., 2012, Zhang et al., 2014). For example, C. 
elegans AD models expressing human Aβ1-42 have identified neuroprotective 
effects of several approved compounds, including antibiotics bacitracin, 
rifampicin (Lublin et al., 2011) and tetracycline (Diomede et al., 2010), the 
antidepressant fluoxetine (Keowkase et al., 2010b), and the 
psychopharmalogical and antihypertensive drug reserpine (Arya et al., 2009) 
in Aβ toxicity. Similarly, dopamine D2 receptor antagonists, in particular 
azaperone, have been shown to effectively ameliorate mutant Tau-induced 
functional defects and reduce aggregation in a frontotemporal dementia with 
parkinsonism-17 (FTDP-17) Tauopathy model (McCormick et al., 2013). A 
wide variety of other neuroprotective compounds have also been identified in 
chemical screens using worm neurodegeneration models including spinal 
muscular atrophy (Sleigh et al., 2011), Parkinson’s (Wolozin et al., 2011) and 
Huntington’s diseases (Voisine et al., 2007). Voisine et al. (Voisine et al., 
2007) demonstrated that FDA-approved drugs including lithium chloride, 
widely used to treat psychiatric conditions like bipolar disorder, the antitumor 
antibiotic mithramycin and trichostatin A, a class I and class II HDAC 
inhibitor, independently and in combination suppressed polyQ-induced 
neurotoxicity. Treatment of a C. elegans model of MJD with valproic acid, 
another HDAC inhibitor, also led to improved locomotor activity accompanied 
by a decrease in mutant ataxin-3 (ATXN3) aggregation (Teixeira-Castro et 
al., 2011). Multiple PD models, notably the toxin-induced models have aided 
in the discovery and validation of bromocriptine (dopamine receptor agonist), 
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rottlerin (protein kinase C inhibitor and regulator of autophagy), selegiline 
(FDA-approved for treating major depressive disorder), amantadine (anti-
viral), acetaminophen (widely prescribed for treatment of mild pain and 
fever) and sorafenibfor (treatment of renal cell carcinoma) as potential 
pharmacological interventions for PD (Wolozin et al., 2011). A mutant SMA 
model facilitated the screening of the NINDS collection of 1040 chemical 
compounds and two FDA-approved drugs, 4-aminopyridine (potassium 
channel-blocking agent that reduces symptoms of multiple sclerosis) and 
gaboxadol hydrochloride (selective GABAA receptor agonist developed for 
treatment of chronic pain and insomnia), were shown to rescue phenotypic 
dysfunction (Sleigh et al., 2011) with potential for further study in vertebrate 
models for the treatment of SMA. Treatment with methylene blue, a tricyclic 
phenothiazine drug (Wainwright and Amaral, 2005) which has been in use as 
a medical drug as well as a staining reagent (Schirmer et al., 2011), was 
shown recently not only to rescue toxic phenotypes (including neuronal 
dysfunction and oxidative stress) associated with mutant TDP-43 and FUS in 
C. elegans and zebrafish ALS models (Vaccaro et al., 2012), but also 
ameliorated Tau mediated toxicity in a newly established Tau pro-aggregant 
strain (Fatouros et al., 2012).  
There is growing evidence for a protective role of antiepileptic drugs 
against a range of neurodegenerative conditions. The traditional first-line 
antiepileptic drug, valproic acid has been shown to significantly inhibit 
production of Aβ and phosphorylated Tau and improve cognitive 
performance in AD mouse models (Qing et al., 2008). The therapeutic effects 
of valproic acid have been ascribed to inhibition of GABA transmission, 
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voltage gated sodium channels, T-type calcium channels and HDACs. 
Treatment of nematodes with moderate concentrations of valproic acid 
extended lifespan and delayed age-related degenerative changes in body 
movement (Evason et al., 2008). Furthermore, valproic acid reduced the 
mutant ATXN3 aggregation and motor dysfunction of a C. elegans model of 
MJD which was dependent upon DAF-16/FOXO and the insulin/IGF-1 
signalling (IIS) pathway (Teixeira-Castro et al., 2011). Valproic acid was also 
shown to have no effect on TDP-43 toxicity (Tauffenberger et al., 2013), but 
significantly protected C. elegans dopaminergic neurons against α-synuclein 
toxicity via an ERK-MAPK-dependent mechanism (Kautu et al., 2013). Other 
established antiepileptic drugs such as clonazepam, phenytoin, 
phenobarbital and carbamazepine, have shown mild neuroprotective activity 
in ischemic models of neuronal injury. Newer anticonvulsants such as 
felbamate, lamotrigine, levetiracetam, topiramate, vigabatrin and zonisamide, 
which have fewer drug interactions and simpler pharmacokinetics may yield 
new efficient treatment strategies due to their antiepileptogenic and  
neuroprotective properties in various animal models (Pitkanen, 2002, 
Willmore, 2005). Topiramate and levetiracetam (Sanchez et al., 2012) were 
recently shown to have neuroprotective effects against the neuropathology 
and behavioural impairment in an AD mouse model engineered to 
overexpress human amyloid precursor protein (APP) and Aβ in the brain. 
They increased Aβ clearance and the activation of AMPK/Akt, up-regulated 
Aβ transport and autophagic degradation, and inhibited GSK-3β activation, 
HDAC activity and amyloidogenic APP processing at the γ-secretase site. A 
multicenter, randomised, double-blind, placebo-controlled study (Murata et 
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al., 2007) in Japan provided data suggesting that zonisamide, has efficacy in 
treating motor symptoms in patients with PD.  
Most compounds identified in C. elegans chemical screens to date are 
effective in only a single neurodegenerative model, suggesting that 
translational potential may be disease-specific. However, some compounds, 
such as resveratrol, have been shown to be protective in a range of worm 
models and also in mammalian systems (Parker et al., 2005, 
Karuppagounder et al., 2009, Bizat et al., 2010, Tauffenberger et al., 2013, 
Kashyap et al., 2014). Resveratrol, a polyphenolic compound naturally 
occurring in plants and found in dietary products was shown to ameliorate 
neurotoxicity induced by expanded huntingtin, mutant TDP-43 and prion 
proteins in transgenic HD (Parker et al., 2005), ALS (Tauffenberger et al., 
2013) and Creutzfeldt-Jakob disease (Bizat et al., 2010) worm models, or as 
a result of loss of an endogenous neuroprotective gene dnj-14 in a new adult-
onset neuronal ceroid lipofuscinosis (ANCL) model (Kashyap et al., 2014). 
This demonstrates that it is possible to identify generally neuroprotective 
compounds that alleviate the functional consequences of protein misfolding 
common to neurodegeneration. In this chapter, we demonstrate that the 
antiepileptic drug ethosuximide could be a promising general modifier of 
early-onset proteotoxicity since it was efficacious in multiple worm ND 
models, reducing proteotoxicity and enhancing lifespan not only in a C. 
elegans null mutant model of ANCL, but also in a distinct worm 
frontotemporal dementia model and polyglutamine expansion diseases 
model based on transgenic expression of mutant human Tau and polyQ 
expansions. Ethosuximide is an FDA approved succinimide most widely 
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prescribed for the treatment of petit mal epileptic absence seizures in 
humans and has recently been explored for its potential as a therapeutic for 
age-related diseases since it was shown to delay degenerative changes and 
extend the lifespan of C. elegans (Evason et al., 2005). But in the context of 
neurodegeneration ethosuximide has been less well documented. In the 
second part of this chapter, the possible mechanisms of action of 
ethosuximide were investigated. While the primary target of ethosuximide in 
clinical uses is low voltage gated T-type calcium channel, our results 
suggested that ethosuximide exerts protective effects via a mechanism that 
is independent of T-type calcium channel. Furthermore, our data revealed an 
imperfect correlation between the ability of ethosuximide to alter biochemical 
endpoints such as levels of soluble and insoluble Tau protein and polyQ 
aggregation and suppress proteotoxicity. We have also excluded the 
possibility that the protective effects of ethosuximide are due to changes in 
the E. coli food source.  
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4.2 RESULTS 
4.2.1 Ethosuximide efficiently attenuated pathological phenotypes 
manifested by different ND models  
4.2.1.1 Ethosuximide consistently improved the survival of an ANCL 
model  
Multiple independent studies have recently demonstrated that the rare 
hereditary human ND adult-onset neuronal ceroid lipofuscinosis (ANCL) is 
caused by mutations in the DNAJC5 gene which encodes a neuronal 
chaperone of the DnaJ/Hsp40 family of molecular chaperones known as 
cysteine string protein (CSP), which prevents the misfolding of presynaptic 
proteins (Zinsmaier et al., 1994, Chamberlain and Burgoyne, 2000, Sharma 
et al., 2011, Greaves et al., 2012, Sharma et al., 2012, Kyle et al., 2013). 
CSP knockout mice have early mortality and exhibit age-related 
neurotransmission defects, sensorimotor dysfunction and presynaptic 
neurodegeneration. The C. elegans model of ANCL established by our 
laboratory for age-dependent neurodegeneration has a mutation in the dnj-14 
gene. DNJ-14 is the worm homologue of CSP and dnj-14 null mutants are 
characterised by reduced lifespan and age-dependent sensorimotor defects 
and neurodegeneration, similar to CSP knockout mice (Fernandez-Chacon et 
al., 2004, Kashyap et al., 2014).  
Aiming to see whether we can use the ANCL model to identify 
compounds with therapeutic potential for ANCL and possibly other 
neurodegenerative diseases, this lab has previously undertaken a focused 
screen of ten chemical compounds with either known lifespan extending or 
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neuroprotective properties on various different ND models or on lifespan in 
wild type (WT) worms. These include lithium chloride (Carmichael et al., 
2002, Berger et al., 2005, Voisine et al., 2007, McColl et al., 2008), C2-8 
(Zhang et al., 2005, Chopra et al., 2007), ethosuximide (Evason et al., 2005), 
mianserin (Petrascheck et al., 2007), mithramycin (Ferrante et al., 2004, 
Voisine et al., 2007) and resveratrol (Wood et al., 2004, Karuppagounder et 
al., 2009), and it was investigated whether they could ameliorate the defects 
caused by loss of dnj-14. The anti-epileptic drug, ethosuximide along with 
resveratrol were observed to produce a robust and reproducible lifespan 
extension in dnj-14(ok237) worms. While work on resveratrol was carried 
over by another PhD student (Kashyap et al., 2014), preliminary findings for 
ethosuximide were further expanded upon in this study.  
To evaluate the potential of ethosuximide and to ascertain the optimal 
concentration for improving the survival of the ANCL model, we examined 
how the dnj-14(ok237) animals responded to different concentrations of 
ethosuximide. We generated a dose response curve by exposing the worms 
to ten concentrations of ethosuximide in plates varying from 0 mg/ml to 4 
mg/ml (Figure 4.1A). It was observed that this effect was concentration-
dependent, with 1 mg/ml ethosuximide offering the most significant lifespan 
increase, raising the mean lifespan of dnj-14(ok237) worms by over 40% 
(Figure 4.1A; Appendix Table A2) compared to the mean lifespan under the 
vehicle PBS. At higher doses (4 mg/ml) ethosuximide was observed to 
shorten lifespan. Notably, none of the concentrations used had any 
significant effect on the lifespan of WT N2 C. elegans (Figure 4.1B). To test if 
ethosuximide was also able to rescue the sensory defect in dnj-14 mutants,  
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Figure 4.1 Ethosuximide increases lifespan and sensory function in a C. elegans ANCL model. 
Dose–response Kaplan–Meier survival curves of synchronously ageing A) RM2754 dnj-14(ok237); B) 
WT N2 hermaphrodites cultured at 20 °C with vehicle alone (0 mg/ml) or with ethosuximide dissolved in 
PBS at the indicated concentrations (0.0001-4 mg/ml), from conception until death. Worms were age-
synchronised by timed-egg lay and once the progeny reached L4 stage, 25 worms were transferred 
onto individual seeded drug/vehicle control plates, and monitored for survival every alternate day and 
transferred to fresh plates to prevent progeny formation. Day 0 corresponds to L4 stage. The lifespan 
of populations of synchronised dnj-14(ok237) worms was observed and compared with the WT N2 
strain. Statistical analysis was performed using Online Application for the Survival Analysis of Lifespan 
Assays (OASIS; http://sbi.postech.ac.kr/oasis/introduction/) (Yang et al., 2011). Log-rank (Mantel-Cox) 
test was used to calculate significance and 0.001 mg/ml and 0.2-4 mg/ml were found to be significant 
compared to vehicle control treated dnj-14 (ok237). Treatment with 1 mg/ml ethosuximide extended the 
mean lifespan of dnj-14(ok237) most significantly (***p<0.0001). Ethosuximide did not significantly 
increase lifespan in N2 control worms, suggesting a specific rescue of the defects caused by loss of 
DNJ-14. Most animals cultured in the presence of 4 mg/ml ethosuximide died or arrested development 
before reaching the fourth larval stage, and the adult lifespan of the rare animals that survived to 
adulthood were analysed. Data shown are derived from a single lifespan assay using 50-55 worms for 
each drug concentration and are displayed as raw survival curves. Statistical detail and combined data 
for repetitions of the experiments are presented in Table A2 of the appendix. C) Ethosuximide rescue 
of the dnj-14 food sensing defect. The time taken to move to a bacterial food source was measured in 
6-day-old wild type N2, dnj-14(ok237) and dnj-14(tm3223) strains in the presence or absence of 2 
mg/ml ethosuximide. Data shown are from a single assay conducted by Dr. Sudhanva Kashyap using 
25-35 worms of each strain per condition. 
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Dr. Sudhanva Kashyap performed a food race assay, which measures the 
time taken for animals to move a defined distance to a bacterial food source. 
As previously observed (Kashyap et al., 2014), dnj-14 mutants were severely 
impaired in this assay, with similar results seen using two different dnj-14 
alleles (ok237 and tm3223). Ethosuximide rescued food sensing activity of 
both mutants, but had no stimulatory activity in WT N2 worms (Figure 4.1C). 
Taken together, these data suggest that ethosuximide is able to ameliorate 
the neurotoxicity induced by the loss of the DNJ-14 synaptic chaperone 
protein. 
4.2.1.2 Ethosuximide alleviated Tau pathology 
To determine if ethosuximide had general neuroprotective activity, we 
evaluated its effects on a C. elegans FTDP-17 Tauopathy model (Kraemer et 
al., 2003). FTDP-17 is one of many human Tauopathies in which 
characteristic neurofibrillary tangles are formed from hyperphosphorylated 
Tau. As shown in Chapter 3, overexpression of human mutant Tau V337M 
throughout the C. elegans nervous system causes severe motility defects, 
neurodegeneration, short lifespan and accumulation of insoluble Tau. The 
highly penetrant and easily observable motility phenotype of this model is 
well suited for assessing drug effects (McCormick et al., 2013). We observed 
that ethosuximide significantly improved the severely impaired motility 
phenotype of Tau V337M transgenic worms. To ensure that suppression of 
locomotion impairment was not a general effect of compounds on C. elegans 
movement or an artifact of the thrashing assay employed, we also treated the 
Tau V337M transgenic worms with two other compounds which affected the 
locomotion, lifespan and neurodegeneration phenotypes of the dnj-14(ok237) 
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mutants in a positive way: resveratrol and its analogue p-propenylanisole 
(resveratrol 1) along with ethosuximide. Their abilities to suppress the 
severe, Tau-induced, motor dysfunction were analysed by exposing Tau 
V337M worms to each drug chronically throughout their life. Quantification of 
the proportion of paralysed versus moving worms revealed an increased 
percentage of motile Tau V337M worms upon ethosuximide treatment, with 
no effect on movement of the WT transgenic control strain (Figure 4.2). 
Resveratrol and its analogue resveratrol 1 resulted in a partial but 
insignificant rescue of locomotion impairment. Resveratrol may have the 
potential to protect against Tau-induced toxicity as it ameliorated the 
behavioural phenotype but this effect was not as strong as the effect of 
ethosuximide. However, ethosuximide’s therapeutic activity was reduced with 
ageing, as the extent of motility amelioration at day 5 and onwards was less 
than that observed at day 1 and 3 with increasing percentage of aged 
transgenic Tau V337M worms displaying impaired mobility. It is likely that 
when the peak of neuronal dysfunction and degeneration occurs, the 
expression level of Tau in aged Tau V337M line might be above the 
threshold for which the drugs can be efficacious against the overt 
proteotoxicity to allow restored locomotion.  
 To ascertain the optimal concentration for improving Tau-induced 
behavioural defects, we next examined how the animals responded to 
different concentrations of ethosuximide. We generated a dose response 
curve by exposing Tau worms to increasing concentrations of ethosuximide 
in plates, and the animals were assessed visually for any effects on the 
phenotype. As shown in Figure 4.3A, the vehicle-treated Tau V337M worms  
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Figure 4.2 Treatment of Tau V337M transgenic animals with chemical compounds. To further 
corroborate the protective effect of ethosuximide, we tested its efficacy in ameliorating motor 
dysfunction associated with mutant Tau expression by treating at birth and measuring responses 
throughout adulthood. Synchronised Tau V337M transgenic worms were hatched and fed on 
compound-containing NGM medium for three days at 20°C. The 3 compounds examined were 
ethosuximide, resveratrol, and its analogue resveratrol 1. 2 mg/ml ethosuximide treatment caused a 
significant increase in the proportion of motile Tau V337M worms compared to the vehicle control 
treated worms at day 1 and day 3 (*p<0.05, **p<0.001), while not affecting the transgenic WT GFP N2 
line. Resveratrol and resveratrol 1 showed no significant rescue of motor dysfunction. However, 
ethosuximide exhibited reduced potency in rescuing the behavioural phenotype induced by aged Tau 
mutants after day 5 of adulthood during which severe behavioural phenotype already has manifested. 
Data shown are pooled from two independent experiments, each with 10-30 worms per data point.  
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were severely impaired in their ability to swim. However, treatment with 
ethosuximide improved the motility in a dose-dependent manner. These 
effects appear to be Tau-specific, because the WT transgenic control worms 
expressing the GFP marker in GABAergic neurons showed normal behaviour 
that was unaltered by the ethosuximide treatment (Figure 4.3B).  
Tau V337M transgenic worms also exhibited a short lifespan 
phenotype (Kraemer et al., 2003). To investigate the effects of ethosuximide 
supplementation on longevity, lifespan assays were performed on 
ethosuximide treated Tau V337M and WT transgenic worms and compared 
with vehicle-treated controls. Ethosuximide significantly enhanced the mean 
lifespan of Tau V337M worms in a concentration-dependent manner as 
compared to the vehicle treated Tau V337M worms (Figure 4.3C; Appendix 
Table A2), but had no effect on transgenic WT control worms (Figure 4.3D). 
Comparable to the dose-dependent longevity effect of ethosuximide seen 
with dnj-14(ok237) mutants, maximal lifespan extension of Tau V337M 
worms was observed at 2 mg/ml, which conferred a 42% lifespan increase, 
while lower dosages caused smaller but significant extensions (Figure 4.4; 
Appendix Table A2). 
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Figure 4.3 Ethosuximide leads to partial amelioration of Tauopathy-induced behavioural deficits 
along with lifespan extension. A-B) Dose–response curves for ethosuximide in mitigating the severe 
behavioural impairment of Tau V337M transgenic lines which manifested since L4. WT control worms 
expressing the GFP marker in GABAnergic neurons showed normal behaviour that was unaltered by 
the ethosuximide treatment compared with vehicle control treated animals. Behavioural results data are 
pooled from two independent experiments, each with 10-15 worms per genotype per concentration and 
are shown as mean ± SEM. Significant (*p<0.05) increases were seen at 1 mg/ml and 2 mg/ml 
ethosuximide in Tau V337M worms. Dose–response Kaplan–Meier survival curves of synchronously 
ageing C) Tau V337M transgenic; D) WT N2 hermaphrodites cultured at 20 °C with vehicle alone (0 
mg/ml) or with ethosuximide dissolved in PBS at the indicated concentrations (0.0001-2 mg/ml). 
Ethosuximide exerted strong protection against mutant Tau–mediated toxicity, but had no measurable 
effect on the behaviour or lifespan of WT transgenic control worms. Ethosuximide treatment for both 
motility and lifespan assays was initiated from the time of hatching and continued until death. Worms 
were age-synchronised by timed-egg lay, survival and body movement were monitored beginning at 
the L4 stage and day 1 of adulthood, respectively. For lifespan analysis, 25 worms were transferred 
onto individual seeded drug/vehicle control plates, and viability was scored at the timepoints indicated 
and transferred to fresh plates to prevent progeny formation. Statistical analysis was performed using 
Online Application for the Survival Analysis of Lifespan Assays (OASIS; 
http://sbi.postech.ac.kr/oasis/introduction/) (Yang et al., 2011). Log-rank (Mantel-Cox) test was used to 
calculate significance and all tested concentration were found to be significant compared to those 
treated under vehicle PBS. Data shown are pooled from two independent lifespan assays using 50-102 
worms for each drug concentration. Statistical details of this experiment are summarised in Table A2 of 
the appendix.  
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Figure 4.4 Comparison of concentration-dependence of mean lifespan extension in 
ethosuximide treated ANCL model and FTDP-17 model. The average percentage change in mean 
lifespan of dnj-14(ok237) mutants and Tau V337M transgenic worms treated with PBS vehicle control 
or 0.0001, 0.001, 0.01, 0.1, 0.5, 1, 2 and 4 mg/ml ethosuximide was plotted as a function of dosage. 
The chemical structure of ethosuximide, which is chemically designated as α-ethyl-α-methyl-
succinimide (3-ethyl-3-methyl-pyrrolidine-2,5-dione) is shown. At lower dosages, ethosuximide 
significantly enhanced the mean lifespan of both ND models, though this effect was not as strong as 
higher dosages (1-2 mg/ml) which conferred the largest increase of lifespan versus the vehicle control 
in lifespan extensions, extending mean lifespan of both models by more than 40%. Statistical details of 
this experiment are summarised in Appendix Table A2 
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4.2.2 Mechanism of action of ethosuximide 
4.2.2.1 Ethosuximide treatment decreases neuronal deposition of 
abnormal Tau but not polyQ aggregation 
Our subsequent work focused on the mechanisms by which ethosuximide 
ameliorates motor dysfunction and extends lifespan. In view of the known 
association of protein misfolding/aggregation with both neurodegeneration 
and ageing, it was reasoned that ethosuximide’s general protective effect, as 
demonstrated above, may be linked to modulation of protein aggregation. 
Detergent insolubility is one of the biochemical markers of pathological Tau 
protein in AD and other Tauopathies. Similarly, it has been shown that in a C. 
elegans Tauopathy model, mutant Tau protein accumulates in detergent 
insoluble aggregates. To clarify whether ethosuximide could influence the 
equilibrium between soluble and insoluble aggregated Tau forms, we 
subjected both vehicle- and ethosuximide-treated Tau V33M transgenic 
worms to a regimen of sequential extractions with buffers of increasing 
solubilising strengths, as previously described (Kraemer et al., 2003). We 
then examined the solubility/aggregation profile of Tau in transgenic Tau 
V337M worms by using monoclonal mouse anti-Tau antibodies in western 
blotting. We observed no major differences in total Tau levels in 
ethosuximide treated Tau transgenic worms as compared to vehicle controls 
(Figures 4.5 A and B). The rescuing effect of ethosuximide is therefore not 
due to transgene suppression or reduced expression of toxic mutant Tau 
protein. The protein levels of mutant Tau V337M were not distributed equally 
between different fractions as only a small fraction of the total Tau protein 
available was abnormal in ethosuximide treated worms while the majority 
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was RAB soluble. Ethosuximide treatment did appear to alter Tau solubility 
as quantification of the RAB high salt soluble and RIPA detergent soluble 
Tau levels relative to total levels of Tau revealed a shift in the equilibrium 
towards more soluble Tau as indicated by the slightly increased RAB Tau 
levels and a significant reduction in detergent-soluble Tau in ethosuximide-
treated compared with untreated worms (Figure 4.5B). However, we 
struggled to detect the most detergent insoluble formic acid (FA) fraction.  
To directly visualise effects of ethosuximide on aggregation of toxic 
proteins, we utilised previously established C. elegans muscle models of 
CAG-repeat disorders expressing YFP alone (Q0), a non-pathogenic Q-
stretch (Q24) or expanded polyQ proteins (Q35 and Q40) (referred to as Q0, 
Q24, Q35 and Q40 worms hereafter). The formation of intracellular polyQ 
deposits in muscle cells can be easily monitored since the expression of 
yellow fluorescent protein (YFP) fused to glutamine expansions greater than 
35-40 residues in worm body wall muscle cells induces polyQ-dependent 
aggregation and toxicity (Satyal et al., 2000, Morley et al., 2002), which 
mimics the polyQ length dependence observed for HD. Q0 and Q24 worms 
which control for phenotypic changes exhibited diffuse soluble fluorescence, 
whereas Q35 and Q40 lines exhibited age-dependent aggregation, 
consistent with previous studies (Nollen et al., 2004). PolyQ stretches in 
Q35::YFP animals caused an intermediate aggregation phenotype with the 
appearance of punctate fluorescence in Q35 worms at day 3 of adulthood, 
while polyQ stretches in Q40::YFP worms produced a more striking 
aggregation phenotype with the premature appearance of polyQ foci in Q40  
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Figure 4.5 Ethosuximide reduces accumulation of detergent-soluble, abnormal Tau but does 
not affect muscle polyglutamine aggregations. A, B) Western blot analysis of Tau protein solubility 
from transgenic strains expressing human mutant Tau V337M treated with or without ethosuximide. 
Sequential extraction of Tau from mixed populations of synchronised Tau V337M transgenic worms 
after treatment with vehicle or 2 mg/ml ethosuximide with buffers of increasing solubilising strength was 
performed as described in the Materials and Methods. Supernatants of each fraction were blotted with 
pan Tau antibody to estimate differing levels of Tau solubility. Representative immunoblot from three 
experiments and quantification of the total, soluble and detergent soluble Tau after ethosuximide 
treatment are shown. No noticeable difference of total Tau expression by ethosuximide treatment was 
observed. Tau was demonstrated prominently in RAB soluble fraction. Ethosuximide treatment led to a 
small and variable increase in RAB soluble Tau accumulation, but considerable decrease in the 
abnormal Tau species extracted with RIPA. Signal intensities were measured by densitometry and 
normalised against the untreated samples (n=3 biological replicates). C) Ethosuximide does not 
prevent polyglutamine aggregation. Fluorescence microscopy was used in order to evaluate if the 
aggregation state of polyQ expressed in the muscle cells could be altered by ethosuximide. 
Representative live ﬂuorescence images of two independent experiments depicting polyQ aggregation 
of Q0, Q35 and Q40 transgenic strains treated with either PBS control (left panel) or ethosuximide at 1 
mg/ml (right panel) from conception at 20°C are shown. Q35 and Q40 body sections showed distinct 
morphology of aggregates in 6 day old worms with or without ethosuximide treatment. Vehicle and 
ethosuximide treated 6-day-old Q0::YFP adults (top) show diffuse GFP distribution, whilst 6-day-old 
Q35::YFP (middle) and Q40::YFP (bottom) treated with and without 1 mg/ml ethosuximide showed 
minimum in vivo aggregation suppression. 10 animals of each strain were scored in two independent 
trials. Scale bar, 100 μm. 
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worms as young as L4 stage. Ethosuximide, however, did not affect the 
diffuse fluorescence distribution exhibited by Q0 animals (Figure 4.5C, top 
right panel). Neither was the widespread punctate fluorescence distribution 
displayed by Q35 and Q40 animals at adult day 6 affected by the drug 
(Figure 4.5C, middle and bottom right panels). 
4.2.2.2 Ethosuximide induced protection is further extended to polyQ 
expansion-associated cellular toxicity  
A direct link between the ameliorated locomotion and the reduced level of 
aggregation of toxic proteins or improved body-wall muscle histology has 
been well established. To determine if ethosuximide leads to functional 
improvement of treated polyQ transgenic worms despite a lack of reduction 
of polyQ aggregates within muscle cells, we studied the effect of 
ethosuximide on the mobility and lifespan of these worms. 1 mg/ml was 
chosen for further experiments because the animals responded to 
ethosuximide in the most consistent manner at this concentration. In line with 
previous studies, we found that the phenotypes observed in worms 
expressing expanded polyQ tracts aggravated as the animals aged, similar to 
the progressive exacerbation of the human polyQ-associated disease 
symptoms with age (Figure 4.6A). Vehicle treated Q35 and Q40 worms 
exhibited significantly enhanced motor neuron dysfunction and hence overt 
neuronal toxicity when compared with Q0 and Q24 worms. At day 0 of 
adulthood, vehicle treated Q35 and Q40 animals showed an unimpaired 
motility similar to that observed in Q0 and Q24, but by adult day 6 they 
exhibited a striking loss of motility. Relative to control WT animals, Q35 and 
Q40 animals exhibited muscle dysfunction resulting in a 97% and 65% loss 
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of motility at 6 days of age, respectively. Relative to Q35 animals that 
exhibited a rapid decline in motility, Q40 animals exhibited an intermediate 
but variable motility defect, while both Q0 and Q24 animals exhibited a 
gradual mild decline in locomotion. Exposure to 1 mg/ml ethosuximide 
improved the motility of aged Q35 and Q40 animals considerably by >50% 
relative to their untreated counterparts, but had no significant effect on Q0 
and Q24 strains (Figure 4.6A). 
We also observed that Q35 and Q40 worms aged more rapidly, their 
mean lifespan being 12.2 days and 14.1 days, respectively; compared to 
18.6 days for Q0 and 17.1 days for Q24 worms (Figure 4.6B; Appendix Table 
A2). Ethosuximide prolonged the mean lifespan for both Q35 (to 14.8 days) 
and Q40 (to 15.9 days) by 21% and 13%, respectively compared with their 
untreated counterparts. Ethosuximide had no significant effect on the lifespan 
of Q0 worms, whereas drug treated Q24 animals exhibited a 20% increase in 
mean lifespan (to 20.6 days) compared with their untreated counterparts 
(17.1 days). 
Collectively, these results show that while muscle function is 
preserved upon ethosuximide treatment, this is not due to gross alterations in 
polyglutamine protein aggregation. Ethosuximide is likely to act non-cell 
autonomously as demonstrated by its differential protective effects on C. 
elegans aggregation models and on the basis that damage of diverse cell 
types collectively contribute to the loss of selective neurons which leads to 
functional defects. However, cell-autonomous effects cannot be ruled out as 
ethosuximide could specifically target a ubiquitous protein expressed in both 
neurons and muscle, and impact upon the disease progression. 
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Figure 4.6 Reduction of polyQ expansion-associated cellular toxicity by ethosuximide A) Effect 
of ethosuximide treatment on age-dependent changes in the locomotion of C. elegans expressing 
polyQ-YFP fusion proteins with 0 (Q0), 24 (Q24), 35 (Q35) or 40 (Q40) glutamine residues in body wall 
muscle cells. Q30 and Q40 worms show progressive muscle degeneration, loss of motility and 
premature death. Rescue of polyQ expansions-associated cellular toxicity was determined by 
comparing the motility of Q35 and Q40 animals treated with either PBS alone or ethosuximide to that of 
Q0 and Q24 animals Ethosuximide specifically alleviates impaired mobility of Q35 and Q40::YFP 
worms relative to vehicle control animals which showed no ethosuximide protection. The graph 
represents the means ± S.E.M (error bars) from two independent experiments (n= 20-40 worms per 
strain per condition; *p<0.05, **p<0.001). B) Effect of ethosuximide on lifespan of C. elegans model of 
poly-Q overexpression. Kaplan-Meier survival survival plot of age-synchronised polyQ worms cultured 
at 20 °C and treated with PBS vehicle control (dashed lines) or 1 mg/ml ethosuximide (solid lines). 1 
mg/ml ethosuximide treatement showed a significant increase in lifespan of Q35 and Q40 worms, and 
Q24 after day 14, while no increase in lifespan was observed in polyQ0. Statistical analysis was 
performed using Online Application for the Survival Analysis of Lifespan Assays (OASIS; 
http://sbi.postech.ac.kr/oasis/introduction/) (Yang et al., 2011). Data shown are derived from a single 
lifespan assay using 50-90 worms for each drug concentration and are displayed as raw survival 
curves. PolyQ transgenics were synchronised and treated with 1 mg/ml ethosuximide at birth and 
harvested at L4 stage to monitor body movement and survival changes. Statistical details of this 
experiment are summarised in Appendix Table A2.  
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4.2.2.3 Ethosuximide action is independent of T-type calcium channels  
Different C. elegans mutants can be utilised to identify the pathways 
modulated by various drugs. Previous studies using vertebrate cultured cells 
have led to the proposal that the efficacy of ethosuximide in generalised 
absence epilepsy is mediated by blockade of the low voltage activated (LVA) 
T-type calcium channel in the soma and dendrites of thalamic relay and 
reticular neurones (Coulter et al., 1990, Gomora et al., 2001, Crunelli and 
Leresche, 2002). The primary sequence and the electrophysiological 
parameters demonstrated that C. elegans CCA-1 is most similar to vertebrate 
T-type calcium channel α1I subunit (42% identity), with typical T-type kinetics, 
voltage dependence and pharmacology (Steger et al., 2005). Based on prior 
studies showing that ethosuximide can increase the lifespan of worms 
mutated for cca-1, which indicates that LVG T-type calcium channel is not 
required for ethosuximide to influence longevity of WT worms (Collins et al., 
2008), we therefore constructed a double mutant Tau V337M; cca-1(ad1650) 
strain (Figure 4.7A) to determine if ethosuximide’s therapeutic action in the 
FTDP-17 model was mediated via inhibition of CCA-1. Double cca-
1(ad1650); dnj-14(ok237) homozygotes cannot be easily generated with both 
mutations on the X-chromosome.  
If ethosuximide functions in a pathway that is dependent on the 
calcium channel, then we would expect the Tau V337M; cca-1(ad1650) 
cross-progeny to be mobile and long-lived and their phenotypic 
improvements abrogated upon ethosuximide exposure. As seen in Figure 
4.7B, loss of cca-1 had minimum effect on toxicity, as a similar large 
percentage of both Tau V337M; cca-1(ad1650) homozygotes (58%) and Tau  
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Figure 4.7 Protective effects of ethosuximide are mediated via a CCA-1-independent 
mechanism. To test the involvement of CCA-1 in ethosuximide activity, we crossed Tau V337M 
transgenic animals with loss-of-function mutations for cca-1(ad1650) to generate a homozygous cross 
progeny and tested if ethosuximide maintained neuroprotective activity. A) PCR confirmation of Tau 
V337M; cca-1(ad1650) double mutant lines. F2 progeny was segregated and were genotyped for cca-
1(ad1650) homozygosity by PCR using primers that flanked the ad1650 deletion. PCR analysis 
identified individual worms homozygous or heterozygous for the ad1650 allele. Tau V337M worms WT 
for cca-1(ad1650) display one PCR product of 3.3 kb, whereas ad1650 heterozygotes detected two 
bands. cca-1(ad1650) homozygotes displayed only the expected 930 bp band. The homozygosity of 
Tau in cca-1(ad1650) was verified by both GFP and PCR. B) CCA-1 repression is not required for 
ethosuximide protection against Tau V337M-induced paralysis. Ethosuximide supplementation 
ameliorated the impaired motility of the Tau V337M transgenic strain and the double mutant Tau 
V337M; cca-1(ad1650) strains to similar extents. C) Ethosuximide extends lifespan in Tau V337M 
mutants in the absence of CCA-1. Kaplan-Meier survival curves illustrate that lifespan of ethosuximide 
treated Tau V337M transgenic worms homozygous for the cca-1(ad1650) allele was strongly protected. 
Lifespan assays were performed on single mutant cca-1(ad1650), transgenic (Tau V337M) and double 
mutant Tau V337M; cca-1(ad1650) strains grown at 20°C in the presence (solid lines) or absence 
(dashed lines) of 1 mg/ml ethosuximide. The lifespan of Tau V337M; cca-1(ad1650) double mutant 
under the vehicle control is similar to Tau V337M single mutant, but is significantly rescued upon 
treatment with ethosuximide. Data shown are pooled from two independent experiments using over 
100 worms in total per strain/condition. 
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V337M transgenic worms (54%) without ethosuximide treatment exhibited 
severely impaired motility phenotype. Ageing exacerbated the motility 
defects, increasing the percentage of Tau V337M worms and Tau V337M; 
cca-1(ad1650) with impaired mobility by 17% and 36%, respectively. 
Ethosuximide treatment, however, mitigated the impaired motility of Tau 
V337M transgenic worms and double mutant harboring a loss-of-function 
mutation of CCA-1 to a similar extent, both at day 1 and day 3 (Figure 4.7B). 
The increase in motility produced by ethosuximide is therefore independent 
of the worm T-type channel. 
This was further corroborated in the subsequent lifespan assay in 
which Tau V337M; cca-1(ad1650) homozygotes and Tau V337M transgenic 
worms displayed a mean adult lifespan 11.3 and 11.5 days, respectively. 
Following ethosuximide supplementation, there was negligible change in 
lifespan of cca-1(ad1650) single mutant control worms. However, the ability 
of ethosuximide to increase longevity in the single Tau V337M transgenic 
strain was fully maintained in the Tau V337M; cca-1(ad1650) homozygotes, 
significantly extending the mean lifespan by 29% and 27%, respectively 
(Figure 4.7C; Appendix Table A2). Taken together, these results indicate that 
the mechanism of ethosuximide action does not does not involve inhibition of 
CCA-1.  
4.2.2.4 Protective effects of ethosuximide are not due to changes in the 
E. coli food source 
One contributor to late-age mortality in C. elegans is the detrimental effect of 
their E. coli food source, and drugs that decrease bacterial pathogenicity 
have been repeatedly shown to extend worm lifespan (Gems and Riddle, 
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2000, Garigan et al., 2002). This therefore raised the possibility that 
ethosuximide was acting as an antibiotic on the OP50 E. coli and thereby 
indirectly affecting worm lifespan. In addition, it has recently been shown that 
some drugs, for example metformin, increase C. elegans lifespan via 
changes to E. coli metabolism (Cabreiro et al., 2013). To determine if such 
bacterial effects contribute to the mechanism of action of ethosuximide in 
lifespan extension, we used the antibiotic kanamycin to kill the OP50 food 
source and thus prevent both bacterial metabolism and pathogenicity. In 
single treatments, 10 mM kanamycin and 1 mg/ml ethosuximide 
supplementation increased the mean lifespan of Tau V337M worms by 37% 
and 48%, respectively (Figure 4.8). A combined treatment of kanamycin and 
ethosuximide caused a significant and approximately additive 72% extension 
in mean lifespan. As kanamycin clearly did not affect the ability of 
ethosuximide to increase lifespan (Figure 4.8; Appendix Table A2), this 
suggests that ethosuximide’s protective effects are independent of bacterial 
metabolism and pathogenicity.  
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Figure 4.8 Ethosuximide extends lifespan through a mechanism distinct from that of antibiotic 
kanamycin. Ethosuximide extends lifespan using an inviable bacterial food source. Lifespan assays 
were performed on Tau V337M worms grown at 20°C in the presence (solid lines) or absence (dashed 
lines) of 1 mg/ml ethosuximide. Tau V337M transgenic worms were cultured with vehicle PBS, 1 mg/ml 
ethosuximide alone, 10 mM kanamycin alone or with both kanamycin and ethosuximide from 
conception until death. Both 1 mg/ml ethosuximide and 10 mM kanamycin significantly extended 
lifespan when applied to worms independently, but their combined treatment produced an additive 
effect. Data shown are from a single lifespan assays using over 80 worms in total per condition. 
178 
 
4.3 DISCUSSION 
There is considerable current interest in the idea of repurposing existing 
medicines for the treatment of neurodegenerative diseases (Corbett et al., 
2012). FDA-approved bioactive compounds, therapeutic agents, and natural 
products with well established safety and bioavailability profile, would require 
far fewer resources to bring to market as repurposed therapeutics for 
neurodegeneration than completely novel drugs needing to go through 
extensive toxicology testing and early-phase clinical trials demonstrating 
safety, disease-speciﬁcity, tolerability and effective cerebrospinal fluid (CSF) 
penetration (Ekins and Williams, 2011, Zhang et al., 2013a). The data 
presented here suggest that ethosuximide may be a candidate for such an 
approach. Ethosuximide, a small heterocyclic ring compound of the 
succinimide class, has been widely prescribed for several decades to treat 
generalised absence seizures in children and has a number of potential 
molecular targets. It is cheap to manufacture, well tolerated at high doses 
and has a good safety record (Goren and Onat, 2007). Ethosuximide also 
has >95% bioavailability and freely crosses the blood-brain barrier, with 
levels of the drug in CSF and multiple brain regions being similar to those 
found in plasma (Goren and Onat, 2007). Perhaps the most intriguing 
therapeutic value for ethosuximide is its potential to reduce the risk and delay 
the onset of age-associated NDs. In this chapter, we expand upon previous 
findings to demonstrate the remarkable versatility of ethosuximide, in 
ameliorating the pathological phenotypes manifested by three distinct worm 
ND models: ANCL, frontotemporal dementia and polyglutamine expansion 
diseases. These models involve deletion of an endogenous neuroprotective 
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gene (dnj-14), pan-neuronal expression of a disease-associated mutant Tau 
protein, and muscle-specific expression of aggregation-prone polyglutamine 
stretches, respectively. Nevertheless, these contrasting models share the 
property of altered proteostasis, suggesting that ethosuximide may act to 
counteract the proteotoxicity common to many NDs. The rescue of impaired 
motor activity and short lifespan, two consistent physiological biomarkers of 
C. elegans ageing and neurodegeneration, was specific to the 
neurodegenerative models used, as ethosuximide had no significant effect on 
the respective WT controls. 
Furthermore, while our work was nearing completion, an independent 
study reported a neuroprotective effect of ethosuximide against human 
mutant mTDP-43-mediated proteotoxicity in a transgenic C. elegans model of 
ALS, and this protection was shown to be daf-16 dependent, but hsf-1, sir-2.1 
and skn-1 independent (Tauffenberger et al., 2013). The ability of 
ethosuximide to ameliorate the phenotypes of so many different worm ND 
models suggests that it merits consideration for therapeutic applications in 
patients. 
Although several reports exist on the therapeutic and experimental 
uses of ethosuximide, data on the mechanism by which ethosuximide exerts 
its anti-epileptic action is scarce and unclear. Varying methods (whole-cell 
patch-clamp, voltage-clamp, ruptured-patch method), cell types (HEK-293-
cells, thalamic neurons, thalamic-cortical cells) and concentrations (0.7 mM 
to 3.05 mM) were employed in previous in vitro electrophysiological studies 
and demonstrated ethosuximide’s antagonistic action towards membrane 
currents. Ethosuximide has long been thought to act by partial blockade of T-
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type calcium channels in thalamocortical reticular nucleus neurons, thus 
preventing oscillatory firing characteristic of absence seizures (Coulter et al., 
1989b, Coulter et al., 1989a, Kostyuk et al., 1992, Huguenard, 1999, Gomora 
et al., 2001). However, there is still controversy over whether this blockade is 
the whole story (Crunelli and Leresche, 2002, Manning et al., 2003), as 
further work has suggested that actions on other voltage-sensitive ion 
channels, such as sodium and potassium channels, contribute to the overall 
therapeutic effect of ethosuximide (Leresche et al., 1998, Crunelli and 
Leresche, 2002, Kobayashi et al., 2009). Ethosuximide was found to 
decrease persistent sodium current (Leresche et al., 1998) and inhibit G 
protein-activated inwardly rectifying potassium channels (Kobayashi et al., 
2009). Farber et al. (Farber et al., 2002) also demonstrated that ethosuximide 
inhibited sodium channels to prevent NMDA receptor hypofunction (NRHypo) 
neurotoxicity that contributes to NDs like AD. Two recent studies further 
implicated ethosuximide in neuronal differentiation and neurogenesis as rat 
muscle-derived stem cells were shown to differentiate primarily into neural-
like cells in the presence of basic fibroblast growth factor and 4 mM 
ethosuximide (Kang et al., 2013), while 1 μM ethosuximide induced 
increasing number of GABAergic neurons generated from cortical stem cells 
(Sondossi et al., 2014). The neurogenic effect of other antiepileptic drugs 
such as valproate (Laeng et al., 2004), lamotrigine, topiramate (Chen et al., 
2010), lithium chloride, and carbamazepine (Higashi et al., 2008) has also 
previously been demonstrated.  
Our finding that the beneficial effects of ethosuximide on motility and 
longevity in a frontotemporal dementia model persist in strains harbouring a 
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null mutation in the C. elegans T-type calcium channel, cca-1, suggests that 
ethosuximide’s neuroprotective activity is not mediated by inhibition of T-type 
channels, nor was it a result of the inhibition of a negative effect of the 
bacterial food source. This conclusion is supported by previous work in C. 
elegans showing that lifespan extension by ethosuximide is unaffected by a 
different mutant allele of cca-1 (Collins et al., 2008). Given that the C. 
elegans genome does not encode voltage-sensitive sodium channels 
(Bargmann, 1998), it seems likely that ethosuximide ameliorates 
neurodegeneration via a novel ion-channel-independent mechanism.  
Using a variety of pharmacological and genetic experiments, previous 
studies of the effects of ethosuximide in C. elegans have suggested several 
potential mechanisms of action. The Kornfeld group first explored 
ethosuximide and several derivatives as lifespan extending compounds in C. 
elegans and showed that ethosuximide supplementation not only promoted 
the longevity but also prevented age-related physiological and reproductive 
decline of WT C. elegans (Evason et al., 2005, Collins et al., 2008). It was 
suggested that the potent pro-longevity effects of ethosuximide are likely due 
to modulation of neuronal signalling specifically by perturbing WT C. elegans 
chemosensory neuron function, which prevents worms from sensing food, 
resulting in a perceived state of dietary restriction and hence lifespan 
increase (Collins et al., 2008). However, it has recently been shown that 
ethosuximide’s ability to extend lifespan persists even under maximal dietary 
restriction conditions (Choi et al., 2013), thus arguing against this 
mechanism. Furthermore, the dnj-14 worm model of ANCL used in this study 
is short-lived and exhibits profound chemosensory impairment, ethosuximide 
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supplementation not only prolonged the survival of dnj-14 null mutant worms 
but also ameliorated their impaired chemotaxis, thus it is difficult to reconcile 
this proposed mechanism with these observations. None of the WT controls 
utilised for all three ND models was affected by ethosuximide both in terms of 
behaviour and lifespan regardless of the concentration used, and we 
observed an actual decrease in lifespan of ethosuximde treated controls. 
This therefore is also inconsistent with the results reported in earlier studies 
wherein a significant increase in lifespan of the WT worms was seen. During 
the course of the present study, another group reported the neuroprotective 
effect of ethosuximide and demonstrated that its ability to ameliorate human 
mutant TDP-43-induced proteotoxicity and protein aggregation in a 
transgenic C. elegans ALS model requires DAF-16, a FOXO transcription 
factor known to regulate development and longevity, but is independent of 
other key regulators of aging and stress signalling such as hsf-1, sir-2.1 and 
skn-1 (Tauffenberger et al., 2013). In contrast, earlier work demonstrated that 
ethosuximide’s protective activity might be mediated through IIS-DAF-16 
pathway-independent mechanisms as lifespan increase in response to 
ethosuximide was still maintained in daf-16 mutants (Evason et al., 2005).  
Manifestations of pathological phenotypes in many C. elegans ND 
models have been linked to the muscular or neuronal aggregation of toxic 
Aβ1-42, α-synuclein proteins, mutant Tau, SOD1 or polyQ peptides (Morley et 
al., 2002, Kraemer et al., 2003, Link et al., 2003, Kuwahara et al., 2006, 
Wang et al., 2009b). The protective role of genetic and pharmacological 
modifiers in functional analyses appears to correlate well with the level of 
aggregation of the specific toxic peptide in most cases. However, in the 
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present study, ethosuximide triggered more significant protection on 
aggregation-associated toxicity as compared with aggregation itself. The 
drug appears to have differential effects on aggregation and the associated 
toxicity depending on the affected cellular function, as we observed a mild 
(although statistically significant) increase in mobility (hence decrease in 
toxicity) of treated Tau and polyQ models was observed, yet ethosuximide 
exposure only slightly reduced the accumulation of abnormal neuronal Tau, 
and did not result in any observable amelioration of the muscle polyQ 
aggregations. Similarly, coffee extract (Dostal et al., 2010), PBT2 (McColl et 
al., 2012) and salidroside (Xiao et al., 2014) have been shown to provide 
protection to pathological protein-induced behavioural dysfunction of C. 
elegans protein aggregation models with no evident effect on aggregating 
proteins. This lack of correlation between toxicity and aggregation has been 
reported by several studies (Kirkitadze et al., 2002, Arrasate et al., 2004, 
Ross and Poirier, 2005, Treusch et al., 2009, Silva et al., 2011b, Voßfeldt et 
al., 2012, Gidalevitz et al., 2013). Using various disease models, they have 
demonstrated that there is genetic uncoupling between suppression of 
aggregation process and interference with the associated toxicity, and total 
insoluble protein abundance does not dictate toxicity which is the outcome of 
a complex series of misfolding events, involving multiple species and 
aberrant interactions within the cell (Silva et al., 2011b). This is also likely 
due to the disparity between muscle and neuronal models which have 
different capabilities in responding to protein misfolding and chemical and 
genetic manipulations (Tauffenberger et al., 2013). Compounds like thioflavin 
have been shown to reduce Aβ and polyQ toxicity in muscle cells (Alavez et 
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al., 2011), but exhibited no activity in neuronal TDP-43 model. It has been 
suggested that an upper/lower aggregation threshold must be reached to 
induce the cellular and behavioural symptoms, yet surpassing the toxic 
threshold is likely to limit the protective efficacy of drugs. Furthermore, 
aggregates and inclusions have been linked both to toxicity and protection 
(Treusch et al., 2009). It was suggested that ethosuximide reduced 
neurotoxicity and mTDP-43 insolubility in treated TDP-43 animals by acting 
through the IIS pathway to increase the cellular capacity to prevent toxic 
insoluble protein accumulation (Tauffenberger et al., 2013). Indeed, drugs 
that interfere with protein aggregation protect protein homeostasis, and can 
influence disease pathology. Ethosuximide activation may have therefore 
upregulated expression of proteasomal subunits and proteasome activity (Arlt 
et al., 2009, Kapeta et al., 2010) to increase the degradation of Tau which 
has previously been directly implicated in protection against Aβ toxicity in cell 
culture models (Park et al., 2009a).  
Interestingly, ethosuximide has also been assessed as a potential 
HDAC inhibitor in cultured cells (Eyal et al., 2004). Moreover, the magnitude 
of ethosuximide-induced protection was strictly dependent on the age of the 
models as ethosuximide treatments were highly effective in early prevention 
of behavioural impairments caused by transgenic Tau and polyQ 
expressions, but were not nearly as effective in older worms. Previous 
studies have also reported that the positive effects of ethosuximide 
supplementation were temperature dependent, observed at 15˚C and 20˚C, 
but not at 25˚C, and results varied in relation to the food substrate on which 
worms were fed (Collins et al., 2008). More recent work has shown that UV-
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exposure converts ethosuximide into a toxic compound that dramatically 
shortens life span. This demonstration of a strict timing requirement in 
addition to culture conditions for the activity suggests a complexity in the 
MOA of this drug. 
It is noteworthy that the selected worm models of NDs may have 
different sensitivities to ethosuximide in rescue of pathological phenotypes. 
Ethosuximide dosage required for optimal functional improvement in the most 
recent study by Tauffenberger et al. (4 mg/ml) is much higher than the ED50 
of ethosuximide presented in this study and by Evason et al. The externally 
applied concentration of 1-2 mg/ml described here equates to a measured 
internal concentration within the worm of 15-30 μg/ml (Evason et al., 2005) 
which is close to the therapeutic dose range of ethosuximide for epilepsy in 
humans (40 to 100 μg/ml) (Goren and Onat, 2007), suggesting that 
neuroprotective doses could be achieved in patients. Prohibitively high doses 
of most exogenously applied pharmacologicals are required to induce robust 
phenotypes in C. elegans due to its extensive physical and enzymatic 
xenobiotic defenses, which could limit the availability of the compound to its 
targets as the drug is unlikely to accumulate to effective concentrations within 
worm tissues and therefore results in considerably reduced potency (Rand 
and Johnson, 1995, Evason et al., 2005, Burns et al., 2010). Indeed, Evason 
et al. reported a 66-fold difference of ethosuximide concentration between 
the external environment and uptake in C. elegans required for a phenotypic 
response. Previous study has also shown that though ethosuximide was 
effective in preventing NRHypo neurotoxicity, its ED50 of 336 mg/kg
 was 10-
fold greater than that reported to be needed to treat pentylenetetrazol-
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induced seizures and was inactive in a mouse maximal electroshock seizure 
(MES) seizure model (Farber et al., 2002). 
Evidently, considerable further work is needed to uncover the exact 
mechanism(s) of action of ethosuximide. We have yet to establish whether 
ethosuximide would maintain its potency when ND models are treated during 
pre- and post-symptomatic periods i.e. from L4 (adult day 0) to adult day 2 
when the initial behavioural symptoms began to develop or later in life, once 
a significant number of aggregates have been formed. A direct link between 
the ameliorated locomotion and the amelioration in body-wall muscle 
histology i.e. preservation of body wall muscle nuclei and sarcomere integrity 
has been documented (Munoz-Lobato et al., 2013). This therefore raises the 
possibility that ethosuximide might be affecting muscle development and 
maintenance. To rule out this possibility, myofibrillar structural changes upon 
ethosuximide treatment could be observed via phalloidin staining. 
Ethosuximide could be influencing the toxicity of aggregation-prone 
proteins by other ways. For instance, mitochondrial deficits are key events in 
most ND (Wang et al., 2012) and have also been related to pathological 
phenotypes in C. elegans models of ND. Indeed, increased mitochondrial 
fragmentation has been reported in Aβ and α-syn worm models (Kamp et al., 
2010, Fonte et al., 2011). Hence modulating the mitochondrial network 
integrity could be a possible mechanism for the protective function. 
Moreover, exposure to low doses of thermal and oxidative stressors such as 
juglone, paraquat and plumbagin which are deleterious to worms at high 
concentrations have been shown to result in pro-longevity through stress 
hormesis mechanisms linked to the antioxidant response (Hunt et al., 2011). 
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Future studies should therefore involve testing these compounds to 
determine if ethosuximide exerts protective effects and minimises toxicity in 
ND models by acting as a hormetic chemical. 
 Taken together, ethosuximide is clearly a potential candidate for 
repurposing as a treatment for NDs. Not only does this pre-approved drug 
have a great economic advantage because of its low cost and high 
tolerability, ethosuximide is also capable of delaying pathology in multiple 
worm models of NDs. Based on our observations, we anticipate more 
detailed examinations of the influence of ethosuximide on the progression of 
a broader spectrum of diseases associated with proteotoxic stress in 
mammalian systems. Pharmacogenetic approaches are ongoing in our study 
to unravel the potential multitarget mechanism that mediates neuroprotective 
effect of ethosuximide and to elucidate all the spectra of genes affected by 
ethosuximide exposure. This in turn should encourage further screening and 
characterisation of other neuroprotective compounds, and ultimately may 
assist in accelerating the clinical evaluation and development of drugs to 
combat protein conformational disorders in general. 
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CHAPTER 5: C. ELEGANS 
TRANSCRIPTOMIC RESPONSE 
TO ETHOSUXIMIDE 
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5.1  INTRODUCTION 
The anticonvulsant drug ethosuximide (2-ethyl-2-methylsuccinimide) is widely 
prescribed for the past decade as a frontline treatment for absence seizures 
in children. In addition to this established therapeutic area, increasing support 
is being given towards its potential neuroprotective and general health-
promoting properties. Indeed, as discussed in Chapter 4, the use of 
antiepileptic drugs (AEDs) as a possible neuroprotective strategy is receiving 
increasing attention due to their potential beneficial effects in reducing 
neuropathologies resulted from brain ischemia, Alzheimer’s disease (AD), 
Parkinson’s disease (PD), amyotrophic lateral sclerosis (ALS) and Machado-
Joseph disease (MJD) in both invertebrates and vertebrates. We have further 
demonstrated in our analyses the general neuroprotective activity of 
ethosuximide since it was able to ameliorate the phenotypes of three 
contrasting worm neurodegenerative disease (ND) models.  
However, exploitation of ethosuximide’s therapeutic applications is 
likely to have been impeded by a lack of molecular understanding of its mode 
of action. Although several reports exist on its therapeutic and experimental 
uses, many questions regarding the pharmacological action of ethosuximide 
remain to be answered and have been a subject of much debate. In humans 
and mammals, ethosuximide is generally believed to act through the 
blockade of low voltage gated T-type currents in a state-dependent manner, 
with potential antagonistic action towards sodium or potassium channels to 
counteract abnormal brain excitability by either decreasing excitatory 
transmissions or enhancing synaptic inhibition in the cortex. Recent studies 
have proposed mechanisms centered around differentiation of different types 
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of stem cells, as ethosuximide was shown to stimulate neuronal 
differentiation of rat skeletal muscle-derived stem cells (Kang et al., 2013) as 
well as promoting neurogenesis of rat GABAergic neurons from cortical stem 
cells (Sondossi et al., 2014). Several studies including our own have 
demonstrated that ethosuximide action in C. elegans is independent of T-
type calcium channels (Collins et al., 2008). It was also suggested that 
ethosuximide elicits its beneficial effects by inhibiting chemosensory function 
and acts in either a daf-16-dependent or -independent pathway (Collins et al., 
2008, Tauffenberger et al., 2013). DAF-16 is an evolutionarily conserved 
FOXO family transcriptional factor (TF) at the intersection of regulations of 
metabolism, ageing, innate immunity, and stress responses. Its associations 
with ethosuximide-mediated neuroprotection and lifespan extension, 
however, have been under much debate. Elucidating the mechanistic action 
of ethosuximide will therefore vastly increase its application range and will 
contribute to neuroprotection and healthy ageing.  
Gene-expression microarray technology and associated bioinformatic 
data mining tools are well-proven approaches that are increasingly employed 
in neuroscience to provide a better understanding of disease pathology and 
development of more specific and effective drugs. By utilising vertebrate and 
invertebrate tissues and cultured cell lines, these techniques have helped to 
identify the simultaneous transcriptional regulation of thousands of targets 
associated with complex disease mechanisms and therapeutic effects. 
Indeed, via a genome wide approach, tremendous progress in understanding 
the mechanics of ageing, neuropsychiatric and neurodegenerative disorders 
(Loring et al., 2001, Chan et al., 2002, Colangelo et al., 2002, Napolitano et 
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al., 2002, Mandel et al., 2003, Bonin et al., 2004, Dangond et al., 2004, 
Grünblatt et al., 2004, Miller et al., 2004, Ricciarelli et al., 2004, Bassilana et 
al., 2005, Borovecki et al., 2005, Strand et al., 2005, Duke et al., 2006, 
Weinreb et al., 2007) as well as the pharmacological responses to chronic 
drug exposure (Altar et al., 2008, Zhou et al., 2008) in vitro and in vivo has 
already been achieved. 
Due to the innate complexity of human nervous tissue i.e. diverse 
neuronal cell types in the brain, variable and low magnitude differences in 
gene expression, and the need to use post-mortem material, relatively few 
microarray studies on NDs have been conducted (Mandel et al., 2003). In the 
past decade, microarray-based transcriptional profiling has been effectively 
applied to C. elegans to investigate changes in tissue-specific gene 
expression associated with larval development (Hill et al., 2000, Jiang et al., 
2001), ageing (Lund et al., 2002, Murphy et al., 2003, Golden and Melov, 
2004, McElwee et al., 2004, Rodriguez et al., 2014), dietary restriction 
(Palgunow et al., 2012), sex differences (Jiang et al., 2001), neuronal 
signalling (Colosimo et al., 2004, Portman and Emmons, 2004, Cinar et al., 
2005, Fox et al., 2005, Kunitomo et al., 2005, Rodriguez et al., 2014), 
organogenesis (Gaudet and Mango, 2002), dauer formation (Shaw et al., 
2007, Than et al., 2013) and developmental defects (Reinke et al., 2000). 
Transcriptional responses of C. elegans to acute environmental stressors 
such as heat (GuhaThakurta et al., 2002), heavy metals (Jeong et al., 2011, 
Caito et al., 2012), environmental xenobiotics (Reichert and Menzel, 2005, 
Jones et al., 2013) or toxins (Cui et al., 2007, Menzel et al., 2009, Kao et al., 
2011, Lewis et al., 2013, Boehler et al., 2014), pathogens (Kim, 2008) and 
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polyphenolic compounds (Viswanathan et al., 2005, Pietsch et al., 2012) 
have also been extensively explored.  
Here, to help better understand the underlying mechanisms of the 
therapeutic effects of ethosuximide exposure, we conducted global gene 
expression analyses using the Affymetrix C. elegans whole genome 
microarray platform and compared the transcriptome of ethosuximide-treated 
adult-onset neuronal ceroid lipofuscinosis (ANCL) models and wild-type (WT) 
worms to that of unexposed controls, and used the results as a framework for 
follow-up experiments. 
We first defined a subset of differentially expressed genes (DEGs) that 
were shared between all ethosuximide-treated strains. Following validation of 
the microarray data by quantitative real-time polymerase chain reaction 
(qRT-PCR) analysis, various downstream bioinformatic investigations 
including Gene Ontology (GO) analyses, regulatory motif discovery, 
publication enrichment analysis, comparative analyses with curated data 
sources and literature were performed which revealed a wide range of DAF-
16-dependent transcriptional alterations. Enrichment analyses of the 
common DEGs resulted in the detection of several overrepresented 
functional categories, of which metabolic, longevity/ageing, chromatin 
remodelling and protein ubiquitination related pathways were most markedly 
enriched. Many DEGs also contained DAF-16 regulatory elements within 
their promoter regions and were known to be among the top most responsive 
DAF-16 TF targets. Moreover, ethosuximide induced transcriptomic alteration 
in all treated strains has shown consistency with ageing-related expression 
profiles from previous genome-wide studies. The importance of DAF-16 TF in 
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ethosuximide-mediated protection was further substantiated by RNA 
interference (RNAi) and cell culture experiments. Ethosuximide was shown to 
consistently induce the transcriptional activity of several mammalian FOXO 
target genes and conferred protection against expanded polyglutamine 
peptides-induced aggregation, and is likely to have differential regulatory 
effects under different cellular contexts. 
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5.2 RESULTS 
5.2.1 Exposure to 1 mg/ml ethosuximide results in significant changes 
in gene expression 
To gain further insight into the molecular basis of ethosuximide-induced 
protection, whole genome C. elegans DNA microarray was utilised to monitor 
and compare the global gene expression profiles of aged dnj-14(ok237 and 
tm3223) mutant worms of ANCL and WT worms treated with or without 
ethosuximide (Figure 5.1). 1 mg/ml was chosen for further experiments 
because the worms have responded to ethosuximide in the most consistent 
manner at this concentration. Cultivations for RNA samples were conducted 
in conjunction with postdoctoral fellow Dr. Hannah McCue. We extracted and 
purified the total RNA from three separate biological replicates of 400 
synchronised ANCL mutants and WT worms exposed to ethosuximide or left 
untreated until day 6 of adult stage. Spectrophotometric quantifications of 
isolated RNA quality and quantity are provided in Table S5.1 in the 
appendices. Subsequent microarray experimentation and initial diagnostic 
and differential expression (DE) analyses of the raw microarray data were 
carried out by Dr. Lucille Rainbow and Dr. Yongxiang Fang from the 
Department of Functional and Comparative Genomics, respectively. The 
correctness of the WT control strain was however in doubt since a reporter 
line with Punc-25::GFP and lin-15 rescuing plasmid co-injected into a 
temperature-sensitive lin-15(n765) mutant background (henceforth referred 
to as Punc-25::GFP) was thought to have been used instead of the canonical 
WT strain N2. As a result, additional samples were prepared and a second 
run of the array experiment measuring triplicate untreated and 
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RNA amplification, labelling and cDNA
hybridisation to C. elegans Affymetrix arrays
qRT-PCR 
validation
Identification of Ethosuximide
-responsive genes for all four 
treated strains
Overrepresentation analysis of stringent DE genes
Between-array normalisation,  global clustering 
and principal-component analysis, fitting the data 
to a linear model
Motif and 
TFs 
discovery
Functional 
annotation 
clustering
Functional analysis
Harvest at day 6 of adulthood
mRNA extraction and purification +  
DNase treatment 
22625 genes
15671 genes
60 genes
254 genes
Identification of Ethosuximide
-responsive genes for at least 
three treated strains
125 genes
385 genes
Untreated Array No. 
Punc-25::GFP w_AM2, _AM3, _AM9
N2 w_AM19, _AM20, _AM24
dnj-14(tm3223) ma_AM6, _AM7, _AM13
dnj-14(ok237) mb_AM1, _AM10, _AM18
Treated Array No. 
Punc-25::GFP tw_AM5, _AM14, _AM15
N2 tw_AM21, _AM22, _AM23
dnj-14(tm3223) tma_AM4, _AM11, _AM16
dnj-14(ok237) tmb_AM8, _ AM12, _AM17
P0: Culture worm strains
F2: Pick at L4 
Bleach
F1: Growth on Ethosuximide plates (1 mg/ml)
Pick gravid adults for timed 
egg-lay synchronisations
Measuring RNA concentration and integrity 
using NanoDrop and Bioanalyser
Scan, quantitate and analyse data
Figure 5.1: Steps for identification of ethosuximide-responsive genes using the microarray. A 
schematic approach to the data analysis. With 22625 probe sets, only 3-13% of all transcripts showed 
medium or high levels of differential expression in response to ethosuximide as compared to the 
untreated. To narrow the scope of our analysis and reduce the number of false-positive DEGs among 
probe sets, we controlled for the FDR at the level of 0.01. Following filtering and removal of duplicate 
identifications, the final analysis resulted in a list of common overlapping set of transcripts with 125 and 
60 stringent ethosuximide-responsive genes identified across either at least three or all four treated 
strains.  
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ethosuximide treated samples drawn from the correct WT strain was 
conducted and analysed. Nevertheless, gene expression profile of Punc-
25::GFP was included in all our downstream data analyses.  
C. elegans full genome microarrays contain 22625 probes transcripts 
for 20149 C. elegans genes. Comparison of the transcriptomes of 
ethosuximide treated strains with those of untreated using first a relaxed 
criterion with a false discovery rate (FDR) of ≤ 0.05, revealed 385 common 
genes (genes overlapping between expression profiles) differentially 
expressed in treated dnj-14(ok237), dnj-14(tm3223) and WT N2 strains 
relative to untreated control group. Of these 385, 134 genes were increased 
in expression and 251 were decreased in expression. Examination of gene 
lists derived for all four ethosuximide treated strains revealed 254 common 
DEGs consisting of 97 up-regulated and 157 down-regulated genes. Multiple 
uncharacterised genes were increased in expression in both dnj-14 mutants 
and/or Punc-25::GFP worms but decreased in expression in WT worms and 
vice versa, In order to narrow the scope of our analysis and reduce the 
number of false-positive DEGs among probe sets, we considered all genes 
extracted from a more stringent FDR cut-off of ≤ 0.01 (Table S5.2i in the 
appendices) that would increase probability of finding genes regulated by 
ethosuximide and focused on the intra-specific responses of all 4 strains after 
exposure to ethosuximide. This reduced our list to 125 triply regulated genes 
consisting of 61 up-regulated and 64 down-regulated genes (Figure 5.1; also, 
see Table S5.2ii in the appendices), and 60 DEGs containing 40 up-
regulated and 20 down-regulated genes being common across all four 
profiles upon exposure to ethosuximide (Figure 5.1; Table S5.2iii). A small 
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number of overlapping genes between multiple profiles is a signature for 
highly specific ethosuximide responses.  
A correlation heatmap (Figure 5.2A) illustrates the genomic similarities 
and divergences between untreated and ethosuximide treated replicate 
samples. In general, most of the replicates demonstrated a high 
reproducibility. All ethosuximide treated samples are distinctly different from 
their untreated counterparts (as indicated by lower correlation coefficients). 
Transcriptomic responses of ANCL models and Punc-25::GFP worms to 
ethosuximide are more similar to each other than either are to the N2. 
Untreated Punc-25::GFP and N2 samples are distinctly different, though less 
differences can be observed between these two samples after ethosuximide 
treatment. Principal components analysis (PCA) on the entire dataset 
showed relatively tight grouping of individual biological samples, therefore 
confirming that the quality of the microarray data was consistent across 
biological replicates for all eight conditions (Figure 5.2B). The expression 
profiles of untreated samples appear to be in close proximity with each other 
and cluster separately from ethosuximide-treated samples. Additional 
exploratory plots for quality assessment and differential gene expression 
analyses can be found in Figures S5.1 A-F. The Venn diagrams in Figures 
5.2 C and D present an overview of the number of stringent DEGs that was 
responsive to ethosuximide and the respective concordance between the 
strains. The complete data including expression values, statistics, and gene 
annotations can be viewed in Tables S5.2 in the appendices. 
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Array No. Sample Type
w_AM2, _AM3, _AM9 Untreated Punc-25::GFP
w_AM19, _AM20, _AM24 Untreated N2
tw_AM5, _AM14, _AM15 Ethosuximide treated  Punc-25::GFP
tw_AM21, _AM22, _AM23 Ethosuximide treated N2
ma_AM6, _AM7, _AM13 Untreated dnj-14(tm3223)
tma_AM4, _AM11, _AM16 Ethosuximide treated dnj-14(tm3223)
mb_AM1, _AM10, _AM18 Untreated dnj-14(ok237)
tmb_AM8, _ AM12, _AM17 Ethosuximide treated dnj-14(ok237)
Punc-25::GFP dnj-14 (tm3223)
dnj-14 (ok237)N2 WT
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Figure 5.2: Whole-genome expression profiling of dnj-14(ok237) and dnj-14(tm3223) mutants, 
Punc-25::GFP and WT N2 treated with ethosuximide: A) Pearson correlation coefficient-based 
heatmap of expression similarity and divergences among eight conditions (4 untreated and 4 
ethosuximide treated) based on genes that showed significant correlations. All three replicates are 
shown independently for each condition. In total, there are 24 different arrays, and the array number for 
each biological replicate and the corresponding sample type are summarised. Samples are clustered 
along both axes based on their correlation value and the diagonal of the heatmap indicates the amount 
of the Pearson correlation between corresponding sample types. High covariance is indicated in dark 
red, low covariance is indicated in dark blue. Yellow and green regions indicate weak 
correlations/uncorrelated assets (see colour bar). B) Comparative analyses of transcription profiles in 
ethosuximide treated strains. The distance between respective worms denoting the similarities or 
dissimilarities between untreated and ethosuximide treated strains is shown using PCA plot. All three 
biological replicates in each condition show a high reproducibility. C-D) Venn diagrams summarising 
the level of overlap of significantly up (left)- or down (right)-regulated genes grown under ethosuximide 
relative to untreated control group. Numbers of regulated genes uniquely expressed in either one of the 
treated strains or commonly expressed in all profiles within each subset are listed. Intersections 
represent shared regulated genes. Only a small portion of DEGs are common among the four 
ethosuximide-treated samples. Selected criteria for inclusion in these subsets were a FDR corrected p-
value less than 0.01 and no FC restrictions.  
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Commonly regulated DEGs that showed at least a 2-fold change (FC, 
up or down) were considered as significant ethosuximide-responsive genes 
and are listed in Table 5.1. Genes whose expression was most significantly 
up-regulated include an hypothetical NADH oxidase (T10B5.8), five 
cytochrome P450 genes (cyp-14A3, cyp-35B1/dod-13, cyp-35C1, cyp-34A2, 
cyp-34A9/dod-16), two short chain dehydrogenase (dhs-26, dhs-2) and six 
UDP-glucoronosyl transferases (ugt-25, ugt-8, ugt-14, ugt-63, ugt-41) 
belonging to Phase I and Phase II cellular metabolism. Several individual 
genes that were up-regulated are also worthy of note. For example, there 
was a 5.3-fold increase in transcript levels of asm-3, one of three C. elegans 
acid sphingomyelinase, homologous to mammalian ASM and is a critical and 
positive regulator of the DAF-2/IIS pathway. ttr-44 of the TransThyretin-
Related (TTR) family which previously exhibited significant induction in long 
lived daf-2 mutants was up-regulated by 3.1-fold. The human TTR gene was 
also recently suggested to have a neuroprotective function in AD by inhibiting 
Aβ aggregation and detoxifying cell damaging conformers (Li and Buxbaum, 
2011). Expression of asparagine synthase (asns-2) which has been predicted 
to function in amino acid metabolism was also up-regulated by 2.5-fold. This 
gene was previously up-regulated under stringent and moderate 
developmental-dietary restriction (Palgunow et al., 2012). The most 
significantly down-regulated common genes contain a high proportion of 
uncharacterised genes and individual genes belonging to the galectin gene 
class (lec-2) that regulates diverse biological phenomena, Toll-interleukin 1 
receptor domain protein (tir-1) that functions as an upstream regulator of a 
conserved mitogen-activated protein kinase (MAPK) signaling pathway in the  
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Ensembl ID Gene title Gene symbol FC FDR
Human 
orthologue
T10B5.8 hypothetical NADH oxidase T10B5.8 8.0 9.73E-03
C10H11.3 UDP-GlucuronosylTransferase ugt-25 7.2 2.47E-03 UGT3A2, UGT3A1
ZK816.5 Short chain DeHydrogenases dhs-26 6.6 1.73E-03 DHRS1
K09A11.4 CYtochrome P450 family cyp-14A3 5.6 2.67E-03 CYP2J2
W03G1.7 Acid SphingoMyelinase asm-3 5.3 1.01E-03 SMPD1
C23G10.6
hypothetical UDP-
glucosyltransferase
UDP-
glucosyltransferase
5.1 3.60E-03
H23N18.3 UDP-GlucuronosylTransferase ugt-8 4.7 2.33E-03
C30G12.2
hypothetical Alcohol 
dehydrogenase
C30G12.2 4.2 3.58E-03
F25D1.5
hypothetical protein 
dehydrogenase
dehydrogenase 3.9 1.43E-03 CTC-490E21.13
H23N18.2 UDP-GlucuronosylTransferase ugt-14 3.9 3.15E-03 UGT3A2, UGT3A1
C04F5.7 UDP-GlucuronosylTransferase ugt-63 3.7 3.46E-03
C06B3.3 CYtochrome P450 family cyp-35C1 3.6 2.81E-03 ACPP
K07C6.4 CYtochrome P450 family cyp-35B1/dod-13 3.2 7.76E-04 CYP2A7P1
C56A3.2
TransThyretin-Related family 
domain
ttr-44 3.1 1.52E-03
C05C10.4
hypothetical protein intestinal acid 
PHOsphatase
pho-11 3.1 3.46E-03 ACP2
T20G5.7
Downstream Of DAF-16 
(regulated by DAF-16)
dod-6 3.0 1.92E-03
F10D2.11 UDP-GlucuronosylTransferase ugt-41 3.0 1.39E-03 UGT3A2, UGT3A1
F55A12.4 Short chain DeHydrogenases dhs-2 3.0 2.99E-03 HSD17B6
T10H4.11 CYtochrome P450 family cyp-34A2 2.7 3.52E-03
B0213.15 CYtochrome P450 family cyp-34A9/dod-16 2.5 3.84E-03
M02D8.4 ASparagiNe Synthetase  asns-2 2.5 2.63E-03 ASNS
F28D1.5 THaumatiN family thn-2 2.3 2.30E-03
T08B1.3 ALdehyde deHydrogenase alh-5 2.2 2.45E-03 ALDH3A2
C32H11.1
hypothetical protein with a CUB 
domain
C32H11.1 2.2 2.18E-03
T04A11.4 hypothetical protein T04A11.4 2.1 2.01E-03 CTC-490E21.13
C24B9.9
Downstream Of DAF-16 
(regulated by DAF-16)
dod-3 2.1 2.03E-03
T09F5.12 --- --- -2.0 9.51E-04
K05F1.10
putative secreted TIL-domain 
protease inhibitor 
K05F1.10 -2.0 4.89E-03
C35E7.5 hypothetical protein C35E7.5 -2.1 5.96E-04
T28A11.19 hypothetical protein T28A11.19 -2.1 1.38E-03
F22F1.1 HIstone H1 Like hil-3 -2.2 5.16E-04 HIST1H1A
T28A11.16 hypothetical protein T28A11.16 -2.3 3.60E-03
ZC247.1 hypothetical protein ZC247.1 -2.4 1.74E-03
Y40B1B.3 F-box B protein fbxb-66 -2.4 1.63E-03
F13B10.1
TIR (Toll and Interleukin 1 
Receptor) domain protein
tir-1 -2.4 3.69E-03 SARM1
F52H3.7 gaLECtin lec-2 -2.5 2.65E-04 LGALSL
UGT3A2, UGT3A1
CYP2A7P1
 
 
  
Table 5.1: 36 significant DEGs which are consistently responsive to ethosuximide treatment in 
all microarray experiments. Selected criteria for inclusion in this gene subset were a FDR corrected 
p-value less than 0.01 and a calculated mean FC in expression greater than 2 or less than -2. Each 
entry in the table represents a common significant ethosuximide-responsive gene which was 
differentially expressed by at least two-fold. Red shading indicates up-regulated genes; green shading 
indicates down-regulated genes. 
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innate immunity and F-box proteins (fbxb-66), which ubiquitinylate misfolded 
proteins to target them for degradation. 
5.2.2 Validation of microarray data by real-time QPCR (qRT-PCR) 
Following optimisations of the compatibility and specificity of designed qPCR 
primers (Figure 5.3A), the reliability of the expression level obtained from the 
microarray analysis was validated. 7 significant DEGs which showed the 
greatest fold up-regulation following ethosuximide exposure in the microarray 
experiments were assessed and independently veriﬁed using qRT-PCR. The 
directionality and amplitude of the expression FC determined by qRT-PCR 
for all 7 candidate genes were concordant with those obtained by 
microarrays (Figure 5.3B). The magnitude of the FC, however, was much 
higher using qRT-PCR than that suggested by microarray analysis. The great 
quantitative-fold differences between these 2 methods have been attributed 
to the use of random hexamer primers in the reverse transcriptase step 
(Laing et al., 2012) and underestimation of expression FCs by microarray 
analysis (Yuen et al., 2002), indicating the higher sensitivity of qRT-PCR 
assay as microarray studies assess thousands of genes simultaneously. 
Despite such exaggerated expression differences, it is important to note that 
there was no change in the expression of level of pph-6 in our microarray 
experiments, which was included in the qRT-PCR analysis as a negative 
control, in addition to the two normalising genes pmp-3 and act-1.  
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Figure 5.3: qRT-PCR confirms up-regulation of selected top ranking-genes in response to 
ethosuximide: A) qRT-PCR primers (Table 2.2) were designed to the following criteria: gene specific 
primers were all between 20 and 25 bp long; the product of the PCR was between 280-330 bp in 
length; the product spanned an intron to give differentially sized genomic and cDNA products; the 
melting temperatures of the primer pairs were matched and were between 55 and 60°C. B) Validation 
of gene expression pattern using qRT-PCR. All of the genes examined (ugt-25, dhs-26, cyp-14A3, cyp-
35B1, ttr-44, dod-6 and cyp-34A9) were proposed to be significantly up-regulated by ethosuximide in 
the current microarray experiment (Table 5.1) and their high level of induction was confirmed by qRT-
PCR. act-1 and pmp-3 showed no significant changes in microarray analysis and was used as 
normalising genes. There was also no change in the expression level of pph-6 in the microarray 
experiments which was included in the qRT-PCR analysis as a negative control. Results are expressed 
as mean FC relative to the unexposed control. Three biological and technical replicates were carried 
out and the error bars represent the standard error of mean.  
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5.2.3 Evaluation of transcript profiles based on annotation enrichment 
analyses  
In all downstream analyses, we concentrated on DEGs that showed 
consistent response to ethosuximide and were shared by at least 3 treated 
strains. In this way, we assume to emphasise those cellular functions specific 
to ethosuximide response. Their transcriptional profiles were subjected to 
detailed analyses to obtain further functional insights into ethosuximide-
induced gene expression responses and to identify pathways linked to its 
mode of actions. The principal approach applied was a functional annotation 
enrichment analysis of common DEG sets, to subdivide the up-and down-
regulated transcripts into meaningful functional groups based on their GO 
identifiers (Table 5.2i). To increase the coverage of annotation, conserved 
protein domains and KEGG (Kyoto Encyclopedia of Genes and Genomes) 
pathways were also assessed. Refinement of transcriptome analysis was 
undertaken using the freely available DAVID software from the National 
Institute of Allergy and Infectious Disease (NIAID) and mENCODE Modmine 
bioinformatic suite which integrate resources from several gene identifier 
databases (Huang et al., 2008) or collections of extensive experimental 
metadata (Smith et al., 2012b), to assign annotation terms to DEGs and 
interpret the functional relevance of identified DEG lists to pharmacological 
mechanism. Both perform statistical analyses to identify significant over-
representation of functional gene classifications within uploaded gene lists 
which is indicative of a significant impact on the biological functions 
associated with the GO identifiers. Fold enrichment (Table 5.2ii) was 
calculated in DAVID after the prevalence of particular gene categories within 
204 
 
the up-loaded gene list was compared to the prevalence of those categories 
in the C. elegans genome as a whole and DEGs within the list were clustered 
based on similar functional annotation terms. 
Functional clustering of commonly regulated DEGs with a stringent 
FDR cut-off of less than 1% revealed a multitude of significantly enriched 
terms by ethosuximide exposure (Tables 5.2i and ii; Figure 5.4; Table S5.3). 
Many were however redundant categories represented by the same genes 
across and within the three GO domains (biological process, cellular 
component, and molecular function). Both DAVID and modMine GO analyses 
agreed that there was a significant enrichment for GO terms related to “lipid 
glycosylation”, “lipid modification”, “oxidation reduction”, “determination of 
adult lifespan” and “chromatin assembly”. 
Common DEGs up-regulated in response to ethosuximide exposure 
clustered into five groups. Table 5.2i depicts the top four clusters all of which 
had significant enrichment scores of greater than 1.3. The most significantly 
enriched group (Cluster 1, enrichment score 5.45) contains eight cytochrome 
P450 (CYPS) genes belonging to the CYP2 families (cyp-14A3, cyp-34A2, 
cyp-34A9/dod-16, cyp-35B1/dod-13, cyp-35C1, cyp-33A1, cyp-35A2, cyp-
35A3), three short chain dehydrogenase genes (dhs-23, dhs-26, dhs-2) and 
an aldehyde dehydrogenase (alh-5). These enriched genes (Table S5.3) 
share annotation terms relating to oxidoreductase activity, ion binding and 
multicellular organismal ageing. Cluster 2 and 3, with an enrichment score of 
4.23 and 4.1 respectively, are essentially overlapping and contains the same 
group of 6 putative UDP-glucuronosyl/glucosyl transferases (UGTs) involved 
in regulation of lipid metabolism (F08A8.2, ugt-51, ugt-8, ugt-41, ugt-14, ugt-
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25). These are also important phase II metabolism enzymes, functioning by 
conjugating glucuronosyl/glucosyl groups to endogenous and exogenous 
compounds to aid in their excretion from the organism. Enriched genes 
(Table S5.3) comprised of cyp-34A9, cyp-35B1, dod-6, dod-3, ftn-1 which are 
amongst the most responsive downstream targets of DAF-16/FOXO, and 
thn-1, spp-1 are associated with the term ageing and lifespan determination 
(cluster 4; enrichment score 3.13). ftn-1, encodes the C. elegans orthologue 
of the iron-storage protein ferritin heavy chain which is known to play an 
important role in iron homeostasis (Ackerman and Gems, 2012, Leibold and 
Anderson, 2014). As demonstrated by previous genetic and genomic studies, 
there is a close interconnection between the insulin/IGF (insulin-like growth 
factor)-like signaling (IIS) pathway-mediated lifespan extension and redox 
homeostasis in C. elegans. This is reflected in our GO analysis since 
ontology terms related to oxidation reduction is essentially overlapping and 
represents the same genes in the ageing cluster (Table S5.3). 
Common DEGs down-regulated in response to ethosuximide 
exposure showed a significant enrichment to chromatin remodelling (Cluster 
1; enrichment score 4.29) related functional categories encompassing 
‘‘cellular macromolecular complex assembly, chromatin assembly or 
disassembly, DNA packaging, nucleosome assembly and chromatin 
organisation’’ (Table 5.2i, Table S5.3i). Enriched genes (Table 5.3) consist of 
a H2B histone (his-8) and H1 linker histone variants (his-24, hil-2, hil-3, hil-7) 
which are important chromatin factors with roles in heterochromatin 
packaging and gene regulation, a pro-apoptotic gene (dct-1) with similarity to 
the mammalian BNIP3 proteins and was previously found to be up-regulated  
206 
 
Gene Ontology Term
Fold 
enrichment 
for common 
DEGs
GO:0055114~oxidation reduction 8.3
GO:0030258~lipid modification 21.2
GO:0030259~lipid glycosylation 24.1
GO:0008340~determination of adult life span 6.1
GO:0006333~chromatin assembly or disassembly 41.5
GO:0006334~nucleosome assembly 58.3
GO:0065004~protein-DNA complex assembly 50.4
GO:0006323~DNA packaging 44.4
GO:0051276~chromosome organisation 15.9
GO:0043933~macromolecular complex subunit organisation 15.4
GO:0000785~chromatin 39.2
GO:0032993~protein-DNA complex 54.5
GO:0005694~chromosome 19.3
GO:0043232~intracellular non-membrane-bounded organelle 4.0
GO:0009055~electron carrier activity 10.5
GO:0046906~tetrapyrrole binding 11.7
GO:0005506~iron ion binding 7.4
GO:0030246~carbohydrate binding 7.3
GO:0003677~DNA binding 3.5
IPR017973:cytochrome P450, C-terminal region 28.3
IPR002213:UDP-glucuronosyl/UDP-glucosyltransferase 22.4
IPR002347:glucose/ribitol dehydrogenase 26.7
IPR002198:short-chain dehydrogenase/reductase SDR 20.2
IPR016040:NAD(P)-binding domain 12.2
IPR001810:cyclin-like F-box 5.0
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Publication Enrichment p -Value
Genes that act downstream of DAF-16 to influence the lifespan of Caenorhabditis elegans. 9.96E-05
CYP35: xenobiotically induced gene expression in the nematode Caenorhabditis elegans. 0.00168
Functional clustering of up-regulated proteins
Cluster Enrichment score
Oxidation reduction 5.45
Lipid metabolism 4.23
NAD binding and reduction 4.10
Longevity/ageing 3.13
Functional clustering of down-regulated proteins
Cluster Enrichment score
Chromatin remodeling 4.29
Cyclin-like F-box 1.90
i 
ii
ii 
iii 
    
Table 5.2: Functional enrichment analysis of common DEGs. i) Functional clustering of DEGs that 
are commonly regulated after ethosuximide treatment. The reported enrichment score was calculated 
by DAVID according to the Fisher exact score of each clustered term. The higher the value, the more 
enriched the cluster. Only clusters that consisted of 4 or more genes with an enrichment score higher 
than 1.3 were considered as significant and included in the final list of overrepresented GO categories. 
Complete information can be found in Table S5.3i. ii) Shown is the fold enrichment for common DEGs 
in relation to the overall count in significantly enriched GO terms. iii) modMine publication analysis 
revealed an enrichment in DAF-16/FOXO regulated genes. Red shading stands for up-, green shading 
for down-regulated genes; respective pale colouring corresponds to p≤0.05, deep colours to p≤0.001. 
Full list of GO terms can be found in Table S5.3ii. 
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Glucose/ribitol dehydrogenase
Short-chain dehydrogenase/reductase SDR
NAD(P)-binding domain
Carboxylesterase, type B
Cytochrome P450, conserved site
Lipase, eukaryotic
Alpha/beta hydrolase fold-1
Partial AB-hydrolase lipase domain
UDP-glucuronosyl/UDP-glucosyltransferase
CUB-like domain
F-box associated type 2
Cyclin-like F-box
Homeobox
BTB/POZ fold
Upregulated Downregulated
Electron carrier activity
Tetrapyrrole binding
Iron ion binding
Carbohydrate binding
Catalytic activity
Oxidoreductase activity
Lipase activity
Nucleosome assembly
Chromatin assembly or disassembly
Protein-DNA complex assembly
DNA packaging
Chromosome organization
Macromolecular complex subunit organization
DNA metabolic process
Multi-organism process
Macromolecular complex assembly
Cellular component organization
Organelle organization
Nitrogen compound metabolic process
Cellular process
DNA binding
Transcription regulator activity
Sequence-specific DNA binding
Transferase activity, transferring nitrogenous 
groups
Pyridoxal phosphate binding
Nucleic acid binding
   
Figure 5.4: Transcriptional effects of ethosuximide in C. elegans. The pie charts depict the most 
frequent GO identifiers found within the stringent common DEGs subsets and represent the actual 
number of enriched DEGs associated with each of the GO-terms. Significantly enriched GO terms 
taken from DAVID and modMine analyses were assigned to stringent up- and down-regulated DEGs 
and revealed that the over-representated and overlapping functional gene classes were related to 
lipid metabolism, biotransformation and cellular macromolecular complex assembly in ethosuximide 
derived transcript profiles.  
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in a SKN-1-independent manner under tert-butyl hydroperoxide-(t-BOOH) 
induced stress (Oliveira et al., 2009), and an unknown gene (Y55B1BR.3). 
The second most enriched cluster (enrichment score: 1.9) for down-regulated 
DEGs included genes associated with F-box B proteins (fbxb-11, fbxb-41, 
fbxb-63 and fbxb-66) and 2 unknown (C33E10.1, C39B5.2) genes. F-box 
proteins are components of Skp1-Cullin-F-box (SCF) E3 ubiquitin ligase 
complex that targets proteins for ubiquitination and eventual degradation. A 
total of 39 enriched DEGs derived from significantly over-represented GO 
terms and their corresponding human orthologues are listed in Table 5.3. 
Detailed information for each functional cluster, including subterms and 
enriched genes within each group are provided in Tables S5.3.  
Moreover, the domain enrichment analysis identified DEGs that were 
significantly enriched for CYP, UDP, SDR, and cyclin F-Box domains (Table 
5.2ii) which are associated with cellular redox balance, metabolism and 
ubiquitin proteosome system. However, both DAVID and modMine analyses 
did not reveal any significant pathway enrichment. DAVID enrichment 
analysis of common DEGs of medium stringeny (FDR ≤ 0.05) did result in the 
detection of glycolysis pathway, which is involved in general energy 
metabolism, in up-regulated genes and Wnt signaling and TGF-β signaling 
pathways in down-regulated genes (data not shown).  
modMine publication enrichment analysis (Table 5.2iii) further 
revealed an enrichment for DAF-16 target genes. These observations 
motivated us to consider the possibility that our microarray might reveal DAF-
16/FOXO-dependent transcriptional responses to ethosuximide. 
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Sequence Gene Gene name Human orthologue
T08B1.3 alh-5
ALdehyde 
deHydrogenase 
ALDH3A2
C30G12.2 C30G12.2 C30G12.2
K09A11.4 cyp-14A3 CYP2A7P1, CYP2J2 
T10H4.11 cyp-34A2 CYP2A7P1
B0213.15 cyp-34A9/dod-16 CYP2A7P2
K07C6.4 cyp-35B1/dod-13 CYP2A7P3
C06B3.3 cyp-35C1 CYP2A7P4
C12D5.7 cyp-33A1 CYP2J2 
C03G6.15 cyp-35A2
K09D9.2 cyp-35A3
F55A12.4 dhs-2 HSD17B6
R08H2.1 dhs-23 HSD17B14
ZK816.5 dhs-26 DHRS1
F25D1.5 F25D1.5
F08A8.2 F08A8.2 F08A8.2 ACOX1
C24B9.9 dod-3
T20G5.7 dod-6
H23N18.2 ugt-14
C10H11.3 ugt-25
F10D2.11 ugt-41
H23N18.3 ugt-8
C03A7.11 ugt-51
C23G10.6 C23G10.6
C54F6.14 ftn-1 FerriTiN FTH1
F28D1.3 thn-1 THaumatiN family
T07C4.4 spp-1
SaPosin-like Protein 
family
Y55B1BR.3 Y55B1BR.3 Y55B1BR.3
C33E10.1 C33E10.1 C33E10.1
C39B5.2 C39B5.2 C39B5.2
F45C12.5 fbxb-11
M01D1.8 fbxb-41
F55C9.13 fbxb-63
Y40B1B.3 fbxb-66
Y73B6BL.9 hil-2
F22F1.1 hil-3
C01B10.5 hil-7
M163.3 his-24
F45F2.12 his-8 HIST1H2BL
C14F5.1 dct-1
DAF-16/FOXO 
Controlled, germline 
Tumor affecting
BNIP3 
HIstone H1 Like
HIST1H1A
HIStone
UGT3A2, UGT3A1
F-box B protein
CYtochrome P450 family
CYP2A7P1
DeHydrogenases, Short 
chain
Downstream Of DAF-16 
(regulated by DAF-16)
UDP-
GlucuronosylTransferase 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Table 5.3: DEGs derived from highly enriched functional clusters Red shading denotes increased 
expression, and green shading denotes decreased expression relative to untreated group. 
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5.2.4 Regulatory motif analysis: Ethosuximide responsive genes are 
enriched in DAF-16-associated element (DAE) 
To investigate further how the ethosuximide target genes might be regulated, 
we analysed the promoter sequences of common DEGs to identify any over-
represented transcription factor binding sites (TFBS) and regulatory elements 
and ultimately TFs responsible for ethosuximide-induced transcriptional 
changes. Since it was demonstrated that highly occupied regions of TF 
binding are located close to the transcription start sites (TSSs) of genes (Van 
Nostrand and Kim, 2013) and the most effective upstream promoter region 
sizes in which responsiveness to certain DNA motifs is largest within a 200 
bp window of TSS (Tepper et al., 2013), 200 bp upstream regions for each of 
promoter sequences of common ethosuximide-responsive genes were mined 
for overrepresented motifs. Regulatory Sequence Analysis Tools (RSAT) 
oligo (Table S5.4) and peak-motifs analyses revealed that the most 
significantly enriched among any of the overlapping datasets was the motif 
CTTATCA (Table 5.4), which is the concensus sequence for the DAF-16-
associated element (DAE). This motif was first identified as an 
overrepresented sequence in the promoters of DAF-16-regulated target 
genes in the IIS pathway (Murphy et al., 2003) and was subsequently 
identified as a predicted erythroid-like TF family (ELT) TF binding site 
(Budovskaya et al., 2008). RSAT peak-motif analysis which integrates a 
combination of tried and tested algorithms and uses systematic analysis of 
regulatory networks ChIP-Seq (Chromatin Immunoprecipitation coupled with 
Next Generation Sequencing) data to find motifs. It further compares the 
over-represented motifs with existing databases that contain collections of 
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experimentally proven binding sites for vertebrate and invertebrate TFs. As 
shown in Table 5.4, ~25% of ethosuximide responsive genes have at least 
one DAE or its variants located 200 bp upstream of the TSS. Multiple copies 
of these motifs were present but the consensus sites were mostly juxtaposed 
in the upstream promoter regions of selected candidates (Figure 5.5). While 
the DAE was the main motif extracted, RSAT peak-motif analysis also 
discovered accessory motifs that co-occurred with DAE and appear to be 
commonly observed core promoter sequence elements in C. elegans. These 
include a TATATAAA motif that co-occurred at more than 20% of the binding 
sites and matches annotation for vertebrate TF TATA-binding protein (TBP), 
forkhead box L1 (FOXL1), myocyte specific enhancer factor (MEF2A) and AT 
rich interactive domain 3A (ARID3A); and a GC-rich motif that matches 
annotation for various subclasses of zinc finger TFs including the Kruppel-like 
factor (KLF4, KLF5) and beta-beta-alpha (EGR1, SP1, and SP2), which 
participate in the cell cycle regulation, transformation of neuroendocrine cells, 
inflammation, immunity, differentiation, cell growth, tumorigenesis, and 
apoptosis. ~15% of DEGs commonly regulated in all four ethosuximide 
treated strains has a ACTACAA High Mobility Group box (HMG) motif known 
to be bound by SOX10. However, no clear match to any known nematode TF 
consensus sequences can be found for these over-represented motifs in any 
databases.  
Since it was suggested that using a combination of different motif 
finding tools maximises the chance of obtaining significant motifs (Tran and 
Huang, 2014), I repeated the motif analysis by querying 3 other motif 
analysing web tools: MEME-DREME, SCOPE motif finder and 
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BioProspector, and observed a reassuring enrichments (Table 5.4) for the 
DAE motif and their variants. MEME and SCOPE detected several similar 
motifs with RSAT analyses that either corresponded to or resembled the 
GATA binding sites. BioProspector also identified the DAE motif and its 
variants but returned the same sequences multiple times and did not uncover 
any other binding motifs. 
While the enrichment of the DAE could be explained by the presence 
of the IIS genes, DAE consensus (TGATAAG/CTTATCA) has more similarity 
to a GATA motif than to the forkhead consensus (TGTTTAC/GTAAACA) and 
it was suggested that DAE was unlikely to be bound by DAF-16 itself, but 
rather should be bound by a separate factor. However, DAE was recently 
shown to be directly bound by DAF-16 in in vitro gel shift assays (Zhang et 
al., 2013b). DAF-16-binding element (DBE) has been considered as the true 
forkhead consensus (TGTTTAC/GTAAACA) that directly binds with DAF-16 
TF and is regulated specifically by the IIS pathway. DBE, however, was not 
among the most over-represented motifs in any of our motif analyses. 
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Sp1 like site 
CNCCGCCC 
krATGGGCGGRG 
 
CYCCGCCCATYM 
 
 
- 24%  X X 
Klf4, 
KLF5, 
SP1, 
SP2 
ZNF263, 
ZNF354C, 
EGR1 
?  
 
Motif 
Logo Occurrences 
Other algorithms that identified 
the regulatory element 
Transcription factor 
Consensus Reverse consensus 
Three 
treated 
strains 
All four 
treated 
strains 
MEME-
DREME 
BioProspector SCOPE Vertebrate Nematode 
DAF-16 
Associated 
Element (DAE) 
CTTATCA 
 
wktCTTATCAGtytt 
 
AARACTGATAAGAMW 
 
 
19% 24%    
GATA2, 
Gata1, 
TAL1::GATA1 
PQM-1, 
NHR-28, 
UNC-62, 
GMEB-1, 
NHR-77, 
ELT-3, 
PHA-4, 
FOS-1, 
DAF-16, 
W03F9-2, 
BLMP-1, 
MDL-1, 
ALR-1 
arraCTGATAAGrawr 
 
YWTYCTTATCAGTYYT 
 
 
25% 25%    
kwwTCTTATCASts 
 
SASTGATAAGAWWM 
 
 
15% - X  X 
TATA box 
GTATA(T/A)(T/
A)AG 
tRTATAAAkr 
 
YMTTTATAYA 
 
 
22% 12%  X  TBP, 
MEF2A, 
ARID3A, 
FOXL1 
 
? 
yyCTTTTATAsm 
 
KSTATAAAAGRR 
 
 
12% - X X X 
? 
msACTACAAcct 
 
AGGTTGTAGTSK 
 
 
- 15% X X X SOX10 ? 
 
 
  
Table 5.4: Ethosuximide-responsive genes are enriched for a DAF-16 Associated Element (DAE) 
motif. To identify candidate regulatory sequence motifs for ethosuximide-responsive genes, 200 bp 
upstream regions for each of promoter sequences of common DEGs were mined for overrepresented 
motifs (see 5.2.2.4.2 in Materials and Methods) using the ‘oligo-analysis’ and ‘peak-motifs analysis’ 
option of RSAT web server. Repeat analyses were also performed using multiple motif analysing 
softwares. Table of overrepresented consensus motifs found by RSAT peak-motifs analysis containing 
graphic representation of motifs identified and their reverse complements, agreement with 
BioProspector, MEME and SCOPE, occurrences and corresponding vertebrate and nematode 
transcription factors. 
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Figure 5.5: Location of putative motifs. 200 bp region upstream of selected common ethosuximide-
responsive genes containing over-represented motifs. Small boxes indicate the location of the motif. 
Bars shown underneath the lines represent elements running in the opposite direction.  
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5.2.5 Comparison of transcript profiles with curated data sources and 
selected microarray datasets from literature 
To determine if similar gene expression profiles had been observed and 
reported by others in the research community and to study transcriptional co-
regulation of ethosuximide responsive genes, stringent subsets of commonly 
up or down-regulated ethosuximide-responsive genes were queried using the 
web based application Serial Pattern of Expression Levels Locator (SPELL 
Version 2.0.3, http://spell.caltech.edu:3000/). SPELL is a transcriptome data 
repository search engine that integrates all previously published C. elegans 
microarray data collected under a variety of experimental conditions (189 
expression datasets to date) (Hibbs et al., 2007) to yield not only an ordered 
graphical representation of significant data sets containing similar spatial and 
temporal expression patterns with the candidate genes, but also predict 
additional genes with a high degree of similarity with respect to expression 
profiles. The degree of expression data similarity represented by weight 
scores and data set classifiers are summarised in Table 5.5i and Table S5.5i 
While ethosuximide-responsive DEGs exhibited most consistent 
concordance with an ageing/longevity expression profile (Golden et al., 2008) 
in all queries performed, the degree of similarity with respect to expression 
profiles was low (1.1%-3.8%). By querying common DEGs separately rather 
than combined, the smaller subset of genes yielded a slightly higher 
expression data similarity (3.1%-8%, data not shown). Despite overlapping 
expression data set associations between the queried DEGs lists, no 
definitive commonalities are implicated within the evaluated dataset due to 
inconsistent and the generally vague overall nature of the data set classifiers.  
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Up Down Up Down
daf-2  pathway targets 
daf-16  pathway targets 6% 4% 5% 2%
Age-regulated genes
Shared dauer and insulin pathway targets 1% 0% 1% 0%
Most responsive daf-16  regulated genes 16% 6% 14% 2%
Genes in response to fasting 0% 11% 0% 11%
Starvation (dietary restriction)
skn-1 pathway targets
Hyperbaric oxygen stress (oxidative stress) 1% 0% 1% 0%
Commonly regulated in oxidative stress and aging 4% 0% 4% 0%
Commonly regulated in oxidative stress and daf-16 8% 0% 7% 0%
Commonly regulated in stress, aging, and daf-16 4% 0% 10% 0%
1 mM Resveratrol regulated genes
200 µM Quercetin regulated genes
300 µM Tannic acid regulated genes
Immune effector genes
daf-2  pathway and Pseudomonas aeruginosa  infection 
Toxin Genes in response to cadmium toxicity 6% 6% 5% 4%
Immune 
response
15% 4%
Polyphenolic 
action
2% 2%
1% 1%
2% 1%
0% 0%
Food 
deprivation 4% 3%
Stress
0% 0%
Gene Array
Triply 
regulated 
Quadruply 
regulated
Longevity 
mutants and 
dauers
14% 8%
3% 2%
Triply regulated Quadruply regulated
Rank Weight PubMedID Tag(s) Weight PubMedID Tag(s)
1 3.60% 18778409 Ageing 3.20% 18778409 Ageing
2 1.60% 21589891 Germline 3.00% 21931806 Chemical stimulus
3 1.60% 23352664 Lifespan 2.40% 23300685 Oxidative stress, lifespan
4 1.60% 21931806 Chemical stimulus 1.90% 20798549 Metabolism
5 1.50% 20798549 Metabolism 1.70% 22560298 Gene expression
6 1.50% 19745112 Gene expression 1.70% 20816092 Insulin-like signaling, stress
7 1.40% 15772128 Development 1.60% 19379696 Germline immortality
8 1.40% 21765926 Stress hormesis 1.60% 22083954 Innate immunity
9 1.30% 21363964 Dosage compensation 1.50% 21363964 Dosage compensation
10 1.20% 23300685 Oxidative stress, lifespan 1.10% 21723504 Lifespan, stress response
Enzyme Total # in Genome Abbr. N2 WT Punc-25 ::GFP 
dnj-14(ok237) dnj-14(tm3223)
Cytochrome P450 75 cyp 8 12 17 12
UDP-glucuronosyl/glucosyl transferase 72 ugt 7 8 15 12
Glutathione peroxidase 8 gpx 0 0 0 0
Glutathione S-transferase 57 gst 1 5 5 3
Superoxide dismutase 5 sod 0 0 1 0
Thioredoxin 5 trx 1 1 1 0
Thioredoxin reductase 2 trxr 0 0 0 0
Catalase 3 ctl 0 0 0 0
Peroxiredoxin 3 prdx 0 0 0 0
Sestrin 1 sesn 0 0 0 0
Isocitrate dehydrogenase 2 idh 0 0 0 0
Glutaredoxin 5 glrx 0 0 0 0
Ferritin 2 ftn 1 1 1 1
i 
ii 
iii 
 
Table 5.5: Data set associations. i) Top ten data set associations for stringent common DEGs 
datasets queried using the SPELL search engine. The highest-scoring (greatest weight) data set is an 
expression profile of ageing (Golden et al., 2008). Gene expression data sets and their associated 
PubMed ID, tags and weight are indicated. ii) Manual comparisons of gene expression patterns of 
relevant gene clusters or transcriptional profiles in the literature to findings in this study. Only a small 
proportion of common DEGs showed an overlap with expression profiles on other various stress 
conditions. iii) Lack of enrichment of known detoxification enzymes in response to ethosuximide 
treatment. Full analyses of database and literature comparisons can be found in Tables S5.5ii and iii. 
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Furthermore, the mRNA levels of ethosuximide-responsive genes also 
co-regulated with ageing/longevity, development and metabolic process 
associated genes when queried over all available data sets. Top 100 hits are 
shown in Table S5.5i. 
A search within the Comparative Toxicogenomic Database (CTD, 
http://ctdbase.org/) which integrates and compares data resources related to 
chemical-gene/protein interactions and chemical- and gene-disease 
associations in both vertebrates and invertebrates revealed 12 top 
ethosuximide interacting genes collated from previous analyses of 
ethosuximide-treated insect microsomes, Xenopus oocyte and fly epileptic 
model. These included 5 cytochromes (CYP19A1, CYP2E1, CYP313A1, 
CYP3A, CYP6A8), 1 GST (GSTE9), 3 potassium inwardly-rectifying channel 
(KCNJ3, KCNJ5, KCNJ6), 1 heat shock protein HSP83, 1 calcium-binding 
protein REGUCALCIN and a fly specific gene GXIVSPLA2. In addition, the 
database also offered possible modes of action and gene-affected cellular 
functions in which GO terms related to transmembrane transport, more 
specifically, voltage-gated potassium channel activity and oxidoreductase 
activity were significantly enriched among genes that interacted with 
ethosuximide. 
To investigate further if ethosuximide-responsive transcripts share an 
interplay of conserved genetic pathways, I compared our stringent datasets 
with selected gene clusters and published transcriptional profiles generated 
from large-scale genomic studies of longevity mutants, dauer larvae 
(McElwee et al., 2004), worms treated with lifespan-extending polyphenols 
(Viswanathan et al., 2005, Pietsch et al., 2012) and worms exposed to 
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ageing (Budovskaya et al., 2008), food deprivation (Van Gilst et al., 2005, 
Palgunow et al., 2012), stress (Park et al., 2009b) and immunity challenging 
conditions (Table 5.5ii). A meta-analysis dataset (Evans et al., 2008) of 
different daf-2 alleles (Murphy et al., 2003, McElwee et al., 2004) and 
immune-challenged nematodes (Troemel et al., 2006, Shapira and Tan, 
2008) was also utilised. The analyses yielded some agreement with 
previously characterised daf-16 targets and immune effectors, but the overall 
overlap between commonly regulated ethosuximide-responsive transcripts 
and transcriptional fingerprints of the conditions assessed was not 
pronounced. 
5.2.6  Ethosuximide does not induce a stress response 
Considerable evidence has shown that C. elegans subjected to mild degrees 
of stresses such as growth factor withdrawal, starvation, exogenous oxidative 
or thermal stress, often enhance stress resistance and increase longevity, 
through a process termed stress-induced hormesis. Therefore, it needs to be 
tested whether ethosuximide is capable of inducing stress and its protective 
effects are merely as a result of an initiated compensatory defensive 
mechanism. From the assessment of microarray data, confirmatory qRT-
PCR (Figure. 5.6A) and literature comparison (Tables 5.5i-iii), it is evident 
that the transcriptomic response to ethosuximide exposure was inconsistent 
with a general stress response. Not only were general stress associated heat 
shock proteins and glutathione-s-transferases (hsp-17, hsp-16.1, hsp-16.49, 
gst-5, gst-1, gst-38, sip-1, hsp-70, sod-4 and hsf-1) absent or minimally 
induced in our microarray experiments, others such as oxidative stress-
related genes (gst-4 and gst-10) which were differentially expressed showed 
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Figure 5.6: Lack of a generalised stress response and hormesis. A) gst-4 and gst-10 are genes 
that have been associated with oxidative stress responses, and they showed no evidence of induction 
in qRT-PCR analysis. B) Ethosuximide does not promote activation of oxidative stress-responsive gene 
reporter. WT N2 young adult worms carrying a Pgst-4::GFP stress reporter transgene were exposed to 
various treatments and observed for transgene expression by fluorescence microscopy as described in 
5.2.1.8 of Materials and Methods. Note lack of Pgst-4::GFP induction following ethosuximide exposure in 
comparison with same worms treated with oxidative stressor juglone and paraquat (positive transgene 
induction controls). All images were taken at 20x magnification using fluorescence microscopy within 
an exposure time of 300 ms. Scale bar represents 200 μm for all panels. C) Longevity by ethosuximide 
is not mediate by hormesis. This experiment was done once. Numerical values and statistical analyses 
for the lifespan experiments presented in this figure are included in Table A2 of the appendix.  
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no significant change in expression (Figure 5.6A; Tables S5.2). Commonly 
regulated DEGs were also not significantly enriched in ROS-detoxifying 
activities or ROS-damage repair activities (Table 5.5iii, Table S5.5iii).  
SKN-1, the sole orthologue of NF-E2-related (Nrf) TF in C. elegans is 
a major mediator of detoxification and longevity, and the transcriptional 
induction of SKN-1 target genes often reﬂects oxidative stress. The activity of 
SKN-1 in vivo can be indirectly measured by monitoring the fluorescence of a 
GFP reporter driven by the promoter of a well-established glutathione S-
transferase (GST) gene target regulated by SKN-1, gst-4 (Pgst-4::GFP). GSTs 
are a large class of detoxification enzymes that catalyse the conjugation of 
glutathione to electrophiles and play central roles in phase II detoxification 
(Pickett and Lu, 1989, Rushmore and Pickett, 1993). In C. elegans, 
expression of gst-4 and Phase II detoxification genes are strongly activated 
by hormetic compounds, redox cycling compounds, electrophiles, and heavy 
metals in a SKN-1 dependent manner (Hasegawa et al., 2008, Kahn et al., 
2008, Leung et al., 2011, Leung et al., 2013). We therefore utilised the 
transgenic worm strain CL2166 expressing the gst-4::GFP translational 
reporter as a biosensor of stress hormesis to monitor if ethosuximide 
activates SKN-1. In parallel, we also subjected dnj-14(ok237) and N2 WT 
control worms to 100 μM paraquat and 40 μM juglone (dosages that have 
previously been shown to result in hormesis-induced lifespan extension) and 
compared their lifespan to those treated with vehicle control, 1 mg/ml 
succinimide and ethosuximide. As shown in Figure 5.6B, 40 µM juglone 
which causes rising intracellular ROS level induced strong Pgst-4::GFP 
expression with increased magnitude of whole worm fluorescence, 
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particularly in hypodermis and intestine. The increase in fluorescence was 
also evident with 100 μM paraquat exposure, Paraquat caused embryonic 
lethality when worms were treated from birth, so images analysis was 
subsequently performed on worms that were treated with paraquat post-L4 
stage. In contrast, the beneficial dose of 1 mg/ml ethosuximide was not 
associated with any changes in Pgst-4::GFP fluorescence, with weak 
expression in the head and body muscles comparable those treated with 
vehicle control. Exposure to succinimide which is similar in chemical structure 
but lacking anticonvulsant activity in vertebrates appeared to slightly increase 
the Pgst-4::GFP fluorescence (Figure 5.6). 
Lifespan analysis (Figure 5.6C) further demonstrated that while 
ethosuximide considerably extended the lifespan of dnj-14(ok237) worms but 
not N2 worms, juglone at hormetic dosage resulted in only minor lifespan 
extension in dnj-14(ok237) mutant while significantly shortened the lifespan 
of N2 WT control. In contrast, succinimide and vehicle control did not 
enhance lifespan in either N2 WT or dnj-14(ok237) worms. Together, these 
data strongly suggest that the ethosuximide-mediated longevity was not the 
result of an over-compensatory increase in oxidative defenses in response to 
increased levels of ROS. 
5.2.7 Role of daf-16-dependent IIS pathway in ethosuximide-mediated 
protection 
5.2.7.1 Ethosuximide did not affect translocation of DAF-16 
Analysis of microarray data strongly suggested that the candidate effector for 
ethosuximide’s benefits is DAF-16/FOXO, the pro-longevity TF that plays a 
central role in IIS pathway. We therefore focused our attention on DAF-
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16/FOXO because of its well-characterised function in C. elegans and 
previous associations with ethosuximide. Considerable evidence has shown 
that the downstream signalling output of DAF-2//IIS pathway can be assayed 
by using a GFP reporter strain (TJ356) (Henderson and Johnson, 2001). In 
presence of ample food and favourable conditions, DAF-16/FOXO is 
sequestered by 14-3-3 proteins in the cytoplasm following AKT-1/AKT-2 
kinase-mediated phosphorylation and remains cytosolic and transcriptionally 
inactive. The DAF-16::GFP fusion protein therefore appears to be evenly 
distributed in the cytoplasm and nucleus of cells throughout the body of the 
worm. Conversely, upon various forms of environmental stressors and some 
mutations causing reduced signalling in the DAF-2//IIS pathway, 
sequestration is alleviated allowing translocation of DAF-16::GFP into the 
nucleus, where it engages in transcriptional regulation of DAF-16 
downstream target genes (Gami and Wolkow, 2006). To explore whether 
ethosuximide modulates the molecular signalling cascade of DAF-2 to DAF-
16 and promotes the transcriptional activities of DAF-16/FOXO and ultimately 
influences longevity, I compared the DAF-16::GFP patterns of ethosuximide 
treated worms to those subjected to stressors. Figures 5.7 A-E show 
representative fluorescent images of DAF-16::GFP-expressing worms 
following different durations of exposure to thermal stress (heat-shocking for 
1.5 hour at 34°C), oxidative stress (exposure to 40 μM juglone), starvation 
(incubation without food), and 1 mg/ml and 4 mg/ml ethosuximide. As 
expected, rapid translocation of the reporter was evident after acute heat-
shocking (Figure 5.7 panel A) and starvation (Figure 5.7 panel C) as DAF-
16::GFP fusion protein was dramatically enriched in the nucleus of cells.  
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Figure 5.7: Ethosuximide does not cause obvious nuclear translocation of DAF-16. The 
fluorescence pattern and protein levels of DAF-16::GFP were monitored. A) Fluorescent micrographs 
of daf-16 translational GFP reporter expression pattern in young TJ356 adults that were subjected to 
different durations of heat-stress (A), oxidative-stress (B), starvation (C) and ethosuximide (D, E) 
exposure. As expected, heat-shocking and overnight starvation gave rise to a dramatic nuclear 
accumulation of DAF-16::GFP (A, C). Upon recovery post-heat shocking, DAF-16::GFP exhibited a 
largely uniform cytosolic distribution pattern (A, upper right panel). Exposure of worms to 40 μM juglone 
(B) resulted in subtle DAF-16 nuclear localisation, but not to the same extent as that found in heat-
shocked or starved worms as cytoplasmic DAF-16::GFP staining remained detectable with some 
punctate pattern observed in the anterior region. In contrast, no nuclear accumulation of DAF-16::GFP 
were observed in the presence of either 1 or 4 mg/ml ethosuximide. This effect was seen uniformly in 
all the animals on the plate (D, E). All images were taken at 20x magnification using fluorescence 
microscopy within an exposure time of 300 ms. Scale bar represents 200 μm for all panels. Time after 
exposure is listed as hours:minutes. n ≥ 25 worms imaged in three independent experiments. F) DAF-
16::GFP protein level was also assessed following ethosuximide exposure by probing western blot with 
anti-GFP and anti-actin antibodies. 
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Upon recovery post-heat shocking, constitutively nuclear DAF-16::GFP was 
lost as nuclear DAF-16::GFP translocated back into the cytosol with 
essentially the same kinetics (Henderson and Johnson, 2001). Interestingly, 
the juglone treated animals showed an intermediate pattern of DAF-16::GFP, 
with evidence of clear enrichment in many nuclei, but not to the same extent 
as that found in heat-shocked and completely starved animals (Figure 5.7 
panel B). In contrast, exposure to 1 mg/ml and 4 mg/ml ethosuximide did not 
alter the localisation pattern of DAF-16::GFP (Figure 5.7 panels D, E).  
Many ethosuximide treated worms appeared to have brighter GFP 
florescence relative to their untreated counterparts, indicating that it is 
possible ethosuximide may have increased DAF-16 protein abundance. To 
address this, western blot analysis was performed on TJ356 worms to 
compare levels of DAF-16::GFP protein to see if there is an increase in total 
protein levels upon ethosuximide treatment (Figure 5.7F). Using an anti-GFP 
antibody, extracts from the DAF-16::GFP showed a high running band that 
corresponded to the DAF-16::GFP fusion protein which are equally highly 
expressed in both vehicle control and ethosuximide treated transgenic strain, 
thereby indicating that ethosuximide does not increase DAF-16::GFP total 
protein levels. 
5.2.7.2 daf-16 and daf-2 show synthetic lethality with dnj-14 
To test the functional significance of DAF-16/FOXO TF in ethosuximide-
mediated protection, double mutants homozygous for dnj-14(ok237) and daf-
16(mu86) were constructed and examined. However, in the presence of 
homozygous daf-16(mu86), most dnj-14(ok237) homozygotes exhibited 
significantly slower growth rate and low brood size and were too sick to grow 
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to adulthood. This synthetically deleterious interaction was also observed 
with loss of function of another IIS pathway regulator daf-2(e1370). 
Following genetic crosses, dnj-14(ok237) homozygosity was 
confirmed by the presence of a smaller band using primers flanking the dnj-
14 deletion region combined with the absence of a band amplified with a 
primer internal to the deletion (Figure 5.8A). dnj-14(ok237) homozygotes 
were also identifiable by their slower growth rates and low brood size. daf-
16(mu86) is an 11 kb genomic deletion that removes nearly all of the winged-
helix domain and ∼1 kb upstream of the 5′UTR (Lin et al., 2001). A 
predicted PCR product of 13038 bp by external primers flanking the deletion 
region is theoretically possible, but it does not amplify under conditions used 
for cycling. Thus internal primers were used to amplify a smaller WT daf-16 
product while external primers amplified an even smaller deletion-sized band 
(Figure 5.8A). However, genotyping of daf-16(mu86) allele in F3 cross 
progeny was inconclusive as it yielded a WT band with an internal primer 
(data not shown). We, therefore, did not characterise this allele further. 
daf-2(e1370) homozygosity was selected for by the exhibition of 
constitutive dauer phenotype at 25°C and dnj-14(ok237) homozygosity was 
scored by PCR as described above. However, all of the F3 adult worms 
genotyped were either heterozygotes or WT and none were homozygous for 
the dnj-14(ok237) allele (Figure 5.8B). 
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Figure 5.8: dnj-14(ok237) shows synthetic deleterious interactions with the IIS pathway 
regulator daf-16(mu86) and daf-2(e1370). Confirmation of synthetic lethality by double mutant 
analysis. dnj-14
-/-
;daf-16
-/+
 and daf-2
-/-
;dnj-14
-/+
 F2 lines were selected by PCR, and F3 progeny were 
then scored for the A) mu86 and/or B) ok237 allele. Homozygosity was verified in putative double 
mutants by two parallel reactions, one with the external primers which flank the deletion regions and 
another with internal primers inside the deletion regions. A) Homozygosity of dnj-14(ok237) was 
verified by the presence of a smaller sized band combined with absence of the mutant band. However, 
PCR from gDNA with the daf-16 primer pair yielded a product with daf-16(+) but not mu86. B) 
Homozygosity of daf-2(e1370) was confirmed, but none of the F3 cross progeny were homozygous for 
the dnj-14(ok237) allele. 
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The penetrance and severity of phenotypes observed in the putative 
double mutants appear to be variable ranging from severe developmental 
delay, low brood phenotype, embryonic and early larval arrest. The overt 
differences in growth rates and brood size were assessed by singling 
individual hermaphrodite larvae from each one of the above genotypes onto 
single 35-mm worm plates. The animals were allowed to self for 15 days, and 
then the central two-thirds of each plate were imaged.  
As shown in Figure 5.8C, daf-16(mu86) single mutants and N2 WT 
worms produced fast growing F1 and F2 progeny that quickly exhausted the 
bacterial food supply (Figure 5.8C, left panels). Plates harbouring cross 
progeny that were homozygous for the dnj-14(ok237) allele, grew slower than 
both daf-16(mu86) and N2 WT worms, and contained only F1 animals 
existing as mature adults that had not yet produced F2 progeny (Figure 5.8C, 
upper right panel). In contrast, plates containing the dnj-14-/-;daf-16-/? animals 
grew the slowest as a thick OP50 bacterial lawn was still evident after 15 
days of incubation (Figure 5.8C, bottom right panels). Putative double 
homozygous progeny were selectively propagated and most were too sick to 
develop into adults as 43% of the cross progeny plates did not result in any 
progeny. Further assays confirmed that dnj-14-/-;daf-16-/? worms have an 
extremely low brood size, producing on the order of > 10-fold fewer progeny 
than the corresponding single mutant strains and N2 WT worms (Figure 
5.8D). dnj-14(ok237) single mutants also showed a considerably lower brood 
size. These results therefore suggest that loss of daf-16(mu86) in dnj-
14(ok237) mutants further reduced the ability of worms to grow and 
reproduce efficiently. 
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B) Macroscopic view of the population growth rate of cross-progeny relative to N2 WT worms and 
single mutants is shown. Single plates initiated with 1 L3-L4 larvae and grown for 15 days before 
imaging the central two-thirds of each plate at equivalent magnification. On the WT and single mutants’ 
plates, the food supply was exhausted rapidly by the fast growing worms; no bacteria remained 
whereas the OP50 lawn remained the same on putative double mutant plate. Worm lines were 
propagated over 7 generations as described. C) Brood sizes were measured by single plating L4 
hermaphrodites from each strain and transferring each adult to a fresh plate daily. Progeny were 
counted immediately after each transfer.  
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5.2.7.3 Ethosuximide-mediated lifespan extensions were dependent on 
daf-16 
Since daf-16(mu86);dnj-14(ok237) and daf-2(e1370);dnj-14(ok237) double 
combinations were not viable, DAF-16 depletion was subsequently derived 
from RNAi mediated inactivation of the daf-16 gene in order to evaluate the 
contribution of DAF-16 to the longevity conferred by ethosuximide. RNAi 
knock-down of DAF-16 expression and lifespan measurement were 
performed in both the dnj-14(ok237) mutant model of ANCL and N2 WT 
worms in the presence or absence of exogenous ethosuximide by feeding 
them bacteria producing DAF-16 dsRNA sequences. C. elegans has eight 
putative daf-16 isoforms with different expression patterns (Bansal et al., 
2014). Our laboratory has the Vidal C. elegans ORF RNAi Library of bacterial 
RNAi feeding strains (Rual et al., 2004) and a search in the database 
revealed the presence of multiple daf-16 clones. Restriction analysis 
identified one of the clones as daf-16 isoform a (daf-16a) which has been 
implicated in C. elegans lifespan regulation (Figure S5.2A in the appendices). 
The Vidal RNAi constructs targeting the coding sequences of daf-16 are 
however not specific and will therefore knockdown all the isoforms, whereas 
RNAi constructs targeting the 3′UTR sequence are gene-specific. 
Ethosuximide treatment of dnj-14(ok237) worms on control RNAi bacteria 
caused a robust 27% extension in mean lifespan (Figures 5.9 B and D; Table 
A2 and Figure S5.2B in the appendices) as previously observed. No 
significant difference (p=0.9164) was observed when equivalent 
ethosuximide treatment was applied in control RNAi bacteria fed N2 WT 
worms (Figures 5.9 A and D; Appendix Table A2). Significant longevity 
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difference between hsp-1 (Figure 5.9E) and daf-16 (Figure 5.9F) RNAi in all 
backgrounds were consistently observed compare to L4440 negative control 
RNAi (Figure 5.9D). In particular, RNAi of hsp-1 resulted in sick and short-
lived worms in the absence of ethosuximide, but allowed for significant 
(p<0.0001) lifespan extension by ethosuximide in all backgrounds (Figure 
5.9E) indicating that hsp-1 is not required for the protective effect of 
ethosuximide. In contrast, while diminishing the function of DAF-16 in the 
absence of ethosuximide substantially reduced the lifespan of all strains 
used, non-specific daf-16 RNAi completely abrogated the longevity effect of 
ethosuximide in dnj-14(ok237).  
Furthermore, loss of daf-16 also markedly reduced the lifespan of the 
sensory mutant strain osm-3(p802) but did not eliminate the lifespan 
extension by ethosuximide (Figures 5.9 C and F) as the drug was able to 
significantly enhance the mean lifespan of all RNAi bacteria fed osm-3(p802) 
(Appendix Table A2). This therefore is not in accordance with previous 
findings that osm-3 mutants were resistant to the lifespan extension effect of 
ethosuximide, and that ethosuximide acts by inhibiting chemosensation in a 
DAF-16-independent pathway. Together, these data confirmed that DAF-16 
is indeed required for the ethosuximide-mediated protection. 
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Figure 5.9: Ethosuiximide increases lifespan in a daf-16 mediated pathway and may function 
independently of hsp-1. Survival curves of A) N2 WT, B) dnj-14(ok237) and C) osm-3(p802) worms 
on E. coli containing D) empty vector L4440 (negative control), E) hsp-1 (positive control) or F) daf-16 
dsRNA-producing vector. All three sets of lifespans were done simultaneously on NGM + Ampicillin + 
IPTG plates in the presence of either vehicle control (dashed line) or 1 mg/ml ethosuximide (solid line). 
Ethosuximide treatment significantly increased the lifespan of dnj-14(ok237) (p<0.0001) and osm-
3(p802) (p<0.005) fed with empty vector control RNAi when compared with N2; L4440 (RNAi). hsp-1 
(E) and daf-16 (F) RNAi knockdown always induced larger lifespan reduction in all genetic 
backgrounds assessed for. While ethosuximide significantly delayed mortality rates of all hsp-1 RNAi 
fed worm strains, RNAi targeting daf-16 completely suppressed the lifespan extension effect of 
ethosuximide in N2 and dnj-14(ok237) worms, but allowed for significant lifespan extension in osm-
3(p802). RNAi bacteria were obtained from the Vidal library. Lifespan analysis was performed on RNAi 
plates as described in Materials and Methods. Worms were grown on RNAi bacteria for 2 generations 
before proceeding with the experiment. A,B) Data is representative of the average of at least two 
independent experiments that were pooled and analysed using Online Application for the Survival 
Analysis of Lifespan Assays (OASIS; http://sbi.postech.ac.kr/oasis/introduction/). (C) Lifespans 
represent one experiment. Numerical values and statistical analyses for all lifespan experiments 
presented in this figure are included in Table A2 of the appendix.  
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5.2.8 Dose-dependent effects of ethosuximide on mammalian FOXO 
target genes 
Given that DAF-16/FOXO is highly conserved between C. elegans and 
mammals, I further tested whether ethosuximide could affect the 
transcriptional activity of DAF-16 homologues FOXO1, FOXO3, and FOXO4-
regulated target genes in the context of a higher eukaryotic system in order 
to definitively validate the activity of DAF-16/FOXO in the enduring effects of 
ethosuximide. FOXOs have been shown to modulate cell cycle arrest, 
apoptosis, autophagy, angiogenesis, differentiation, stress resistance, insulin 
signalling, stem cell maintenance and metabolism (Salih and Brunet, 2008). 
Nine mammalian FOXO target genes involved in cell cycle regulation (Ccng2, 
Cdkn1a, Cdkn1b, Rbl2), DNA repair (Gadd45a), apoptosis (Bim), stress 
response (Cat, Sod2) and insulin signalling (Eif4ebp1) were selected and 
their mRNA expression levels in a mouse neuroblastoma cell line (N2A) 
following ethosuximide exposure were then examined using qRT-PCR. 
Analysis was initially performed on undifferentiated N2A cells treated with 
increasing ethosuximide concentrations at different time points which 
resulted in either no change in gene expression or great experimental and 
gene expression pattern variations (data not shown). N2A cells were then 
differentiated following plating with retinoic acid (RA) for 24 hours before 
exposure to either ethosuximide or the vehicle control for 5 hours. As a 
result, the mRNA expression of several FOXO target genes increased 
following ethosuximide treatment in a dose-dependent manner. Ethosuximide 
therefore appears to play a more substantial role in regulating FOXO target 
genes in differentiated N2A cells relative to undifferentiated. As depicted in 
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Figure 5.10, there was a lack of significant change in gene expression at the 
pharmacological dose of 100 μg/ml. At 0.56 mg/ml, the optimal concentration 
which stimulated neuronal differentiation in muscle-derived stem cells (Kang 
et al., 2013), and 1 mg/ml, which was the physiologically significant 
concentration in worm ND models, ethosuximide significantly up-regulated 
the mRNA expression of FOXO target genes involved in cell cycle regulation 
(Ccng2, Cdkn1b, Rbl2) and DNA damage repair (Gadd45a). The ability of 
ethosuximide to induce the transcriptional activity of FOXOs in N2A cells 
therefore further substantiated our C. elegans data, namely that the 
downstream signalling of the IIS pathway was triggered by ethosuximide. 
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Figure 5.10: Dose-dependent effects of ethosuximide on mammalian FOXO target genes mRNA 
expression levels. Expression levels of several FOXO target genes, which include p27 (Cdkn1b), 
p130 (Rbl2), Ccng2, and Gadd45a were induced in presence of ethosuximide. Mouse qPCR primers 
were checked for compatibility and specificity (Figure S5.3). All experiments were performed in 
biological and technical triplicates. Data represented are a compilation of the 3 independent 
experiments and are represented as mean ± SEM. * denotes a p-value ≤ 0.05, **denotes a p-value ≤ 
0.01.  
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5.2.9 Ability of ethosuximide to suppress neuronal aggregation 
formation in mammalian cells 
To gain further insight into the protective mechanism of ethosuximide against 
the pathological protein-induced toxicity within neuronal cells, we assessed 
the effect of ethosuximide on a previously described cell polyQ model which 
transiently expresses a strongly aggregating polyQ97 construct (Park et al., 
2013). The aggregation of polyQ in cells was visualised by the fluorescence 
of EGFP. N2A cells which were transiently transfected with either non-
pathological polyQ25 stretches or pathological polyQ97 proteins fused to 
EGFP were subjected to confocal microscopy analyses at 24, 48 and 72 
hours post-transfection (Figures 5.11 A and B). As expected, there was 
barely any aggregation of polyQ25 either in the presence or absence of 
ethosuximide, since transfected polyQ25 proteins were evenly distributed 
throughout the cytosol. In contrast, there was a marked increase in the 
number of cells with polyQ97 aggregates. As shown in Figure 5.11B, while 
the polyQ25 expressing cells looked healthy, several distributions of 
intracellular polyQ aggregates were observed in the cytoplasm of most 
polyQ97 transfected N2A cells (arrows). Some appeared in the forms of 
isolated and prominent aggresomes, while others were small and scattered 
throughout the cytosol. When aggregates appeared, many cells rounded up, 
which is indicative of toxicity. Moreover, because the remaining EGFP-
fluorescence in the cytosol was low, the field of view were dominated by only 
bright aggregates. The amount of total condensed aggregates increased over 
incubation time up to 72 hours (Figure 5.11A). After that period, it was difficult 
to discriminate aggregates since most of the polyQ97-expressing cells were  
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Figure 5.11: Effect of ethosuximide on intracellular aggregate formation of polyQ linked 
pathological stretches and cell death induction in neuro2a (N2A) cells. Expression of the non-
pathological stretches (polyQ25) and pathological stretches (polyQ97) fused to EGFP in N2A cells at 
24, 48 and 72 hours after transfection. Ethosuximide treatment ameliorated polyQ97 peptides-induced 
toxicity. A) The number of polyQ-EGFP transfected N2A cells bearing fluorescent aggregates versus 
total transfected green cells were quantified at indicated post-transfection times both manually and by 
ImageJ thresholding analysis (data are mean ± SEM of 3 independent experiments; *p < 0.05). 
Transfection efficiencies were however much lower for expanded polyQ97 peptide constructs compare 
to the control polyQ25 peptide. B) Overlay of EGFP (green) and SYTOX orange staining (red) confocal 
images which illustrated that the presence of aggregated proteins was only observed in polyQ97-
expressing cells. Aggregates appeared relatively sparse in the cytoplasm at 24h, but the amount of 
polyQ97-EGFP aggregates increased in time. Cell death was also simultaneously monitored by 
staining the live cultures with the SYTOX orange dye which specifically stains dying or dead cells. 
However, barely any double positive cells were detected. Confocal images were produced using 
identical scan-settings. Scale bar: left panels of either polyQ25- or polyQ97-EGFP, 100 μm; right 
panels (magnified views), 5 μm. The arrows indicate condensed aggregates. Approximately 100 cells 
were counted from randomly selected fields in each experiment. 
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too shrunken. An additional complication was that the transfection efficiency 
was much lower for N2A cells expressing polyQ97 peptide constructs 
compared to those bearing control polyQ25 peptide in either absence or 
presence of ethosuximide. Following manual and thresholding analyses of 
total number of transfected cells, the presence of aggregates was confirmed 
by eye in each field. Individual polyQ-EGFP aggregates were counted and 
the percentage of polyQ-EGFP transfected N2A cells bearing fluorescent 
aggregates was determined. Ethosuximide treatment was able to significantly 
reduce the fraction of transfected cells bearing aggregates by 20% (p<0.036) 
as compared with the vehicle control (Figure 5.11A). 
To determine whether ethosuximide could influence polyQ peptides-
induced toxicity and cell death, the viability of transfected N2A cells was 
simultaneously monitored by staining the live cultures with SYTOX orange 
dye that specifically labels the nuclei of dying or dead cells with compromised 
membranes but not living cells. Expression of expanded polyQ peptides 
should result in increased numbers of SYTOX Orange-positive cells. 
Interestingly, the rate of cell death could not be quantified since majority of 
the transfected polyQ97 cells retained the viability of the cells despite 
abundant aggregations. Cell crenulations and cell shrinkage were 
occasionally observed but hardly any SYTOX Orange and GFP double-
positive cells indicative of cell death were detected in Q97-EGFP transfected 
N2A cells. It is likely that cell death correlated with a concomitant loss of 
EGFP and gain of the SYTOX Orange dye, but the uptake of SYTOX Orange 
dye into polyQ peptide expressing cells could have been preceded by the 
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rapid loss of GFP fluorescence, thus a much more sensitive method of 
detection such as flow cytometry analysis would be needed.  
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5.3 DISCUSSION 
Since many gaps remain in our knowledge of the molecular mechanisms 
underlying ethosuximide-induced protection, we sought to, in this chapter, 
delineate the whole picture of transcriptional changes in response to 
ethosuximide by using full-genome DNA microarrays. A recent study 
assessing the transcriptomic changes induced by various AEDs in a 
Drosophila epilepsy model (Singh et al., 2011) revealed that, while DEGs 
showed enrichment of processes related to metabolism in flies treated with 
gabapentin and levetiracetam, ethosuximide treated flies lacked DEGs and 
enriched GO categories. Their results further suggested that AEDs’ 
transcriptomic effect is mediated by neutralisation of up-regulated genes 
related to cell communication pathways i.e. inositol phosphate metabolism, 
phosphatidylinositol signaling, endocytosis, and hedgehog signalling, as well 
as the gene expression pathways encompassing spliceosome, RNA 
degradation, and ribosome. To the best of our knowledge, transcriptomic 
response of nematodes to ethosuximide exposure has not previously been 
described and it would therefore give us a unique starting point in 
understanding the beneficial effects and mode of action of ethosuximide. 
Based on our annotation analyses, ethosuximide treatment positively-
regulated transcripts highly enriched in processes related to lipid metabolism, 
redox regulation and longevity/ageing, while down-regulating transcripts 
strongly enriched in functions related to chromatin remodelling and UPS 
activity. 
The concerted action of detoxification enzymes cytochrome P450 
(CYP), short-chain dehydrogenase (SDR), UDP-glucuronosil/transferase 
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(UGT) and glutathione-S-transferase (GST) in the three successive phases 
of evolutionarily conserved endobiotic or xenobiotic metabolism has been 
well characterised in different organisms (Timchalk et al., 2002, Viñuela et 
al., 2010). Their inductions in long-lived daf-2 mutants and dauer larvae have 
further led to the proposal of their potential roles in longevity assurance 
(McElwee et al., 2004). Both CYPs and SDRs including alcohol 
dehydrogenases catalyse oxidation, hydroxylation, and dealkylation reactions 
in phase I drug metabolism to modify substrates and result in chemically 
reactive functional groups. These groups are required for entry into Phase II 
metabolism, which represent the actual detoxification reactions as major 
effectors GSTs, UGTs, sulfotransferases, and acetyltransferases catalyse the 
conjugation of drugs to sulphate, glutathione, or carbohydrates to enhance 
solubility, which in turn greatly facilitates their clearances from the cell during 
Phase III metabolism (Omiecinski et al., 2011).  
While the transcriptomic response to ethosuximide might appear at 
first glance to be dominated by induction of genes required to maintain 
proper redox homeostasis, which point towards detoxification and stress 
responses, care needs to be taken when interpreting the complex 
transcriptional responses to drug exposure and drawing links between gene 
expression profiles and physiological effects (Gerhold et al., 2001, Gerhold et 
al., 2002, Laing et al., 2012). It has been reported that short drug exposure 
provides a measure of transcriptome changes that are likely to be affected 
directly by the action of the drugs (i.e. primary targets), whereas prolonged 
exposure provides a measure of transcriptome changes caused by both 
direct and indirect effects. Thus it is essential to resolve genes whose 
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transcript levels are changed by direct ethosuximide effects from unintended 
gene expression induced by secondary effects (Chengalvala et al., 2007, 
Plant et al., 2009). Secondary drug targets indirectly affected through gene 
regulatory networks were also found to mainly function in stress response 
(Eckdahl et al., 2008). In addition, the substrates specificity for drug-
conjugating and drug transporter proteins are either poorly understand or in 
the case of CYPs, broad with overlapping roles in many constitutive 
biological processes i.e. biosynthesis of steroids, fatty acids, prostaglandins, 
and vitamin D in addition to drug metabolism (Danielson, 2002). Indeed, 
several of the induced xenobiotic enzymes in our GO annotation analysis 
overlapped into other functional categories and are therefore more likely to 
implicate them in ageing and endogenous lipid metabolism rather than 
xenobiotic metabolism.  
Moreover, ethosuximide significantly induced the expression of CYPs, 
SDRs, and UGTs without any GST inductions. There were other indications 
of a lack of generalised stress response, ROS-detoxifying or ROS-damage 
repair activities upon ethosuximide treatment, since heat shock proteins 
(HSPs) and many of the genes implicated in the oxidative stress response, 
including, catalases (ctl-2 and ctl-1/3), superoxide dismutase (sod-4), 
peroxiredoxin (prdx-3), glutaredoxin (glrx-10), glutathione peroxidase (gpx-2), 
and glutathione S-transferase (gst-4) were either absent or showed no 
evidence of induction in both the microarray and qRT-PCR analyses. Limited 
overlap was also observed in genes regulated by skn-1 in response to toxins, 
pathogens or oxidative stress and those that were induced by ethosuximide. 
The lack of detectable induction of GST-4::GFP, DAF-16::GFP nuclear 
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enrichment and hormetic prolongevity activity further suggest that the 
protective effects of ethosuximide were not as a result of an over-
compensatory increase in response to increased levels of various stresses.   
Our transcriptomic results were based on the analyses of only a 
subset of the total genes represented on the microarray (3%), since our 
criteria for identifying ethosuximide-responsive genes was very focused and 
thus resulted in the loss of a large number of genes during stringent 
downstream filtering of the data. This was therefore likely to have excluded 
many genes that are in fact affected by ethosuximide but are 
uncharacterised. Low stringency criteria are expected to detect more genes 
associated with ethosuximide at the expense of increasing the number of 
false-positives to be validated by other bioinformatic and experimental 
means. Several individual DEGs which were significantly induced but have 
not been ascribed a functional annotation were also excluded from the GO-
clusters. An example of this is ttr-44 of Transthyretin-like genes (TTRs) which 
is a well known transport protein that binds and carries steroid hormone. 
Transthyretin was previously shown to be significantly induced in long lived 
daf-2 mutants and/or dauer larvae (McElwee et al., 2004), and has in recent 
years been acknowledged as a neuroprotective component in NDs, such as 
AD and PD (Fleming et al., 2009). While increased production of TTR 
following activation of HSF-1 in vitro potently inhibited both Aβ aggregation 
and toxicity (Wang et al., 2014), expression of human WT or Ala60-mutated 
TTR was also shown to protect against the amyloid beta (Aβ)-induced 
proteotoxicity in a worm AD model (Diomede et al., 2012). Interestingly, 
another significant DEG that was absent in the enriched GO clusters, asm-3, 
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one of the 3 worm orthologues of mammalian acid sphingomyelinases which 
was previously uncovered as an ageing gene in C.elegans genome-wide 
RNAi screen (Kim and Sun, 2007) and was subsequently shown by the same 
group as a positive regulator of DAF-2/IIS signalling and a potential anti-
ageing target (Kim and Sun, 2012), was in fact up-regulated in our study. 
Multiple biochemical, molecular, cellular and clinical evidence have 
suggested that activation of lysosomal ASM and the resultant generation of 
ceramide play a central role in several common disease pathologies (Smith 
and Schuchman, 2008). More recent work demonstrated that elevated ASM 
activity plays a negative role in ageing (Kim and Sun, 2012) as well as AD 
pathogenesis (Lee et al., 2014), and proposed restoration of ASM activity to 
the normal range as a potential therapeutic strategy for aging and AD 
pathology, since pharmacological inhibition of ASM resulted in significant 
lifespan extension in C. elegans as well as increased autophagic degradation 
and improvement of pathological and clinical findings in validated mouse 
model of AD. While asm-3 was shown to regulate C. elegans lifespan by 
modulating the daf-2/IIS pathway (Kim and Sun, 2012), ASM was directly 
linked to autophagy–lysosome pathway function (Lee et al., 2014). ASM was 
also suggested as a key target of antidepressant drugs in the hippocampus 
which in turn mediates neurogenesis and neuronal networks that determine 
behaviour (Gulbins et al., 2013). Thus our finding that ethosuximide 
significantly induced asm-3 expression is difficult to interpret and will require 
additional study.  
It is also noteworthy that a sharp decline in the expression and activity 
of transcriptional targets with advancing age has been reported as 
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transcriptome to compounds such as leonardite humic acid HuminFeed® 
(Menzel et al., 2012) and oxidative stressor juglone (Przybysz et al., 2009) 
were shown to be more responsive in young larvae and/or adults than old 
adults. DEGs that were dramatically regulated in young larvae had no 
significant changes in older animals due to a marked reduction in their ability 
to mount an adaptive response to drug treatment (Zhao and Wang, 2012). 
Our microarray was performed on aged day 6 worms since dnj-14 mutant 
models of ANCL exhibit age-dependent phenotypes that culminate at day 6 
of adulthood. This could have therefore excluded many additional 
ethosuximide genes that are differentially regulated and, in turn, enriched in 
additional processes and pathways in young adults but weren’t detected in 
aged animals.  
Furthermore, it has been shown that not all cellular processes are 
controlled at the level of gene expression. Some processes, such as protein 
synthesis and modification, occur post-transcriptionally or post-translationally. 
An example of this is chronically administered mood-stabilising agents lithium 
and valproic acid which were proposed to modulate signaling pathways 
through a post-transcriptional or post-translational mechanism (Plant et al., 
2009) . 
As discussed in Chapter 4, the regulatory role of DAF-16/FOXO TF in 
ethosuximide-mediated protection is the subject of much active debate and 
research. C. elegans DAF-16 is homologous to the mammalian FOXO3a, 
one of the four members of the evolutionarily conserved FOXO TFs that 
function as sensors of the insulin signaling pathway and is implicated in the 
regulation of a wide range of physiological processes which are important to 
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longevity, development, stem cell maintenance, innate immunity, metabolic 
responses, tumour suppression, energy generation and cellular stress 
responses (Antebi, 2007). Much of our current understanding of the complex 
and multifaceted FOXO regulatory network and several of its converging 
signalling pathways comes from experimental and bioinformatic studies done 
on the C. elegans DAF-16. Here, we provided several lines of evidence 
suggesting that DAF-16/FOXO TF does indeed play a prominent role in 
ethosuximide’s mode of action.  
modMine publication enrichment analysis first revealed a significant 
overrepresentation of genes known to be transcriptionally regulated by DAF-
16/FOXO. Comparisons of stringent ethosuximide-responsive genes with 
expression data from various literatures also revealed a degree of overlap 
with characterised DAF-16 targets. Major differences in the experimental 
techniques and data analysis methods employed in previous studies, such as 
different experimental platforms, statistical cut-offs and downstream data 
processing may partially explain the lack of agreement between the 
published results.  
Next, our consensus motif analyses revealed a high representation of 
genes whose upstream binding regions included a motif matching the DAE in 
the regulation of ethosuximide. According to the previous studies, both DAE 
and DBE were found to be the most enriched in the promoters of DAF-16 
targets. While presence of DBEs (a longevity-associated promoter element) 
suggests direct DAF-16 regulation in response to reduced IIS signal or DAF-
16 nuclear localisation, the GATA-containing motif DAE was considered not a 
true forkhead consensus and lacked a definitive binding trans-factor. 
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Kenyon’s lab, however, demonstrated that DAF-16 can directly bind the DAE 
both in vitro and in vivo, though with a much lower affinity compared to the 
canonical DBE (Zhang et al., 2013b). Multiple studies using different 
algorithms have also noted an overrepresentation of the canonical DBE and 
its variants in the C. elegans genome (van Helden et al., 1998, Bussemaker 
et al., 2000, Furuyama et al., 2000, Lee et al., 2003, McElwee et al., 2003, 
Murphy et al., 2003). 78% of all C. elegans promoters were initially found to 
contain the DBE within 5 kb upstream regions despite only few of these 
genes were DAF-16 targets (Murphy et al., 2003). Following re-assessment 
by Kenyon and Murphy, it was reported that 88% of 514 DAF-16 target genes 
contain either the DBE or the DAE in the assessed 5-kb upstream regulatory 
regions (Kenyon and Murphy, 2006, Murphy, 2006). Thus, this suggests that 
the presence of the DBE alone was not sufficient to predict DAF-16-induced 
expression. In our motif analysis, DBE was in fact not detected by any of the 
four web tools we used despite numerous of the DEGs being among the list 
of most responsive daf-16 targets and subsequent manual search revealed 
37-44% of the common ethosuximide-responsive genes had at least one 
DBE located 200 bp upstream of the promoter region. It is possible that the 
motif analysing softwares could not find known binding motifs common to the 
C. elegans genome, and instead detected only statistically significant de 
novo motifs. However, the detection of two conserved and commonly 
observed core promoter elements Sp1 and TATA which are known cis-
regulatory elements in our upstream regions by multiple motif analysing web 
tools are difficult to interpret. It is possible that these cis-regulatory elements 
which direct the initiation of transcription and participate in the specificity of 
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enhancer function are important for other mechanisms that are still largely 
undefined. Indeed, despite a well characterised genome, the binding 
specificities of most of the putative C. elegans TF are not known, particularly 
many of the zinc finger proteins. TFBS have also been identified for only a 
dozen of the TFs encoding genes and transcriptional regulation is understood 
for only a few genes. Recent advances in ChIP-chip and high-throughput 
ChIP-Seq technologies (Kim et al., 2013) have facilitated genome-wide 
identification of TFBS and have already been utilised to untangle the complex 
developmental (Niu et al., 2011) and aging (Van Nostrand and Kim, 2013) 
regulatory networks. Thus future work using ChIP-Seq might permit more 
accurate identification of novel ethosuximide regulators. 
As mentioned above, several of the ageing-related and tissue-specific 
C. elegans GATA TFs such as ELT-2, ELT-3, ELT-4 were proposed to bind 
the DAE and cooperate with DAF-16 to regulate longevity genes in the 
intestine (Maduro and Rothman, 2002, Budovskaya et al., 2008, Kormish et 
al., 2010, McGee et al., 2011), their relation however, have been under much 
debate. Using a combination of computational and experimental methods, 
Bussemaker’s lab (Tepper et al., 2013) recently demonstrated that DAF-16 
directly up-regulates Class I genes through the DBE, while DAE correlates 
with responsiveness to both Class I and II genes. Class I genes are positive 
targets of DAF-16 which are consistently up-regulated and are enriched for 
the GO categories of oxidation, reduction, and energy metabolism, whereas 
Class II genes are negative targets of DAF-16 that are consistently down-
regulated and are enriched for biosynthesis, growth, reproduction, and 
development. A novel TF PQM-1 was shown to activate Class II DAF-16 
248 
 
down-regulated gene expression and some of the Class I DAF-16 up-
regulated gene expression via binding to DAE motifs at the posttranslational 
level. Moreover, in response to different upstream stimuli, PQM-1 and DAF-
16/FOXO were shown to be regulated reciprocally by IIS as they mutually 
antagonise each other with regard to localisation in the nucleus - where 
nuclear translocation of PQM-1 (promoted by DAF-2) results in depletion of 
DAF-16 from the nucleus and vice-versa. It is possible that PQM-1 TF is not 
involved in the regulation of ethosuximide as our analysis indicated that the 
expression level of Class I genes were more commonly modulated by 
ethosuximide than Class II genes.  
Exposure to ethosuximide however did not promote the nuclear 
translocation of a functional DAF-16::GFP fusion protein. In previous studies, 
several long-lived IIS mutants showed very weak and transient nuclear 
localisation of DAF-16::GFP (Henderson and Johnson, 2001, Patel et al., 
2008). In particular, age-1(hx546) mutants, which are classical IIS mutants 
defective in the conserved phosphatidylinositol 3-kinase (PI 3-kinase)/Akt 
pathway and require DAF-16 for lifespan extension, did not exhibit increased 
nuclear DAF-16-GFP at all under normal culture conditions (Henderson and 
Johnson, 2001). It is possible that the effect of ethosuximide on nuclear 
enrichment of DAF-16::GFP or the amount of nuclear DAF-16/FOXO 
required for the effects on lifespan might simply be below the detection 
threshold in this experiment. The cytoplasmic/nuclear retention of DAF-
16/FOXO upon ethosuximide treatment also does not necessarily reflect the 
fate of the whole DAF-16 cellular pool and protective effects of ethosuximide 
could be due to stimulated daf-16 transcriptional activity without an 
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accompanying significant change in DAF-16 subcellular localisation or even 
any nuclear localisation being required. A novel conserved pathway called 
the EAK (enhancer-of-akt-1) pathway has recently been shown to act in 
parallel to the Akt/PKB kinases and modulate aging by regulating the 
transcriptional activity of DAF-16/FOXO, without modifying its nuclear 
abundance (Williams et al., 2010). Alternatively, the effect of ethosuximide on 
DAF-16::GFP nuclear localisation might be negated by a role for the zinc 
finger TF PQM-1 in the localisation of DAF-16 (Tepper et al., 2013). Studies 
by Tissenbaum’s group also demonstrated that the subcellular localisation of 
daf-16 and the kinetics of translocation are isoform and temperature-
dependent (Bansal et al., 2014). daf-16 isoforms respond differently to 
changes in the levels of IIS. While a small decrease in IIS was able to induce 
rapid and strong DAF-16a nuclear localisation, the kinetics of DAF-16d/f 
translocation was much slower and nuclear enrichment of DAF-16d/f 
occurred only after substantial decreases in IIS.  
Recent analyses of IIS-dependent and IIS-independent epigenetic 
modifications have yielded new insights into additional layers of DAF-16 
regulation in the process of ageing and longevity. Hatta and Cirillo (Hatta and 
Cirillo, 2007) first reported that the diverse regulatory roles of FOXO could be 
attributed to its dynamic chromatin-remodelling ability. Riedel et al. (Riedel et 
al., 2013) and several follow-up studies provided further mechanistic insights 
into DAF-16/FOXO-mediated transcriptional regulation by demonstrating that 
upon pro-longevity stimuli, unphosphorylated DAF-16/FOXO translocates to 
the nucleus and binds the DAE (CTTATCA) consensus sequence to recruit a 
BAF-like subclass of the SWI/SNF (SWItch/sucrose non-fermentable) family 
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of ATP-dependent chromatin remodellers to target promoters. This in turn 
induces local restructuring and mobilisation of nucleosomes to create a zone 
of low nucleosome occupancy where the cis-regulatory promoter elements 
become exposed and therefore more accessible to binding of multiple factors 
that coordinately act on DAF-16 to ensure proper transcriptional outcomes. 
Bansal et al. further demonstrated using a RNAi screen that the SWI/SNF 
complex specifically regulates the age-dependent expression of daf-16d/f but 
not daf-16a and that ELT-2 and ELT-4 GATA factors promote longevity by 
regulating intestinal daf-16 expression (Bansal et al., 2014). In line with these 
evidence, our microarray data have shown a marked decline in the 
expression of several H1 linker histone subunits which are essential 
stabilisers of nucleosomes and assist the chromatin condensation into higher 
order structure. Ethosuximide-induced changes in nucleosome composition 
and arrangement through changing the expression of histone gene cluster in 
this study were likely to have loosened the normally compact chromatin 
structure to create a permissive environment for transcription and expression 
of DAF-16/FOXO targets.  
Over the past years, apart from ongoing research in elucidating the 
direct and indirect transcriptional targets of DAF-16/FOXO as well as 
functional and molecular interactions between its co-regulators (Murphy et 
al., 2003, McElwee et al., 2004), the therapeutic potential of IIS reduction, 
IIS-regulated TF including DAF-16/FOXO and its interactors in NDs has also 
been extensively explored (Cohen and Dillin, 2008, Moll et al., 2014). Indeed, 
numerous studies, including our own repeatedly demonstrated that genetic or 
pharmacological modulations of various components of the IIS cascade and 
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other converging signalling pathways effectively countered proteotoxicity of 
neurodegeneration-linked aggregative proteins in multiple well-characterised 
worm ND models. IIS reduction by daf-2 RNAi conferred protection against 
not only Aβ aggregation and Aβ-associated paralysis (Cohen et al., 2006, 
Florez-McClure et al., 2007, McColl et al., 2010), but also ALS-linked 
mutated TDP-43 (Zhang et al., 2011) and SOD-1-induced aggregations and 
the resulting locomotion impairments (Boccitto et al., 2012). IIS reduction by 
age-1 RNAi alleviated HD-associated polyQ stretches (polyQ82-YFP) 
aggregation in worm embryos and protected adult nematodes from polyQ 
aggregation-associated motility impairment (Morley et al., 2002). Similarly, 
reducing IIS activity via daf-2 or age-1 depletions lessened the toxicity 
associated with the aggregation of MJD-linked polyQ-containing protein 
ATXN-3 (Teixeira-Castro et al., 2011). Most of the compounds that were 
recently shown to alleviate proteotoxicity with counter-neurodegeneration 
potential are derived from natural products including blueberries (Wilson et 
al., 2006), herbs (Wu et al., 2002), green tea (Brown et al., 2006, Abbas and 
Wink, 2009), royal jelly (Honda et al., 2011) and cocoa (Martorell et al., 
2013). Indeed, blueberry polyphenols, caffeine (Sutphin et al., 2012), EGCG, 
myricetin, quercetin, kaempferol, aspalathin, naringenin, fisetin, apigenin and 
trehalose (Koch et al., 2014) were shown to enhance lifespan and protect C. 
elegans from Aβ- and/or polyQ-associated proteotoxicity by modulating the 
components of the IIS cascade. Parallel to our study, compounds with pre-
approved indications such as the amyloid binding dye, thioflavin T (Alavez et 
al., 2011), and anti-inflammatory drugs celecoxib (Ching et al., 2011) and 
aspirin (Ayyadevara et al., 2013, Wan et al., 2013), were proposed as 
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potential candidates for repurposing as treatments for age-related diseases 
due to their ability to slow ageing, increase lifespan and protect nematodes 
from Aβ-and/or polyQ-mediated toxicity. Here, we demonstrated that the 
protective effects of ethosuximide are highly dependent on the DAF-
16/FOXO TF by using both C. elegans and a mouse neuroblastoma cell line. 
Similarly, previous studies also utilised several complementary experimental 
platforms to corroborate that the identified compounds such as 
psammaplysene A and NT219 modulate proteostasis via a DAF-16/FOXO-
dependent IIS pathway (Mojsilovic-Petrovic et al., 2009, Calamini et al., 
2011, El-Ami et al., 2014), while novel compounds such as choline analogs 
JWB1-84-1 and JAY2-22-33 protected against Aβ toxicity through a 
multitarget mechanism involving both DAF-16-independent but HSF-1-
dependent IIS pathway as well nicotinic acetylcholine receptors (Keowkase 
et al., 2010a).  
As discussed in Chapter 4, several lines of evidence support the idea 
that genetic and pharmacological perturbations of chemosensory perception 
influence both the insulin/IGF-1-dependent and -independent components to 
regulate lifespan. Mutations that impair sensory neuronal structure and/ or 
their function, laser-ablation of ASI chemosensory neurons, or defects in 
neurosecretion were shown to confer longevity by activating DAF-16/FOXO. 
Anticonvulsants were also shown to promote longevity of invertebrate model 
animals as ethosuximide and trimethadione extended lifespan in C. elegans 
while lamotrigine lengthened lifespan in Drosophila. Inability of ethosuximide 
to further extend the lifespan of long-lived chemosensory mutants led to the 
proposal that the pro-longevity effects of ethosuximide are due to inhibition of 
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chemosensory neuron function, which prevents worms from sensing food, 
resulting in a perceived state of dietary restriction and hence lifespan 
increase (Collins et al., 2008).  
However, in this chapter, the reported chemosensory inhibition-
induced longevity was not evident since osm-3 mutants had a shorter 
lifespan than N2 WT. In contrast to earlier work which demonstrated that the 
osm-3 mutation resulted in a small but significant increase in daf-16 mutant 
lifespan (Apfeld and Kenyon, 1999, Lans and Jansen, 2007), depletion of 
DAF-16 here significantly decreased osm-3 mutant lifespan. In addition, 
ethosuximide treatment was able to increase the mean lifespan of both osm-
3 and osm-3 depleted of daf-16 but failed to augment lifespan in both daf-16 
RNAi fed N2 and dnj-14(ok237) worms. The lifespan prolongation by 
ethosuximide was shown to be dependent on DAF-16 as depletion of daf-16 
completely blocked the lifespan-extending effects of the ethosuximide. In 
contrast, osm-3 mutants did not show resistance to ethosuximide as 
previously observed, but instead lifespan extension was maintained in both 
osm-3 mutants and osm-3 mutants depleted of DAF-16. This therefore is 
consistent with the results presented in this work, further arguing against the 
mechanism that ethosuximide extend lifespan by inhibiting the function of 
specific chemosensory neurons. In addition, preliminary qRT-PCR analysis 
also found that some of the top ethosuximide-responsive genes from the 
microarray analysis were also induced in ethosuximide treated osm-3 relative 
to those with vehicle control (data not shown). 
Whilst the role of C. elegans DAF-16 in longevity and protein 
homeostasis appear to be well-characterised, to date, relatively little is known 
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about the therapeutic potential of FOXO network in protein quality control, 
protein aggregation and neurodegeneration. Whether activation or inhibition 
of FOXO transcriptional activity attenuate or aggravate ND pathogenesis 
remains a subject of debate, and the differences between FOXOs’ beneficial 
and harmful effects have been attributed to cell-type and context dependent 
activation and specific posttranslational modifications (Birkenkamp and 
Coffer, 2003). It is possible that the beneficial net outcome might require the 
same FOXO activity to be modulated in opposing fashions (Cohen and Dillin, 
2008)  
Analogous to its roles in regulating DAF-16 target genes and 
modulating aggregation formation in C. elegans, ethosuximide was shown in 
this chapter to induce the transcriptional activity of a subset of mammalian 
FOXO target genes and conferred protection against polyQ aggregation in 
neuronal cells, highlighting the conservation of DAF-16/FOXO-regulated 
ethosuximide response pathways in mammals. DAF-16 homologue FOXO3a 
is highly expressed in adult brain, and recent work suggested that it could 
have key regulatory roles in neuronal survival under both basal and disease 
conditions (Kops et al., 2002, Mojsilovic-Petrovic et al., 2009, Peng et al., 
2010). FOXO3a partially mediated the neuroprotection by Sirt1 in the striatal 
cell model of Huntington's disease (Jiang et al., 2012) and moderate FOXO3 
activation was also shown to oppose α-synuclein accumulation and 
proteotoxicity (Pino et al., 2014). Two studies further demonstrated that 
genetic and/or pharmacological activation of DAF-16/FOXO3a pathway could 
be broadly neuroprotective across phyla using both in vitro and in vivo 
models of motor neuron diseases (Mojsilovic-Petrovic et al., 2009) and 
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Parkinson's disease. While erythropoietin induced the expression of 
phosphorylated FOXO3a (Jia et al., 2014), compound psammaplysene A 
evoked a dose-dependent increase in FOXO-dependent transcription 
(Mojsilovic-Petrovic et al., 2009) which is in agreement with the role of 
ethosuximide in increasing FOXO’s ability to induce cell cycle arrest and 
DNA repair.  
Of particular interest was the observation that ethosuximide treatment 
resulted in significant induction of FOXO targets in differentiated N2A cells. 
This response was however absent in undifferentiated N2A cells, as 
ethosuximide was either suppressive or had no effect on FOXO target 
expression. This discordance between differentiated and undifferentiated 
neuroblastoma cells together with the observed differential protective effects 
of ethosuximide on C. elegans aggregation models further suggests that 
ethosuximide is likely to act non-cell autonomously in worms and mammals 
and the drug response may be neuron-specific. 
In conclusion, preliminary analyses of gene expression profiles 
obtained by using microarrays in this chapter have shed light on the potential 
molecular mechanisms of ethosuximide. Our work confirmed the important 
role of DAF-16/FOXO TF in the regulation of ethosuximide and further 
extended the protective activity of ethosuximide in mammalian neurons. 
Further studies are needed to evaluate the physiological importance of the 
increased or decreased levels of ethosuximide-responsive DEGs, and to 
assess the magnitude and complexity of expression changes elicited by 
ethosuximide at multiple exposure time points. As a complementary 
approach to the use of DNA microarrays, proteomic profiling could also be 
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performed in the future to identify to what extent a particular protein product 
is functionally altered by ethosuximide. 
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CHAPTER 6: CONCLUSION 
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6.1 SUMMARY 
Age-associated neurodegenerative diseases (NDs) are increasingly common 
and exert large costs on society. A major goal of neurodegeneration research 
is therefore to identify potential new therapies for these devastating diseases. 
There is considerable current interest in the idea of repurposing existing 
medicines for the treatment of NDs, since screening pre-approved drugs with 
well established safety and toxicity profiles obviates the need for early toxicity 
trials and thus expediting translation to clinical testing (Corbett et al., 2012). 
In this thesis, the nematode C. elegans was used as a pharmacological 
model system to identify generally neuroprotective compounds that alleviate 
the functional consequences of protein misfolding common to 
neurodegeneration. Using a combination of physiological, biochemical, and 
genetic tools, the research presented in this thesis demonstrated that 
ethosuximide, a widely prescribed anti-epileptic drug was efficacious in 
improving the pathological phenotypes of several worm ND models, and was 
further shown to induce the transcriptional activity of several mammalian 
FOXO target genes and conferred protection against expanded 
polyglutamine peptides-induced aggregation in cell culture experiments. 
Ethosuximide therefore is a potential candidate for repurposing as a 
treatment for NDs. These findings prompted further investigation into the 
protective effects of ethosuximide at the molecular level and have opened 
several directions for the future studies 
The first aim of this thesis was to test the applicability of established C. 
elegans ND models and select models with robust and readily-assayable 
screening phenotypes that are comparable to the human NDs. Chapter 3 
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describes the selection and phenotypic characterisation of nine neuronal ND 
models, of which many have already made substantial contribution to our 
understanding of the molecular mechanisms underlying aggregation and 
proteotoxicity in many human NDs. However, utility of most of these selected 
models for testing chemical modifiers are limited due to their lack of 
penetrance, variable phenotypes, incomplete manifestations and failure to 
reproduce published phenotypes. AD and HD transgenic models displayed 
highly variant neurodegenerative phenotypes that lack robustness and 
penetrance, while transgenic PD models have limited and variable 
phenotypes. The toxin-based PD model and the SMA null mutant model 
exhibited moderately robust phenotypes, but their usages for screening are 
restricted by their technical difficulties. Our data support the utility of a C. 
elegans null mutant model of ANCL, a distinct worm FTDP-17 model and an 
ALS model for subsequent modifier screening since they exhibited 
statistically robust and reproducible phenotypes. These models involve 
deletion of an endogenous neuroprotective gene (dnj-14), and pan-neuronal 
transgenic expression of disease-associated mutant Tau or SOD1 proteins, 
respectively. Pharmacological screening using ANCL and FTDP-17 models 
have already uncovered promising therapeutic interventions (McCormick et 
al., 2013, Kashyap et al., 2014).  
The second part of this thesis (Chapter 4) demonstrated that the AED 
ethosuximide is a promising general modifier of early-onset proteotoxicity 
since it was efficacious in three contrasting worm ND models, reducing 
proteotoxicity and enhancing lifespan not only in the null mutant model of 
ANCL, but also the FTDP-17 and a polyQ model based on pan-neuronal and 
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muscle-specific expression of mutant human Tau protein and aggregation-
prone polyglutamine stretches, respectively. Possible mechanisms of 
ethosuximide protection were subsequently addressed. Our finding that the 
beneficial effects of ethosuximide on motility and longevity in the FTDP-17 
model persist in strains harbouring a null mutation in the C. elegans T-type 
calcium channel, cca-1, suggests that ethosuximide’s neuroprotective activity 
is not mediated by inhibition of T-type channels. This conclusion is supported 
by previous work in C. elegans showing that lifespan extension by 
ethosuximide is unaffected by a different mutant allele of cca-1 (Collins et al., 
2008). Our data also revealed an imperfect correlation between the ability of 
ethosuximide to alter biochemical endpoints such as levels of soluble and 
insoluble Tau protein and polyQ aggregation and suppress proteotoxicity. We 
further excluded the possibility that the protective effects of ethosuximide are 
due to changes in the E. coli food source.  
The third part of the thesis aimed to understand the mechanism of 
action of ethosuximide. An Affymetrix microarray comparing the whole 
genome mRNA expression of untreated to ethosuximide-treated ANCL 
models and N2 WT animals was performed. The major findings in this part 
are: 1) Gene expression profiles of all worms following ethosuximide 
treatment are distinctly different from their untreated counterparts. 2) Genes 
commonly regulated in ethosuximide-treated animals have varied roles in 
lipid metabolism, redox homeostatsis, longevity/ageing, cell cycle and 
ubiquitination. 3) DAF-16/FOXO TF contributes to the observed protective 
action of ethosuximide. 4) Ethosuximide induced the transcriptional activity of 
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a subset of mammalian FOXO target genes and conferred protection against 
polyQ aggregation in mammalian neuronal cells.  
 
6.2 FUTURE DIRECTIONS 
Our data, combined with other studies, support a growing field investigating 
existing Medicines and Healthcare products Regulatory Agency (MHRA)-
approved medications for new indications. The anticonvulsant ethosuximide 
is clearly a potential candidate for repurposing as a treatment for NDs as 
demonstrated by its general neuroprotective activity in various different worm 
ND models which was also extended in mammalian cells. Our microarray 
data further substantiated that DAF-16/FOXO is a major component of the 
transcriptional network that regulates ethosuximide-mediated protection. 
Many questions still await to be addressed, and there are a number of 
possibilities to be followed-up in the near future.  
Numerous research studies involving the structure-function analysis of 
known compounds such as resveratrol (Richard et al., 2011), hydroxylamine 
(Haldimann et al., 2011), icariin (Cai et al., 2011) and celecoxib (Ching et al., 
2011) and their respective derivatives, have demonstrated their promising 
anti-ageing and anti-neurodegenerative activities. Polyphenols, in particular 
resveratrol, were shown to have neuroprotective effects in a range of worm 
models and also in mammalian systems (Parker et al., 2005, 
Karuppagounder et al., 2009, Bizat et al., 2010, Tauffenberger et al., 2013, 
Kashyap et al., 2014), as resveratrol not only rescued Htt-polyQ toxicity in 
both worm and neuronal culture models (Parker et al., 2005), but also 
protected against neurodegeneration both in a transgenic ALS model 
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overexpressing mutant TDP-43 (Tauffenberger et al., 2013) and a dnj-14 null 
mutant model of ANCL (Kashyap et al., 2014). Several of the resveratrol 
derivatives such as scirpusin A and ε-viniferin glucoside have also been 
demonstrated to effectively modulate multiple mechanisms of the AD 
pathology (Richard et al., 2011). Treating C. elegans muscle polyQ model 
with hydroxylamine, icariin and celecoxib derivatives: NG-094, Icariside II and 
OSU-03012 ameliorated polyQ-mediated protein aggregation and conferred 
protection against polyQ proteotoxicity (Cai et al., 2011, Ching et al., 2011, 
Haldimann et al., 2011). Studies have also previously demonstrated that 
trimethadione and 3,3-diethyl-2-pyrrolidinone, which are two other 
succinimide anticonvulsants structurally related to ethosuximide, can extend 
C. elegans lifespan and delay age-related degenerative changes (Evason et 
al., 2005). In this perspective, a potential next step could be to utilise both 
computer-assisted drug design/computer modeling methods and laboratory 
techniques to visualise and characterise the molecular structure of 
ethosuximide, and refine it to increase its specificity. This in turn could 
facilitate the identification of more potent and selective ethosuximide 
derivatives with multiple variations, as well as development of novel 
compounds which are currently not in clinical use, but may be screened for 
actions on neurodegeneration and neuronal loss associated with protein 
misfolding and aggregation (Caldwell et al., 2008). 
As previously discussed, the drawbacks of certain worm ND models 
include subtle, low penetrance and variable phenotypes, or phenotypes that 
are cumbersome to score, while others recapitulate the pathology of 
corresponding human NDs, but the severity of the defects make identification 
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of modifiers of the phenotype very demanding. Together, these limit the 
potential use of such models in modifier screening. During the course of my 
studies, not only have new worm ND models been developed (McColl et al., 
2012, Christie et al., 2014), ways to circumvent or overcome the technical 
difficulties and reduce data variability of the old models have also been 
discovered. While automation of labour intensive and low-throughput 
behaviour assays facilitates precise and rapid phenotypic data acquisition, 
development of novel technologies such as macro-scale flow-cytometry, 
microfluidics and optic techniques for rapid worm immobilisation, sorting, 
screening and automated long-term imaging have opened the possibility for 
performing high throughput analyses (Hulme and Whitesides, 2011, Yanik et 
al., 2011). Continuing refinement of high-throughput methods that require 
expensive or specialised equipment (Burns et al., 2006, Rohde et al., 2007, 
Doitsidou et al., 2008, Boyd et al., 2010, Gosai et al., 2010, Swierczek et al., 
2011) have led to the development of affordable systems that automate 
accurate and high-throughput scoring of a greater range of phenotypic 
endpoints of C. elegans (Mathew et al., 2012). In one recent report, a semi-
automated motion tracking analysis was applied on the neuronal AD model 
which allowed for a more efficient, accurate and detailed assessment of the 
behaviour deficits of strain CL2355 (Machino et al., 2014). Therefore, these 
platforms could potentially overcome some of the limitations associated with 
ND models as discussed above, to allow accurate analysis and quantification 
of behaviour defects and other neurological phenotypes that can be 
potentially rescued by ethosuximide with high-throughput. 
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It was demonstrated that the worm dnj-14 phenotype is reminiscent of 
dnajc5 KO mice which are relatively normal at birth, but have a short lifespan 
associated with progressive sensorimotor defects and neurodegeneration 
(Fernandez-Chacon et al., 2004). dnj-14 mutants also develop profound 
chemosensory neuron impairments with increasing age (Kashyap et al., 
2014), and this selectivity in the types of neurons affected bears a striking 
similarity with the selective vulnerability of photoreceptors and GABAergic 
neurons (Schmitz et al., 2006, Garcia-Junco-Clemente et al., 2010) observed 
in CSPα null models and ANCL patients. Therefore, the efficacy of 
ethosuximide would be further evaluated in the dnajc5 KO mouse model of 
ANCL to see if the treatment can abrogate the motor impairments, lethality 
and neurodegeneration caused by the loss of CSPα function. 
In line with previous work, we have shown in Chapter 4 that 
ethosuximide-mediated protection is independent of CCA-1, the sole worm 
orthologue of mammalian T-type calcium channel. Given that the C. elegans 
genome does not encode voltage-sensitive sodium channels or display 
typical voltage-gated sodium currents (Bargmann, 1998), it seems likely that 
ethosuximide ameliorates neurodegeneration via a novel ion-channel-
independent mechanism. To validate this experimentally, we should proceed 
to investigate the role of other voltage-gated calcium channels such as UNC-
2 (CaV2 or N/P/Q-type), EGL-19 (CaV1 or L-type), and non-selective cation 
channels NCA-1 and NCA-2 channels (Liu et al., 2011a) in ethosuximide 
action by generating and analysing the responses of respective double 
mutants to ethosuximide exposure. To determine whether K+ channels are 
important in ethosuximide action, functional analyses of double mutants with 
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deletions in the voltage-gated channels SHL-1 and SHK-1, and the Ca2+/Cl−-
gated channel SLO-2 should be performed. 
Our studies also did not address the functioning of the nervous system 
beyond gross behavioural experiments. Further experiments could include a 
more in-depth observation of the neurotransmitter systems that were not 
quantitatively assessed in these studies, such as assessing ND models 
treated with ethosuximide for sensitivity to acetylcholinesterase inhibitor 
aldicarb and nicotinic agonist levamisole, which could reveal potential impact 
of ethosuximide on synaptic transmission. 
Our microarray analysis in Chapter 5 has laid an excellent foundation 
for the discovery of therapeutic targets of ethosuximide as well as future 
explorations into the regulation of gene transcription and the exact molecular 
alterations that occur with ND processes. PQM-1, a novel TF was recently 
discovered to regulate Class II (down-regulated) DAF-16/FOXO targets by 
binding to the DAE located in the promoter of these genes, whereas DAF-16 
regulates Class I (up-regulated) DAF-16/FOXO targets by binding to the DBE 
(Tepper et al., 2013). However, the common ethosuximide-regulated gene 
set with a significant enrichment in DAE consists more of the most 
responsive Class I than Class II genes. Therefore whether PQM-1 TF has a 
regulatory role in ethosuximide-mediated protection awaits future studies. As 
experimental follow-up, the effect of ethosuximide treatment on pqm-1-/-, 
double mutant involving pqm-1 deletion, and nuclear localisation of PQM-
1::GFP worms would be investigated. Fully exploring whether the DAE 
binding to either DAF-16 or PQM-1 is direct or indirect is also a high priority. 
As noted by Tepper et al.(Tepper et al., 2013), there are several other DAE-
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binding TFs over-represented in Class I and Class II targets and ones that 
are of potential interest include PHA-4, a FoxA TF required for dietary-
restriction-mediated longevity (Panowski et al., 2007) with similar consensus 
site as DAF-16 (DAF-16: TTGTTTAC and PHA-4: T(A/G)TT(T/G)(A/G)(T/C) 
(Gaudet and Mango, 2002, Lee and Batzoglou, 2003); NHR-28, a nuclear 
hormone receptor and UNC-62, a developmental regulator (He et al., 2014). 
They have all been identified as putative aging regulatory TFs in a recent 
ChIP-seq screen (Van Nostrand and Kim, 2013). Their potential roles in 
regulating ethosuximide-mediated protection could be explored in a similar 
way as DAF-16.  
Our microarray work has concentrated on DEGs commonly regulated 
by ethosuximide. Additional experiments should further address the 
contributions of these genes in ethosuximide-mediated protection and test 
whether knocking them down by RNAi affect the phenotypes of untreated 
and treated dnj-14 mutants. DEGs which are of particular interest include 
individual significant genes (ttr-44, asm-3), downstream targets of DAF-
16/FOXO (cyp-34A9, cyp-35B1, dod-6, dod-3, ftn-1) and F-box proteins 
(fbxb-11, fbxb-41, fbxb-63 and fbxb-66). Since F-box proteins were also 
enriched in our analysis for common DEGs down-regulated in response to 
ethosuximide, the effect of ethosuximide on the regulation of 
polyubiquitination and proteasome-mediated proteolysis should be 
addressed. To achieve this, a sur-5::UbV-GFP reporter strain that expresses 
ubiquitin with an C-terminal glycine to valine mutation fused to GFP under the 
control of the sur-5 promoter in various somatic tissues (Segref et al., 2011) 
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would be used and through assessing its GFP expression and protein levels, 
the ubiquitin proteasome system (UPS) activity would be monitored.  
An interesting extension of this work would be to investigate the 
effects of ethosuximide on various ages. Likewise, complex analyses of 
expression profile changes between other genotypes, several ethosuximide 
treatment regimes and incorporation of previously published datasets and 
whole genome transcriptome analyses with newer technologies such as 
ChIP-seq and RNA-Seq could also be performed. This combinatory approach 
would be more informative than any one approach alone. In addition, 
functional proteomics could also be utilised to define the network of protein 
components whose synthesis and degradation are regulated by 
ethosuximide. 
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NDs Model 
Strain/transgene 
name/(plasmid) 
Expression in 
C. elegans 
Phenotypes 
Efficacious compounds 
identified/validated 
References 
Transgenic overexpression of human neurodegeneration-associated protein/peptide 
AD 
 
Punc-54::Aβ1–42 (wild type); Dimer 
Aβ1–42 or Met
35
Cys Aβ1–42 
CL2005, CL2006, 
CL1019, CL1118, 
CL1119, CL1120, 
CL1121, CL2120; 
CL2109, CL3109; 
CL3115 
Constitutive 
muscles 
Age-dependent progressive paralysis; 
forms amyloid deposits; increased 
oxidative stress.  
CL2109, CL3109 and CL3115: no 
formation of amyloid deposits and no 
increase in oxidative stress 
CL2006: caffeine, tannic acid 
and bacitracin; epigallocatechin 
gallate; reserpine; Ginkgo biloba 
extract EGb 761; soya 
isoflavone glycitein; rifampicin; 
thioflavin T; curcumin; ferulic 
acid; fluoxetine; JWB1-84-1 and 
JAY2-22-33; NT219 
CL2120: PBT2 
(Link, 1995, Fay et 
al., 1998, Yatin et 
al., 1999, Link et 
al., 2001) 
dvIs100 [pCL354(unc-54:DA- 
Aβ1–42) + pCL26(mtl-2: GFP)]. 
GMC101 
Severe and fully penetrant paralysis 
within 48 hours after temperature shift 
PBT2 
(McColl et al., 
2012) 
smg-1(cc546);Is [Pmyo-3::Aβ1–
42::let UTR) + (rol-6(su1006)] 
CL4176 
Inducible body 
wall muscles 
Rapid paralysis; oxidative stress 
precedes amyloid deposition; 
autophagosome accumulation 
coffee extracts, tetracycline and 
related analogs; copper; Ginkgo 
biloba extract EGb 761 and 
Ginkgolide A and J; Liuwei 
Dihuang (LWDH); galanthamine; 
icariside II; cocoa peptide 
(Drake et al., 2003, 
Link et al., 2003, 
Florez-McClure et 
al., 2007) 
smg-1(cc546); Is[Pmyo-
3::GFP::degron + Pmtl-2::GFP] 
CL2337 
Rapid paralysis; formation of stable 
perinuclear deposits 
 (Link, 2006) 
smg-1(cc546); Is[Psnb-1::Aβ1-42 + 
Pmtl-2::GFP] 
CL2241, CL2355 
Inducible pan-
neuronal 
CL2241 exhibit WT movement. CL2355 
is defective in chemotaxis toward 
benzaldehyde, associative learning, and 
thrashing in liquid; hypersensitive to 
serotonin; forms amyloid deposits; has 
partial sterility due to germline 
proliferation defects and embryonic 
lethality 
CL2355: Ginkgo biloba extract 
EGb 761 
(Link, 2006, Wu et 
al., 2006, Dosanjh 
et al., 2010) 
N2; Is [Peat-4::ssAβ1-42(N-
terminus) + Peat-4::gfp + Pmyo-
2::mCherry] 
UA166 
Glutamatergic 
neurons 
Loss of GFP-marked glutamatergic 
neurons in an age-related manner; at 
day 3 only 48% of worms had five intact 
glutamatergic neurons, and at day 7 only 
25% did  
clioquinol 
(Treusch et al., 
2011) 
N2; ynIs13[Psnb-1::APL-1] 
N2; ynIs104[Prab-3::apl-1::GFP] 
LGIII, LGV, LGX 
Constitutive pan-
neuronal 
Defects in brood size, movement, and 
viability; severe chemotaxis defects and 
diminished touch habituation 
 
(Hornsten et al., 
2007, Ewald et al., 
2012) 
ALS 
N2; Is[Phsp-16.2::SOD-1 (WT, A4V, 
G37R, G93A) + Pmyo-3::SOD-1 
(WT, A4V)::GFP + rol-
6(su1006)] 
 
Heat shock 
inducible body 
wall muscles 
Paraquat hypersensitivity; formation of 
aggregates under oxidative stress 
 (Oeda et al., 2001) 
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ALS 
Psnb-1::SOD1(WT,G85R) -YFP iwIs8gf 
Constitutive pan-
neuronal 
 
G85R and G85R-YFP: severely reduced 
forward crawling, thrashings and strong 
resistance to aldicarb. H46R/H48Q-YFP 
produced a movement defect less 
prominent than that seen in G85R-YFP  
 
(Wang et al., 
2009b) 
N2; Is [Psng-1::SOD-1 (WT, A4V, 
G37R , G93C)– EGFP] 
 
Increased aggregation formaton; 
SOD1(G85R) heterodimeric worms have 
significantly impaired locomotion and 
reduced lifespan 
 (Witan et al., 2008) 
lin -15(n765ts); [Prgef-1::FUS (WT, 
R514G, R521G, R522G, R524S 
and P525L) + Ppab-1:: mcherry; 
lin-15(+)]  
pJH897 
Formation of cytoplasmic FUS 
aggregates; R522G, P525L, FUS513 
and FUS501: significantly shorter 
lifespan. P525L, FUS513 and FUS501: 
partially or completely paralysed, 
severely shrunken by 8 days of age  
 
(Murakami et al., 
2002) 
Punc-54::SOD1(WT, G85R, G93A, 
G127insTGGGstop)::YFP  
AM263; AM265 
Constitutive 
muscles 
Accumulation of mutant SOD1 causes 
25-30% decrease in motility on day 2 of 
adulthood, and further decrease by 
approx. 10% on day 6 of adulthood 
 
(Gidalevitz et al., 
2009, Silva et al., 
2011a) 
unc-119(ed3);Is[Punc-47::TDP-43-
(WT, A315T) + unc-119(+)] 
unc-119(ed3); Is[Punc-47::FUS-
(WT, S57Δ) + unc-119(+)] 
xqIs132, xqIs133, 
xqIs173, xqIs98 
GABAergic motor 
neurons 
Have normal lifespan, but displayed 
adult-onset, age-dependent loss of 
motility, progressive paralysis, neuronal 
degeneration, accumulation of highly 
insoluble TDP-43 and FUS proteins 
methylene blue, salubrinal, 
guanabenz, and phenazine; 
resveratrol, rolipram, reserpine, 
trolox, propyl gallate, and 
ethosuximide 
(Vaccaro et al., 
2012) 
[Psnb-1::TDP-43-YFP 
WT(iwIs26)], [Psnb-1::TDP-C25-
YFP(iwIs22)], [Psnb-1::TDP-43-
YFP Q331K(iwEx20)], [Psnb-
1::TDP-43-YFP M337V(iwEx28)], 
[Psnb-1::SOD1-YFP WT(iwIs27)] 
and [Psnb-1::SOD1-YFP 
G85R(iwIs8)] 
IW63, IW33, IW20, 
IW46, IW31, IW8 
Constitutive pan-
neuronal 
Transgenic models developed robust 
locomotion defects and protein 
aggregation 
 (Zhang et al., 2011) 
Punc-25::G93A SOD1-GFP  
GABAergic motor 
neurons 
Age-dependent paralysis; G93A SOD1 
aggregates in neural cell bodies and 
causes axon guidance defects 
 (Li et al., 2013) 
ALS/ 
FTLD-U 
N2; Is[Psnb-1::TDP-43 (WT, 
G290A, A315T, M337V) + Psnb-
1::GFP] 
CK405, CK406, 
CK410; CK422; 
CK423; CK426 
Constitutive pan-
neuronal 
Mutant TDP-43: significantly impaired 
locomotion; degeneration of GABAergic 
motor neurons  
PHA767491; LDN-0130436 
(Liachko et al., 
2010) 
ALS/ 
FTLD-U 
Is[Punc-25::SNB-1::GFP ] + 
Ex[Psnb-1::TDP-43; Pregf-1:: 
DsRed2; Punc--122::RFP] 
CL2609, CL1681, 
CL1682 
Unc and abnormal motor neuron 
synapses  
 (Ash et al., 2010) 
271 
 
NDs Model 
Strain/transgene 
name/(plasmid) 
Expression in 
C. elegans 
Phenotypes 
Efficacious compounds 
identified/validated 
References 
FTDP-17 
N2; Is[Paex-3:: 4R1N human tau 
(WT, V337M , P301L) + Pmyo-
2::GFP] 
CK10, CK49, CK1301, 
CK1310 
Constitutive pan-
neuronal 
Mutant tau: strong age-dependent 
progressive uncoordination and 
accumulation of insoluble tau; 
neurodegeneration; presynaptic 
cholinergic transmission defect; reduced 
lifespan  
azaperone, clofazimine, 
isoniazid, lorglumide, nefopam, 
and trazodone 
(Kraemer et al., 
2003) 
Pro-aggregant lines: N2; Is[Prab-
3::F3ΔK280 + Pmyo-2::mCherry] 
BR5270, BR5485, 
BR5944, BR5706 
Strongly defective locomotion at day 1 of 
adulthood, accelerated aggregation of 
insoluble Tau, severe developmental 
defects of nervous syetem, impaired 
presynaptic transmission 
methylene blue, BSc3094, bb14 
and cmp16 
(Fatouros et al., 
2012) 
Anti-aggregant lines: N2; Is[Prab-
3::F3ΔK280(I277P)(I308P) + 
Pmyo-2::mCherry] 
BR5271, BR5486, 
BR6516, BR6427 
No obvious locomotion defects and 
minimum perturbation of the 
development of the nervous system 
N2; Is [Pmec-7::tau WT(0N4R, 
0N3R) + rol-6(su1006)] 
tmIs82, tmIs83, 
tmIs84, tmIs85, 
tmIs171; tmIs110, 
tmIs173 
Touch neurons 
(ALML/R, AVM, 
PLML/R, PVM); 
weak in FLP, PVD, 
BDU 
Age-dependent progressive impairment 
in touch response; neurodegeneration; 
tau WT4R: little tau accumulation in PLM 
neuron 
 
(Miyasaka et al., 
2005) 
N2; Is [Pmec-7:: tau (P301L, 
R406W) + rol-6(su1006)] 
tmIs81, tmIs178, 
tmIs179; tmIs146, 
tmIs147, tmIs148, 
tmIs149 
Strong age-dependent progressive 
impairment in touch response; 
neurodegeneration; strong tau 
accumulation in PLM neuron  
 
pha-1(e2123ts); Ex[Prgef-1:: 
Tau352 (WT, PHP,  Ala10) + pha-
1(+)] 
VH255, VH1016, 
VH1018; VH254, 
VH1014, VH1015; 
VH418, VH421 
Constitutive pan-
neuronal 
Both WT and PHP tau352 showed age-
dependent progressive uncoordination 
and neurodegeneration; no change in 
motor neuron viability. Mutant PHP tau: 
altered motor neuron development. 
Ala10 tau: early onset of movement 
defects and reduced lifespan 
 (Brandt et al., 2009) 
 
 
HD 
 
 
Punc-54::polyQ-GFP/YFP/CFP 
pEGFP-N1-Q19, 
pEGFP-N1-Q82 
Constitutive 
muscles 
Length-dependent formation of 
aggregates; growth rates slowed down; 
reduced motility 
icariside II; NG-094; aspirin 
(Satyal et al., 2000, 
Morley et al., 2002, 
Wang et al., 2006) 
Punc-54::DRPLAP-Q(32, 40, 56, 
79)-GFP 
pCKX2004, 
pCKX2003, 
pCKX2002, 
pCKX2001 
Q>40: formation of cytoplasmic 
aggregates 
 
(Yamanaka et al., 
2004) 
Pmec-3::htt57Q(19, 88, 128)-GFP 
Pmec-3::htt57Q(19, 88, 128) ::CFP 
+ Pmec-7::YFP 
ID24, ID1 
Mechanosensory 
neurons 
Highly penetrant posterior touch 
insensitivity, significant anterior Mec 
phenotype; significant deposits and 
morphological abnormalities in PLM cell 
axons   
resveratrol 
(Parker et al., 2001, 
Lejeune et al., 
2012) 
272 
 
NDs Model 
Strain/transgene 
name/(plasmid) 
Expression in 
C. elegans 
Phenotypes 
Efficacious compounds 
identified/validated 
References 
 
 
 
 
 
HD 
N2; rmEx[Prgef-1::HttQ 
(0,19,35,40,67,86)-CFP/YFP] 
CFP lines: (Q35) 
AM303; (Q40) AM305; 
(Q67) AM308; (Q86) 
AM313. YFP lines: 
(Q35) AM78 and 
AM80; (Q40) AM85 
and AM87; (Q67) 
AM81 and AM83; 
(Q86) AM322 and 
AM324 
Constitutive pan-
neuronal 
PolyQ length-dependent aggregation; 
overt neuronal dysfunction; polyQ 
length-dependent decrease of thrashing, 
pharyngeal pumping and erratic 
defecation cycle 
β-lapachone 
(Brignull et al., 
2006b) 
rtIs11[Posm-10::GFP + Posm-
10::HttQ150 +Dpy-20(+)] 
HA659 
Chemosensory 
neurons 
Severe defect in the nose touch 
response  
 (Faber et al., 2002) 
pqe-1(rt13) III; rtIs11[Posm-
10::GFP + Posm-10::HttQ150 + 
Dpy-20(+)] 
HA759 
Accelerated polyQ mediated 
neurodegeneration. Vast majority 
(>90%) of ASH neurons undergo cell 
death in less than three days  
lithium chloride, mithramycin, 
trichostatin; rotenone, 
oligomycin and 4-dinitrophenol; 
D. officinarum extracts; 
salidroside 
(Varma et al., 2007, 
Voisine et al., 2007) 
N2; rmIs[Punc-54::polyQ(0, 24, 35, 
37, 40)::YFP] 
(Q35) AM140; (Q37) 
AM470; (Q40) AM141 
Constitutive 
muscles 
Q35 and Q37 aggregation in muscle 
cells causes a significant motility defect  
AM140: ML346; celecoxib; 
NT219 
AM141: salidroside 
(Silva et al., 2011a) 
MJD 
Full-length ATXN-3 expressing  
lines: Prgef-1::AT3q14, AT3q75, 
AT3q130::YFP 
AM491, AM513, 
AM509, AM494, 
AM519, AM520, 
AM666, AM685, 
AM599 Constitutive pan-
neuronal 
PolyQ length-dependent aggregation 
and motor dysfunction 
17-(allylamino)-17-
demethoxygeldanamycin (17-
AAG), valproic acid 
(Teixeira-Castro et 
al., 2011) 
C-terminal  ATXN-3 expressing  
lines: Prgef-1::257cAT3q14, 
257cAT3q75, 257cAT3q80, 
257cAT3q128::YFP  
AM396, AM416, 
AM422, AM391, 
AM428, AM419, 
AM420, AM684, 
AM683, AM702 
Worms with truncated ATXN3 
expression have similar aggregation 
profiles in their neurons  and have more 
severe motility defects 
N2; [Punc-54257cAT3(Q45)::YFP] 
or Punc-54257cAT3(Q63)::YFP 
 
Constitutive 
muscles 
PolyQ length-dependent toxicity; 
aggregation and toxicity are not 
significantly modulated by aging 
 
(Christie et al., 
2014) 
 
PD 
 
N2; Is[Punc-54::α-syn::GFP + rol-
6(su1006)]  
UA49 
Constitutive 
muscles 
α-syn misfolding and  accumulation   
(Hamamichi et al., 
2008) 
Is[Punc-54::α-syn::YFP + unc-
119(+)] 
NL5901 Formation of inclusions 10-O-trans-p-Coumaroylcatalpol 
(van Ham et al., 
2008) 
Paex-3::α-syn (WT, A53T) + Paex-
3::GFP/Pdat-1::GFP 
 
Constitutive pan-
neuronal Motility deficits, significant dopaminergic 
neuron loss and dendritic breaks  
 (Lakso et al., 2003) 
P(acr-2, unc-30)::α-syn (WT, A53T) + 
Paex-3::GFP/Pdat-1::GFP  
 Motor neurons 
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PD 
N2; Is[Punc-119::α-syn (WT, A53T, 
β-syn) + pDPSU006-GFP] 
 
Constitutive pan-
neuronal 
A53T: greater vulnerability to rotenone-
induced toxicity, exhibiting 68.4% lower 
survival after 4 days of 50 μM rotenone 
treatment.  
 (Ved et al., 2005) 
Pdat-1::α-syn (WT, A53T) + Pdat-
1::GFP  
BY273, UA18, UA31, 
UA44 
Dopaminergic 
neuron 
Mean life span was similar among the 
non-Tg, WT, and A53T α-synuclein-
expressing strains; significant DAergic 
neuron loss and dendritic breaks 
acetaminophen; bromocriptine 
and quinpirole;valproic acid 
(Lakso et al., 2003, 
Cao et al., 2005, 
Kuwahara et al., 
2006, Settivari et 
al., 2009) 
Pdat-1 ::α-syn (A30P, A53T, 
A56P) + Pdat-1::mCherry 
 
Dopaminergic 
neuron 
Increased neurodegeneration; A30P or 
A53T: failure in modulation of 
locomotory rate in response to food and 
markedly reduced DA content (∼1 ng/g 
vs N2 ∼5 ng/g). A56P: more impaired in 
DA-dependent behaviour  
 
(Karpinar et al., 
2009) 
N2; Is[Punc-51::α-syn (WT, A53T, 
A30P) + Punc-51::EGFP] 
 
Constitutive pan-
neuronal 
No motor deterioration or retardation in 
growth 
 
(Kuwahara et al., 
2008) N2; Is[Pmec-7::α-syn (WT, A53T) 
+ rol-6 (su1006)] 
 
Mechanosensory 
neurons 
Moderate impairments in touch response 
Punc-51::S129A or S129D α-syn + 
Punc-51::EGFP 
Punc-51::S129A or S129D α-syn + 
Punc-25:: SNB-1::GFP 
 
Constitutive pan-
neuronal 
Strikingly severe motor defects 
throughout development and aging, 
growth retardation, and synaptic 
abnormality. SNB-1::GFP fluorescence 
was broadly diminished in the nerve 
cord.  
 
(Kuwahara et al., 
2012) 
lin-15(n765ts); Is[ Psnb-1::LRRK2 
(WT, G2019S, R1441C, KD, 
R1441C/KD) + Pmec-4::GFP; lin-
15 (+)] 
wlzIs1-7 
Constitutive pan-
neuronal 
G2019S LRRK2 increased vulnerability 
of dopaminergic neurons to 
mitochondrial stress. Reduced lifespan 
in mutant LRRK2 (G2019S or R1441C) 
 (Saha et al., 2009) 
N2; baIn20 [Pdat-1::LRRK2 
(G2019S) + Pdat-1 ::GFP] 
UA118 
Dopaminergic 
neuron 
Age-dependent degeneration of DAergic 
neurons, behavioural deficit, locomotor 
dysfunction and depletion of 
dopamine(~72% loss). G2019S causes 
more rapid progression of behavioural 
deficits than others 
GW5074 indoline; sorafenib (Liu et al., 2011b) BY250;  baEx129[Pdat-
1::LRRK2(G2019S/D1994A)] 
UA215, UA216 
lin-15(n765ts) X; Is[Pdat-1::LRRK2 
(WT,R1441C, G2019S, K1347A) 
+ Pdat-1 ::GFP + lin-15 (+)] 
SGC722, SGC851, 
SGC856, SGC862 
TTT-3002 and LRRK2-IN1 
(Yao et al., 2010, 
Yao et al., 2012) 
lin-15(n765ts) X; cwrEx900 [Pdat-
1::GFP, Pdat-
1::LRRK2(R1441C/A2016T), lin-
15(+)]  
SG900, SGC910, 
Double mutants displayed DAergic 
defects and neurodegeneration similar to 
R1441C- and G2019S-LRRK2 models.  
(Yao et al., 2012) 
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Prion 
lin-15(n765ts); [Pmec-7::PrP(WT, 
PG13) + PStr-1:: GFP; Pmec-7::GFP 
+ lin-15 (+)] 
 
Mechanosensory 
neurons 
Progressive loss of response to touch at 
the tail caused by mutant (PG13-PrP) 
PrP expression without causing cell 
death  
quinacrine, resveratrol (Bizat et al., 2010) 
Pric-19::PrP + Pric-19::GFP  cgIs51, cgIs52, cgIs53 
Constitutive pan-
neuronal 
High PrP levels cause abnormal 
morphology, striking neuropathogenic 
phenotypes and remarkable reductions 
in lifespan  
 
 
 
(Park and Li, 2011) 
 
rmIs319[Punc-54::sup35(rΔ2-5, 
nm, r2e2)::yfp], 
AM801, AM803, 
AM806 
Constitutive 
muscles 
Profound cell autonomous and cell non-
autonomous disruption of mitochondrial 
integrity, embryonic and larval arrest, 
developmental delay, widespread tissue 
defects, and loss of organismal 
proteostasis 
 
(Nussbaum-
Krammer et al., 
2013)  
Mutant/RNAi 
AD 
apl-1(yn10)   
 
Larval lethality, defects in molting and 
morphogenesis  
 
(Lakowski and 
Hekimi, 1998) 
apl-1(RNAi)   
 
Reduced body size, with some worms 
exhibiting L4 molting problems  
 
(Hornsten et al., 
2007) 
sel-12(ar131) and (ar171)  GS1894 
 
Exhibit thermotaxis defects   
(Levitan and 
Greenwald, 1998, 
Wittenburg et al., 
2000) 
ANCL 
dnj-14(ok237)  
dnj-14(tm3223) 
RM2754 
TM3223  
Age-dependent progressive impairment 
in locomotion, severe progressive 
chemosensory defects which precede 
neurodegeneration of sensory neurons 
and significantly shorter lifespan 
resveratrol 
(Kashyap et al., 
2014) 
PD 
lrk-1(km17), (km41), (tm1898) 
and (RNAi)  
 
 
Mitochondrial stress, ER stress sensitive   (Saha et al., 2009) 
pdr-1(lg103), (XY1046, Parkin 
KO3) and (RNAi)  
 
 
Display severe developmental defects 
and lethality at early larval stages in 
presence of ER stressors. Majority died 
or arrested at, or prior to, the larval L3 
stage. 15.4% shorter life span than that 
of non-Tg strain  
 
(Springer et al., 
2005, Ved et al., 
2005) 
pink-1(tm1779)   
 
Increased sensitivity to a 3-day exposure 
to 150 mM paraquat  
 
(Sämann et al., 
2009) 
 
djr-1.1(RNAi) 
 
 
 
Significantly more sensitive to rotenone 
treatment than control nematodes  
 (Ved et al., 2005) 
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SMA 
smn-1(ok355) I/hT2[bli-4(e937) 
let-?(q782) qIs48] (I;III) 
LM99 
 
Thrashing rate progressively declined 
and almost completely ceased after 5 
days post-L1. Pharyngeal pumping rates 
showed a rapid and progressive decline. 
Mean lifespan is 6.0 days Vs 17.7 days 
for N2 
riluzole (Briese et al., 2009) 
smn-1(cb131)I LL2073 
 
Body length and lifespan was 
significantly shorter than that of the WT; 
defective motility, egg-laying and 
hatching 
4-aminopyridine, gaboxadol 
hydrochloride, N-
acetylneuraminic acid 
(Sleigh et al., 2011) 
Chemical treatment 
PD 
vtIs7[Pdat-1::GFP] subjected to 6-
hydroxydopamine (6-OHDA)  
BY250, BY200 
 
Neuronal process blebbing, cell body 
rounding with process loss and cell body 
loss reproducibly appear in this order 
within a few hours.  
bromocriptine, quinpirole and 
memantine; acetaminophen 
(Nass et al., 2001, 
Cao et al., 2005, 
Ruan et al., 2010) 
N2; [Pcat-2::GFP], egIs1[Pdat-
1::GFP] subjected to 1-methyl-4-
phenyl-1,2,3,6-
tetrahydropyridine (MPTP)  
BZ555 
 
Reduced mobility, increased lethality 
and DA neurodegeneration,  
lisuride, apomorphine and 
rottlerin; P7C3, P7C3A20; 
polysaccharides from 
Chaenomeles speciosa; 
acetylcorynoline; n-
butylidenephthalide 
(Braungart et al., 
2004) 
N2; [Pdat-1::α-syn+ Pdat-1::GFP]  
subjected to Manganese (Mn
2+
)  
 
 
Oxidative stress, mitochondrial stress, 
enhanced  DA neurodegeneration, 
reduced DA levels  
 
(Settivari et al., 
2009) 
pink-1(tm1779) subjected to 
Paraquat  
 
 
Oxidative stress   
(Sämann et al., 
2009) 
pdr-1(XY1046), Psnb-1::α-syn WT, 
Punc-119::α-syn A53T, N2, lrk-
1(km17), Psnb-1::LRRK2 (WT, 
R1441C, G2019S) subjected to 
Rotenone  
 
 
Mitochondrial stress, reduced viability 
D-α-hydroxybutyrate in 
combination with 
tauroursodeoxycholic acid 
(Ved et al., 2005, 
Saha et al., 2009) 
Pdat-1::GFP  subjected to 
Streptomyces venezuelae 
secondary metabolite  
 
 
DA neurodegeneration   
(Caldwell et al., 
2009) 
 
Table A1: An inclusive list of published C. elegans models of human neurodegenerative diseases that were utilised to study specific neurodegenerative diseases. 
Potential drugs that were shown to confer neuroprotection are also listed. Human neuorodegenerative diseases (NDs): AD, Alzhe imer’s disease; ANCL, Adult-onset neuronal 
ceroid lipofuscinosis; ALS, Amyotrophic lateral sclerosis; CJD, Creutzfeldt-Jakob disease; FTDP-17, Frontotemporal dementia with parkinsonism-17; FTLD-U,frontotemporal 
lobar degeneration with ubiquitinated inclusions; HD, Huntington’s disease, MJD, Machado–Joseph disease (or spinocerebellar ataxia type 3); PD, Parkinson’s disease, SMA, 
Spinal muscular atrophy  
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Strains Drug treatments
∆ 
(mg/ml) 
Mean lifespan ± 
S.E.M (days) 
% Change in 
mean lifespan
§
 
p-value 
75% mortality 
(days) 
90% mortality 
(days) 
Maximum 
(days) 
Total number of 
worms analysed 
N2 
PBS control 19.69 ± 1.05 - - 27 29 31 53 
Juglone (40 μM) 16.43 ± 0.55** -16.56% 0.0021 18
†††
 23
†
 25 52 
Succinimide (1) 15.91 ± 0.57** -19.20% 0.0003 18
†††
 21
†
 25 52 
Ethosuximide (1) 20.39 ± 1.02 3.56% 0.3966 27 29 33 54 
PBS control 18.55 ± 0.64 - - 22 24 25 52 
Ethosuximide (2) 18.79 ± 1.06 1.29% 0.5061 24 25 29 52 
Ethosuximide (4) 17.12 ± 0.98 -7.71% 0.5000 21 23 26 52 
N2; L4440 (RNAi) 
PBS control 19.48 ± 0.30 - - 22 25 27 131 
Ethosuximide (1) 19.08 ± 0.38 -2.05% 0.9164 22 25 27 130 
N2; hsp-1 (RNAi) 
PBS control 12.19 ± 0.24*** - 0.0e+00 14
†††
 15 17 116 
Ethosuximide (1) 14.35 ± 0.38*** 17.72% 2.2e-08 17
†††
 20 25 118 
N2; daf-16a (RNAi) 
PBS control 15.73 ± 0.33*** - 0.0e+00 18
†††
 20
††
 22 128 
Ethosuximide (1) 15.90 ± 0.33 1.08% 0.8868 18 20 25 128 
dnj-14(ok237) 
PBS control 15.87 ± 0.62 - - 18 21 23 56 
Juglone (40 μM) 18.01 ± 0.57* 13.48% 0.0070 21 23 25 58 
Succinimide (1) 16.71 ± 0.51 5.29% 0.3586 18 21 25 54 
Ethosuximide (1) 21.56 ± 0.79*** 35.85% 1.1e-07 21 23 25 58 
PBS control 15.76 ± 0.61 - - 17 21 27 52 
Ethosuximide (0.0001) 16.66 ± 0.76 5.71% 0.4174 19
†
 23
†
 24 52 
Ethosuximide (0.001) 18.40  ± 0.84* 16.75%
 
0.0217 21
††
 24
††
 26 52 
Ethosuximide (0.01) 16.59  ± 0.60 5.27% 0.3757 19 22 25 50 
Ethosuximide (0.1) 17.46 ± 0.78 10.79% 0.1722 21 25
†
 26 53 
Ethosuximide (0.2) 19.27 ±  0.78** 22.27% 0.0017 23
†
 24 29 52 
Ethosuximide (0.5) 20.15 ±  0.98** 27.86% 0.0005 24
††
 26
††
 32 52 
Ethosuximide (1) 22.26 ± 1.25*** 41.24% 2.6e-06 29
††
 32
†
 34 112 
Ethosuximide (2) 21.11 ± 1.21** 33.95% 0.0002 26
††
 32
†
 33 52 
Ethosuximide (4) 18.73 ± 0.75** 18.85% 0.0038 22
††
 24 26 55 
dnj-14(ok237); L4440 (RNAi) 
PBS control 16.81 ± 0.32*** - 3.5e-09 20
†††
 22
†
 25 118 
Ethosuximide (1) 21.23 ± 0.44*** 26.29% 1.2e-06 25
††
 27
†
 31 125 
dnj-14(ok237); hsp-1 (RNAi) 
PBS control 14.16 ± 0.28*** - 0.0e+00 15††† 17†† 22 120 
Ethosuximide (1) 17.39 ± 0.39*** 22.81% 0.0e+00 20††† 25††† 27 119 
dnj-14(ok237); daf-16a (RNAi) 
PBS control 15.37 ± 0.37* - 0.0113 18 20 22 114 
Ethosuximide (1) 16.23 ± 0.33 5.60% 0.1518 18 20 22 126 
osm-3(p802); L4440 (RNAi) PBS control 17.84 ± 0.63 - - 22 25 29 68 
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Strains Drug treatments
∆ 
(mg/ml) 
Mean lifespan ± 
S.E.M (days) 
% Change in 
mean lifespan
§
 
p-value 
75% mortality 
(days) 
90% mortality 
(days) 
Maximum 
(days) 
Total number of 
worms analysed 
Ethosuximide (1) 20.51 ± 0.63** 14.97% 0.0046 22 25 31 65 
osm-3(p802); hsp-1 (RNAi) 
PBS control 13.33 ± 0.41*** - 6.3e-08 15
†††
 17
†
 22 60 
Ethosuximide (1) 19.13 ± 0.81*** 43.51% 0.0e+00 22
†††
 27
†††
 29 60 
osm-3(p802); daf-16a (RNAi) 
PBS control 15.06 ± 0.46*** - 0.0e+00 17
†
 20 22 60 
Ethosuximide (1) 17.03 ± 0.58* 13.08% 0.0102 20 22 25 60 
 
lin-25(n756)X; juIs76[Punc-25::GFP + 
lin-15(+)] 
PBS control 15.28 ± 0.41 - - 18 20 22 102 
Ethosuximide (0.1) 16.02 ± 0.59 4.84% 0.1813 19 20 22 50 
Ethosuximide (0.2) 14.53 ± 0.58 -4.91% 0.5148 18 20 22 50 
Ethosuximide (0.5) 14.99 ± 0.79 -1.90% 0.8618 20 21 22 50 
Ethosuximide (1) 14.61 ± 0.65 -4.38% 0.8320 18 20 22 52 
Ethosuximide (2) 14.56 ± 0.76 -4.71% 0.5504 18
†
 19
†
 22 52 
bkIs10 [Paex-3::h4R1N TauV337M + 
Pmyo-2::GFP] 
PBS control 10.94 ± 0.27 - - 13 14 16 102 
Ethosuximide (0.0001) 13.18 ± 0.49** 20.48% 0.0002 16 17 20 52 
Ethosuximide (0.001) 13.51± 0.27*** 23.49% 1.1e-06 15
†
 16 17 52 
Ethosuximide (0.01) 13.80 ± 0.52*** 26.14% 5.6e-06 15
†
 20 21 52 
Ethosuximide (0.1) 13.79 ± 0.36*** 26.05% 8.8e-09 16
†††
 18
†
 20 102 
Ethosuximide (0.2) 14.04 ± 0.36*** 28.34% 2.4e-09 16
†††
 17
†
 20 102 
Ethosuximide (0.5) 13.76 ± 0.34*** 25.78% 5.6e-09 15
†††
 16
†
 19 102 
Ethosuximide (1) 14.17 ±  0.37*** 29.52% 0.0e+00 16
††
 19 20 102 
Ethosuximide (2) 15.50 ± 0.40*** 41.68% 0.0e+00 18
†††
 20
†
 21 102 
PBS control 11.28 ± 0.30 - - 13 14 17 92 
PBS control + Kanamycin 15.50 ± 0.46*** 37.41% 0.0e+00 17
†††
 19
†
 25 81 
Ethosuximide (1) 16.71 ± 0.51*** 48.14% 0.0e+00 21 23 25 80 
Ethosuximide (1) + Kanamycin 19.41 ± 0.60*** 72.07% 0.0e+00 23 25 29 80 
cca-1(ad1650) 
PBS control 17.50 ± 0.55 - - 21 24 27 108 
Ethosuximide (1) 17.82 ± 0.57 1.83% 0.5423 21 26 27 107 
bkIs10 [Paex-3::h4R1N TauV337M + 
Pmyo-2::GFP] 
PBS control 11.45  ± 0.33 - - 14 15 17 116 
Ethosuximide (1) 14.80 ± 0.43*** 29.26% 6.5e-09 17
††
 19
†
 22 116 
CK10; cca-1(ad1650) 
PBS control 11.27 ± 0.31 - - 14 15 19 114 
Ethosuximide (1) 14.27 ± 0.35*** 26.62% 2.2e-09 16 17
††
 23 112 
rmIs126 [Punc-54::Q0::YFP::unc-54 
3′-UTR] 
PBS control 18.60 ± 0.43 - - 21 23 27 81 
Ethosuximide (1) 17.25 ± 0.67 -7.26% 0.2014 20 21 25 60 
rmIs130 [Punc-54::Q24::YFP::unc-
54 3′-UTR] 
PBS control 17.12 ± 0.54 - - 20 23 25 62 
Ethosuximide (1) 20.57 ± 0.70*** 20.15% 0.0005 23
††
 25
††
 27 50 
278 
 
Strains Drug treatments
∆ 
(mg/ml) 
Mean lifespan ± 
S.E.M (days) 
% Change in 
mean lifespan
§
 
p-value 
75% mortality 
(days) 
90% mortality 
(days) 
Maximum 
(days) 
Total number of 
worms analysed 
rmIs132 [Punc-54::Q35::YFP::unc-
54 3′-UTR] 
PBS control 12.21 ± 0.31 - - 14 16 18 66 
Ethosuximide (1) 14.80 ± 0.50*** 21.21% 9.1e-06 16
††
 20 21 51 
rmIs133 [Punc-54::Q40::YFP::unc-
54 3′-UTR] 
PBS control 14.06 ± 0.24 - - 16 18 20 77 
Ethosuximide (1) 15.87 ± 0.34*** 12.87% 4.0e-05 18
††
 20 25 88 
Table A2: Statistical analysis of lifespan extension in C. elegans. Adult mean lifespan ± SEM in days observed in lifespan analysis. The strains and concentrations of the 
drugs tested were indicated. Lifespan experiments were carried out at 20°C. We used Online Application for the Survival Analysis of Lifespan Assays (OASIS; 
http://sbi.postech.ac.kr/oasis/introduction/) (Yang et al., 2011) for statistical analysis and to determine means and percentiles. Mean lifespans were compared using the log-rank 
(Mantel-Cox) test (*p<0.05; **p<0.005;***p<0.0001), and mortality at more specific time points was compared using Fisher’s exact test (
†
p<0.05 
††
p<0.005;
 †††
p<0.0001). ∆Drug 
treatments were from conception until death. PBS was used to solubilise ethosuximide, and PBS alone was the control treatment for ethosuximide. For the antibiotic kanamycin 
treatment of OP50 E.coli, 80 μl of 10 mM kanamycin solubilised by water was added after 24 hours of bacterial growth as described, kanamycin alone was the control treatment 
for kanamycin + ethosuximide combined treatment. §The percentage change and the statistical significance of this change were determined by comparing the experimental 
ethosuximide treatments to PBS control. The experimental treatment kanamycin + ethosuximide was compared to kanamycin. 
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A 
B 
  
Figure S5.1 A) Heatmap for contrast between ethosuximide-treated group with corresponding 
untreated sample groups. B) The M-A plot illustrates the estimated log2FC values for 9 contrasts. Log2 
FC (M) vs mean log2 expression (A) plot for each contrast. The DEGs are highlighted as red colour. 
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C 
D 
  
Figure S5.1 C) Histogram of p-values. The plot shows the significance test results of estimated logFC 
for each contrast. Each panel is for one contrast. The first bar in the left end in each panel shows how 
many probe-set are with p-value < 0.01, in corresponding contrast. D) Volcano scatter plot of -log10 p-
values vs log2 FC. The DEGs are highlighted as red colour.  
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Figure S5.1 E) Pairwise scatter plot of log2FC of DE probe-set identified from contrasts of sample 
groups. 
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Figure S5.2 A) Restriction analysis identified one of the 3 daf-16 clones in Vidal C. elegans ORF RNAi 
Library as daf-16 isoform a (daf-16a). B) Percent mean lifespan differences between RNAi fed mutants 
and WT control worms treated with either vehicle control or ethosuximide. Bars represent the degree of 
lifespan shortening or extension relative to control (*p<0.05; **p<0.005;***p<0.0001). 
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Figure S5.3 Mouse qRT-PCR primers obtained from PrimerBank were validated by RT-PCR and gel 
electrophoresis (Table 2.2) 
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